data_1whl_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1whl _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 19.4 mt . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.85 0.357 . . . . 0.0 111.048 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -140.0 179.58 6.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.3 t -60.3 129.18 22.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 86.28 43.93 6.08 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.476 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -144.21 137.04 13.66 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.635 0.255 . . . . 0.0 110.929 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.22 132.31 12.47 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.466 2.111 . . . . 0.0 112.324 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.7 m -155.55 145.79 12.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.211 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 59.4 mttt -81.34 127.43 32.73 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.89 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.2 t -109.98 131.03 62.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.08 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -97.02 113.62 25.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.881 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 58.7 mt -82.03 -44.27 16.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.91 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -98.33 179.29 4.78 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.931 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.8 m -82.4 87.77 6.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.922 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.43 54.91 30.66 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.54 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -115.37 -50.01 2.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.929 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 17.5 tt0 -176.62 126.87 0.18 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.1 mttt -96.03 116.68 29.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.826 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.415 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 30.0 m-85 -86.92 131.48 44.87 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -73.42 145.52 38.23 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.478 2.119 . . . . 0.0 112.265 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.3 154.59 24.59 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.605 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -91.65 135.53 26.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.798 0.333 . . . . 0.0 111.0 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.0 t -65.17 132.26 30.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.196 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -113.5 -30.13 6.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.045 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -152.8 168.35 26.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.878 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.425 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 16.2 ttt-85 -155.81 123.95 5.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.847 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.64 142.47 3.71 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.465 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo . . . . . 0 C--N 1.345 0.357 0 C-N-CA 122.492 2.128 . . . . 0.0 112.252 179.989 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.1 mt . . . . . 0 C--O 1.232 0.179 0 CA-C-O 120.793 0.33 . . . . 0.0 111.053 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -86.47 136.1 33.22 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.425 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 10.8 m-85 -115.66 111.89 21.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.95 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -71.47 119.64 7.87 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.382 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.8 t -129.86 136.69 58.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.77 0.319 . . . . 0.0 110.978 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -92.34 119.1 31.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 19.5 mt -59.07 133.91 56.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.981 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.7 -179.9 7.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.816 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.7 -29.52 39.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.062 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -63.35 -55.01 28.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.831 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.415 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -110.87 32.24 6.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.413 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 8.3 ttt180 -68.72 135.6 51.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 110.98 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 94.02 37.35 5.46 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 64.0 mm-40 -140.89 33.25 1.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.843 0.354 . . . . 0.0 110.948 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -102.51 145.74 16.56 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.48 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 7.6 p90 -109.94 -50.58 2.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.322 . . . . 0.0 110.972 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.5 t -62.77 -41.84 99.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.911 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 11.4 t70 60.02 30.45 19.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.988 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.415 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 94.26 -17.3 59.18 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.753 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.9 p -119.15 138.8 48.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.828 0.347 . . . . 0.0 111.18 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 7.1 t80 -130.14 110.05 11.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.814 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 61.77 28.66 17.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.955 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 100.01 -27.78 18.7 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.568 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -80.27 114.65 19.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.789 0.328 . . . . 0.0 111.018 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 28.6 tp60 -81.36 92.11 6.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.903 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.405 HD13 ' CZ ' ' A' ' 79' ' ' PHE . 48.1 mt -70.46 -46.61 63.48 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.972 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.415 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.5 p90 -144.24 168.96 18.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.945 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.85 130.1 55.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.892 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 1.2 m -149.93 172.06 15.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.905 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -68.78 -179.98 1.6 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -71.65 121.14 18.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.944 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 60.81 51.57 4.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.878 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 27.4 m -130.1 -46.75 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.994 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -67.17 141.71 39.92 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.612 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 20.7 m -156.99 141.14 7.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.361 . . . . 0.0 111.112 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.405 ' CZ ' HD13 ' A' ' 69' ' ' LEU . 5.7 m-85 -110.42 134.14 52.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 18.4 m -156.9 156.6 4.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.083 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.53 154.34 42.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.062 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 6.5 tp -50.37 -43.86 54.47 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.917 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -56.57 -28.0 59.22 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.576 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.7 mttm -79.61 -27.11 41.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.787 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 92.6 mt -80.73 152.45 28.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.904 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -124.91 108.37 11.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.855 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 20.1 tp -59.88 124.31 19.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 31.1 mt . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.112 -179.998 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 27.0 mt . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.814 0.34 . . . . 0.0 111.099 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -155.16 -177.8 6.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.826 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 37.7 t -61.7 124.23 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.085 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.14 42.34 5.3 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.437 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -138.95 138.81 21.88 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.623 0.249 . . . . 0.0 110.95 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -77.37 117.56 4.38 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.502 2.134 . . . . 0.0 112.398 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.0 m -146.8 138.47 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.117 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.9 mttm -81.37 156.88 25.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.992 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.2 t -133.3 127.23 53.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.041 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -88.49 124.06 33.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.878 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 40.2 mt -102.92 -40.13 6.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -85.59 179.88 7.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.812 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 64.7 m -95.61 79.83 3.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 73.12 49.87 14.65 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.525 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -116.73 -69.51 0.85 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.757 0.313 . . . . 0.0 110.867 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -161.93 138.3 7.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.867 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 13.2 mttt -95.67 146.13 24.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -106.0 127.74 27.78 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.788 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.28 137.84 34.83 Favored 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.461 2.107 . . . . 0.0 112.348 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.92 174.96 29.24 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.512 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.3 p -120.38 125.66 74.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.827 0.346 . . . . 0.0 111.017 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.4 t -59.27 123.55 11.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.164 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.5 mmt180 -112.07 -31.91 6.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.889 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -144.62 166.26 25.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.412 ' HD3' ' CE2' ' A' ' 46' ' ' PHE . 38.5 ttp85 -156.77 124.3 5.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.842 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 166.6 145.17 4.36 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.419 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo . . . . . 0 C--N 1.345 0.357 0 C-N-CA 122.511 2.14 . . . . 0.0 112.356 -179.99 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 13.8 mm . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.834 0.349 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -104.36 121.35 43.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.412 ' CE2' ' HD3' ' A' ' 32' ' ' ARG . 13.6 m-85 -101.55 119.11 38.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.964 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.402 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -83.85 117.74 4.52 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.428 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.5 t -122.84 131.99 72.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.808 0.337 . . . . 0.0 111.092 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -85.18 117.73 24.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.885 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 14.0 mt -60.24 134.87 57.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.937 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 16.5 mt -80.01 -179.96 7.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.863 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -54.36 -29.66 49.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.05 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -60.36 -51.33 69.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.855 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -117.95 35.39 4.08 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.378 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -73.59 145.86 45.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 0.0 110.901 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.4 27.99 28.7 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.466 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -134.17 31.04 3.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.842 0.354 . . . . 0.0 110.89 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.17 149.81 18.46 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.519 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 13.4 p90 -109.94 -49.88 3.04 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.737 0.303 . . . . 0.0 110.928 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.0 t -62.21 -48.25 80.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.856 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 58.17 37.04 26.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.97 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.423 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.94 -24.09 32.72 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.512 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.8 p -119.43 132.03 70.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.786 0.327 . . . . 0.0 111.132 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -118.55 113.62 21.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.815 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 60.08 28.7 18.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.976 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.07 -24.08 32.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.571 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.95 114.07 21.43 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.821 0.343 . . . . 0.0 110.989 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 6.9 tp60 -78.47 116.42 18.86 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.855 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 72.1 mt -98.92 -37.71 9.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.879 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.423 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 1.8 p90 -154.41 172.68 17.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.93 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -105.29 111.44 24.17 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.001 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . 0.401 ' HB2' ' CE2' ' A' ' 70' ' ' PHE . 0.5 OUTLIER -127.44 167.88 15.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.907 179.933 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.8 175.27 3.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.911 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -72.53 117.89 14.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.924 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 60.83 49.5 6.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.841 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 28.5 m -130.0 -49.97 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.912 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -67.06 146.23 47.66 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.531 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 25.8 m -156.78 142.23 9.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.778 0.323 . . . . 0.0 111.179 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.402 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 14.8 m-85 -109.89 131.89 54.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.917 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 30.6 m -152.61 158.05 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.112 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.94 156.61 38.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.132 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 12.9 tp -51.15 -45.41 61.68 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -57.07 -28.22 62.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.638 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -81.17 -27.02 35.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.865 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 84.9 mt -84.11 130.28 34.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.902 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 57.0 tt0 -113.78 114.01 25.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.899 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.5 tp -63.48 142.68 58.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.893 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 20.6 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.094 179.971 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 5.2 mt . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.767 0.318 . . . . 0.0 111.04 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -131.78 -177.94 4.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.927 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.9 t -67.53 135.67 28.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.141 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.38 46.25 7.57 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.451 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -145.09 145.75 28.23 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 120.757 0.313 . . . . 0.0 110.962 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.09 130.02 12.79 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.579 2.186 . . . . 0.0 112.269 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.8 m -158.02 138.51 4.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.14 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 47.1 mttm -79.23 140.45 37.65 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.05 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 18.4 t -115.91 135.87 54.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.062 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -97.25 110.07 22.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.857 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 83.0 mt -84.99 -56.26 3.65 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.97 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -75.06 171.99 13.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.944 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.4 m -78.01 80.26 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.885 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.62 55.49 26.84 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -120.45 -58.16 1.86 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 110.838 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -154.08 151.92 29.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.818 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -121.49 135.8 55.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.424 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 37.8 m-85 -106.11 136.49 19.32 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.838 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -73.09 143.22 35.64 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.438 2.092 . . . . 0.0 112.431 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.98 156.58 27.98 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.526 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -95.52 126.52 48.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.771 0.32 . . . . 0.0 111.044 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.6 t -59.87 135.84 24.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.119 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -119.46 -38.41 3.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.01 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.412 ' CD2' ' HB3' ' A' ' 69' ' ' LEU . 23.4 t80 -140.82 169.09 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.889 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 3.5 ttt180 -160.94 124.34 3.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.905 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 165.54 144.97 4.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.478 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo . . . . . 0 C--N 1.344 0.335 0 C-N-CA 122.537 2.158 . . . . 0.0 112.349 179.986 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.5 mt . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.763 0.316 . . . . 0.0 111.077 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -90.37 128.57 36.51 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.921 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.417 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 4.8 m-85 -111.74 109.9 19.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.875 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.46 122.68 11.01 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.344 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.9 t -137.9 130.94 41.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.805 0.336 . . . . 0.0 111.092 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -86.39 121.02 28.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.857 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 30.9 mt -60.45 141.27 56.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.049 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 13.3 mt -88.77 -179.88 6.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.83 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.06 -27.24 43.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.18 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -64.92 -41.57 95.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.966 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.424 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -132.13 38.67 1.86 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.47 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -74.31 161.33 29.99 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.851 0.358 . . . . 0.0 110.859 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.0 29.82 68.56 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.5 mm100 -135.86 34.14 2.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.816 0.341 . . . . 0.0 110.927 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.4 147.67 16.86 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.499 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -109.85 -47.78 3.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.813 0.34 . . . . 0.0 110.813 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.4 t -62.2 -47.93 82.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.943 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 59.76 32.53 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.964 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.433 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.1 -24.82 28.32 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.564 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.7 p -120.85 133.28 68.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.864 0.364 . . . . 0.0 111.133 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 12.5 t80 -116.88 110.4 18.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.852 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 13.3 mt-30 60.45 31.01 20.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 98.04 -26.61 22.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.55 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.9 tptm -75.15 110.72 9.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.797 0.332 . . . . 0.0 110.904 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 24.2 tp60 -79.83 95.24 5.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.835 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.412 ' HB3' ' CD2' ' A' ' 31' ' ' PHE . 75.4 mt -81.65 -36.56 28.69 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.989 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.433 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.7 p90 -156.38 166.94 31.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.957 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -102.4 116.08 31.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.909 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -132.27 176.34 8.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.914 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -79.39 -179.94 7.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -77.69 121.35 23.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 59.7 48.04 9.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.005 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 26.6 m -129.93 -58.34 1.08 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.902 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -62.71 149.6 48.82 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.419 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 15.3 m -158.0 146.54 9.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.873 0.368 . . . . 0.0 111.15 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -108.95 131.8 54.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 13.2 m -151.01 160.35 3.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.073 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.86 153.46 36.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.054 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 11.0 tp -49.73 -44.3 48.32 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.904 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.9 t0 -58.27 -30.96 66.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.602 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 9.6 mtmt -78.08 -25.3 47.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.837 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 32.9 mt -81.7 130.87 35.21 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.849 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.14 105.21 14.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.963 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 27.3 tp -62.14 139.59 58.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 16.0 mt . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.074 179.964 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 31.4 mt . . . . . 0 N--CA 1.458 -0.044 0 CA-C-O 120.851 0.358 . . . . 0.0 111.063 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 54.2 m-20 -124.75 -174.91 3.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.4 t -65.14 136.88 25.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.037 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.19 46.56 6.94 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.475 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -140.49 136.89 17.0 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.618 0.247 . . . . 0.0 110.908 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -76.47 117.03 4.45 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.45 2.1 . . . . 0.0 112.308 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.3 m -141.99 138.3 30.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.154 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 30.3 mttp -81.4 132.46 35.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.6 t -113.3 131.71 64.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.047 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -87.07 112.94 22.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 15.0 mt -93.83 -44.98 7.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.19 179.59 7.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.3 p -75.24 76.51 2.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.9 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.4 35.2 84.17 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.489 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.92 -62.42 1.47 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.802 0.334 . . . . 0.0 110.895 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.22 142.25 19.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.915 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 18.3 mttm -98.26 115.56 28.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.782 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -75.71 128.12 84.32 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.831 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -73.05 139.35 29.66 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.423 2.082 . . . . 0.0 112.311 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.49 157.91 29.62 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.614 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.1 p -95.86 136.05 28.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.774 0.321 . . . . 0.0 111.01 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.9 t -70.0 130.69 34.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.078 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . 0.412 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 24.9 mmt180 -114.52 -29.42 6.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.209 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -148.49 167.2 25.97 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.881 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.416 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 7.2 ttp180 -162.93 131.73 4.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.857 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.27 150.28 5.66 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.572 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo . . . . . 0 C--N 1.345 0.354 0 C-N-CA 122.613 2.209 . . . . 0.0 112.333 179.967 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 4.2 mp . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.797 0.332 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -82.95 139.24 33.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.869 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.416 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 7.6 m-85 -117.93 113.66 22.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.986 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -78.21 117.49 4.68 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 20.2 t -123.49 143.37 36.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.766 0.317 . . . . 0.0 111.09 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -97.72 115.0 27.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.93 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.9 mt -59.07 128.29 36.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.032 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.2 mt -80.54 -179.93 7.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.867 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -54.85 -29.28 54.77 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.067 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.99 -41.81 99.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.892 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.04 34.64 3.05 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.563 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.9 ttt180 -71.99 144.59 48.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.773 0.321 . . . . 0.0 110.926 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 90.2 31.02 11.2 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.464 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -137.12 32.57 2.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.847 0.356 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.28 143.52 15.67 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.443 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.6 p90 -109.99 -47.92 3.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.824 0.345 . . . . 0.0 110.991 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -66.47 -42.81 86.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.973 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.1 t0 60.03 29.2 18.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.088 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 85.55 26.25 36.34 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.61 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -164.04 133.29 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.775 0.322 . . . . 0.0 111.123 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 17.9 t80 -123.76 117.09 24.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 61.27 29.16 18.52 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.869 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.71 -26.86 21.44 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.547 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 22.2 tptt -76.87 111.93 12.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.84 0.352 . . . . 0.0 110.879 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 10.9 tp60 -80.99 108.4 14.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.841 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 44.9 mt -86.63 -31.16 21.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.046 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.412 ' CD2' ' HB2' ' A' ' 30' ' ' ARG . 7.1 p90 -161.35 163.2 30.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -99.0 132.63 44.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.939 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -150.48 170.61 18.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.808 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -70.24 179.96 2.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.806 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -74.35 118.71 17.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 61.17 52.06 4.11 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.97 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 36.1 m -130.06 -51.79 1.12 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.967 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -64.17 138.05 41.1 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.519 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 17.7 m -150.29 140.35 16.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.761 0.315 . . . . 0.0 111.207 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -104.13 122.4 45.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.838 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 4.5 m -145.85 164.73 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.208 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -76.68 155.94 32.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.189 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 13.2 tp -50.42 -40.84 51.29 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.737 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.8 t0 -58.45 -29.97 66.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.55 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.1 mmtt -78.83 -23.41 45.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.866 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 78.7 mt -82.75 143.59 30.77 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.93 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -130.29 97.59 4.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.814 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 19.6 tp -58.69 130.72 48.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.969 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 18.7 mt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.091 179.985 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.5 mt . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.824 0.345 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -131.72 173.03 11.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.783 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.2 t -59.65 141.81 15.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.102 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 73.35 48.39 19.06 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.45 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -145.06 141.52 17.34 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.69 0.281 . . . . 0.0 110.954 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.87 121.81 6.45 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.622 2.215 . . . . 0.0 112.418 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.7 m -153.2 138.36 10.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.101 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.3 mttt -75.01 138.03 41.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.949 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 18.6 t -119.17 136.02 57.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.12 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -90.84 112.62 24.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.972 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 23.3 mt -83.62 -66.27 0.91 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -73.77 172.83 10.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.874 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -76.1 85.76 2.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 61.74 54.09 38.26 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.443 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -112.5 -61.52 1.71 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.798 0.333 . . . . 0.0 110.849 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -162.78 133.09 4.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -95.23 121.9 37.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.858 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.406 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 50.0 m-85 -97.96 142.15 24.12 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.819 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.16 148.37 55.94 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.463 2.109 . . . . 0.0 112.36 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -167.24 154.42 24.7 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.509 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -98.36 127.15 51.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.834 0.349 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.2 t -59.98 131.91 24.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.999 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -116.41 -30.64 5.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.181 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -146.79 166.0 27.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.866 0.365 . . . . 0.0 111.005 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.1 ttp180 -165.79 141.28 4.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.831 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 142.73 134.75 2.96 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.548 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo . . . . . 0 C--N 1.346 0.416 0 C-N-CA 122.508 2.139 . . . . 0.0 112.245 -179.976 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.7 mt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.828 0.347 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -100.09 149.85 23.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.978 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.421 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 12.6 m-85 -127.8 116.98 21.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.925 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.66 120.67 5.27 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.41 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.5 t -133.6 129.2 55.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.868 0.366 . . . . 0.0 111.134 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -84.28 121.32 27.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.896 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.2 mt -59.99 150.23 29.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -96.71 -179.86 4.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.876 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -52.66 -30.02 29.56 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.143 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -62.86 -44.1 97.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.811 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.406 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -124.63 36.4 2.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.453 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt180 -75.48 140.49 42.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.898 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.8 29.85 11.27 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.518 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 48.4 mm-40 -137.21 36.25 2.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.41 142.43 15.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.576 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -105.65 -45.83 4.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.778 0.323 . . . . 0.0 110.864 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -63.38 -44.02 95.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.969 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.1 t0 57.72 33.73 23.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.928 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.423 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.72 -24.84 27.76 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.533 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.1 p -113.0 135.35 52.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.8 0.334 . . . . 0.0 111.098 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 4.0 t80 -116.82 110.43 18.36 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 77.6 mt-30 60.25 30.88 20.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.841 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.96 -26.3 23.96 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.604 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -81.85 114.11 20.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 110.968 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 31.7 tp60 -74.68 98.76 3.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.813 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 55.3 mt -79.79 -40.46 28.61 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.938 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.423 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -152.64 175.01 13.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.994 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.39 113.97 24.47 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 11.9 p -131.0 -180.0 5.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.01 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -65.65 179.95 0.76 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.96 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.12 118.84 22.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.034 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 59.56 50.04 7.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.023 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 43.1 m -129.98 -45.54 1.15 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.983 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -60.91 146.39 47.53 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.563 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 16.1 m -157.63 138.3 4.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.731 0.301 . . . . 0.0 111.074 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -109.23 127.73 54.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.93 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 31.0 m -150.22 165.68 2.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.117 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.15 156.9 35.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.058 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 11.0 tp -49.55 -43.88 46.21 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.893 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -57.01 -29.85 63.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.55 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 12.5 mmtt -76.43 -25.64 54.64 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.814 179.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 79.2 mt -90.39 137.69 32.15 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.911 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.2 tm-20 -111.65 109.1 18.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 23.8 tp -64.56 128.24 34.92 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.965 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 22.1 mt . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.07 179.944 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 23.1 mt . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.82 0.343 . . . . 0.0 111.092 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -156.84 -172.14 3.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.846 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 t -60.67 136.83 23.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.212 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 75.03 46.58 15.93 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.59 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 3.0 t -144.32 131.74 10.49 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.604 0.24 . . . . 0.0 110.969 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.08 122.97 6.97 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.479 2.119 . . . . 0.0 112.386 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.6 m -148.48 138.86 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.0 mttt -76.17 139.46 41.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.902 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.28 141.67 36.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.115 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -98.84 115.7 29.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.932 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 39.9 mt -98.39 -59.74 1.69 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 19.0 mtt85 -60.35 168.54 2.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.869 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.9 p -74.3 75.75 1.85 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.82 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.26 55.7 26.27 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.537 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -119.51 -67.25 1.0 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -147.9 154.51 40.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -112.31 152.09 28.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.865 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -116.69 135.63 23.0 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -73.01 140.32 31.26 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.477 2.118 . . . . 0.0 112.312 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.79 148.51 16.06 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.635 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.3 p -89.83 140.66 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.737 0.303 . . . . 0.0 110.979 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.9 t -72.34 131.17 35.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.098 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 5.8 mmm180 -112.83 -30.8 6.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.126 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -152.5 167.41 28.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.907 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.41 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 0.0 OUTLIER -154.72 130.04 9.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.755 179.931 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.33 151.12 6.14 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.507 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo . . . . . 0 C--N 1.344 0.326 0 C-N-CA 122.61 2.207 . . . . 0.0 112.29 179.993 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.7 mp . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.829 0.347 . . . . 0.0 111.096 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -125.82 156.9 38.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.949 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.41 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 11.7 m-85 -126.78 109.89 12.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.95 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.98 132.73 31.26 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.356 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.7 t -144.12 130.53 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.899 0.38 . . . . 0.0 111.22 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -88.13 116.73 26.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.827 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 29.3 mt -59.97 131.96 52.48 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 12.0 mt -77.61 -179.89 6.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -53.41 -29.79 36.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.149 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -61.04 -55.47 32.39 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.914 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -112.05 32.44 6.33 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.514 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 8.8 ttt180 -72.83 135.26 45.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.913 0.387 . . . . 0.0 110.866 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 98.61 31.97 6.17 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.526 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 64.4 mm-40 -143.4 33.39 1.31 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.858 0.361 . . . . 0.0 110.932 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -99.8 147.99 18.4 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.521 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 23.7 p90 -109.51 -50.35 3.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.747 0.308 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 8.7 t -68.84 -48.57 63.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.887 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 53.89 30.48 11.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.089 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.415 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 106.3 -26.38 20.46 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.506 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.5 p -120.82 132.8 69.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 111.087 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -119.06 113.77 21.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.932 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 61.26 24.87 14.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.072 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 104.54 -27.9 17.2 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.555 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.2 tpmp? -79.24 117.59 20.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.923 0.392 . . . . 0.0 110.913 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 8.6 tp60 -85.1 106.0 16.25 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.884 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 91.6 mt -91.01 -34.45 15.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.415 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 7.4 p90 -153.95 171.21 19.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 4.9 mm100 -102.77 121.15 41.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.922 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -136.52 172.85 12.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.807 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.93 173.78 10.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.905 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -65.53 118.67 9.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.991 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 59.55 52.15 5.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.852 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 87.0 m -130.07 -63.93 0.88 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -58.87 137.03 50.75 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.488 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 5.7 m -148.07 129.79 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.792 0.329 . . . . 0.0 111.208 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -93.02 129.77 38.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.785 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 4.6 m -150.32 164.56 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.235 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.7 162.58 20.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.176 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 12.8 tp -52.35 -47.99 65.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.805 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -57.64 -29.0 64.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.604 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 1.7 mttp -79.49 -25.35 41.87 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.809 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 52.5 mt -87.57 128.02 35.26 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.864 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -114.0 111.35 21.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.836 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 17.4 tp -60.04 134.13 56.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.957 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 29.3 mt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.105 -179.952 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 29.2 mt . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.761 0.315 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -153.35 -168.94 3.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.9 t -70.16 135.27 28.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.125 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.9 46.17 7.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.408 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -144.73 137.42 13.6 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.677 0.275 . . . . 0.0 110.99 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.1 118.07 4.61 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.477 2.118 . . . . 0.0 112.364 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 24.1 m -146.68 138.32 18.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.196 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.2 mttm -77.06 129.87 36.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.967 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 23.3 t -106.16 128.03 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.002 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 30.2 tt0 -97.24 110.32 22.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.912 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 88.9 mt -80.99 -45.55 16.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.835 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.28 -174.3 5.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.968 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.51 84.25 4.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.82 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.05 55.2 29.41 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.539 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 -117.25 -65.69 1.16 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.776 0.322 . . . . 0.0 110.892 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -158.43 123.07 4.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.866 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 24.2 mttt -90.57 144.06 26.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -107.98 127.54 27.46 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.864 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -68.39 131.84 24.2 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.397 2.064 . . . . 0.0 112.262 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.66 163.38 30.35 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.9 p -102.6 125.95 56.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.822 0.344 . . . . 0.0 110.97 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.3 t -59.88 126.91 18.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -114.38 -31.79 6.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.054 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 28.0 t80 -142.58 167.43 22.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.934 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.42 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 13.5 ttp180 -159.22 129.47 5.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.72 148.34 5.15 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.505 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo . . . . . 0 C--N 1.344 0.338 0 C-N-CA 122.561 2.174 . . . . 0.0 112.274 179.998 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.2 mt . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.775 0.321 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -106.99 150.39 26.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.98 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.42 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 9.5 m-85 -123.34 114.9 20.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.971 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.424 ' N ' ' CD1' ' A' ' 79' ' ' PHE . . . -74.93 121.84 6.77 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.48 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.5 t -129.95 133.76 64.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.823 0.344 . . . . 0.0 111.113 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -90.02 115.91 27.65 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 37.3 mt -58.88 133.59 56.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.993 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -81.55 -179.89 7.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.921 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -53.14 -29.63 32.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.106 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -60.86 -58.35 8.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -111.12 32.72 6.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.465 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -69.74 133.06 47.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.769 0.319 . . . . 0.0 110.907 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.46 35.8 4.56 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.53 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.8 mt-30 -141.47 31.36 1.69 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.342 . . . . 0.0 110.877 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.72 147.39 16.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.513 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -108.56 -49.23 3.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.75 0.31 . . . . 0.0 110.863 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.3 t -59.43 -43.78 93.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.957 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.0 t0 59.82 29.38 18.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.052 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.423 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.47 -19.57 53.62 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.69 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.2 p -124.22 140.38 47.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.865 0.364 . . . . 0.0 111.178 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -122.85 109.96 14.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.923 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER 60.22 26.6 16.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.001 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.12 -30.27 9.54 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.592 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.34 117.93 19.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.951 0.405 . . . . 0.0 110.925 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 2.9 tp60 -84.91 92.69 8.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.861 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 71.1 mt -69.49 -44.57 70.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.912 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.423 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.9 p90 -147.77 177.78 9.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.961 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -113.83 123.92 50.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.885 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 17.7 p -150.0 163.06 39.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.891 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -60.12 178.51 0.18 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.936 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -75.71 124.55 27.45 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 60.79 49.86 5.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.909 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 53.7 m -129.99 -45.93 1.14 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.907 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -69.41 132.17 24.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.519 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 7.7 m -142.15 131.16 22.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.886 0.374 . . . . 0.0 111.094 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.424 ' CD1' ' N ' ' A' ' 47' ' ' GLY . 9.1 m-85 -101.53 127.06 48.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.93 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 31.5 m -151.71 164.15 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.159 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -81.13 162.38 23.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.204 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -51.9 -49.57 62.78 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.887 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -56.89 -28.33 61.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.672 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.0 mtmm -80.03 -25.86 40.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.815 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.3 mt -82.86 161.05 22.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.913 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -137.97 104.59 5.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.84 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 19.8 tp -59.68 137.71 57.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.984 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 32.3 mt . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.117 179.973 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.0 mt . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -143.1 -172.02 3.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.881 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.2 t -64.48 127.78 25.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.038 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 87.84 43.28 5.77 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.537 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -141.44 137.04 16.12 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 120.617 0.246 . . . . 0.0 110.952 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -76.34 116.84 4.43 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.526 2.151 . . . . 0.0 112.343 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.8 m -144.34 138.74 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.169 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.3 mttt -80.42 141.23 35.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.071 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 31.9 t -115.63 133.6 61.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.053 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -94.52 121.54 36.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.915 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 57.4 mt -101.93 -54.48 2.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.919 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.8 -174.78 0.05 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.839 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 51.7 p -93.0 48.37 1.34 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.918 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 95.51 57.89 1.16 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.469 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -121.43 -51.93 2.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.818 0.342 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -170.02 152.4 4.32 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 10.8 mttt -107.74 138.29 44.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -95.08 123.14 58.21 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.769 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -65.97 138.86 54.22 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.464 2.109 . . . . 0.0 112.263 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -166.74 146.6 11.02 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.571 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.2 p -83.37 145.83 7.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.803 0.335 . . . . 0.0 110.961 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.7 t -77.86 138.87 19.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.158 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -117.78 -40.19 3.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.804 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.411 ' CD2' ' N ' ' A' ' 32' ' ' ARG . 58.1 t80 -140.05 163.8 31.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.793 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.412 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 22.5 ttp85 -158.99 140.79 13.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.911 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.83 161.33 9.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.482 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo . . . . . 0 C--N 1.344 0.292 0 C-N-CA 122.556 2.171 . . . . 0.0 112.287 179.974 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.2 mp . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.82 0.343 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -117.96 146.58 43.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.918 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.412 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 7.0 m-85 -118.28 112.94 20.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.924 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.429 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -68.44 141.4 37.02 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.589 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 25.7 t -153.52 140.92 13.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.792 0.329 . . . . 0.0 111.006 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -98.79 113.94 26.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.871 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.4 mt -57.76 128.6 37.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.056 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 19.8 mt -78.0 -179.9 6.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.54 -30.03 52.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.079 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -60.64 -48.68 80.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.846 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -121.57 37.13 3.03 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.488 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.1 ttt180 -74.1 151.89 40.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.802 0.334 . . . . 0.0 110.9 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 84.3 27.91 35.07 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.492 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 68.5 mm-40 -133.92 36.69 3.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.837 0.351 . . . . 0.0 110.918 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.41 145.86 15.99 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.456 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -109.98 -47.38 3.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.821 0.343 . . . . 0.0 110.921 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.3 t -69.98 -40.47 75.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.831 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.6 t0 58.43 29.46 18.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.043 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.42 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 99.01 -20.25 51.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.67 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.9 p -118.56 134.59 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.867 0.365 . . . . 0.0 111.124 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.412 ' CE1' ' HG3' ' A' ' 65' ' ' GLN . 50.4 t80 -122.59 110.02 15.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.858 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . 0.412 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 28.8 mt-30 58.94 26.54 15.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.037 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 105.72 -28.05 15.57 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.568 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.0 118.08 21.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.83 0.348 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 7.7 tp60 -84.08 90.08 7.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.913 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 84.7 mt -71.36 -31.78 67.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.825 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.42 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.1 p90 -161.49 164.82 29.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.858 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -112.0 119.42 38.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.887 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 1.3 m -137.17 179.95 6.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.907 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -71.69 179.96 2.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.885 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -72.33 123.24 22.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.001 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 60.02 50.59 6.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 27.9 m -130.04 -49.28 1.11 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.983 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -62.65 127.14 38.77 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.558 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.3 m -146.11 156.23 12.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.748 0.309 . . . . 0.0 111.128 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.429 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 7.9 m-85 -124.47 136.61 54.16 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.889 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 28.6 m -156.59 160.04 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.11 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -73.3 157.48 36.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.116 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.8 tp -51.14 -46.41 61.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.845 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.6 p-10 -57.16 -28.94 63.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.599 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 5.0 mmtt -79.28 -25.21 42.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 43.7 mt -83.17 154.98 24.0 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.02 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -141.45 104.66 4.62 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.853 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 19.0 tp -59.51 135.14 57.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.002 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.3 mt . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.113 -179.991 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.1 mt . . . . . 0 N--CA 1.458 -0.049 0 CA-C-O 120.918 0.39 . . . . 0.0 111.059 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -138.82 179.77 6.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.842 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.2 t -64.04 133.13 29.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.011 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 84.36 45.53 6.15 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.383 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -149.87 143.63 16.89 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 120.663 0.268 . . . . 0.0 110.953 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.3 138.14 21.96 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.582 2.188 . . . . 0.0 112.267 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.3 m -158.49 138.69 4.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.232 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.3 mttt -82.82 125.94 31.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.948 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 22.0 t -104.49 138.46 29.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.03 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -102.96 112.09 24.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.939 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -85.78 -40.12 16.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.866 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -84.31 -176.3 6.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 71.8 p -100.04 48.26 0.93 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.874 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 105.71 56.89 0.66 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.553 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.95 -60.45 1.08 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.803 0.335 . . . . 0.0 110.904 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -161.63 146.18 13.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.863 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 14.8 mttt -109.21 150.62 27.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.417 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 27.3 m-85 -113.63 127.26 27.03 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.838 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.18 146.17 40.37 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.436 2.091 . . . . 0.0 112.318 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.82 153.4 21.53 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.489 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.8 p -93.27 138.85 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.772 0.32 . . . . 0.0 111.066 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.3 t -72.78 133.32 31.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.098 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 20.0 mmt180 -115.91 -30.45 6.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.038 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -142.78 168.3 20.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.948 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.425 ' CD ' ' CZ ' ' A' ' 46' ' ' PHE . 24.3 ttp180 -161.23 123.53 3.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.858 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 168.37 145.7 4.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.545 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo . . . . . 0 C--N 1.344 0.338 0 C-N-CA 122.583 2.189 . . . . 0.0 112.25 -179.964 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 32.9 mt . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.794 0.331 . . . . 0.0 111.095 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -90.39 147.81 23.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.952 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.425 ' CZ ' ' CD ' ' A' ' 32' ' ' ARG . 12.1 m-85 -117.12 111.95 20.21 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.67 110.27 2.99 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.498 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.97 132.13 67.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.846 0.355 . . . . 0.0 111.039 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -88.53 117.54 27.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 52.8 mt -59.15 135.19 57.56 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.993 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -79.78 -179.93 7.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.821 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -55.13 -30.2 59.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.079 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -63.01 -60.1 3.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.79 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.417 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -101.58 30.86 9.47 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.442 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -69.74 137.87 52.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.79 0.328 . . . . 0.0 110.88 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.01 34.06 6.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.47 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 31.1 mm-40 -140.9 43.84 1.81 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.906 0.384 . . . . 0.0 110.918 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -108.1 143.15 16.05 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.525 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -110.03 -32.1 7.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.87 0.367 . . . . 0.0 110.932 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -85.76 -42.31 14.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.899 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.6 t0 57.08 31.19 19.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.999 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.435 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 93.1 -16.8 59.65 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.676 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.7 p -123.01 142.1 40.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.856 0.36 . . . . 0.0 111.141 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 13.4 t80 -129.09 110.24 11.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.873 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 61.67 24.54 14.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.154 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.18 -27.81 14.7 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.566 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.6 119.53 23.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.947 0.403 . . . . 0.0 110.948 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -82.87 95.61 8.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 78.5 mt -70.83 -51.13 28.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.435 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -144.99 166.1 26.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.913 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.32 124.24 46.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.881 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 9.3 p -149.58 177.1 10.05 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -71.89 175.93 5.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.877 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -78.82 127.79 32.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 60.5 41.22 16.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.902 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 23.7 m -127.53 -46.66 1.45 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.909 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -68.32 132.25 27.67 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.538 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 12.4 m -148.44 135.96 13.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.806 0.336 . . . . 0.0 111.158 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -102.18 130.01 48.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 4.2 m -150.15 166.74 2.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.148 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.98 158.76 21.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.137 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 9.3 tp -50.55 -44.05 56.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.899 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -57.82 -28.82 64.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.603 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.4 mttt -82.6 -24.85 33.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.86 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 52.7 mt -88.88 128.45 35.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.013 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.9 tm-20 -114.89 107.95 16.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.81 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 13.7 tp -57.74 138.54 55.41 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.997 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 27.3 mt . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 -179.997 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 20.2 mt . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.828 0.346 . . . . 0.0 111.02 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -120.57 -179.59 4.03 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.3 t -66.86 137.33 25.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.027 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.75 46.82 7.02 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.399 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -140.72 140.96 23.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.623 0.249 . . . . 0.0 110.955 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -76.51 117.17 4.49 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.566 2.177 . . . . 0.0 112.343 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.9 m -144.38 138.9 23.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.129 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -87.38 140.98 28.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.5 t -121.0 140.4 45.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.095 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -97.96 110.06 22.7 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.6 mt -84.57 -58.69 2.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.89 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.42 -174.99 0.74 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.83 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -83.77 68.72 10.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 69.18 45.35 62.09 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.536 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -99.48 -44.72 6.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 0.0 110.916 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -176.66 131.56 0.2 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -88.29 124.85 34.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.825 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -89.84 128.06 51.67 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.832 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -72.33 139.4 31.89 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.445 2.097 . . . . 0.0 112.328 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -154.82 167.05 32.6 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.515 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.6 p -108.73 124.0 64.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.75 0.31 . . . . 0.0 111.014 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.7 t -59.46 128.55 20.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.13 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -115.73 -29.92 6.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.112 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 40.5 t80 -148.74 165.96 29.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.914 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.419 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 15.1 ttp180 -158.46 135.66 9.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.984 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.68 137.32 2.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo . . . . . 0 C--N 1.346 0.435 0 C-N-CA 122.516 2.144 . . . . 0.0 112.339 -179.992 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 16.2 mt . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.795 0.331 . . . . 0.0 111.099 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -120.2 138.92 53.36 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.939 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.419 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 6.4 m-85 -120.84 109.91 15.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.845 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.18 119.93 9.07 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.485 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 22.3 t -134.04 130.83 55.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.774 0.321 . . . . 0.0 111.03 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -83.62 119.06 24.28 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.932 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.9 mt -62.26 141.95 57.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.014 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.7 mt -86.73 -179.93 6.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.854 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -54.42 -30.03 51.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.037 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -61.73 -47.06 86.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.871 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.43 38.38 2.39 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.482 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -77.09 151.83 35.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.819 0.342 . . . . 0.0 110.869 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.18 28.13 37.99 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.543 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -135.35 46.55 2.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.804 0.335 . . . . 0.0 110.859 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -118.15 150.44 18.19 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.556 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -110.09 -50.55 2.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.7 t -69.03 -48.07 63.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.962 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 55.54 32.74 19.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.044 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 105.1 -25.41 25.26 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.545 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.7 p -121.93 126.54 74.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.807 0.336 . . . . 0.0 111.103 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -116.03 113.89 23.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.86 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 12.9 mt-30 62.39 26.8 16.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.943 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.83 -24.39 32.35 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.616 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 12.2 tptm -81.67 114.56 20.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.882 0.372 . . . . 0.0 110.903 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.8 tp60 -82.64 97.24 8.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.924 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 79.0 mt -80.87 -34.74 33.46 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.012 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.413 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -156.39 169.81 23.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.986 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -103.47 124.74 49.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.889 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -140.61 173.84 11.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.823 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -76.43 179.96 5.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -76.96 120.52 22.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 60.2 41.71 16.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.885 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 78.2 m -125.18 -52.83 1.63 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.945 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -64.62 130.14 36.84 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.454 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 5.6 m -142.33 143.46 26.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.853 0.359 . . . . 0.0 111.133 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -105.87 124.69 49.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.867 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 29.4 m -146.65 155.77 11.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.15 155.67 40.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.2 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -50.57 -44.51 56.76 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.927 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -56.48 -27.03 55.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.663 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 11.8 mmtt -81.52 -26.75 34.86 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.838 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 90.2 mt -79.3 140.91 37.43 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.823 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -115.75 103.34 10.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.846 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 23.4 tp -59.54 130.38 46.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 13.6 mt . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.007 179.987 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 30.0 mt . . . . . 0 N--CA 1.457 -0.095 0 CA-C-O 120.82 0.343 . . . . 0.0 111.1 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -134.75 -177.84 4.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.971 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 26.6 t -60.98 135.68 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.133 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.43 46.15 7.04 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.466 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -141.66 138.82 17.65 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.668 0.27 . . . . 0.0 110.865 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -74.48 117.25 4.89 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 122.503 2.136 . . . . 0.0 112.383 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.9 m -142.99 138.55 27.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.12 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 27.0 mttt -83.63 142.89 30.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.978 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.0 t -123.43 132.03 72.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -93.27 118.93 31.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 18.1 mt -95.07 -55.8 2.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.98 -170.27 0.22 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.877 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 69.0 m -88.75 79.16 7.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.871 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.83 44.22 98.29 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.523 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -101.62 -66.54 0.91 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.798 0.333 . . . . 0.0 110.836 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -152.92 142.39 21.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.938 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.7 mtpt -103.73 133.13 49.25 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.826 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.405 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 25.8 m-85 -92.84 129.76 38.87 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.78 133.87 17.49 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.427 2.085 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.16 155.39 26.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.594 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -94.52 132.95 37.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.822 0.344 . . . . 0.0 111.067 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.4 t -63.75 133.83 29.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.097 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.28 -36.4 4.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.005 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 52.9 t80 -143.19 164.34 30.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.921 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.412 ' HG3' ' CE2' ' A' ' 46' ' ' PHE . 4.3 ttt180 -154.29 135.91 14.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 160.04 126.82 0.86 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.455 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo . . . . . 0 C--N 1.346 0.421 0 C-N-CA 122.435 2.09 . . . . 0.0 112.295 179.995 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.0 mt . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.75 0.309 . . . . 0.0 111.072 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -102.28 134.94 44.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.841 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.412 ' CE2' ' HG3' ' A' ' 32' ' ' ARG . 8.7 m-85 -121.69 113.01 19.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.446 ' N ' ' CD1' ' A' ' 79' ' ' PHE . . . -73.08 118.21 6.26 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.358 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.6 t -125.73 131.42 71.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 111.124 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -90.55 114.81 27.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.839 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.3 mt -58.32 135.99 57.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.073 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -82.28 -179.97 7.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.896 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.72 -29.66 54.04 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.09 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -61.33 -50.49 72.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.902 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.405 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -121.84 37.59 2.87 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.479 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.57 145.34 41.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.794 0.33 . . . . 0.0 110.911 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 85.95 33.13 15.98 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.539 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 7.7 mm-40 -137.3 30.86 2.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.862 0.363 . . . . 0.0 110.933 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.38 154.41 18.99 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.502 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -109.47 -49.79 3.07 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.799 0.333 . . . . 0.0 110.869 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.7 t -62.31 -46.26 89.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.946 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 57.51 35.37 25.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.003 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.49 -27.56 16.89 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.469 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.8 p -117.46 124.83 73.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 0.0 111.053 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 37.3 t80 -111.91 115.05 28.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.96 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 30.7 mt-30 59.37 25.77 14.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.137 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.84 24.66 22.47 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.61 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.65 109.82 10.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.83 0.348 . . . . 0.0 110.859 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -75.71 97.01 3.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.946 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 79.0 mt -82.65 -30.81 29.1 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.858 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.413 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.9 p90 -152.82 174.64 13.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.938 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.79 110.02 19.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 26.5 p -133.17 174.71 10.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -72.55 179.97 3.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.881 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -74.78 119.31 18.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.975 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 60.75 51.25 4.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.906 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 47.6 m -129.98 -49.34 1.12 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.916 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -71.65 134.63 22.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.502 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.1 m -141.9 132.61 25.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.805 0.336 . . . . 0.0 111.113 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 47' ' ' GLY . 7.9 m-85 -100.83 118.34 36.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.897 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 27.4 m -145.3 161.92 12.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.109 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.66 156.05 35.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.127 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 6.5 tp -50.43 -43.97 55.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.825 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -57.57 -29.27 64.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.573 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 22.6 mmtm -80.62 -27.02 37.41 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.79 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 39.4 mt -84.33 146.59 27.64 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.985 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -131.46 110.96 11.38 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.912 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.5 tp -62.6 136.14 57.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.99 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 26.9 mt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.183 179.944 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 20.2 mt . . . . . 0 N--CA 1.457 -0.088 0 CA-C-O 120.755 0.312 . . . . 0.0 111.172 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -157.91 -176.65 6.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.7 t -58.89 138.93 19.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.146 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 72.06 47.33 31.52 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.512 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -147.31 136.38 11.52 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.585 0.231 . . . . 0.0 110.893 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -76.19 130.2 11.91 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.512 2.141 . . . . 0.0 112.298 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.3 m -151.67 138.75 13.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.156 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -81.89 135.21 35.43 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.4 t -116.83 139.9 41.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.14 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -103.26 116.29 32.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.937 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 50.6 mt -89.72 -44.65 9.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.954 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -86.38 172.17 10.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.87 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 43.2 t -76.43 76.22 3.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.11 69.2 1.39 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.509 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -133.38 -57.7 0.89 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.887 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -156.12 132.7 10.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.847 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -102.87 128.1 49.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.874 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 42.6 m-85 -93.18 129.56 38.88 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.817 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -76.06 138.59 20.73 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.435 2.09 . . . . 0.0 112.282 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.27 151.49 22.8 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.552 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.0 p -92.38 130.94 40.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.791 0.329 . . . . 0.0 111.018 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.1 t -64.77 140.54 19.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.051 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.3 mmt180 -122.22 -41.07 2.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.042 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -138.25 164.47 29.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.947 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.42 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 3.3 ttp180 -158.11 141.94 15.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.857 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.04 149.18 4.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.478 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo . . . . . 0 C--N 1.344 0.294 0 C-N-CA 122.604 2.203 . . . . 0.0 112.339 -179.99 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.6 mt . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.749 0.309 . . . . 0.0 111.063 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -136.71 147.23 46.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.941 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.42 ' CZ ' ' HD2' ' A' ' 32' ' ' ARG . 9.6 m-85 -123.99 109.89 14.1 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.855 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.31 120.68 9.49 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.477 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.5 t -133.21 133.11 58.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.874 0.368 . . . . 0.0 111.107 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -90.24 116.93 28.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.881 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 63.6 mt -60.43 145.33 48.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.941 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.6 mt -86.44 -179.85 6.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.923 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -53.24 -29.35 32.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.111 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.09 -51.95 65.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.884 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -112.21 29.64 8.22 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.514 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -68.17 144.97 54.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.888 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.67 39.24 14.59 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.519 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -145.4 35.19 1.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.774 0.321 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.05 152.09 19.26 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -110.0 -43.87 3.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 0.0 110.979 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.4 t -77.61 -40.38 42.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.899 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 51.12 26.83 3.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.302 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.42 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 106.31 -31.74 8.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.622 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -111.78 128.79 68.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.89 0.376 . . . . 0.0 111.091 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.417 ' CE1' ' HG3' ' A' ' 65' ' ' GLN . 30.9 t80 -113.28 110.01 19.68 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.896 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . 0.417 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 9.9 mt-30 57.72 28.84 16.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.034 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 102.22 -26.81 22.97 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.498 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.6 tmtt? -82.17 116.82 21.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.918 0.39 . . . . 0.0 110.952 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 19.5 tp60 -78.96 98.91 6.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.832 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 79.0 mt -81.13 -37.86 28.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.949 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.42 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.0 p90 -155.96 173.3 16.99 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.936 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -107.72 123.36 48.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.889 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -139.58 177.2 8.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.911 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -76.05 179.92 5.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.886 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -73.52 114.01 11.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.913 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 42.2 m-20 60.83 45.21 10.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.912 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 62.6 m -125.63 -46.17 1.74 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.894 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -65.1 135.82 37.36 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.525 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.6 m -148.49 138.86 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.803 0.335 . . . . 0.0 111.164 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -105.15 134.52 48.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 30.5 m -155.79 168.56 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.182 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -87.39 161.24 17.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.191 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 7.0 tp -49.99 -44.3 50.87 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -55.82 -27.1 49.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.665 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 16.1 mmtt -95.86 19.65 11.1 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.934 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 88.2 mt -129.18 126.71 39.82 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.93 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -107.8 110.39 22.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.963 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 12.2 tp -67.14 117.47 9.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.996 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.0 mp . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.152 179.923 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.7 mt . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.769 0.318 . . . . 0.0 111.058 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.65 -175.54 3.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.924 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 28.3 t -64.42 128.86 27.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.018 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 88.47 43.92 5.4 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.444 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -145.63 139.21 14.6 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.643 0.259 . . . . 0.0 110.963 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -76.72 130.03 11.27 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.513 2.142 . . . . 0.0 112.303 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.6 m -151.1 138.8 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.141 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 50.2 mttt -82.21 127.49 33.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.962 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.4 t -108.69 137.01 42.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.029 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -92.98 121.41 34.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.971 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.1 mt -100.41 -42.49 6.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.956 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.9 mtt85 -79.68 -178.22 6.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.81 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -80.49 73.54 7.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.825 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.75 41.21 99.88 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.491 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -101.94 -61.86 1.33 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.747 0.308 . . . . 0.0 110.865 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -148.43 159.6 43.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.902 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 2.0 mttm -125.3 126.38 45.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -89.65 137.31 28.72 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.766 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -73.88 146.15 37.23 Favored 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.424 2.082 . . . . 0.0 112.331 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -163.29 152.21 22.16 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.502 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.5 p -94.1 129.16 44.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.324 . . . . 0.0 111.138 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.7 t -62.3 126.58 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.07 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 40.0 mmt180 -112.11 -31.05 7.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.012 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -148.25 167.73 24.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.976 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.42 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 9.6 ttp180 -160.85 119.39 2.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.865 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.52 156.34 11.8 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.55 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo . . . . . 0 C--N 1.344 0.325 0 C-N-CA 122.586 2.19 . . . . 0.0 112.357 -179.981 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.9 mp . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.794 0.33 . . . . 0.0 111.153 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -85.5 124.24 31.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.42 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 5.8 m-85 -98.16 120.0 37.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.999 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.56 131.64 10.52 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.418 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.5 t -139.35 126.39 24.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.876 0.37 . . . . 0.0 111.161 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -83.0 117.14 22.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.845 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 13.1 mt -58.62 130.15 45.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.934 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 5.1 mt -76.67 -179.94 5.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.867 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -53.88 -29.2 40.56 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.134 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -61.87 -43.6 98.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.946 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.24 35.33 2.86 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.528 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -72.61 143.44 48.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.779 0.323 . . . . 0.0 110.889 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.48 34.48 11.86 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.475 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 30.5 mm-40 -141.69 37.63 1.65 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.83 0.348 . . . . 0.0 110.843 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -110.16 155.22 16.21 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.521 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -109.92 -50.55 2.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.775 0.321 . . . . 0.0 110.929 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.2 t -64.61 -48.21 75.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.929 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 56.64 27.8 13.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.154 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.421 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 107.35 -27.05 16.61 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.571 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -117.69 138.12 49.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 111.158 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -121.44 109.97 15.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.911 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 17.1 mt-30 61.29 25.17 15.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.091 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.45 -29.27 10.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.571 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.1 tmtt? -79.27 119.15 21.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.864 0.364 . . . . 0.0 110.984 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 17.9 tp60 -82.13 97.09 8.02 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.91 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 80.5 mt -76.85 -43.92 34.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.958 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.421 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.2 p90 -151.46 170.92 18.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.89 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.02 134.45 44.0 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -156.85 165.81 35.15 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -66.92 173.71 3.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -72.68 121.66 20.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 60.38 49.41 6.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.91 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 60.4 m -129.96 -51.65 1.13 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -66.56 142.83 42.99 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.487 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.0 m -151.37 143.67 16.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.834 0.349 . . . . 0.0 111.113 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.5 m-85 -109.74 128.39 55.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.881 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 30.5 m -149.85 154.93 8.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.101 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.52 156.24 33.19 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.092 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -50.89 -47.7 60.55 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.939 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -55.84 -28.58 57.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.545 179.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.2 mmmp? -75.85 -26.32 57.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.727 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 77.7 mt -84.16 137.68 33.4 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.852 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -124.62 108.03 11.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.1 tp -60.91 142.54 56.26 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.88 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 21.5 mt . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.169 179.935 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 31.1 mt . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.819 0.342 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -122.39 -175.75 3.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.924 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.3 t -66.09 135.17 28.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.077 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.75 45.85 7.05 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.514 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -143.62 139.8 16.7 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.64 0.257 . . . . 0.0 110.877 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -74.77 122.8 7.55 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.427 2.085 . . . . 0.0 112.234 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 15.8 m -147.13 138.39 18.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.154 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 20.3 mttm -84.69 133.43 34.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.036 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 18.0 t -114.22 139.57 39.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.106 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -91.16 122.28 33.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.888 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 45.9 mt -104.59 -52.2 2.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.965 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.6 mtt85 -68.45 -175.86 0.7 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.2 p -94.7 70.21 3.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.82 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 81.06 47.54 6.5 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -111.92 -68.8 0.91 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.804 0.335 . . . . 0.0 110.888 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -157.57 163.09 38.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 17.0 mttm -114.72 112.29 22.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.902 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -72.25 133.41 83.42 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.746 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.57 143.95 31.3 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.36 2.04 . . . . 0.0 112.392 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -162.76 156.3 27.95 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.487 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.3 p -95.12 131.47 41.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.346 . . . . 0.0 111.046 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.0 t -65.9 129.75 30.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.039 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 5.1 mmt180 -114.88 -29.92 6.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -147.37 166.65 26.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.883 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.42 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.3 ttp180 -164.38 141.43 6.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.885 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.86 147.99 4.81 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.483 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo . . . . . 0 C--N 1.344 0.299 0 C-N-CA 122.568 2.179 . . . . 0.0 112.336 179.921 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.7 mp . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.878 0.37 . . . . 0.0 111.065 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -95.1 137.13 34.57 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.892 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.42 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 5.3 m-85 -114.59 109.92 18.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.408 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -70.97 118.85 7.73 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.297 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 24.2 t -130.99 131.61 64.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.863 0.363 . . . . 0.0 111.139 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -89.71 116.76 28.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.801 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 91.8 mt -57.14 145.57 30.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.149 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 13.3 mt -90.08 -179.88 5.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.836 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -53.19 -27.83 23.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.145 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -63.1 -54.92 30.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.862 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -116.59 35.65 4.12 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.3 mtt85 -74.69 123.87 25.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.818 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 113.58 25.49 4.28 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.726 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 39.2 mm-40 -135.45 45.72 2.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.847 0.356 . . . . 0.0 110.929 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.62 148.34 18.4 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.47 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 16.3 p90 -109.91 -49.95 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.794 0.33 . . . . 0.0 110.981 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -59.26 -46.2 89.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.0 t0 59.45 26.98 16.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.119 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.21 -25.49 23.92 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.712 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.6 p -114.18 147.92 17.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.809 0.337 . . . . 0.0 111.161 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 31.7 t80 -132.08 110.01 10.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 53.4 mt-30 60.21 29.62 19.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.914 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.49 -28.33 15.98 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.475 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 8.7 tmtt? -79.66 114.58 18.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.792 0.33 . . . . 0.0 110.932 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 24.5 tp60 -71.51 99.64 2.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.942 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 73.0 mt -78.08 -39.05 42.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.413 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -163.71 167.9 20.47 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.86 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 17.4 mm-40 -93.82 129.36 40.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.942 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.64 173.96 12.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.91 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -83.27 167.62 17.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.799 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -66.04 118.35 9.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 60.56 44.34 11.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.946 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 86.8 m -127.61 -55.84 1.31 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.94 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.17 135.42 51.75 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.546 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.1 m -143.73 143.84 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.803 0.335 . . . . 0.0 111.107 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.408 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 3.8 m-85 -109.68 131.48 55.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 20.4 m -155.96 157.72 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.082 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.54 155.12 41.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.999 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 10.2 tp -50.4 -45.8 55.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -57.26 -29.54 63.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.606 179.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 14.2 mttm -77.9 -24.68 48.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.902 179.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 66.6 mt -81.82 158.09 24.2 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -142.99 109.31 5.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.92 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.6 tp -61.8 135.81 57.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.965 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.4 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.052 -179.995 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.407 HG21 HD11 ' A' ' 8' ' ' ILE . 32.1 mt . . . . . 0 N--CA 1.457 -0.096 0 CA-C-O 120.83 0.348 . . . . 0.0 111.109 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -122.51 172.93 8.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.888 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 37.2 t -60.65 133.08 26.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.117 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 85.5 45.14 5.91 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.455 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -145.44 139.26 14.75 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 120.638 0.256 . . . . 0.0 110.908 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -74.17 133.33 17.76 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.486 2.124 . . . . 0.0 112.253 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.2 m -153.83 138.87 10.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.139 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -84.02 131.16 34.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.968 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 16.8 t -113.26 132.4 62.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.102 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.59 116.02 28.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.957 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 36.7 mt -91.56 -57.33 2.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -70.44 -172.11 0.56 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.941 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 t -84.5 79.52 9.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.5 39.04 94.43 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.486 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -95.03 -61.97 1.39 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.858 0.361 . . . . 0.0 110.905 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -155.54 144.58 20.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 21.3 mttt -106.72 124.84 50.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.862 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -87.84 132.59 39.79 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.77 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_endo -73.72 141.64 31.02 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.426 2.084 . . . . 0.0 112.34 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.67 147.83 14.67 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.557 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.9 p -90.47 133.13 33.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.771 0.32 . . . . 0.0 110.984 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.4 t -65.07 136.68 26.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.138 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 13.9 mmm180 -117.68 -38.04 3.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.021 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -143.11 166.27 25.13 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.877 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.427 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.8 ttp180 -159.6 133.84 7.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.81 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 155.3 151.45 5.87 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.511 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 C--N 1.344 0.319 0 C-N-CA 122.56 2.173 . . . . 0.0 112.233 -179.973 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.9 mm . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.827 0.346 . . . . 0.0 111.034 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -114.87 139.38 49.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.427 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 7.6 m-85 -120.85 109.93 15.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -72.06 128.82 14.58 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.414 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.5 t -137.12 136.78 47.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.796 0.331 . . . . 0.0 111.065 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -94.19 115.4 27.67 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 65.2 mt -59.17 130.94 49.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.918 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 12.5 mt -77.5 -179.94 6.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.852 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.05 -29.8 45.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.067 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -61.79 -42.97 99.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.958 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.89 34.46 3.57 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.445 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -75.74 132.54 40.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.864 0.364 . . . . 0.0 110.874 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.04 29.96 6.94 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.524 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -140.97 33.38 1.76 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.802 0.334 . . . . 0.0 110.888 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -99.51 152.67 19.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.529 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -109.98 -50.95 2.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.853 0.358 . . . . 0.0 110.941 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.1 t -66.58 -48.56 69.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.947 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.4 t70 60.36 23.77 13.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.203 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.433 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 103.81 -31.96 8.09 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.671 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -103.7 133.73 46.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.861 0.362 . . . . 0.0 111.199 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -118.95 109.98 16.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.879 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 60.21 28.11 17.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.956 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.37 23.82 25.72 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.596 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 5.6 tttm -132.3 109.95 10.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.861 0.363 . . . . 0.0 110.88 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 11.9 tp60 -69.72 95.56 0.89 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 83.0 mt -82.32 -37.53 25.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.92 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.433 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.5 p90 -149.0 165.45 31.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -98.25 128.36 44.66 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.907 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.39 164.51 32.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.781 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.89 174.24 9.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -62.84 113.17 2.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.888 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 60.33 54.63 3.85 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.858 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 68.7 m -129.57 -56.47 1.14 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.57 140.28 48.08 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.511 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.0 m -156.61 127.84 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.754 0.311 . . . . 0.0 111.157 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -90.4 130.31 36.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.848 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 6.1 m -150.41 164.86 2.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.181 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.87 157.4 22.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.128 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 11.3 tp -50.39 -44.21 54.81 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.848 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -57.39 -28.75 63.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.571 179.698 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 5.2 mtmt -81.4 -26.67 35.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.813 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 83.8 mt -85.42 146.16 27.11 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -133.35 107.89 8.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.925 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 12.4 tp -60.07 121.65 12.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.92 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 1.9 mp . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.162 179.864 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.3 mt . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.799 0.333 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -150.72 -177.83 6.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.3 t -59.71 127.66 19.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.027 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 84.89 43.59 6.7 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.478 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -139.51 139.32 22.12 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.66 0.267 . . . . 0.0 110.923 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -77.38 117.38 4.33 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.516 2.144 . . . . 0.0 112.427 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.7 m -145.67 138.52 20.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.075 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -84.16 141.19 31.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.072 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.9 t -117.29 134.84 59.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.067 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -92.79 110.1 21.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.946 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.419 HD11 ' CE2' ' A' ' 25' ' ' PHE . 71.2 mt -81.5 -47.05 13.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.801 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.53 145.8 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.957 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 30.2 t -74.57 86.75 2.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.958 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.83 67.8 1.44 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.437 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -149.46 -58.46 0.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.833 0.349 . . . . 0.0 110.984 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -175.97 164.09 2.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 40.6 mttt -117.11 160.36 21.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.896 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.422 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 56.6 m-85 -126.4 121.92 23.77 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.822 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.04 140.6 60.66 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.513 2.142 . . . . 0.0 112.4 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.9 158.0 28.99 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.403 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.9 p -99.46 129.21 50.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.868 0.365 . . . . 0.0 111.098 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.5 t -65.4 132.65 31.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.097 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 4.5 mmm180 -116.05 -35.55 4.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.006 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -146.37 169.45 18.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.931 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.423 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 9.6 ttt180 -157.54 120.76 4.01 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.879 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -178.86 146.94 7.53 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.492 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo . . . . . 0 C--N 1.344 0.326 0 C-N-CA 122.603 2.202 . . . . 0.0 112.252 -179.896 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.0 mt . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.758 0.313 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.414 ' HB3' ' CD1' ' A' ' 79' ' ' PHE . 82.8 m-85 -104.67 144.79 31.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.912 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.423 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 6.2 m-85 -119.46 109.93 16.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.87 119.86 8.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.4 t -132.03 133.09 61.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.869 0.366 . . . . 0.0 111.189 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -87.71 116.61 25.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 94.5 mt -60.18 130.41 46.52 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.952 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 mt -78.82 -179.93 6.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.767 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.24 -30.06 48.96 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.057 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -61.43 -41.54 97.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.873 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.422 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -127.5 34.04 3.13 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.445 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 mtt180 -72.88 138.26 46.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.799 0.333 . . . . 0.0 110.868 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.42 29.52 8.79 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.513 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -141.51 43.42 1.75 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.792 0.33 . . . . 0.0 110.898 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -113.18 150.18 18.5 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.525 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 5.6 p90 -110.06 -51.22 2.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.78 0.324 . . . . 0.0 110.879 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 9.3 t -69.72 -48.32 59.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.835 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 53.91 36.22 23.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.09 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.424 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 97.97 -26.15 24.6 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.555 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.0 p -118.51 137.23 53.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.809 0.337 . . . . 0.0 111.104 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 3.1 t80 -122.68 111.13 16.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.945 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 62.18 27.15 16.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.037 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 103.04 -28.43 15.85 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.526 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -79.44 116.63 19.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.871 0.367 . . . . 0.0 110.956 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 21.7 tp60 -80.31 99.5 7.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.417 HD12 ' CE2' ' A' ' 79' ' ' PHE . 88.0 mt -79.21 -44.93 20.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.853 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.424 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.8 p90 -146.81 176.45 9.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.93 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 2.5 mm-40 -99.37 128.6 45.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -152.05 165.59 34.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -80.66 171.94 14.38 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 -68.9 126.21 29.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 59.02 43.79 17.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 37.5 m -129.87 -60.84 1.02 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -58.6 135.66 51.74 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.535 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 22.1 m -148.05 141.28 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.788 0.328 . . . . 0.0 111.131 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.417 ' CE2' HD12 ' A' ' 69' ' ' LEU . 3.0 m-85 -104.99 126.82 52.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.842 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 28.9 m -150.22 164.24 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.105 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.26 158.04 29.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.113 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.6 tp -50.68 -44.41 57.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.867 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -57.42 -29.27 63.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.591 179.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.26 -26.03 42.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.763 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 89.0 mt -82.19 125.04 30.45 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.954 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 5.2 tm-20 -112.05 107.48 16.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.6 tp -60.36 131.19 50.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.906 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 4.9 mt . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.109 -179.999 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 30.8 mt . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.82 0.343 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -144.58 -172.52 3.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.812 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 33.9 t -65.42 144.49 14.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.152 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 68.88 49.11 44.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.506 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -145.89 139.91 15.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 120.662 0.268 . . . . 0.0 111.002 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.09 126.7 8.8 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.544 2.163 . . . . 0.0 112.293 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.3 m -154.04 138.27 9.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.153 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 39.3 mttt -88.32 138.11 31.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.005 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 26.2 t -117.35 141.57 35.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.0 tt0 -103.11 110.03 21.82 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.881 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.1 mt -80.78 -51.07 9.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.02 -169.84 1.72 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.9 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -104.75 87.09 2.59 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.865 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 67.96 56.6 10.38 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.452 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.03 -52.86 1.75 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.36 . . . . 0.0 110.935 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -176.06 139.89 0.39 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.913 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -100.96 122.79 44.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.91 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.419 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 46.6 m-85 -87.67 129.84 49.29 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.821 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_endo -73.0 141.02 32.34 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.503 2.135 . . . . 0.0 112.301 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.47 150.22 20.09 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.51 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.7 p -93.78 133.75 33.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.836 0.35 . . . . 0.0 111.085 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.8 t -67.96 136.23 26.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.11 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -118.86 -38.75 3.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.984 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -139.88 165.98 25.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.412 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 36.9 ttp85 -160.49 127.55 4.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.33 146.56 4.67 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.45 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo . . . . . 0 C--N 1.345 0.356 0 C-N-CA 122.504 2.136 . . . . 0.0 112.325 179.967 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.5 mt . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.835 0.35 . . . . 0.0 111.191 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -119.44 139.96 51.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.412 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 6.5 m-85 -118.56 109.95 16.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.92 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.09 140.9 34.96 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.557 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.9 t -152.37 134.64 6.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.844 0.355 . . . . 0.0 111.109 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -92.62 116.34 28.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 74.7 mt -60.03 136.55 58.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.986 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -81.08 -179.94 7.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -53.8 -30.04 43.19 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.141 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -62.26 -47.48 84.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.847 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.419 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -120.12 35.76 3.67 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.444 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -76.88 133.84 39.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.774 0.321 . . . . 0.0 110.898 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.28 30.26 6.71 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.586 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -140.68 38.84 1.84 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 0.0 110.936 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.57 150.31 17.17 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.456 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 10.5 p90 -109.35 -45.73 3.67 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.747 0.308 . . . . 0.0 110.852 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 8.8 t -71.0 -48.45 53.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.927 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 56.05 28.6 13.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.126 179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.414 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.15 -24.88 28.14 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.702 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -117.59 129.95 73.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.865 0.364 . . . . 0.0 111.151 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 62.4 t80 -114.95 110.01 18.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.946 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 59.37 24.71 13.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.113 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.13 23.66 16.74 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.558 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -125.37 109.81 13.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.89 0.376 . . . . 0.0 110.812 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 17.5 tp60 -71.47 95.25 1.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.906 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 44.1 mt -84.5 -38.09 20.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.0 p90 -152.25 171.54 17.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.843 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -101.01 112.63 25.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -137.85 170.07 16.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.913 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -78.96 172.3 13.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.925 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -72.14 123.4 22.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.922 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 60.34 37.91 19.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.885 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 34.7 m -121.46 -64.61 1.21 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.939 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.14 144.62 44.94 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.502 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 15.3 m -152.41 142.78 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.347 . . . . 0.0 111.201 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -104.24 119.52 39.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.837 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 27.1 m -142.77 163.59 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.239 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -76.31 161.27 28.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.241 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 13.6 tp -51.55 -47.46 63.41 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.912 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -56.5 -27.23 56.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.711 179.719 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -80.91 -5.26 57.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.232 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 43.8 mt -104.58 140.43 38.01 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.894 0.378 . . . . 0.0 111.032 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -122.02 110.16 15.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.802 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.9 tp -59.16 138.52 57.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.05 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 5.3 mt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.037 179.982 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 33.4 mt . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.782 0.325 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -144.77 -177.58 5.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.931 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.3 t -67.04 129.71 31.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.132 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 88.04 43.9 5.53 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.482 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -142.35 140.36 18.95 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.584 0.23 . . . . 0.0 110.893 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.14 118.87 4.83 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.528 2.152 . . . . 0.0 112.366 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.5 m -141.8 138.92 31.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.135 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.01 126.44 33.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.996 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.8 t -102.24 128.81 54.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.997 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -89.31 131.65 35.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.947 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -111.37 -56.84 2.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.812 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -67.65 171.3 6.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.932 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.2 m -72.71 78.4 1.11 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.923 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.17 62.24 6.42 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.535 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -122.44 -65.09 1.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.811 0.339 . . . . 0.0 110.84 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -143.39 162.51 35.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.891 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.5 mttt -127.03 113.06 15.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.887 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -76.89 127.72 83.21 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.823 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -71.32 149.99 58.0 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.452 2.102 . . . . 0.0 112.34 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -170.59 149.93 13.44 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.521 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.7 p -88.36 132.71 32.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.826 0.346 . . . . 0.0 111.072 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.4 t -67.96 132.2 32.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.018 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -114.59 -37.0 4.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.959 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -136.93 166.74 22.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.934 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.415 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -164.36 120.34 1.55 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.882 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.54 154.04 7.56 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.51 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo . . . . . 0 C--N 1.343 0.262 0 C-N-CA 122.616 2.211 . . . . 0.0 112.328 -179.999 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 25.2 mt . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 120.834 0.35 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -124.24 142.59 51.12 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.858 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.415 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 10.4 m-85 -123.92 111.05 15.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.848 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -75.76 117.73 5.24 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.438 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.31 127.22 62.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.811 0.339 . . . . 0.0 111.132 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -84.14 118.84 24.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.913 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 18.8 mt -58.93 139.26 56.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.095 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -84.52 -179.84 7.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.827 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -50.63 -28.8 9.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.188 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.04 -61.56 2.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.854 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -108.58 29.0 10.44 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.459 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt180 -64.76 126.3 27.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.855 0.359 . . . . 0.0 110.933 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.8 36.26 4.31 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.485 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -141.08 32.57 1.75 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.835 0.35 . . . . 0.0 110.924 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -92.47 150.56 20.17 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.485 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -110.04 -33.63 6.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.739 0.304 . . . . 0.0 110.945 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.7 t -83.34 -44.36 14.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.941 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.0 t0 54.93 30.21 13.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.069 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.415 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.44 -28.02 14.92 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.438 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.0 p -115.09 122.99 70.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.749 0.309 . . . . 0.0 111.107 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -108.1 114.11 27.77 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.941 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 43.0 mt-30 59.55 26.08 15.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.057 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.08 24.94 23.48 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.601 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -134.15 109.92 9.23 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.866 0.365 . . . . 0.0 110.89 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -67.3 121.28 15.37 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.876 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 95.3 mt -108.89 -32.38 7.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.415 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -156.71 170.48 22.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.838 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.66 116.93 32.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.803 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 5.0 p -139.55 175.31 9.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.69 170.4 15.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.83 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -66.84 116.39 7.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.932 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 60.79 46.0 9.34 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 65.7 m -125.56 -45.93 1.77 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.896 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -68.85 139.75 33.47 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.541 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.3 m -150.56 131.5 4.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.789 0.328 . . . . 0.0 111.175 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 14.1 m-85 -99.99 119.93 39.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.835 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 29.1 m -142.2 168.77 14.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.124 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -81.56 159.69 24.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.194 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 6.3 tp -50.06 -43.18 51.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.894 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -57.02 -28.06 62.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.595 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -81.79 -27.07 33.89 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.792 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.7 142.41 27.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.922 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -133.43 112.93 11.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.885 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.45 140.09 56.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 6.2 mt . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.063 179.881 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 22.5 mt . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.864 0.364 . . . . 0.0 111.138 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -133.55 -169.27 2.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.846 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 26.1 t -74.28 135.4 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.063 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.32 45.9 7.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.509 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -143.26 136.84 14.21 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 120.561 0.22 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -74.58 118.4 5.31 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.54 2.16 . . . . 0.0 112.327 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 17.9 m -145.66 138.46 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.15 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.0 mtpt -74.36 133.63 42.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.907 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 23.5 t -111.07 139.63 34.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.012 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -98.69 129.45 45.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.6 mt -100.1 -52.46 3.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.35 171.94 10.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 65.2 p -68.27 74.4 0.23 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.837 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.89 66.35 2.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.492 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.8 tt0 -124.79 -47.19 1.82 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.816 0.341 . . . . 0.0 110.921 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -167.27 132.75 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.836 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 4.9 mttt -104.06 129.41 51.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.96 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -96.33 135.05 22.74 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.781 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.82 140.78 35.96 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.432 2.088 . . . . 0.0 112.328 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.85 146.47 10.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.506 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.2 p -85.1 143.06 12.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 111.025 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.2 t -72.99 136.81 24.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.022 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -116.93 -32.45 5.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.21 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 30.8 t80 -150.39 167.84 25.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.8 0.333 . . . . 0.0 111.003 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.426 ' HG3' ' CE2' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -153.38 125.51 7.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.923 179.924 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.62 158.0 18.31 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.473 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo . . . . . 0 C--N 1.344 0.325 0 C-N-CA 122.479 2.119 . . . . 0.0 112.301 -179.98 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.5 mt . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.838 0.351 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -103.24 174.01 6.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.947 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.426 ' CE2' ' HG3' ' A' ' 32' ' ' ARG . 28.6 m-85 -145.89 109.93 4.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.9 118.35 8.14 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.457 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.0 t -126.37 140.08 49.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.743 0.306 . . . . 0.0 111.069 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -99.19 114.47 27.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.866 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 34.4 mt -57.49 138.27 55.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.038 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.8 mt -80.41 -179.9 7.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.802 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -54.48 -29.96 51.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.046 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -61.14 -60.46 3.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.816 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -103.26 28.5 15.42 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.488 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -67.67 131.06 44.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 110.919 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.55 33.57 4.42 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.522 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -140.25 34.54 1.89 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.85 0.357 . . . . 0.0 110.916 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.1 146.52 16.09 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.49 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 32.3 p90 -109.88 -49.23 3.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.749 0.309 . . . . 0.0 110.912 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.9 t -63.51 -48.49 77.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.898 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 55.38 29.96 14.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.083 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.423 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 98.35 -28.78 13.24 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.35 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -110.72 128.24 67.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.864 0.364 . . . . 0.0 111.102 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -116.29 112.02 20.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.946 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 58.95 26.93 15.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.103 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.93 21.35 33.64 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.564 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 3.4 tptp -126.46 109.82 12.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.834 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 18.4 tp60 -68.08 89.99 0.31 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.856 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 16.8 mt -78.16 -42.29 32.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.888 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.423 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.0 p90 -151.15 169.52 21.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.918 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.43 134.22 40.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.918 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -159.49 165.57 32.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -72.26 176.24 5.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.89 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -75.2 120.97 21.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 60.7 47.63 7.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.971 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 84.8 m -130.03 -58.8 1.07 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.851 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.3 139.63 48.54 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.616 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 27.3 m -151.54 125.68 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 111.049 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -89.45 127.86 35.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.952 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 31.0 m -148.65 157.89 7.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.079 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.02 156.99 38.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.101 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 6.6 tp -51.17 -46.55 62.13 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -56.88 -28.86 62.37 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.651 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 17.1 mmtt -77.78 -24.27 48.94 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.879 179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 62.1 mt -83.48 151.59 25.36 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.989 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -135.37 105.86 6.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.839 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 16.8 tp -61.09 133.8 56.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.975 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 28.0 mt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.12 180.0 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 19.7 mt . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.5 -176.94 3.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.903 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.3 t -66.43 138.69 22.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.018 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.65 38.63 13.7 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.552 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.12 139.4 31.73 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-O 120.658 0.266 . . . . 0.0 110.929 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.3 118.5 5.21 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.548 2.165 . . . . 0.0 112.304 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.4 m -144.76 138.5 22.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.209 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 35.6 mttt -77.87 126.33 30.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.934 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 26.3 t -105.46 137.68 34.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.049 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -99.06 112.24 24.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.915 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 88.4 mt -73.77 -58.4 3.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.95 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 8.0 ttt-85 -83.96 168.91 15.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.888 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.8 m -80.13 61.07 3.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.852 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 103.61 64.22 0.69 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.499 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -130.0 -66.4 0.79 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.782 0.325 . . . . 0.0 110.883 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -164.96 130.04 2.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.2 mttt -95.33 111.45 23.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.918 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.409 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 38.4 m-85 -86.56 138.87 33.56 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.759 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -68.79 148.85 72.11 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.496 2.13 . . . . 0.0 112.43 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.83 148.05 11.47 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.519 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.9 p -88.76 132.45 33.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.79 0.328 . . . . 0.0 111.142 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.6 t -66.18 135.17 28.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.114 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -118.28 -36.09 3.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -141.16 166.0 25.99 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.917 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.429 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 5.1 ttt180 -158.7 114.91 2.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.875 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.46 145.46 5.63 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.447 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo . . . . . 0 C--N 1.345 0.391 0 C-N-CA 122.527 2.152 . . . . 0.0 112.287 179.992 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 35.4 mt . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.761 0.315 . . . . 0.0 111.11 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 14.5 m-85 -91.08 144.97 25.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.843 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.429 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 6.4 m-85 -119.34 123.88 45.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.996 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -87.48 131.5 10.64 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.323 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.7 t -139.37 127.5 26.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.758 0.313 . . . . 0.0 111.209 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -85.89 116.66 24.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.764 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 60.1 mt -55.98 140.32 43.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.19 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -87.55 -179.89 6.42 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.85 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -51.97 -29.71 21.74 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.207 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -60.24 -51.34 69.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.889 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.409 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -122.31 38.96 2.42 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.468 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.6 ttt180 -76.52 133.15 39.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.843 0.354 . . . . 0.0 110.931 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.57 23.36 8.9 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.681 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 -130.75 45.37 2.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.861 0.362 . . . . 0.0 110.818 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -107.86 148.45 16.62 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.576 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -110.05 -47.98 3.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.771 0.32 . . . . 0.0 110.908 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.4 t -65.29 -44.84 86.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.994 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.3 t0 57.28 30.6 18.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.061 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.43 -28.17 14.33 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.426 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.8 p -113.47 125.02 70.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.819 0.342 . . . . 0.0 111.063 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 51.7 t80 -111.25 110.09 20.42 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 58.46 28.45 16.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.084 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.28 24.38 22.04 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.492 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.8 tptt -131.55 109.89 10.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.795 0.331 . . . . 0.0 110.805 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 15.3 tp60 -71.07 89.92 0.83 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.939 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 9.0 mt -75.24 -30.73 60.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.915 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -161.89 166.98 25.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -103.28 119.21 38.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.897 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 6.8 p -144.28 176.26 9.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.959 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -72.16 176.21 5.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.9 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -75.59 119.71 20.01 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 60.72 36.5 19.38 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.918 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 86.6 m -118.21 -38.98 3.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.952 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -79.09 146.87 29.77 Favored Glycine 0 N--CA 1.452 -0.233 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.473 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 5.2 m -159.4 134.4 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.842 0.353 . . . . 0.0 111.072 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -96.71 138.9 33.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.874 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 29.1 m -156.19 166.46 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.122 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.29 164.65 17.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.203 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -52.15 -50.51 61.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.841 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -57.14 -28.28 62.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.643 179.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 12.3 mmtt -79.65 -25.11 41.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.835 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 62.6 mt -84.25 159.64 20.93 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.874 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -142.22 101.51 3.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.82 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.9 143.39 51.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.983 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 22.4 mt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.101 179.944 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.183 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 m -135.0 64.97 1.58 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.924 0.392 . . . . 0.0 110.865 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 37.5 m -82.04 -31.47 30.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 131.02 43.14 0.19 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.536 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.3 m -127.06 -67.06 0.86 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.848 0.356 . . . . 0.0 110.982 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 18.6 m 60.17 -172.89 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.927 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 161.97 103.56 0.18 Allowed Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.521 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 19.4 mt -102.12 137.14 31.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.85 0.357 . . . . 0.0 111.048 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -140.0 179.58 6.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.3 t -60.3 129.18 22.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 86.28 43.93 6.08 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.476 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -144.21 137.04 13.66 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.635 0.255 . . . . 0.0 110.929 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.22 132.31 12.47 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.466 2.111 . . . . 0.0 112.324 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.7 m -155.55 145.79 12.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.211 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 59.4 mttt -81.34 127.43 32.73 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.89 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.2 t -109.98 131.03 62.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.08 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -97.02 113.62 25.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.881 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 58.7 mt -82.03 -44.27 16.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.91 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -98.33 179.29 4.78 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.931 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.8 m -82.4 87.77 6.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.922 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.43 54.91 30.66 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.54 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -115.37 -50.01 2.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.929 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 17.5 tt0 -176.62 126.87 0.18 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.1 mttt -96.03 116.68 29.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.826 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.415 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 30.0 m-85 -86.92 131.48 44.87 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -73.42 145.52 38.23 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.478 2.119 . . . . 0.0 112.265 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.3 154.59 24.59 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.605 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -91.65 135.53 26.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.798 0.333 . . . . 0.0 111.0 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.0 t -65.17 132.26 30.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.196 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -113.5 -30.13 6.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.045 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -152.8 168.35 26.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.878 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.425 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 16.2 ttt-85 -155.81 123.95 5.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.847 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.64 142.47 3.71 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.465 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -56.67 -173.16 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.492 2.128 . . . . 0.0 112.252 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.425 HD11 ' CG ' ' A' ' 45' ' ' PHE . 96.2 mt -148.57 -61.29 0.24 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 9.8 mp -83.16 -178.41 7.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.89 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -152.06 92.5 1.72 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.132 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 59.32 33.06 22.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.973 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 3.1 mtm180 -103.85 -31.46 9.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.839 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 37.4 m -141.09 -61.49 0.48 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.903 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.0 p -156.46 138.96 6.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.095 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 13.9 m -80.73 94.64 6.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -148.99 134.93 5.18 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.567 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.1 mt -75.49 130.23 36.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.793 0.33 . . . . 0.0 111.053 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.425 ' CG ' HD11 ' A' ' 35' ' ' LEU . 65.0 m-85 -86.47 136.1 33.22 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.917 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.425 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 10.8 m-85 -115.66 111.89 21.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.95 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -71.47 119.64 7.87 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.382 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.8 t -129.86 136.69 58.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.77 0.319 . . . . 0.0 110.978 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -92.34 119.1 31.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 19.5 mt -59.07 133.91 56.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.981 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.7 -179.9 7.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.816 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.7 -29.52 39.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.062 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -63.35 -55.01 28.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.831 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.415 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -110.87 32.24 6.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.413 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 8.3 ttt180 -68.72 135.6 51.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 110.98 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 94.02 37.35 5.46 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 64.0 mm-40 -140.89 33.25 1.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.843 0.354 . . . . 0.0 110.948 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -102.51 145.74 16.56 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.48 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 7.6 p90 -109.94 -50.58 2.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.322 . . . . 0.0 110.972 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.5 t -62.77 -41.84 99.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.911 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 11.4 t70 60.02 30.45 19.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.988 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.415 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 94.26 -17.3 59.18 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.753 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.9 p -119.15 138.8 48.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.828 0.347 . . . . 0.0 111.18 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.409 ' CZ ' HD13 ' A' ' 35' ' ' LEU . 7.1 t80 -130.14 110.05 11.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.814 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 61.77 28.66 17.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.955 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 100.01 -27.78 18.7 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.568 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -80.27 114.65 19.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.789 0.328 . . . . 0.0 111.018 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 28.6 tp60 -81.36 92.11 6.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.903 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.405 HD13 ' CZ ' ' A' ' 79' ' ' PHE . 48.1 mt -70.46 -46.61 63.48 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.972 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.415 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.5 p90 -144.24 168.96 18.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.945 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.85 130.1 55.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.892 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 1.2 m -149.93 172.06 15.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.905 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -68.78 -179.98 1.6 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -71.65 121.14 18.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.944 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 60.81 51.57 4.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.878 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 27.4 m -130.1 -46.75 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.994 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -67.17 141.71 39.92 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.612 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 20.7 m -156.99 141.14 7.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.361 . . . . 0.0 111.112 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.405 ' CZ ' HD13 ' A' ' 69' ' ' LEU . 5.7 m-85 -110.42 134.14 52.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 18.4 m -156.9 156.6 4.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.083 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.53 154.34 42.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.062 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 6.5 tp -50.37 -43.86 54.47 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.917 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -56.57 -28.0 59.22 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.576 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.7 mttm -79.61 -27.11 41.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.787 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 92.6 mt -80.73 152.45 28.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.904 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -124.91 108.37 11.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.855 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 20.1 tp -59.88 124.31 19.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 31.1 mt -112.05 138.61 40.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.112 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -65.73 141.46 58.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.895 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 9.4 t -98.4 35.45 1.79 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.866 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -139.53 66.13 0.52 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.541 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.27 -41.68 64.64 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.573 2.182 . . . . 0.0 112.28 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 81.0 p -102.59 117.91 35.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.853 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 82.2 p -148.95 127.47 12.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.947 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.34 -1.255 . . . . 0.0 112.511 -179.992 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.235 0 N-CA-C 112.529 -0.228 . . . . 0.0 112.529 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -140.97 157.07 45.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.858 0.361 . . . . 0.0 110.859 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.2 100.98 0.66 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.929 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 105.33 159.13 23.1 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.496 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.6 m -160.84 145.13 13.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.77 0.319 . . . . 0.0 110.895 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.5 m -79.33 -77.62 0.17 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.894 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 112.85 103.74 2.65 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.457 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 27.0 mt -87.07 145.89 7.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.814 0.34 . . . . 0.0 111.099 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -155.16 -177.8 6.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.826 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 37.7 t -61.7 124.23 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.085 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.14 42.34 5.3 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.437 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -138.95 138.81 21.88 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.623 0.249 . . . . 0.0 110.95 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -77.37 117.56 4.38 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.502 2.134 . . . . 0.0 112.398 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.0 m -146.8 138.47 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.117 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.9 mttm -81.37 156.88 25.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.992 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.2 t -133.3 127.23 53.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.041 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -88.49 124.06 33.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.878 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 40.2 mt -102.92 -40.13 6.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -85.59 179.88 7.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.812 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 64.7 m -95.61 79.83 3.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 73.12 49.87 14.65 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.525 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -116.73 -69.51 0.85 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.757 0.313 . . . . 0.0 110.867 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -161.93 138.3 7.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.867 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 13.2 mttt -95.67 146.13 24.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -106.0 127.74 27.78 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.788 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.28 137.84 34.83 Favored 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.461 2.107 . . . . 0.0 112.348 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.92 174.96 29.24 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.512 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.3 p -120.38 125.66 74.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.827 0.346 . . . . 0.0 111.017 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.4 t -59.27 123.55 11.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.164 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.5 mmt180 -112.07 -31.91 6.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.889 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -144.62 166.26 25.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.412 ' HD3' ' CE2' ' A' ' 46' ' ' PHE . 38.5 ttp85 -156.77 124.3 5.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.842 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 166.6 145.17 4.36 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.419 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.72 -176.98 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.511 2.14 . . . . 0.0 112.356 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.418 HD23 ' CE2' ' A' ' 64' ' ' TYR . 19.4 mt -95.73 -63.58 1.14 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.838 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -90.49 -174.8 4.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.774 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -121.32 31.32 6.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.083 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 53.5 mm-40 -80.45 157.27 26.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.933 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 18.0 mtt180 -66.75 -31.83 72.73 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.86 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.8 t -103.5 117.35 34.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.91 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.0 p -131.38 145.75 34.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.044 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.8 p -74.53 -38.63 62.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.81 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -179.99 173.07 44.66 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.478 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 13.8 mm -87.17 148.8 4.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.834 0.349 . . . . 0.0 111.076 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -104.36 121.35 43.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.412 ' CE2' ' HD3' ' A' ' 32' ' ' ARG . 13.6 m-85 -101.55 119.11 38.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.964 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.402 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -83.85 117.74 4.52 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.428 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.5 t -122.84 131.99 72.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.808 0.337 . . . . 0.0 111.092 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -85.18 117.73 24.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.885 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 14.0 mt -60.24 134.87 57.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.937 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 16.5 mt -80.01 -179.96 7.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.863 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -54.36 -29.66 49.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.05 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -60.36 -51.33 69.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.855 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -117.95 35.39 4.08 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.378 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -73.59 145.86 45.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 0.0 110.901 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.4 27.99 28.7 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.466 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -134.17 31.04 3.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.842 0.354 . . . . 0.0 110.89 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.17 149.81 18.46 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.519 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 13.4 p90 -109.94 -49.88 3.04 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.737 0.303 . . . . 0.0 110.928 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.0 t -62.21 -48.25 80.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.856 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 58.17 37.04 26.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.97 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.423 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.94 -24.09 32.72 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.512 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.8 p -119.43 132.03 70.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.786 0.327 . . . . 0.0 111.132 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.418 ' CE2' HD23 ' A' ' 35' ' ' LEU . 0.3 OUTLIER -118.55 113.62 21.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.815 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 60.08 28.7 18.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.976 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.07 -24.08 32.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.571 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.95 114.07 21.43 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.821 0.343 . . . . 0.0 110.989 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 6.9 tp60 -78.47 116.42 18.86 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.855 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 72.1 mt -98.92 -37.71 9.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.879 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.423 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 1.8 p90 -154.41 172.68 17.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.93 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -105.29 111.44 24.17 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.001 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . 0.401 ' HB2' ' CE2' ' A' ' 70' ' ' PHE . 0.5 OUTLIER -127.44 167.88 15.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.907 179.933 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.8 175.27 3.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.911 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -72.53 117.89 14.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.924 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 60.83 49.5 6.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.841 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 28.5 m -130.0 -49.97 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.912 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -67.06 146.23 47.66 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.531 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 25.8 m -156.78 142.23 9.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.778 0.323 . . . . 0.0 111.179 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.402 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 14.8 m-85 -109.89 131.89 54.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.917 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 30.6 m -152.61 158.05 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.112 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.94 156.61 38.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.132 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 12.9 tp -51.15 -45.41 61.68 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -57.07 -28.22 62.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.638 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -81.17 -27.02 35.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.865 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 84.9 mt -84.11 130.28 34.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.902 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 57.0 tt0 -113.78 114.01 25.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.899 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.5 tp -63.48 142.68 58.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.893 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 20.6 mt -95.51 146.82 6.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.094 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -112.63 159.42 18.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.8 t 56.28 96.38 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.961 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -77.55 163.83 51.77 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.467 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.27 -61.47 0.5 Allowed 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.596 2.198 . . . . 0.0 112.325 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.2 m -98.89 88.5 4.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.931 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.4 p -129.94 131.96 46.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.923 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.399 -1.223 . . . . 0.0 112.48 -179.992 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.201 0 N-CA-C 112.527 -0.229 . . . . 0.0 112.527 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 m -84.57 -32.36 23.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.749 0.309 . . . . 0.0 110.827 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 33.7 t -143.79 157.86 44.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.932 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -111.65 -156.46 13.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.519 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.9 m -147.98 145.43 28.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.775 0.321 . . . . 0.0 110.95 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.8 m -117.76 -171.35 2.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.956 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.97 114.64 1.12 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.429 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 5.2 mt -122.09 138.84 50.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.767 0.318 . . . . 0.0 111.04 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -131.78 -177.94 4.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.927 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.9 t -67.53 135.67 28.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.141 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.38 46.25 7.57 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.451 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -145.09 145.75 28.23 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 120.757 0.313 . . . . 0.0 110.962 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.09 130.02 12.79 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.579 2.186 . . . . 0.0 112.269 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.8 m -158.02 138.51 4.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.14 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 47.1 mttm -79.23 140.45 37.65 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.05 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 18.4 t -115.91 135.87 54.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.062 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -97.25 110.07 22.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.857 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 83.0 mt -84.99 -56.26 3.65 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.97 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -75.06 171.99 13.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.944 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.4 m -78.01 80.26 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.885 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.62 55.49 26.84 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -120.45 -58.16 1.86 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 110.838 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -154.08 151.92 29.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.818 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -121.49 135.8 55.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.424 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 37.8 m-85 -106.11 136.49 19.32 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.838 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -73.09 143.22 35.64 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.438 2.092 . . . . 0.0 112.431 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.98 156.58 27.98 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.526 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -95.52 126.52 48.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.771 0.32 . . . . 0.0 111.044 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.6 t -59.87 135.84 24.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.119 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -119.46 -38.41 3.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.01 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.412 ' CD2' ' HB3' ' A' ' 69' ' ' LEU . 23.4 t80 -140.82 169.09 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.889 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 3.5 ttt180 -160.94 124.34 3.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.905 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 165.54 144.97 4.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.478 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -73.34 177.68 7.59 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.537 2.158 . . . . 0.0 112.349 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 60.9 mt -124.1 -66.52 0.98 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.838 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -169.47 -178.08 2.98 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.831 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.03 178.51 5.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.055 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -137.03 -70.28 0.45 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.904 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.5 mmt85 -145.45 -46.83 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.978 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.6 m -161.07 35.42 0.14 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.926 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 12.2 p -130.37 135.99 59.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.054 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.3 t -141.02 116.12 9.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.951 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -157.43 157.95 28.56 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.527 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.5 mt -94.37 136.65 25.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.763 0.316 . . . . 0.0 111.077 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -90.37 128.57 36.51 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.921 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.417 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 4.8 m-85 -111.74 109.9 19.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.875 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.46 122.68 11.01 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.344 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.9 t -137.9 130.94 41.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.805 0.336 . . . . 0.0 111.092 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -86.39 121.02 28.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.857 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 30.9 mt -60.45 141.27 56.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.049 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 13.3 mt -88.77 -179.88 6.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.83 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.06 -27.24 43.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.18 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -64.92 -41.57 95.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.966 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.424 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -132.13 38.67 1.86 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.47 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -74.31 161.33 29.99 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.851 0.358 . . . . 0.0 110.859 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.0 29.82 68.56 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.5 mm100 -135.86 34.14 2.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.816 0.341 . . . . 0.0 110.927 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.4 147.67 16.86 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.499 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -109.85 -47.78 3.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.813 0.34 . . . . 0.0 110.813 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.4 t -62.2 -47.93 82.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.943 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 59.76 32.53 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.964 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.433 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.1 -24.82 28.32 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.564 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.7 p -120.85 133.28 68.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.864 0.364 . . . . 0.0 111.133 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 12.5 t80 -116.88 110.4 18.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.852 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 13.3 mt-30 60.45 31.01 20.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 98.04 -26.61 22.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.55 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.9 tptm -75.15 110.72 9.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.797 0.332 . . . . 0.0 110.904 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 24.2 tp60 -79.83 95.24 5.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.835 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.412 ' HB3' ' CD2' ' A' ' 31' ' ' PHE . 75.4 mt -81.65 -36.56 28.69 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.989 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.433 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.7 p90 -156.38 166.94 31.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.957 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -102.4 116.08 31.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.909 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -132.27 176.34 8.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.914 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -79.39 -179.94 7.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -77.69 121.35 23.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 59.7 48.04 9.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.005 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 26.6 m -129.93 -58.34 1.08 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.902 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -62.71 149.6 48.82 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.419 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 15.3 m -158.0 146.54 9.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.873 0.368 . . . . 0.0 111.15 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -108.95 131.8 54.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 13.2 m -151.01 160.35 3.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.073 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.86 153.46 36.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.054 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 11.0 tp -49.73 -44.3 48.32 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.904 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.9 t0 -58.27 -30.96 66.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.602 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 9.6 mtmt -78.08 -25.3 47.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.837 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 32.9 mt -81.7 130.87 35.21 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.849 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.14 105.21 14.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.963 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 27.3 tp -62.14 139.59 58.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 16.0 mt -102.26 128.04 55.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.074 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -120.96 -176.34 3.24 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.892 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 60.3 p -78.9 -34.32 44.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.873 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -67.24 146.12 47.19 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.503 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.59 142.84 33.26 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.582 2.188 . . . . 0.0 112.354 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 59.61 172.63 0.08 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.94 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -152.55 119.0 5.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.342 -1.255 . . . . 0.0 112.507 179.95 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.247 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -170.36 126.94 0.8 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.816 0.341 . . . . 0.0 110.911 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.4 m -135.38 128.23 31.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.887 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.25 75.81 0.19 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.486 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 83.3 p -119.33 -68.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.804 0.335 . . . . 0.0 110.912 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -155.27 -45.89 0.08 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.94 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 76.17 105.02 0.13 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.516 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 31.4 mt -112.3 128.68 68.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.851 0.358 . . . . 0.0 111.063 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 54.2 m-20 -124.75 -174.91 3.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.4 t -65.14 136.88 25.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.037 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.19 46.56 6.94 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.475 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -140.49 136.89 17.0 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.618 0.247 . . . . 0.0 110.908 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -76.47 117.03 4.45 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.45 2.1 . . . . 0.0 112.308 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.3 m -141.99 138.3 30.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.154 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 30.3 mttp -81.4 132.46 35.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.6 t -113.3 131.71 64.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.047 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -87.07 112.94 22.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 15.0 mt -93.83 -44.98 7.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.19 179.59 7.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.3 p -75.24 76.51 2.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.9 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.4 35.2 84.17 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.489 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.92 -62.42 1.47 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.802 0.334 . . . . 0.0 110.895 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.22 142.25 19.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.915 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 18.3 mttm -98.26 115.56 28.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.782 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -75.71 128.12 84.32 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.831 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -73.05 139.35 29.66 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.423 2.082 . . . . 0.0 112.311 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.49 157.91 29.62 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.614 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.1 p -95.86 136.05 28.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.774 0.321 . . . . 0.0 111.01 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.9 t -70.0 130.69 34.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.078 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.412 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 24.9 mmt180 -114.52 -29.42 6.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.209 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -148.49 167.2 25.97 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.881 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.416 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 7.2 ttp180 -162.93 131.73 4.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.857 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.27 150.28 5.66 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.572 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -55.68 160.31 9.75 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.613 2.209 . . . . 0.0 112.333 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.414 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 10.3 mt -121.02 -55.41 1.98 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.801 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.8 mt -143.0 151.42 40.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.808 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -143.62 33.03 1.29 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -110.07 110.16 20.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.89 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 6.8 mtm180 60.26 32.6 20.84 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.808 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.6 t -166.41 136.89 3.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.935 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 12.2 p -125.11 128.81 73.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.135 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.25 -48.15 0.2 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.944 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 123.72 -145.54 16.04 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.515 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 4.2 mp -92.62 128.29 44.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.797 0.332 . . . . 0.0 111.089 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.414 ' CE1' ' HB2' ' A' ' 35' ' ' LEU . 66.1 m-85 -82.95 139.24 33.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.869 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.416 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 7.6 m-85 -117.93 113.66 22.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.986 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -78.21 117.49 4.68 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 20.2 t -123.49 143.37 36.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.766 0.317 . . . . 0.0 111.09 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -97.72 115.0 27.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.93 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.9 mt -59.07 128.29 36.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.032 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.2 mt -80.54 -179.93 7.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.867 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -54.85 -29.28 54.77 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.067 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.99 -41.81 99.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.892 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.04 34.64 3.05 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.563 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.9 ttt180 -71.99 144.59 48.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.773 0.321 . . . . 0.0 110.926 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 90.2 31.02 11.2 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.464 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -137.12 32.57 2.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.847 0.356 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.28 143.52 15.67 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.443 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.6 p90 -109.99 -47.92 3.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.824 0.345 . . . . 0.0 110.991 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -66.47 -42.81 86.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.973 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.1 t0 60.03 29.2 18.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.088 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 85.55 26.25 36.34 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.61 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -164.04 133.29 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.775 0.322 . . . . 0.0 111.123 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 17.9 t80 -123.76 117.09 24.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 61.27 29.16 18.52 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.869 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.71 -26.86 21.44 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.547 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 22.2 tptt -76.87 111.93 12.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.84 0.352 . . . . 0.0 110.879 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 10.9 tp60 -80.99 108.4 14.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.841 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 44.9 mt -86.63 -31.16 21.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.046 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.412 ' CD2' ' HB2' ' A' ' 30' ' ' ARG . 7.1 p90 -161.35 163.2 30.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -99.0 132.63 44.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.939 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -150.48 170.61 18.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.808 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -70.24 179.96 2.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.806 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -74.35 118.71 17.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 61.17 52.06 4.11 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.97 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 36.1 m -130.06 -51.79 1.12 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.967 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -64.17 138.05 41.1 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.519 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 17.7 m -150.29 140.35 16.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.761 0.315 . . . . 0.0 111.207 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -104.13 122.4 45.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.838 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 4.5 m -145.85 164.73 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.208 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -76.68 155.94 32.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.189 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 13.2 tp -50.42 -40.84 51.29 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.737 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.8 t0 -58.45 -29.97 66.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.55 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.1 mmtt -78.83 -23.41 45.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.866 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 78.7 mt -82.75 143.59 30.77 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.93 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -130.29 97.59 4.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.814 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 19.6 tp -58.69 130.72 48.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.969 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 18.7 mt -82.97 151.71 4.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.091 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -114.03 139.24 49.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.928 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.5 p -72.72 110.6 7.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -107.15 144.27 15.9 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.504 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo -74.0 167.65 26.7 Favored 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.572 2.181 . . . . 0.0 112.32 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 23.2 t -80.28 129.11 34.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.916 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.1 m -140.2 122.95 16.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.899 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.438 -1.201 . . . . 0.0 112.464 -179.971 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.182 0 N-CA-C 112.577 -0.209 . . . . 0.0 112.577 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.2 m -127.9 31.68 5.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.757 0.313 . . . . 0.0 110.836 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -109.51 130.12 55.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.934 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -70.22 -174.68 15.27 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.533 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 42.3 t -67.18 -42.59 83.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.833 0.349 . . . . 0.0 110.948 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -166.73 172.3 10.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.904 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.5 -42.48 3.4 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.479 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.5 mt -103.29 139.83 23.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.824 0.345 . . . . 0.0 111.142 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -131.72 173.03 11.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.783 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.2 t -59.65 141.81 15.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.102 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 73.35 48.39 19.06 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.45 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -145.06 141.52 17.34 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.69 0.281 . . . . 0.0 110.954 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.87 121.81 6.45 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.622 2.215 . . . . 0.0 112.418 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.7 m -153.2 138.36 10.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.101 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.3 mttt -75.01 138.03 41.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.949 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 18.6 t -119.17 136.02 57.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.12 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -90.84 112.62 24.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.972 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 23.3 mt -83.62 -66.27 0.91 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -73.77 172.83 10.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.874 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -76.1 85.76 2.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 61.74 54.09 38.26 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.443 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -112.5 -61.52 1.71 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.798 0.333 . . . . 0.0 110.849 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -162.78 133.09 4.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -95.23 121.9 37.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.858 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.406 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 50.0 m-85 -97.96 142.15 24.12 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.819 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.16 148.37 55.94 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.463 2.109 . . . . 0.0 112.36 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -167.24 154.42 24.7 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.509 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -98.36 127.15 51.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.834 0.349 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.2 t -59.98 131.91 24.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.999 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -116.41 -30.64 5.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.181 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -146.79 166.0 27.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.866 0.365 . . . . 0.0 111.005 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.1 ttp180 -165.79 141.28 4.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.831 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 142.73 134.75 2.96 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.548 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -55.27 158.55 11.93 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.508 2.139 . . . . 0.0 112.245 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 61.6 mt -105.55 -56.9 2.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.795 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -108.21 143.48 36.98 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.784 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -146.26 48.02 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.075 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -177.68 -40.59 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.951 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 9.7 mpt_? -77.14 65.25 2.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.911 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 65.9 m 62.87 -78.95 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.021 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.0 m -56.91 142.47 12.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.212 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.3 t -168.73 109.75 0.51 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -160.86 156.96 28.41 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.568 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.7 mt -82.42 119.66 32.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.828 0.347 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -100.09 149.85 23.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.978 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.421 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 12.6 m-85 -127.8 116.98 21.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.925 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.66 120.67 5.27 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.41 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.5 t -133.6 129.2 55.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.868 0.366 . . . . 0.0 111.134 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -84.28 121.32 27.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.896 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 5.2 mt -59.99 150.23 29.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -96.71 -179.86 4.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.876 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -52.66 -30.02 29.56 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.143 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -62.86 -44.1 97.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.811 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.406 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -124.63 36.4 2.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.453 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt180 -75.48 140.49 42.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.898 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.8 29.85 11.27 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.518 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 48.4 mm-40 -137.21 36.25 2.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.41 142.43 15.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.576 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -105.65 -45.83 4.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.778 0.323 . . . . 0.0 110.864 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -63.38 -44.02 95.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.969 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.1 t0 57.72 33.73 23.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.928 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.423 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.72 -24.84 27.76 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.533 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.1 p -113.0 135.35 52.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.8 0.334 . . . . 0.0 111.098 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 4.0 t80 -116.82 110.43 18.36 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 77.6 mt-30 60.25 30.88 20.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.841 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.96 -26.3 23.96 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.604 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -81.85 114.11 20.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 110.968 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 31.7 tp60 -74.68 98.76 3.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.813 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 55.3 mt -79.79 -40.46 28.61 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.938 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.423 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -152.64 175.01 13.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.994 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.39 113.97 24.47 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 11.9 p -131.0 -180.0 5.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.01 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -65.65 179.95 0.76 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.96 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.12 118.84 22.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.034 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 59.56 50.04 7.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.023 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 43.1 m -129.98 -45.54 1.15 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.983 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -60.91 146.39 47.53 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.563 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 16.1 m -157.63 138.3 4.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.731 0.301 . . . . 0.0 111.074 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -109.23 127.73 54.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.93 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 31.0 m -150.22 165.68 2.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.117 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.15 156.9 35.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.058 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 11.0 tp -49.55 -43.88 46.21 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.893 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -57.01 -29.85 63.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.55 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 12.5 mmtt -76.43 -25.64 54.64 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.814 179.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 79.2 mt -90.39 137.69 32.15 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.911 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.2 tm-20 -111.65 109.1 18.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 23.8 tp -64.56 128.24 34.92 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.965 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 22.1 mt -88.81 139.79 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.07 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -101.26 136.28 41.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.969 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.3 -41.32 2.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.831 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.402 ' N ' ' CD ' ' A' ' 92' ' ' PRO . . . 90.87 51.87 2.55 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.604 180.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 91' ' ' GLY . 57.0 Cg_endo -70.92 -178.51 2.82 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.536 2.158 . . . . 0.0 112.29 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -177.01 152.33 0.9 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.964 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 54.4 p -85.81 171.06 11.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.142 0 CA-C-O 118.456 -1.191 . . . . 0.0 112.49 -179.987 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.1 m -154.38 155.68 35.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 0.0 110.88 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 t -164.54 -177.6 4.92 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.832 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.85 166.59 20.73 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.497 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.8 t -149.48 104.12 3.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.871 0.367 . . . . 0.0 110.881 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.6 m -89.38 -177.59 5.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.925 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.61 -92.03 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.461 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 23.1 mt -89.52 147.62 5.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.82 0.343 . . . . 0.0 111.092 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -156.84 -172.14 3.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.846 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 t -60.67 136.83 23.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.212 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 75.03 46.58 15.93 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.59 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 3.0 t -144.32 131.74 10.49 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.604 0.24 . . . . 0.0 110.969 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.08 122.97 6.97 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.479 2.119 . . . . 0.0 112.386 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.6 m -148.48 138.86 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.0 mttt -76.17 139.46 41.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.902 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.28 141.67 36.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.115 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -98.84 115.7 29.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.932 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 39.9 mt -98.39 -59.74 1.69 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 19.0 mtt85 -60.35 168.54 2.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.869 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.9 p -74.3 75.75 1.85 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.82 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.26 55.7 26.27 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.537 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -119.51 -67.25 1.0 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -147.9 154.51 40.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -112.31 152.09 28.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.865 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -116.69 135.63 23.0 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -73.01 140.32 31.26 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.477 2.118 . . . . 0.0 112.312 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.79 148.51 16.06 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.635 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.3 p -89.83 140.66 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.737 0.303 . . . . 0.0 110.979 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.9 t -72.34 131.17 35.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.098 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 5.8 mmm180 -112.83 -30.8 6.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.126 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -152.5 167.41 28.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.907 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.41 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 0.0 OUTLIER -154.72 130.04 9.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.755 179.931 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.33 151.12 6.14 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.507 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.04 -177.95 1.86 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.61 2.207 . . . . 0.0 112.29 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.418 HD11 ' CE1' ' A' ' 64' ' ' TYR . 4.7 mt -117.66 -50.04 2.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.924 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.5 mt -118.04 -179.51 3.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . 60.66 79.01 0.26 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.134 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -85.6 -31.61 22.52 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 8.2 mmm180 -74.92 -33.13 61.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.865 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.9 m -142.09 126.75 17.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.884 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.6 p -69.56 118.26 13.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.116 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.4 t -110.12 -40.51 4.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.897 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -158.86 115.78 0.68 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.483 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.7 mp -92.21 156.02 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.829 0.347 . . . . 0.0 111.096 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.408 ' CE1' HD12 ' A' ' 35' ' ' LEU . 18.6 m-85 -125.82 156.9 38.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.949 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.41 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 11.7 m-85 -126.78 109.89 12.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.95 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -66.98 132.73 31.26 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.356 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.7 t -144.12 130.53 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.899 0.38 . . . . 0.0 111.22 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -88.13 116.73 26.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.827 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 29.3 mt -59.97 131.96 52.48 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 12.0 mt -77.61 -179.89 6.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -53.41 -29.79 36.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.149 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -61.04 -55.47 32.39 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.914 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -112.05 32.44 6.33 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.514 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 8.8 ttt180 -72.83 135.26 45.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.913 0.387 . . . . 0.0 110.866 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 98.61 31.97 6.17 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.526 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 64.4 mm-40 -143.4 33.39 1.31 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.858 0.361 . . . . 0.0 110.932 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -99.8 147.99 18.4 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.521 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 23.7 p90 -109.51 -50.35 3.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.747 0.308 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 8.7 t -68.84 -48.57 63.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.887 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 53.89 30.48 11.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.089 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.415 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 106.3 -26.38 20.46 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.506 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.5 p -120.82 132.8 69.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 111.087 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.418 ' CE1' HD11 ' A' ' 35' ' ' LEU . 40.2 t80 -119.06 113.77 21.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.932 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 61.26 24.87 14.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.072 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 104.54 -27.9 17.2 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.555 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.2 tpmp? -79.24 117.59 20.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.923 0.392 . . . . 0.0 110.913 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 8.6 tp60 -85.1 106.0 16.25 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.884 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 91.6 mt -91.01 -34.45 15.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.415 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 7.4 p90 -153.95 171.21 19.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 4.9 mm100 -102.77 121.15 41.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.922 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -136.52 172.85 12.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.807 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.93 173.78 10.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.905 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -65.53 118.67 9.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.991 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 59.55 52.15 5.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.852 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 87.0 m -130.07 -63.93 0.88 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -58.87 137.03 50.75 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.488 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 5.7 m -148.07 129.79 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.792 0.329 . . . . 0.0 111.208 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -93.02 129.77 38.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.785 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 4.6 m -150.32 164.56 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.235 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.7 162.58 20.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.176 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 12.8 tp -52.35 -47.99 65.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.805 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -57.64 -29.0 64.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.604 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 1.7 mttp -79.49 -25.35 41.87 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.809 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 52.5 mt -87.57 128.02 35.26 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.864 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -114.0 111.35 21.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.836 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 17.4 tp -60.04 134.13 56.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.957 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 29.3 mt -93.46 128.86 44.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.105 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -83.54 152.82 24.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.915 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 3.0 t -161.01 49.31 0.23 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -148.46 92.47 0.15 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.493 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.98 149.88 72.33 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.561 2.174 . . . . 0.0 112.22 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 15.9 t -119.99 112.13 18.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.935 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 49.4 m -81.77 -31.58 31.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.903 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.116 0 CA-C-O 118.35 -1.25 . . . . 0.0 112.461 179.957 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.176 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.6 p -165.1 176.41 8.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.825 0.345 . . . . 0.0 110.944 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.0 m -156.71 124.59 5.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.82 -69.01 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.412 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.9 m -163.28 -45.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.877 0.37 . . . . 0.0 110.912 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -162.2 171.1 17.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.911 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -120.91 -39.1 0.61 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.444 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 29.2 mt -113.08 155.13 14.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.761 0.315 . . . . 0.0 111.142 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -153.35 -168.94 3.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.9 t -70.16 135.27 28.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.125 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.9 46.17 7.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.408 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -144.73 137.42 13.6 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.677 0.275 . . . . 0.0 110.99 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.1 118.07 4.61 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.477 2.118 . . . . 0.0 112.364 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 24.1 m -146.68 138.32 18.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.196 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.2 mttm -77.06 129.87 36.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.967 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 23.3 t -106.16 128.03 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.002 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 30.2 tt0 -97.24 110.32 22.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.912 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 88.9 mt -80.99 -45.55 16.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.835 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.28 -174.3 5.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.968 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.51 84.25 4.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.82 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.05 55.2 29.41 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.539 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 -117.25 -65.69 1.16 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.776 0.322 . . . . 0.0 110.892 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -158.43 123.07 4.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.866 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 24.2 mttt -90.57 144.06 26.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -107.98 127.54 27.46 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.864 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -68.39 131.84 24.2 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.397 2.064 . . . . 0.0 112.262 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.66 163.38 30.35 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.9 p -102.6 125.95 56.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.822 0.344 . . . . 0.0 110.97 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.3 t -59.88 126.91 18.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -114.38 -31.79 6.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.054 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 28.0 t80 -142.58 167.43 22.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.934 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.42 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 13.5 ttp180 -159.22 129.47 5.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.72 148.34 5.15 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.505 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.61 147.36 51.2 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.561 2.174 . . . . 0.0 112.274 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.404 HD23 ' CG ' ' A' ' 64' ' ' TYR . 8.0 mt -86.51 -67.73 0.79 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.867 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -88.84 93.57 9.63 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.815 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -121.3 31.62 6.26 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.098 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.54 -50.05 6.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.895 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -104.02 85.45 2.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.968 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 96.9 m 57.06 97.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.908 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.2 p -72.0 141.56 16.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.095 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.4 t -167.88 35.18 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.908 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -164.1 89.36 0.1 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.513 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.2 mt -82.72 135.43 24.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.775 0.321 . . . . 0.0 111.18 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -106.99 150.39 26.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.98 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.42 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 9.5 m-85 -123.34 114.9 20.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.971 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.424 ' N ' ' CD1' ' A' ' 79' ' ' PHE . . . -74.93 121.84 6.77 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.48 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.5 t -129.95 133.76 64.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.823 0.344 . . . . 0.0 111.113 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -90.02 115.91 27.65 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 37.3 mt -58.88 133.59 56.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.993 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -81.55 -179.89 7.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.921 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -53.14 -29.63 32.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.106 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -60.86 -58.35 8.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -111.12 32.72 6.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.465 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -69.74 133.06 47.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.769 0.319 . . . . 0.0 110.907 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.46 35.8 4.56 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.53 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.8 mt-30 -141.47 31.36 1.69 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.342 . . . . 0.0 110.877 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.72 147.39 16.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.513 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -108.56 -49.23 3.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.75 0.31 . . . . 0.0 110.863 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.3 t -59.43 -43.78 93.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.957 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.0 t0 59.82 29.38 18.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.052 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.423 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.47 -19.57 53.62 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.69 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.2 p -124.22 140.38 47.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.865 0.364 . . . . 0.0 111.178 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.404 ' CG ' HD23 ' A' ' 35' ' ' LEU . 52.7 t80 -122.85 109.96 14.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.923 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER 60.22 26.6 16.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.001 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.12 -30.27 9.54 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.592 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.34 117.93 19.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.951 0.405 . . . . 0.0 110.925 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 2.9 tp60 -84.91 92.69 8.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.861 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 71.1 mt -69.49 -44.57 70.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.912 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.423 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.9 p90 -147.77 177.78 9.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.961 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -113.83 123.92 50.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.885 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 17.7 p -150.0 163.06 39.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.891 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -60.12 178.51 0.18 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.936 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -75.71 124.55 27.45 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 60.79 49.86 5.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.909 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 53.7 m -129.99 -45.93 1.14 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.907 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -69.41 132.17 24.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.519 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 7.7 m -142.15 131.16 22.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.886 0.374 . . . . 0.0 111.094 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.424 ' CD1' ' N ' ' A' ' 47' ' ' GLY . 9.1 m-85 -101.53 127.06 48.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.93 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 31.5 m -151.71 164.15 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.159 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -81.13 162.38 23.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.204 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -51.9 -49.57 62.78 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.887 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -56.89 -28.33 61.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.672 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.0 mtmm -80.03 -25.86 40.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.815 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.3 mt -82.86 161.05 22.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.913 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -137.97 104.59 5.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.84 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 19.8 tp -59.68 137.71 57.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.984 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 32.3 mt -106.69 155.62 7.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.117 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -125.53 -48.77 1.67 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.966 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 92.3 p -115.35 -40.96 3.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.9 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.23 -148.83 16.52 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.461 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.85 145.19 61.6 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.502 2.135 . . . . 0.0 112.328 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.4 m -109.83 -42.23 4.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.978 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 38.4 m -84.61 130.54 34.71 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.968 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.128 0 CA-C-O 118.361 -1.244 . . . . 0.0 112.459 -179.963 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.163 0 N-CA-C 112.499 -0.24 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.5 t 61.26 153.77 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.831 0.348 . . . . 0.0 110.904 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.5 p 58.18 179.6 0.06 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.4 91.93 1.28 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.516 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.1 m -140.35 -170.95 3.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.854 0.359 . . . . 0.0 110.901 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 74.4 m -134.46 136.34 43.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.872 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.91 -94.62 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.521 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 46.0 mt -100.85 125.75 54.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -143.1 -172.02 3.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.881 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 29.2 t -64.48 127.78 25.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.038 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 87.84 43.28 5.77 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.537 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -141.44 137.04 16.12 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 120.617 0.246 . . . . 0.0 110.952 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -76.34 116.84 4.43 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.526 2.151 . . . . 0.0 112.343 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.8 m -144.34 138.74 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.169 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.3 mttt -80.42 141.23 35.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.071 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 31.9 t -115.63 133.6 61.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.053 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -94.52 121.54 36.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.915 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 57.4 mt -101.93 -54.48 2.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.919 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.8 -174.78 0.05 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.839 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 51.7 p -93.0 48.37 1.34 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.918 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 95.51 57.89 1.16 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.469 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -121.43 -51.93 2.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.818 0.342 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -170.02 152.4 4.32 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 10.8 mttt -107.74 138.29 44.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -95.08 123.14 58.21 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.769 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -65.97 138.86 54.22 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.464 2.109 . . . . 0.0 112.263 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -166.74 146.6 11.02 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.571 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.2 p -83.37 145.83 7.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.803 0.335 . . . . 0.0 110.961 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.7 t -77.86 138.87 19.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.158 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -117.78 -40.19 3.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.804 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.411 ' CD2' ' N ' ' A' ' 32' ' ' ARG . 58.1 t80 -140.05 163.8 31.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.793 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.412 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 22.5 ttp85 -158.99 140.79 13.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.911 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.83 161.33 9.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.482 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.9 136.09 31.75 Favored 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.556 2.171 . . . . 0.0 112.287 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 72.2 mt -62.95 -64.93 0.77 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.918 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -122.89 156.87 33.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.843 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.36 153.76 40.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.11 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -149.88 161.37 42.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.867 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.4 -31.38 7.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.886 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.7 t -91.11 -34.64 14.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.919 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.6 p -169.47 124.79 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 31.1 t -98.91 96.36 7.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -62.38 116.51 9.47 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.467 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.2 mp -93.42 135.62 27.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 111.064 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -117.96 146.58 43.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.918 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.412 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 7.0 m-85 -118.28 112.94 20.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.924 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.429 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -68.44 141.4 37.02 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.589 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 25.7 t -153.52 140.92 13.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.792 0.329 . . . . 0.0 111.006 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -98.79 113.94 26.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.871 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 3.4 mt -57.76 128.6 37.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.056 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 19.8 mt -78.0 -179.9 6.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.54 -30.03 52.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.079 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -60.64 -48.68 80.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.846 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -121.57 37.13 3.03 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.488 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.1 ttt180 -74.1 151.89 40.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.802 0.334 . . . . 0.0 110.9 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 84.3 27.91 35.07 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.492 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 68.5 mm-40 -133.92 36.69 3.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.837 0.351 . . . . 0.0 110.918 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.41 145.86 15.99 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.456 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -109.98 -47.38 3.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.821 0.343 . . . . 0.0 110.921 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.3 t -69.98 -40.47 75.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.831 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.6 t0 58.43 29.46 18.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.043 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.42 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 99.01 -20.25 51.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.67 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.9 p -118.56 134.59 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.867 0.365 . . . . 0.0 111.124 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.412 ' CE1' ' HG3' ' A' ' 65' ' ' GLN . 50.4 t80 -122.59 110.02 15.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.858 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . 0.412 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 28.8 mt-30 58.94 26.54 15.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.037 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 105.72 -28.05 15.57 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.568 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.0 118.08 21.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.83 0.348 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 7.7 tp60 -84.08 90.08 7.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.913 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 84.7 mt -71.36 -31.78 67.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.825 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.42 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.1 p90 -161.49 164.82 29.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.858 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -112.0 119.42 38.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.887 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 1.3 m -137.17 179.95 6.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.907 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -71.69 179.96 2.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.885 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -72.33 123.24 22.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.001 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 60.02 50.59 6.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 27.9 m -130.04 -49.28 1.11 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.983 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -62.65 127.14 38.77 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.558 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.3 m -146.11 156.23 12.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.748 0.309 . . . . 0.0 111.128 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.429 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 7.9 m-85 -124.47 136.61 54.16 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.889 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 28.6 m -156.59 160.04 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.11 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -73.3 157.48 36.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.116 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.8 tp -51.14 -46.41 61.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.845 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.6 p-10 -57.16 -28.94 63.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.599 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 5.0 mmtt -79.28 -25.21 42.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 43.7 mt -83.17 154.98 24.0 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.02 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -141.45 104.66 4.62 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.853 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 19.0 tp -59.51 135.14 57.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.002 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.3 mt -93.61 126.57 46.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.113 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -119.68 -38.49 2.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.024 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 7.6 p 61.49 41.51 12.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.926 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 122.29 161.16 11.18 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.458 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -68.49 124.62 11.81 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.615 2.21 . . . . 0.0 112.3 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 23.1 t -79.09 121.25 24.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.889 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.42 -31.12 53.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.903 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.411 -1.216 . . . . 0.0 112.542 179.968 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.166 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.2 m 60.43 95.45 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.792 0.33 . . . . 0.0 110.89 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.5 m -158.08 160.44 37.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.927 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 132.21 174.4 13.62 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.472 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 99.3 p -98.82 31.5 2.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.838 0.351 . . . . 0.0 110.93 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 m -100.59 178.16 4.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.75 -51.86 1.25 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.533 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.1 mt -127.4 143.69 39.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.918 0.39 . . . . 0.0 111.059 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -138.82 179.77 6.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.842 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.2 t -64.04 133.13 29.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.011 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 84.36 45.53 6.15 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.383 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -149.87 143.63 16.89 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 120.663 0.268 . . . . 0.0 110.953 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.3 138.14 21.96 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.582 2.188 . . . . 0.0 112.267 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.3 m -158.49 138.69 4.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.232 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.3 mttt -82.82 125.94 31.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.948 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 22.0 t -104.49 138.46 29.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.03 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -102.96 112.09 24.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.939 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -85.78 -40.12 16.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.866 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -84.31 -176.3 6.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 71.8 p -100.04 48.26 0.93 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.874 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 105.71 56.89 0.66 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.553 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.95 -60.45 1.08 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.803 0.335 . . . . 0.0 110.904 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -161.63 146.18 13.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.863 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 14.8 mttt -109.21 150.62 27.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.417 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 27.3 m-85 -113.63 127.26 27.03 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.838 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.18 146.17 40.37 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.436 2.091 . . . . 0.0 112.318 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.82 153.4 21.53 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.489 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.8 p -93.27 138.85 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.772 0.32 . . . . 0.0 111.066 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.3 t -72.78 133.32 31.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.098 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 20.0 mmt180 -115.91 -30.45 6.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.038 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -142.78 168.3 20.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.948 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.425 ' CD ' ' CZ ' ' A' ' 46' ' ' PHE . 24.3 ttp180 -161.23 123.53 3.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.858 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 168.37 145.7 4.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.545 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -54.96 -169.31 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.583 2.189 . . . . 0.0 112.25 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.416 HD11 ' CE2' ' A' ' 45' ' ' PHE . 12.9 mt -118.21 -64.06 1.34 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.5 mp -130.74 139.08 50.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.7 77.42 0.12 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.085 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -93.56 -38.32 11.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.897 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 26.8 mtm180 -110.92 -33.31 6.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.939 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.8 m -151.39 147.6 27.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.886 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.7 p -77.55 146.36 8.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.084 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 13.0 t -107.07 -67.43 0.95 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.888 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -176.18 145.6 7.63 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.515 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 32.9 mt -81.17 123.36 37.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.794 0.331 . . . . 0.0 111.095 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.416 ' CE2' HD11 ' A' ' 35' ' ' LEU . 52.7 m-85 -90.39 147.81 23.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.952 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.425 ' CZ ' ' CD ' ' A' ' 32' ' ' ARG . 12.1 m-85 -117.12 111.95 20.21 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.67 110.27 2.99 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.498 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.97 132.13 67.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.846 0.355 . . . . 0.0 111.039 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -88.53 117.54 27.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 52.8 mt -59.15 135.19 57.56 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.993 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -79.78 -179.93 7.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.821 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -55.13 -30.2 59.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.079 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -63.01 -60.1 3.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.79 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.417 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -101.58 30.86 9.47 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.442 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -69.74 137.87 52.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.79 0.328 . . . . 0.0 110.88 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.01 34.06 6.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.47 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 31.1 mm-40 -140.9 43.84 1.81 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.906 0.384 . . . . 0.0 110.918 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -108.1 143.15 16.05 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.525 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -110.03 -32.1 7.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.87 0.367 . . . . 0.0 110.932 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -85.76 -42.31 14.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.899 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.6 t0 57.08 31.19 19.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.999 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.435 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 93.1 -16.8 59.65 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.676 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.7 p -123.01 142.1 40.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.856 0.36 . . . . 0.0 111.141 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.414 ' CZ ' HD12 ' A' ' 35' ' ' LEU . 13.4 t80 -129.09 110.24 11.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.873 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 61.67 24.54 14.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.154 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.18 -27.81 14.7 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.566 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.6 119.53 23.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.947 0.403 . . . . 0.0 110.948 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -82.87 95.61 8.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 78.5 mt -70.83 -51.13 28.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.435 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -144.99 166.1 26.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.913 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.32 124.24 46.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.881 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 9.3 p -149.58 177.1 10.05 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -71.89 175.93 5.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.877 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -78.82 127.79 32.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 60.5 41.22 16.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.902 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 23.7 m -127.53 -46.66 1.45 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.909 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -68.32 132.25 27.67 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.538 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 12.4 m -148.44 135.96 13.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.806 0.336 . . . . 0.0 111.158 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -102.18 130.01 48.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 4.2 m -150.15 166.74 2.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.148 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.98 158.76 21.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.137 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 9.3 tp -50.55 -44.05 56.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.899 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -57.82 -28.82 64.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.603 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.4 mttt -82.6 -24.85 33.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.86 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 52.7 mt -88.88 128.45 35.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.013 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.9 tm-20 -114.89 107.95 16.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.81 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 13.7 tp -57.74 138.54 55.41 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.997 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 27.3 mt -94.19 133.53 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.3 mt-10 -136.18 103.75 5.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -64.63 121.23 13.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.903 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -158.38 -96.74 0.12 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.49 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -73.5 145.12 37.23 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.542 2.161 . . . . 0.0 112.285 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 69.3 p -161.06 -63.87 0.06 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.958 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.5 m -88.21 -51.5 5.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.941 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.313 -1.271 . . . . 0.0 112.509 -179.995 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.217 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -103.5 144.6 31.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.886 0.374 . . . . 0.0 110.85 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.1 m -157.4 120.31 3.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.858 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 148.84 158.36 8.01 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.462 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.3 t -170.82 -51.02 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.813 0.34 . . . . 0.0 110.927 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.6 m 60.31 166.88 0.08 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.28 104.19 2.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.506 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 20.2 mt -128.15 138.26 55.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.828 0.346 . . . . 0.0 111.02 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -120.57 -179.59 4.03 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.3 t -66.86 137.33 25.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.027 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.75 46.82 7.02 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.399 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -140.72 140.96 23.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.623 0.249 . . . . 0.0 110.955 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -76.51 117.17 4.49 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.566 2.177 . . . . 0.0 112.343 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.9 m -144.38 138.9 23.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.129 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -87.38 140.98 28.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.5 t -121.0 140.4 45.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.095 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -97.96 110.06 22.7 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.6 mt -84.57 -58.69 2.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.89 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.42 -174.99 0.74 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.83 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -83.77 68.72 10.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 69.18 45.35 62.09 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.536 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -99.48 -44.72 6.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 0.0 110.916 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -176.66 131.56 0.2 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -88.29 124.85 34.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.825 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -89.84 128.06 51.67 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.832 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -72.33 139.4 31.89 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.445 2.097 . . . . 0.0 112.328 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -154.82 167.05 32.6 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.515 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.6 p -108.73 124.0 64.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.75 0.31 . . . . 0.0 111.014 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.7 t -59.46 128.55 20.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.13 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -115.73 -29.92 6.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.112 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 40.5 t80 -148.74 165.96 29.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.914 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.419 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 15.1 ttp180 -158.46 135.66 9.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.984 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.68 137.32 2.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.96 164.5 2.47 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.516 2.144 . . . . 0.0 112.339 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 13.7 mt -125.28 69.34 1.15 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.806 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 mt 59.92 176.96 0.09 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.82 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -171.3 124.37 0.6 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.157 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -128.73 103.43 7.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 9.5 mtt180 60.77 36.18 19.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.894 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.5 t -143.34 159.44 42.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.834 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.0 p -64.19 143.29 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.093 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.0 p -67.9 103.57 1.5 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.868 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -112.44 115.0 3.64 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.55 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 16.2 mt -73.45 146.99 9.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.795 0.331 . . . . 0.0 111.099 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -120.2 138.92 53.36 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.939 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.419 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 6.4 m-85 -120.84 109.91 15.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.845 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.18 119.93 9.07 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.485 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 22.3 t -134.04 130.83 55.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.774 0.321 . . . . 0.0 111.03 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -83.62 119.06 24.28 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.932 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.9 mt -62.26 141.95 57.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.014 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.7 mt -86.73 -179.93 6.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.854 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -54.42 -30.03 51.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.037 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -61.73 -47.06 86.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.871 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.43 38.38 2.39 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.482 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -77.09 151.83 35.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.819 0.342 . . . . 0.0 110.869 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.18 28.13 37.99 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.543 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -135.35 46.55 2.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.804 0.335 . . . . 0.0 110.859 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -118.15 150.44 18.19 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.556 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -110.09 -50.55 2.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.7 t -69.03 -48.07 63.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.962 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 55.54 32.74 19.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.044 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 105.1 -25.41 25.26 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.545 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.7 p -121.93 126.54 74.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.807 0.336 . . . . 0.0 111.103 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -116.03 113.89 23.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.86 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 12.9 mt-30 62.39 26.8 16.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.943 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.83 -24.39 32.35 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.616 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 12.2 tptm -81.67 114.56 20.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.882 0.372 . . . . 0.0 110.903 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.8 tp60 -82.64 97.24 8.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.924 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 79.0 mt -80.87 -34.74 33.46 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.012 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.413 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -156.39 169.81 23.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.986 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -103.47 124.74 49.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.889 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -140.61 173.84 11.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.823 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -76.43 179.96 5.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -76.96 120.52 22.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 60.2 41.71 16.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.885 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 78.2 m -125.18 -52.83 1.63 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.945 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -64.62 130.14 36.84 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.454 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 5.6 m -142.33 143.46 26.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.853 0.359 . . . . 0.0 111.133 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -105.87 124.69 49.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.867 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 29.4 m -146.65 155.77 11.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.15 155.67 40.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.2 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -50.57 -44.51 56.76 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.927 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -56.48 -27.03 55.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.663 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 11.8 mmtt -81.52 -26.75 34.86 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.838 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 90.2 mt -79.3 140.91 37.43 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.823 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -115.75 103.34 10.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.846 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 23.4 tp -59.54 130.38 46.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 13.6 mt -103.04 153.5 5.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.007 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -139.08 150.99 46.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.917 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -140.61 -68.52 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.44 94.9 0.93 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.529 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -68.14 -41.74 6.84 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.539 2.159 . . . . 0.0 112.322 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.8 m -103.45 151.42 22.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.0 m -161.98 89.42 0.72 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.422 -1.21 . . . . 0.0 112.506 -179.984 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 112.545 -0.222 . . . . 0.0 112.545 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.42 176.65 0.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.802 0.334 . . . . 0.0 110.902 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.5 t -90.33 -65.85 0.98 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.874 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 132.15 77.67 0.14 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.537 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.9 m -88.41 -61.34 1.73 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.845 0.355 . . . . 0.0 110.895 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.1 m -92.01 -78.0 0.42 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.874 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.66 103.17 2.21 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.61 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 30.0 mt -105.7 132.44 52.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.82 0.343 . . . . 0.0 111.1 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -134.75 -177.84 4.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.971 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 26.6 t -60.98 135.68 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.133 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.43 46.15 7.04 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.466 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -141.66 138.82 17.65 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.668 0.27 . . . . 0.0 110.865 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -74.48 117.25 4.89 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 122.503 2.136 . . . . 0.0 112.383 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.9 m -142.99 138.55 27.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.12 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 27.0 mttt -83.63 142.89 30.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.978 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.0 t -123.43 132.03 72.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -93.27 118.93 31.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 18.1 mt -95.07 -55.8 2.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.98 -170.27 0.22 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.877 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 69.0 m -88.75 79.16 7.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.871 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.83 44.22 98.29 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.523 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -101.62 -66.54 0.91 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.798 0.333 . . . . 0.0 110.836 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -152.92 142.39 21.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.938 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.7 mtpt -103.73 133.13 49.25 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.826 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.405 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 25.8 m-85 -92.84 129.76 38.87 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.78 133.87 17.49 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.427 2.085 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.16 155.39 26.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.594 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -94.52 132.95 37.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.822 0.344 . . . . 0.0 111.067 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.4 t -63.75 133.83 29.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.097 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.28 -36.4 4.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.005 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 52.9 t80 -143.19 164.34 30.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.921 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.412 ' HG3' ' CE2' ' A' ' 46' ' ' PHE . 4.3 ttt180 -154.29 135.91 14.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 160.04 126.82 0.86 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.455 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -54.74 -174.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.435 2.09 . . . . 0.0 112.295 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.408 HD11 ' CD2' ' A' ' 64' ' ' TYR . 21.5 mt -144.74 91.45 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.881 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.0 mt 60.74 34.06 19.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.981 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -88.08 132.98 34.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.083 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -67.15 -74.97 0.1 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.941 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -131.14 -78.24 0.52 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.882 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.9 t -138.36 28.78 2.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.9 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 3.2 m -103.3 32.09 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.115 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -160.01 -60.64 0.06 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.885 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.28 130.44 5.84 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.473 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.0 mt -59.48 149.26 6.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.75 0.309 . . . . 0.0 111.072 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -102.28 134.94 44.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.841 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.412 ' CE2' ' HG3' ' A' ' 32' ' ' ARG . 8.7 m-85 -121.69 113.01 19.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.446 ' N ' ' CD1' ' A' ' 79' ' ' PHE . . . -73.08 118.21 6.26 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.358 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.6 t -125.73 131.42 71.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 111.124 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -90.55 114.81 27.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.839 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.3 mt -58.32 135.99 57.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.073 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -82.28 -179.97 7.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.896 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.72 -29.66 54.04 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.09 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -61.33 -50.49 72.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.902 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.405 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -121.84 37.59 2.87 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.479 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.57 145.34 41.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.794 0.33 . . . . 0.0 110.911 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 85.95 33.13 15.98 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.539 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 7.7 mm-40 -137.3 30.86 2.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.862 0.363 . . . . 0.0 110.933 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.38 154.41 18.99 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.502 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -109.47 -49.79 3.07 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.799 0.333 . . . . 0.0 110.869 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.7 t -62.31 -46.26 89.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.946 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 57.51 35.37 25.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.003 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.49 -27.56 16.89 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.469 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.8 p -117.46 124.83 73.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 0.0 111.053 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.408 ' CD2' HD11 ' A' ' 35' ' ' LEU . 37.3 t80 -111.91 115.05 28.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.96 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 30.7 mt-30 59.37 25.77 14.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.137 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.84 24.66 22.47 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.61 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.65 109.82 10.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.83 0.348 . . . . 0.0 110.859 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -75.71 97.01 3.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.946 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 79.0 mt -82.65 -30.81 29.1 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.858 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.413 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.9 p90 -152.82 174.64 13.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.938 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.79 110.02 19.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 26.5 p -133.17 174.71 10.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -72.55 179.97 3.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.881 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -74.78 119.31 18.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.975 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 60.75 51.25 4.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.906 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 47.6 m -129.98 -49.34 1.12 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.916 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -71.65 134.63 22.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.502 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.1 m -141.9 132.61 25.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.805 0.336 . . . . 0.0 111.113 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 47' ' ' GLY . 7.9 m-85 -100.83 118.34 36.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.897 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 27.4 m -145.3 161.92 12.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.109 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.66 156.05 35.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.127 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 6.5 tp -50.43 -43.97 55.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.825 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -57.57 -29.27 64.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.573 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 22.6 mmtm -80.62 -27.02 37.41 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.79 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 39.4 mt -84.33 146.59 27.64 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.985 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -131.46 110.96 11.38 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.912 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.5 tp -62.6 136.14 57.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.99 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 26.9 mt -79.57 130.86 35.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.183 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -118.31 144.25 45.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.893 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 p -95.5 -47.43 6.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.919 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -177.91 89.81 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.511 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.08 95.47 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.547 2.165 . . . . 0.0 112.32 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 68.7 m -105.82 177.38 4.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.887 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.2 m -149.01 -48.09 0.14 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.332 -1.26 . . . . 0.0 112.51 179.993 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 112.462 -0.255 . . . . 0.0 112.462 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.4 m -93.43 154.25 18.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.825 0.345 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 90.5 p -91.04 -46.9 7.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.917 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.69 124.15 3.78 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.443 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 p -120.88 62.48 0.87 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.931 0.396 . . . . 0.0 110.852 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.8 m 59.84 -176.78 0.1 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.977 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -161.34 -81.44 0.04 OUTLIER Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.533 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 20.2 mt -126.93 150.08 32.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.755 0.312 . . . . 0.0 111.172 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -157.91 -176.65 6.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.7 t -58.89 138.93 19.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.146 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 72.06 47.33 31.52 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.512 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -147.31 136.38 11.52 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.585 0.231 . . . . 0.0 110.893 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -76.19 130.2 11.91 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.512 2.141 . . . . 0.0 112.298 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.3 m -151.67 138.75 13.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.156 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -81.89 135.21 35.43 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.4 t -116.83 139.9 41.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.14 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -103.26 116.29 32.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.937 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 50.6 mt -89.72 -44.65 9.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.954 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -86.38 172.17 10.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.87 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 43.2 t -76.43 76.22 3.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.11 69.2 1.39 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.509 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -133.38 -57.7 0.89 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.887 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -156.12 132.7 10.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.847 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -102.87 128.1 49.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.874 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 42.6 m-85 -93.18 129.56 38.88 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.817 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -76.06 138.59 20.73 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.435 2.09 . . . . 0.0 112.282 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.27 151.49 22.8 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.552 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.0 p -92.38 130.94 40.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.791 0.329 . . . . 0.0 111.018 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.1 t -64.77 140.54 19.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.051 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.3 mmt180 -122.22 -41.07 2.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.042 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -138.25 164.47 29.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.947 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.42 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 3.3 ttp180 -158.11 141.94 15.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.857 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.04 149.18 4.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.478 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.71 154.16 64.14 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.604 2.203 . . . . 0.0 112.339 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.409 HD13 ' CE1' ' A' ' 45' ' ' PHE . 9.7 mt -84.47 58.01 4.62 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.9 mt 59.8 172.9 0.08 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.949 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -157.88 163.01 38.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.188 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -91.59 -67.08 0.88 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.874 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.67 -33.24 6.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.013 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.0 t -133.05 141.51 48.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.8 m -83.55 76.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.071 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.3 m -113.1 92.65 4.08 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.972 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 149.95 76.72 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.51 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.6 mt -90.9 150.73 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.749 0.309 . . . . 0.0 111.063 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.409 ' CE1' HD13 ' A' ' 35' ' ' LEU . 83.0 m-85 -136.71 147.23 46.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.941 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.42 ' CZ ' ' HD2' ' A' ' 32' ' ' ARG . 9.6 m-85 -123.99 109.89 14.1 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.855 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.31 120.68 9.49 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.477 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.5 t -133.21 133.11 58.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.874 0.368 . . . . 0.0 111.107 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -90.24 116.93 28.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.881 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 63.6 mt -60.43 145.33 48.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.941 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.6 mt -86.44 -179.85 6.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.923 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -53.24 -29.35 32.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.111 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.09 -51.95 65.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.884 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -112.21 29.64 8.22 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.514 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -68.17 144.97 54.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.888 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.67 39.24 14.59 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.519 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -145.4 35.19 1.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.774 0.321 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.05 152.09 19.26 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -110.0 -43.87 3.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 0.0 110.979 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.4 t -77.61 -40.38 42.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.899 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 51.12 26.83 3.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.302 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.42 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 106.31 -31.74 8.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.622 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -111.78 128.79 68.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.89 0.376 . . . . 0.0 111.091 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.417 ' CE1' ' HG3' ' A' ' 65' ' ' GLN . 30.9 t80 -113.28 110.01 19.68 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.896 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . 0.417 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 9.9 mt-30 57.72 28.84 16.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.034 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 102.22 -26.81 22.97 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.498 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.6 tmtt? -82.17 116.82 21.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.918 0.39 . . . . 0.0 110.952 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 19.5 tp60 -78.96 98.91 6.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.832 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 79.0 mt -81.13 -37.86 28.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.949 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.42 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.0 p90 -155.96 173.3 16.99 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.936 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -107.72 123.36 48.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.889 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -139.58 177.2 8.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.911 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -76.05 179.92 5.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.886 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -73.52 114.01 11.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.913 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 42.2 m-20 60.83 45.21 10.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.912 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 62.6 m -125.63 -46.17 1.74 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.894 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -65.1 135.82 37.36 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.525 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.6 m -148.49 138.86 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.803 0.335 . . . . 0.0 111.164 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -105.15 134.52 48.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 30.5 m -155.79 168.56 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.182 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -87.39 161.24 17.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.191 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 7.0 tp -49.99 -44.3 50.87 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -55.82 -27.1 49.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.665 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 16.1 mmtt -95.86 19.65 11.1 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.934 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 88.2 mt -129.18 126.71 39.82 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.93 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -107.8 110.39 22.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.963 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 12.2 tp -67.14 117.47 9.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.996 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.0 mp -86.17 158.23 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.152 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -146.8 161.75 40.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.931 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.75 113.91 9.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.878 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -134.25 -146.35 5.42 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.473 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.37 -26.73 40.94 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.524 2.149 . . . . 0.0 112.366 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.3 m -66.51 99.52 0.58 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 m 60.9 178.91 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.345 -1.253 . . . . 0.0 112.433 179.981 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 112.484 -0.247 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.0 t -174.81 178.28 1.88 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.834 0.349 . . . . 0.0 110.888 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.3 t -159.82 -45.33 0.05 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.922 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.01 177.18 48.34 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.516 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 60.0 p -150.26 -50.38 0.13 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.816 0.341 . . . . 0.0 110.917 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.5 m -112.92 153.92 27.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.912 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 121.18 104.99 1.95 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.456 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.7 mt -102.11 125.85 56.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.769 0.318 . . . . 0.0 111.058 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.65 -175.54 3.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.924 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 28.3 t -64.42 128.86 27.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.018 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 88.47 43.92 5.4 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.444 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -145.63 139.21 14.6 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.643 0.259 . . . . 0.0 110.963 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -76.72 130.03 11.27 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.513 2.142 . . . . 0.0 112.303 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.6 m -151.1 138.8 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.141 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 50.2 mttt -82.21 127.49 33.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.962 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.4 t -108.69 137.01 42.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.029 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -92.98 121.41 34.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.971 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.1 mt -100.41 -42.49 6.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.956 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.9 mtt85 -79.68 -178.22 6.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.81 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -80.49 73.54 7.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.825 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.75 41.21 99.88 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.491 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -101.94 -61.86 1.33 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.747 0.308 . . . . 0.0 110.865 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -148.43 159.6 43.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.902 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 2.0 mttm -125.3 126.38 45.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -89.65 137.31 28.72 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.766 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -73.88 146.15 37.23 Favored 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.424 2.082 . . . . 0.0 112.331 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -163.29 152.21 22.16 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.502 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.5 p -94.1 129.16 44.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.324 . . . . 0.0 111.138 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.7 t -62.3 126.58 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.07 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 40.0 mmt180 -112.11 -31.05 7.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.012 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -148.25 167.73 24.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.976 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.42 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 9.6 ttp180 -160.85 119.39 2.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.865 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.52 156.34 11.8 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.55 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.08 174.53 9.65 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.586 2.19 . . . . 0.0 112.357 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 4.6 mt -98.78 -33.21 10.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.919 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.5 mp -138.89 147.65 42.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.886 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -164.38 87.92 0.49 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.061 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -115.43 -73.07 0.66 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.954 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 5.2 mtp180 -86.57 -36.07 19.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.937 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.3 m -162.35 150.22 14.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.955 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 10.0 m -88.08 142.81 12.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.135 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 5.1 m -98.8 -36.22 9.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.845 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -175.98 -157.26 16.78 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.468 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.9 mp -142.54 117.02 4.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.794 0.33 . . . . 0.0 111.153 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -85.5 124.24 31.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.42 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 5.8 m-85 -98.16 120.0 37.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.999 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.56 131.64 10.52 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.418 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.5 t -139.35 126.39 24.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.876 0.37 . . . . 0.0 111.161 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -83.0 117.14 22.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.845 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 13.1 mt -58.62 130.15 45.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.934 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 5.1 mt -76.67 -179.94 5.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.867 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -53.88 -29.2 40.56 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.134 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -61.87 -43.6 98.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.946 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.24 35.33 2.86 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.528 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -72.61 143.44 48.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.779 0.323 . . . . 0.0 110.889 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.48 34.48 11.86 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.475 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 30.5 mm-40 -141.69 37.63 1.65 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.83 0.348 . . . . 0.0 110.843 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -110.16 155.22 16.21 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.521 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -109.92 -50.55 2.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.775 0.321 . . . . 0.0 110.929 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.2 t -64.61 -48.21 75.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.929 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 56.64 27.8 13.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.154 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.421 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 107.35 -27.05 16.61 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.571 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -117.69 138.12 49.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 111.158 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -121.44 109.97 15.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.911 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 17.1 mt-30 61.29 25.17 15.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.091 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.45 -29.27 10.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.571 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.1 tmtt? -79.27 119.15 21.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.864 0.364 . . . . 0.0 110.984 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 17.9 tp60 -82.13 97.09 8.02 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.91 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 80.5 mt -76.85 -43.92 34.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.958 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.421 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.2 p90 -151.46 170.92 18.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.89 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.02 134.45 44.0 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -156.85 165.81 35.15 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -66.92 173.71 3.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -72.68 121.66 20.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 60.38 49.41 6.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.91 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 60.4 m -129.96 -51.65 1.13 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -66.56 142.83 42.99 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.487 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.0 m -151.37 143.67 16.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.834 0.349 . . . . 0.0 111.113 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.5 m-85 -109.74 128.39 55.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.881 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 30.5 m -149.85 154.93 8.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.101 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.52 156.24 33.19 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.092 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -50.89 -47.7 60.55 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.939 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -55.84 -28.58 57.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.545 179.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.2 mmmp? -75.85 -26.32 57.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.727 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 77.7 mt -84.16 137.68 33.4 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.852 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -124.62 108.03 11.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.1 tp -60.91 142.54 56.26 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.88 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 21.5 mt -98.11 133.48 40.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.169 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.69 -36.08 4.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.923 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.3 p -92.89 -75.25 0.5 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.966 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.82 122.43 0.73 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.422 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -74.27 -44.21 0.45 Allowed 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.43 2.087 . . . . 0.0 112.37 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 27.2 m -113.73 124.34 52.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.915 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -142.72 118.12 10.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.897 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.393 -1.226 . . . . 0.0 112.521 -179.995 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.259 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.9 p -99.34 34.35 2.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.892 0.377 . . . . 0.0 110.939 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.0 t -64.51 177.11 0.94 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.839 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.91 124.49 1.33 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.543 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.97 120.35 27.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.788 0.328 . . . . 0.0 110.956 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.5 m -91.48 146.19 24.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.98 -95.05 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.529 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 31.1 mt -120.32 119.64 60.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.819 0.342 . . . . 0.0 111.142 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -122.39 -175.75 3.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.924 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.3 t -66.09 135.17 28.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.077 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.75 45.85 7.05 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.514 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -143.62 139.8 16.7 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.64 0.257 . . . . 0.0 110.877 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -74.77 122.8 7.55 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.427 2.085 . . . . 0.0 112.234 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 15.8 m -147.13 138.39 18.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.154 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 20.3 mttm -84.69 133.43 34.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.036 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 18.0 t -114.22 139.57 39.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.106 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -91.16 122.28 33.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.888 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 45.9 mt -104.59 -52.2 2.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.965 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.6 mtt85 -68.45 -175.86 0.7 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.2 p -94.7 70.21 3.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.82 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 81.06 47.54 6.5 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -111.92 -68.8 0.91 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.804 0.335 . . . . 0.0 110.888 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -157.57 163.09 38.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 17.0 mttm -114.72 112.29 22.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.902 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -72.25 133.41 83.42 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.746 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.57 143.95 31.3 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.36 2.04 . . . . 0.0 112.392 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -162.76 156.3 27.95 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.487 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.3 p -95.12 131.47 41.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.346 . . . . 0.0 111.046 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.0 t -65.9 129.75 30.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.039 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 5.1 mmt180 -114.88 -29.92 6.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -147.37 166.65 26.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.883 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.42 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.3 ttp180 -164.38 141.43 6.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.885 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.86 147.99 4.81 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.483 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -71.02 152.13 62.51 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.568 2.179 . . . . 0.0 112.336 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 27.6 mt -62.01 -45.81 91.97 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.906 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 9.3 mp -118.13 160.94 20.68 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.932 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -122.08 90.16 3.25 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.035 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -112.16 -14.87 13.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.29 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.7 mtt180 62.7 43.96 6.95 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.946 0.403 . . . . 0.0 110.737 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.8 t -154.16 -47.81 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.81 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.7 m -71.85 177.86 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.102 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 9.7 t -141.47 86.74 2.03 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -148.12 61.99 0.44 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.509 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.7 mp -79.33 118.05 26.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.878 0.37 . . . . 0.0 111.065 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -95.1 137.13 34.57 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.892 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.42 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 5.3 m-85 -114.59 109.92 18.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.408 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -70.97 118.85 7.73 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.297 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 24.2 t -130.99 131.61 64.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.863 0.363 . . . . 0.0 111.139 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -89.71 116.76 28.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.801 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 91.8 mt -57.14 145.57 30.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.149 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 13.3 mt -90.08 -179.88 5.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.836 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -53.19 -27.83 23.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.145 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -63.1 -54.92 30.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.862 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -116.59 35.65 4.12 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.3 mtt85 -74.69 123.87 25.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.818 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 113.58 25.49 4.28 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.726 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 39.2 mm-40 -135.45 45.72 2.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.847 0.356 . . . . 0.0 110.929 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.62 148.34 18.4 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.47 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 16.3 p90 -109.91 -49.95 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.794 0.33 . . . . 0.0 110.981 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -59.26 -46.2 89.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.0 t0 59.45 26.98 16.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.119 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.21 -25.49 23.92 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.712 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.6 p -114.18 147.92 17.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.809 0.337 . . . . 0.0 111.161 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 31.7 t80 -132.08 110.01 10.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 53.4 mt-30 60.21 29.62 19.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.914 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.49 -28.33 15.98 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.475 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 8.7 tmtt? -79.66 114.58 18.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.792 0.33 . . . . 0.0 110.932 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 24.5 tp60 -71.51 99.64 2.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.942 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 73.0 mt -78.08 -39.05 42.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.413 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -163.71 167.9 20.47 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.86 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 17.4 mm-40 -93.82 129.36 40.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.942 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.64 173.96 12.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.91 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -83.27 167.62 17.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.799 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -66.04 118.35 9.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 60.56 44.34 11.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.946 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 86.8 m -127.61 -55.84 1.31 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.94 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.17 135.42 51.75 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.546 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.1 m -143.73 143.84 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.803 0.335 . . . . 0.0 111.107 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.408 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 3.8 m-85 -109.68 131.48 55.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 20.4 m -155.96 157.72 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.082 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -70.54 155.12 41.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.999 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 10.2 tp -50.4 -45.8 55.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -57.26 -29.54 63.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.606 179.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 14.2 mttm -77.9 -24.68 48.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.902 179.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 66.6 mt -81.82 158.09 24.2 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -142.99 109.31 5.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.92 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.6 tp -61.8 135.81 57.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.965 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.4 mt -103.1 140.33 21.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.052 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -134.71 173.55 11.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.954 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 p -72.79 117.41 14.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.933 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -168.6 76.74 0.11 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.515 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.18 133.91 48.71 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.528 2.152 . . . . 0.0 112.347 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.9 p -152.08 160.58 43.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 44.7 p -68.38 120.67 14.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.913 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.389 -1.228 . . . . 0.0 112.559 -179.918 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.163 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.37 -37.26 4.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.863 0.363 . . . . 0.0 110.894 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -98.26 -169.97 1.89 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.899 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.59 158.4 19.23 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.509 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 m -100.26 -31.76 11.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.842 0.354 . . . . 0.0 110.94 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.8 m -119.61 178.04 4.71 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.916 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 120.4 106.1 2.08 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.53 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.407 HG21 HD11 ' A' ' 8' ' ' ILE . 32.1 mt -97.07 125.77 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.83 0.348 . . . . 0.0 111.109 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -122.51 172.93 8.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.888 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 37.2 t -60.65 133.08 26.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.117 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 85.5 45.14 5.91 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.455 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -145.44 139.26 14.75 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 120.638 0.256 . . . . 0.0 110.908 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -74.17 133.33 17.76 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.486 2.124 . . . . 0.0 112.253 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.2 m -153.83 138.87 10.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.139 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -84.02 131.16 34.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.968 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 16.8 t -113.26 132.4 62.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.102 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.59 116.02 28.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.957 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 36.7 mt -91.56 -57.33 2.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -70.44 -172.11 0.56 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.941 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 t -84.5 79.52 9.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.5 39.04 94.43 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.486 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -95.03 -61.97 1.39 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.858 0.361 . . . . 0.0 110.905 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -155.54 144.58 20.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 21.3 mttt -106.72 124.84 50.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.862 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -87.84 132.59 39.79 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.77 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_endo -73.72 141.64 31.02 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.426 2.084 . . . . 0.0 112.34 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.67 147.83 14.67 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.557 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.9 p -90.47 133.13 33.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.771 0.32 . . . . 0.0 110.984 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.4 t -65.07 136.68 26.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.138 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 13.9 mmm180 -117.68 -38.04 3.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.021 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -143.11 166.27 25.13 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.877 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.427 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.8 ttp180 -159.6 133.84 7.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.81 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 155.3 151.45 5.87 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.511 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -54.33 157.29 11.83 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.56 2.173 . . . . 0.0 112.233 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.414 ' HG ' ' CD1' ' A' ' 45' ' ' PHE . 71.0 mt -127.06 80.9 1.98 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.804 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -113.48 152.72 29.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.987 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -167.87 33.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.984 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -170.33 -65.72 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.956 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -176.13 -68.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.866 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.9 t -59.08 161.79 4.87 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.962 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.2 p -167.45 150.63 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.027 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 9.1 t -91.23 -38.22 12.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 154.58 -157.39 27.52 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.532 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.9 mm -75.56 141.37 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.827 0.346 . . . . 0.0 111.034 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.414 ' CD1' ' HG ' ' A' ' 35' ' ' LEU . 83.5 m-85 -114.87 139.38 49.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.427 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 7.6 m-85 -120.85 109.93 15.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -72.06 128.82 14.58 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.414 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.5 t -137.12 136.78 47.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.796 0.331 . . . . 0.0 111.065 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -94.19 115.4 27.67 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 65.2 mt -59.17 130.94 49.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.918 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 12.5 mt -77.5 -179.94 6.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.852 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.05 -29.8 45.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.067 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -61.79 -42.97 99.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.958 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.89 34.46 3.57 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.445 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -75.74 132.54 40.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.864 0.364 . . . . 0.0 110.874 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.04 29.96 6.94 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.524 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -140.97 33.38 1.76 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.802 0.334 . . . . 0.0 110.888 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -99.51 152.67 19.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.529 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -109.98 -50.95 2.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.853 0.358 . . . . 0.0 110.941 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.1 t -66.58 -48.56 69.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.947 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.4 t70 60.36 23.77 13.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.203 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.433 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 103.81 -31.96 8.09 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.671 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -103.7 133.73 46.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.861 0.362 . . . . 0.0 111.199 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -118.95 109.98 16.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.879 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 60.21 28.11 17.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.956 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.37 23.82 25.72 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.596 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 5.6 tttm -132.3 109.95 10.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.861 0.363 . . . . 0.0 110.88 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 11.9 tp60 -69.72 95.56 0.89 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 83.0 mt -82.32 -37.53 25.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.92 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.433 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.5 p90 -149.0 165.45 31.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -98.25 128.36 44.66 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.907 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.39 164.51 32.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.781 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.89 174.24 9.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -62.84 113.17 2.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.888 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 60.33 54.63 3.85 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.858 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 68.7 m -129.57 -56.47 1.14 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.57 140.28 48.08 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.511 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.0 m -156.61 127.84 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.754 0.311 . . . . 0.0 111.157 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -90.4 130.31 36.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.848 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 6.1 m -150.41 164.86 2.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.181 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.87 157.4 22.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.128 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 11.3 tp -50.39 -44.21 54.81 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.848 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -57.39 -28.75 63.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.571 179.698 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 5.2 mtmt -81.4 -26.67 35.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.813 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 83.8 mt -85.42 146.16 27.11 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -133.35 107.89 8.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.925 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 12.4 tp -60.07 121.65 12.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.92 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 1.9 mp -81.26 135.91 24.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.162 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -70.48 -174.69 0.9 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.881 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.8 p -77.96 -51.82 9.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.876 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -167.55 170.61 41.78 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.515 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -54.15 -171.78 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.595 2.197 . . . . 0.0 112.248 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.68 164.97 25.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.921 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.8 m -60.77 -73.11 0.1 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.428 -179.939 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.217 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -119.32 35.67 4.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.844 0.354 . . . . 0.0 110.864 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 p -131.14 132.75 44.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.931 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 169.65 172.97 36.77 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.52 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 44.1 m -96.34 -64.79 1.02 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.779 0.323 . . . . 0.0 110.907 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.44 -172.21 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.843 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.85 -31.88 0.22 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.505 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.3 mt -118.01 145.23 24.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.799 0.333 . . . . 0.0 111.051 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -150.72 -177.83 6.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.3 t -59.71 127.66 19.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.027 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 84.89 43.59 6.7 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.478 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -139.51 139.32 22.12 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.66 0.267 . . . . 0.0 110.923 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_endo -77.38 117.38 4.33 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.516 2.144 . . . . 0.0 112.427 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.7 m -145.67 138.52 20.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.075 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -84.16 141.19 31.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.072 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 21.9 t -117.29 134.84 59.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.067 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -92.79 110.1 21.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.946 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.419 HD11 ' CE2' ' A' ' 25' ' ' PHE . 71.2 mt -81.5 -47.05 13.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.801 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.53 145.8 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.957 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 30.2 t -74.57 86.75 2.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.958 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.83 67.8 1.44 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.437 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -149.46 -58.46 0.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.833 0.349 . . . . 0.0 110.984 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -175.97 164.09 2.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 40.6 mttt -117.11 160.36 21.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.896 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.422 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 56.6 m-85 -126.4 121.92 23.77 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.822 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.04 140.6 60.66 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.513 2.142 . . . . 0.0 112.4 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.9 158.0 28.99 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.403 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.9 p -99.46 129.21 50.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.868 0.365 . . . . 0.0 111.098 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.5 t -65.4 132.65 31.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.097 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 4.5 mmm180 -116.05 -35.55 4.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.006 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -146.37 169.45 18.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.931 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.423 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 9.6 ttt180 -157.54 120.76 4.01 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.879 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -178.86 146.94 7.53 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.492 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -73.1 177.13 8.18 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.603 2.202 . . . . 0.0 112.252 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 84.0 mt -132.08 31.18 4.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.926 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 24.8 mt 60.62 -176.21 0.11 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -129.29 108.37 10.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.119 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 59.0 mm-40 -97.29 -67.44 0.85 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.818 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.68 31.75 3.35 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.92 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.3 t -158.93 173.9 15.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.839 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 4.7 m -97.64 33.78 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.186 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.6 p -59.9 127.18 30.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.965 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -102.71 -146.76 18.04 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.487 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.0 mt -70.05 134.33 30.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.758 0.313 . . . . 0.0 111.168 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.414 ' HB3' ' CD1' ' A' ' 79' ' ' PHE . 82.8 m-85 -104.67 144.79 31.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.912 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.423 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 6.2 m-85 -119.46 109.93 16.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.87 119.86 8.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.4 t -132.03 133.09 61.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.869 0.366 . . . . 0.0 111.189 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -87.71 116.61 25.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 94.5 mt -60.18 130.41 46.52 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.952 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 mt -78.82 -179.93 6.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.767 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.24 -30.06 48.96 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.057 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -61.43 -41.54 97.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.873 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.422 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -127.5 34.04 3.13 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.445 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 mtt180 -72.88 138.26 46.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.799 0.333 . . . . 0.0 110.868 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.42 29.52 8.79 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.513 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -141.51 43.42 1.75 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.792 0.33 . . . . 0.0 110.898 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -113.18 150.18 18.5 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.525 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 5.6 p90 -110.06 -51.22 2.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.78 0.324 . . . . 0.0 110.879 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 9.3 t -69.72 -48.32 59.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.835 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 53.91 36.22 23.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.09 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.424 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 97.97 -26.15 24.6 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.555 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.0 p -118.51 137.23 53.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.809 0.337 . . . . 0.0 111.104 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 3.1 t80 -122.68 111.13 16.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.945 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 62.18 27.15 16.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.037 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 103.04 -28.43 15.85 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.526 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -79.44 116.63 19.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.871 0.367 . . . . 0.0 110.956 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 21.7 tp60 -80.31 99.5 7.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.417 HD12 ' CE2' ' A' ' 79' ' ' PHE . 88.0 mt -79.21 -44.93 20.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.853 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.424 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.8 p90 -146.81 176.45 9.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.93 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 2.5 mm-40 -99.37 128.6 45.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -152.05 165.59 34.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -80.66 171.94 14.38 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 -68.9 126.21 29.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 59.02 43.79 17.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 37.5 m -129.87 -60.84 1.02 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -58.6 135.66 51.74 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.535 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 22.1 m -148.05 141.28 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.788 0.328 . . . . 0.0 111.131 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.417 ' CE2' HD12 ' A' ' 69' ' ' LEU . 3.0 m-85 -104.99 126.82 52.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.842 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 28.9 m -150.22 164.24 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.105 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.26 158.04 29.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.113 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.6 tp -50.68 -44.41 57.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.867 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -57.42 -29.27 63.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.591 179.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.26 -26.03 42.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.763 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 89.0 mt -82.19 125.04 30.45 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.954 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 5.2 tm-20 -112.05 107.48 16.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.6 tp -60.36 131.19 50.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.906 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 4.9 mt -86.46 140.93 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.109 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -152.73 129.49 10.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.842 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 47.9 t -86.47 -46.5 10.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -166.13 -161.2 14.64 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.473 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.2 -41.12 67.41 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.587 2.191 . . . . 0.0 112.358 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -124.19 105.04 9.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.845 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 15.4 p -175.92 -43.61 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.867 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.423 -1.209 . . . . 0.0 112.457 -179.989 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.203 0 N-CA-C 112.469 -0.253 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.29 31.89 20.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.875 0.369 . . . . 0.0 110.961 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.34 31.2 5.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.989 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -118.91 129.54 8.17 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.527 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.2 m -113.36 104.84 12.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.751 0.31 . . . . 0.0 110.902 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.1 m -141.79 150.73 42.08 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.73 -69.03 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.529 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 30.8 mt -123.61 136.65 59.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.82 0.343 . . . . 0.0 111.115 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -144.58 -172.52 3.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.812 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 33.9 t -65.42 144.49 14.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.152 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 68.88 49.11 44.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.506 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -145.89 139.91 15.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 120.662 0.268 . . . . 0.0 111.002 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.09 126.7 8.8 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.544 2.163 . . . . 0.0 112.293 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.3 m -154.04 138.27 9.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.153 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 39.3 mttt -88.32 138.11 31.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.005 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 26.2 t -117.35 141.57 35.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.997 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.0 tt0 -103.11 110.03 21.82 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.881 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.1 mt -80.78 -51.07 9.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.02 -169.84 1.72 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.9 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -104.75 87.09 2.59 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.865 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 67.96 56.6 10.38 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.452 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.03 -52.86 1.75 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.36 . . . . 0.0 110.935 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -176.06 139.89 0.39 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.913 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -100.96 122.79 44.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.91 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.419 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 46.6 m-85 -87.67 129.84 49.29 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.821 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_endo -73.0 141.02 32.34 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.503 2.135 . . . . 0.0 112.301 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.47 150.22 20.09 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.51 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.7 p -93.78 133.75 33.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.836 0.35 . . . . 0.0 111.085 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.8 t -67.96 136.23 26.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.11 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -118.86 -38.75 3.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.984 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -139.88 165.98 25.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.412 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 36.9 ttp85 -160.49 127.55 4.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.33 146.56 4.67 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.45 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -54.04 169.78 0.59 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.504 2.136 . . . . 0.0 112.325 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.414 HD11 ' CZ ' ' A' ' 64' ' ' TYR . 6.9 mt -120.08 -60.97 1.65 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.817 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.6 mp -121.31 124.93 45.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.881 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -162.25 111.69 1.47 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.137 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -160.81 -58.71 0.05 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.867 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.04 -33.09 6.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.928 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.6 t -127.83 121.95 31.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.821 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.4 m -67.71 132.78 32.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.164 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 19.6 m -113.06 -50.44 2.88 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.877 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 130.6 161.3 10.3 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.45 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.5 mt -77.52 150.93 5.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.835 0.35 . . . . 0.0 111.191 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -119.44 139.96 51.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.412 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 6.5 m-85 -118.56 109.95 16.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.92 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.09 140.9 34.96 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.557 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.9 t -152.37 134.64 6.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.844 0.355 . . . . 0.0 111.109 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -92.62 116.34 28.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 74.7 mt -60.03 136.55 58.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.986 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -81.08 -179.94 7.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -53.8 -30.04 43.19 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.141 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -62.26 -47.48 84.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.847 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.419 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -120.12 35.76 3.67 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.444 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -76.88 133.84 39.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.774 0.321 . . . . 0.0 110.898 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.28 30.26 6.71 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.586 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -140.68 38.84 1.84 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 0.0 110.936 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.57 150.31 17.17 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.456 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 10.5 p90 -109.35 -45.73 3.67 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.747 0.308 . . . . 0.0 110.852 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 8.8 t -71.0 -48.45 53.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.927 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 56.05 28.6 13.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.126 179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.414 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.15 -24.88 28.14 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.702 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -117.59 129.95 73.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.865 0.364 . . . . 0.0 111.151 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.414 ' CZ ' HD11 ' A' ' 35' ' ' LEU . 62.4 t80 -114.95 110.01 18.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.946 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 59.37 24.71 13.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.113 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.13 23.66 16.74 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.558 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -125.37 109.81 13.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.89 0.376 . . . . 0.0 110.812 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 17.5 tp60 -71.47 95.25 1.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.906 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 44.1 mt -84.5 -38.09 20.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.0 p90 -152.25 171.54 17.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.843 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -101.01 112.63 25.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -137.85 170.07 16.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.913 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -78.96 172.3 13.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.925 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -72.14 123.4 22.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.922 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 60.34 37.91 19.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.885 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 34.7 m -121.46 -64.61 1.21 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.939 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.14 144.62 44.94 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.502 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 15.3 m -152.41 142.78 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.347 . . . . 0.0 111.201 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -104.24 119.52 39.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.837 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 27.1 m -142.77 163.59 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.239 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -76.31 161.27 28.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.241 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 13.6 tp -51.55 -47.46 63.41 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.912 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -56.5 -27.23 56.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.711 179.719 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -80.91 -5.26 57.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.232 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 43.8 mt -104.58 140.43 38.01 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.894 0.378 . . . . 0.0 111.032 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -122.02 110.16 15.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.802 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.9 tp -59.16 138.52 57.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.05 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 5.3 mt -109.28 158.53 9.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.037 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -85.34 102.46 13.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.87 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 20.8 p -109.35 103.18 12.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 177.01 -60.2 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.587 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -71.96 -178.56 3.23 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.605 2.203 . . . . 0.0 112.316 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 66.9 m -105.23 91.08 3.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.88 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.1 t -155.82 -54.87 0.09 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.915 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.101 0 CA-C-O 118.36 -1.245 . . . . 0.0 112.473 -179.997 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.176 0 N-CA-C 112.526 -0.229 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 m -82.66 -43.43 16.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.892 0.377 . . . . 0.0 110.944 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 56.5 m -69.53 106.42 3.0 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.874 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 132.66 87.66 0.35 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.531 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.4 t -159.09 31.95 0.21 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.844 0.354 . . . . 0.0 110.95 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.2 m -166.08 177.5 6.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.36 -63.91 0.26 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.518 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 33.4 mt -81.4 146.47 7.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.782 0.325 . . . . 0.0 111.142 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -144.77 -177.58 5.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.931 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.3 t -67.04 129.71 31.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.132 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 88.04 43.9 5.53 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.482 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -142.35 140.36 18.95 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.584 0.23 . . . . 0.0 110.893 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.14 118.87 4.83 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.528 2.152 . . . . 0.0 112.366 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.5 m -141.8 138.92 31.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.135 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.01 126.44 33.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.996 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.8 t -102.24 128.81 54.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.997 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -89.31 131.65 35.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.947 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -111.37 -56.84 2.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.812 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -67.65 171.3 6.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.932 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.2 m -72.71 78.4 1.11 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.923 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.17 62.24 6.42 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.535 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -122.44 -65.09 1.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.811 0.339 . . . . 0.0 110.84 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -143.39 162.51 35.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.891 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.5 mttt -127.03 113.06 15.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.887 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -76.89 127.72 83.21 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.823 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -71.32 149.99 58.0 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.452 2.102 . . . . 0.0 112.34 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -170.59 149.93 13.44 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.521 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.7 p -88.36 132.71 32.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.826 0.346 . . . . 0.0 111.072 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.4 t -67.96 132.2 32.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.018 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -114.59 -37.0 4.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.959 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -136.93 166.74 22.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.934 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.415 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -164.36 120.34 1.55 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.882 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.54 154.04 7.56 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.51 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.88 146.48 53.4 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.616 2.211 . . . . 0.0 112.328 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.419 HD13 ' CE1' ' A' ' 64' ' ' TYR . 74.0 mt -74.85 -68.88 0.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.82 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 mt -161.4 163.68 30.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.868 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -134.6 119.61 18.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.054 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -130.31 -68.43 0.7 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -120.41 -40.18 2.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.984 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.0 t -66.69 173.08 3.68 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.0 p -66.33 158.33 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.068 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 40.6 t -92.8 95.8 9.75 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.993 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -107.82 -169.5 21.67 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.542 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 25.2 mt -129.11 154.43 40.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.834 0.35 . . . . 0.0 111.139 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.414 ' CD2' ' HG ' ' A' ' 35' ' ' LEU . 85.9 m-85 -124.24 142.59 51.12 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.858 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.415 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 10.4 m-85 -123.92 111.05 15.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.848 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -75.76 117.73 5.24 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.438 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.3 t -130.31 127.22 62.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.811 0.339 . . . . 0.0 111.132 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -84.14 118.84 24.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.913 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 18.8 mt -58.93 139.26 56.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.095 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -84.52 -179.84 7.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.827 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -50.63 -28.8 9.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.188 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.04 -61.56 2.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.854 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -108.58 29.0 10.44 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.459 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt180 -64.76 126.3 27.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.855 0.359 . . . . 0.0 110.933 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.8 36.26 4.31 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.485 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -141.08 32.57 1.75 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.835 0.35 . . . . 0.0 110.924 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -92.47 150.56 20.17 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.485 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -110.04 -33.63 6.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.739 0.304 . . . . 0.0 110.945 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.7 t -83.34 -44.36 14.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.941 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.0 t0 54.93 30.21 13.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.069 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.415 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.44 -28.02 14.92 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.438 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.0 p -115.09 122.99 70.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.749 0.309 . . . . 0.0 111.107 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.419 ' CE1' HD13 ' A' ' 35' ' ' LEU . 21.2 t80 -108.1 114.11 27.77 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.941 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 43.0 mt-30 59.55 26.08 15.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.057 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.08 24.94 23.48 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.601 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -134.15 109.92 9.23 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.866 0.365 . . . . 0.0 110.89 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -67.3 121.28 15.37 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.876 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 95.3 mt -108.89 -32.38 7.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.415 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -156.71 170.48 22.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.838 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.66 116.93 32.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.803 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 5.0 p -139.55 175.31 9.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.69 170.4 15.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.83 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -66.84 116.39 7.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.932 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 60.79 46.0 9.34 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 65.7 m -125.56 -45.93 1.77 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.896 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -68.85 139.75 33.47 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.541 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.3 m -150.56 131.5 4.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.789 0.328 . . . . 0.0 111.175 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 14.1 m-85 -99.99 119.93 39.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.835 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 29.1 m -142.2 168.77 14.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.124 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -81.56 159.69 24.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.194 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 6.3 tp -50.06 -43.18 51.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.894 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -57.02 -28.06 62.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.595 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -81.79 -27.07 33.89 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.792 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.7 142.41 27.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.922 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -133.43 112.93 11.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.885 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.45 140.09 56.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 6.2 mt -103.2 148.88 7.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.063 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 79.8 mt-10 -121.36 -69.51 0.83 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.2 t -176.86 -40.17 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 110.57 -168.06 12.84 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.487 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -52.16 -49.31 17.81 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.621 2.214 . . . . 0.0 112.329 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -88.29 132.98 34.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.27 87.35 7.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.883 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.368 -1.24 . . . . 0.0 112.565 179.98 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -113.91 116.11 28.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.831 0.348 . . . . 0.0 110.831 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.8 m 61.35 113.24 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.961 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.42 -174.47 29.63 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.508 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.7 m -137.02 177.98 7.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.831 0.348 . . . . 0.0 110.848 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -156.64 163.91 38.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.988 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.49 111.25 2.72 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.617 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 22.5 mt -95.39 136.91 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.864 0.364 . . . . 0.0 111.138 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -133.55 -169.27 2.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.846 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 26.1 t -74.28 135.4 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.063 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.32 45.9 7.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.509 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -143.26 136.84 14.21 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 120.561 0.22 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -74.58 118.4 5.31 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.54 2.16 . . . . 0.0 112.327 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 17.9 m -145.66 138.46 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.15 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.0 mtpt -74.36 133.63 42.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.907 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 23.5 t -111.07 139.63 34.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.012 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -98.69 129.45 45.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.6 mt -100.1 -52.46 3.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.35 171.94 10.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 65.2 p -68.27 74.4 0.23 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.837 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.89 66.35 2.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.492 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.8 tt0 -124.79 -47.19 1.82 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.816 0.341 . . . . 0.0 110.921 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -167.27 132.75 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.836 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 4.9 mttt -104.06 129.41 51.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.96 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -96.33 135.05 22.74 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.781 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.82 140.78 35.96 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.432 2.088 . . . . 0.0 112.328 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.85 146.47 10.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.506 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.2 p -85.1 143.06 12.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 111.025 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.2 t -72.99 136.81 24.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.022 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -116.93 -32.45 5.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.21 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 30.8 t80 -150.39 167.84 25.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.8 0.333 . . . . 0.0 111.003 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.426 ' HG3' ' CE2' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -153.38 125.51 7.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.923 179.924 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.62 158.0 18.31 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.473 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.97 163.46 38.36 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.479 2.119 . . . . 0.0 112.301 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.413 HD11 ' CD2' ' A' ' 64' ' ' TYR . 28.1 mt -153.01 -71.99 0.14 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.9 mt -120.25 145.79 46.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.968 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -106.51 95.41 5.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.11 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -102.15 133.28 47.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 60.8 mtt85 62.85 -79.61 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.088 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.02 146.49 31.96 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.962 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 10.9 p -78.67 134.95 26.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.091 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 15.2 t 60.21 100.73 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.9 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -129.22 131.84 6.91 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.483 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.5 mt -93.25 135.3 28.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.838 0.351 . . . . 0.0 111.152 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -103.24 174.01 6.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.947 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.426 ' CE2' ' HG3' ' A' ' 32' ' ' ARG . 28.6 m-85 -145.89 109.93 4.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.9 118.35 8.14 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.457 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.0 t -126.37 140.08 49.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.743 0.306 . . . . 0.0 111.069 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -99.19 114.47 27.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.866 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 34.4 mt -57.49 138.27 55.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.038 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.8 mt -80.41 -179.9 7.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.802 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -54.48 -29.96 51.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.046 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -61.14 -60.46 3.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.816 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -103.26 28.5 15.42 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.488 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -67.67 131.06 44.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 110.919 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.55 33.57 4.42 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.522 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -140.25 34.54 1.89 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.85 0.357 . . . . 0.0 110.916 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.1 146.52 16.09 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.49 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 32.3 p90 -109.88 -49.23 3.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.749 0.309 . . . . 0.0 110.912 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.9 t -63.51 -48.49 77.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.898 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 55.38 29.96 14.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.083 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.423 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 98.35 -28.78 13.24 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.35 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -110.72 128.24 67.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.864 0.364 . . . . 0.0 111.102 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.413 ' CD2' HD11 ' A' ' 35' ' ' LEU . 0.8 OUTLIER -116.29 112.02 20.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.946 -179.867 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 58.95 26.93 15.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.103 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.93 21.35 33.64 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.564 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 3.4 tptp -126.46 109.82 12.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.834 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 18.4 tp60 -68.08 89.99 0.31 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.856 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 16.8 mt -78.16 -42.29 32.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.888 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.423 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.0 p90 -151.15 169.52 21.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.918 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.43 134.22 40.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.918 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -159.49 165.57 32.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -72.26 176.24 5.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.89 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -75.2 120.97 21.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 60.7 47.63 7.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.971 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 84.8 m -130.03 -58.8 1.07 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.851 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.3 139.63 48.54 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.616 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 27.3 m -151.54 125.68 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 111.049 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -89.45 127.86 35.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.952 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 31.0 m -148.65 157.89 7.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.079 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.02 156.99 38.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.101 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 6.6 tp -51.17 -46.55 62.13 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -56.88 -28.86 62.37 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.651 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 17.1 mmtt -77.78 -24.27 48.94 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.879 179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 62.1 mt -83.48 151.59 25.36 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.989 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -135.37 105.86 6.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.839 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 16.8 tp -61.09 133.8 56.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.975 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 28.0 mt -91.23 134.61 29.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.12 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -161.65 122.45 2.7 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.888 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 10.3 p 59.78 110.6 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.95 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 155.32 99.75 0.17 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.525 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.7 176.47 5.06 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.499 2.132 . . . . 0.0 112.253 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.73 158.86 18.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.2 t -97.47 -39.95 8.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.933 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.427 -1.207 . . . . 0.0 112.574 179.979 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.2 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 76.7 p -163.39 130.14 3.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.854 0.359 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.36 30.82 4.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.879 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.44 58.08 0.62 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.513 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -168.73 -69.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.779 0.323 . . . . 0.0 110.876 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -60.41 -173.3 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.864 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 118.46 24.45 3.17 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.897 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 19.7 mt -68.39 94.95 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.5 -176.94 3.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.903 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.3 t -66.43 138.69 22.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.018 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.65 38.63 13.7 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.552 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.12 139.4 31.73 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-O 120.658 0.266 . . . . 0.0 110.929 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.3 118.5 5.21 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.548 2.165 . . . . 0.0 112.304 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.4 m -144.76 138.5 22.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.209 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 35.6 mttt -77.87 126.33 30.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.934 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 26.3 t -105.46 137.68 34.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.049 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -99.06 112.24 24.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.915 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 88.4 mt -73.77 -58.4 3.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.95 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 8.0 ttt-85 -83.96 168.91 15.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.888 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.8 m -80.13 61.07 3.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.852 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 103.61 64.22 0.69 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.499 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -130.0 -66.4 0.79 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.782 0.325 . . . . 0.0 110.883 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -164.96 130.04 2.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.2 mttt -95.33 111.45 23.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.918 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.409 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 38.4 m-85 -86.56 138.87 33.56 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.759 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -68.79 148.85 72.11 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.496 2.13 . . . . 0.0 112.43 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.83 148.05 11.47 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.519 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.9 p -88.76 132.45 33.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.79 0.328 . . . . 0.0 111.142 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.6 t -66.18 135.17 28.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.114 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -118.28 -36.09 3.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -141.16 166.0 25.99 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.917 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.429 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 5.1 ttt180 -158.7 114.91 2.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.875 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.46 145.46 5.63 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.447 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -54.76 -170.26 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.527 2.152 . . . . 0.0 112.287 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.413 HD12 ' CZ ' ' A' ' 45' ' ' PHE . 82.4 mt -115.94 -71.67 0.73 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.881 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.28 171.66 11.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.871 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -120.63 113.78 20.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.106 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -163.03 169.74 19.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.862 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.39 -30.9 11.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.8 t -61.33 -47.5 85.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.912 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.5 m -77.75 177.58 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.156 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.4 t -176.39 68.63 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -138.88 124.11 2.75 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.541 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 35.4 mt -97.43 129.11 48.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.761 0.315 . . . . 0.0 111.11 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.413 ' CZ ' HD12 ' A' ' 35' ' ' LEU . 14.5 m-85 -91.08 144.97 25.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.843 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.429 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 6.4 m-85 -119.34 123.88 45.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.996 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -87.48 131.5 10.64 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.323 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.7 t -139.37 127.5 26.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.758 0.313 . . . . 0.0 111.209 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -85.89 116.66 24.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.764 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 60.1 mt -55.98 140.32 43.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.19 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -87.55 -179.89 6.42 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.85 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -51.97 -29.71 21.74 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.207 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -60.24 -51.34 69.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.889 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.409 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -122.31 38.96 2.42 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.468 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.6 ttt180 -76.52 133.15 39.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.843 0.354 . . . . 0.0 110.931 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.57 23.36 8.9 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.681 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 -130.75 45.37 2.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.861 0.362 . . . . 0.0 110.818 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -107.86 148.45 16.62 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.576 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -110.05 -47.98 3.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.771 0.32 . . . . 0.0 110.908 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.4 t -65.29 -44.84 86.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.994 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.3 t0 57.28 30.6 18.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.061 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.43 -28.17 14.33 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.426 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.8 p -113.47 125.02 70.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.819 0.342 . . . . 0.0 111.063 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 51.7 t80 -111.25 110.09 20.42 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 58.46 28.45 16.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.084 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.28 24.38 22.04 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.492 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.8 tptt -131.55 109.89 10.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.795 0.331 . . . . 0.0 110.805 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 15.3 tp60 -71.07 89.92 0.83 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.939 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 9.0 mt -75.24 -30.73 60.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.915 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -161.89 166.98 25.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -103.28 119.21 38.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.897 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 6.8 p -144.28 176.26 9.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.959 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -72.16 176.21 5.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.9 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -75.59 119.71 20.01 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 60.72 36.5 19.38 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.918 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 86.6 m -118.21 -38.98 3.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.952 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -79.09 146.87 29.77 Favored Glycine 0 N--CA 1.452 -0.233 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.473 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 5.2 m -159.4 134.4 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.842 0.353 . . . . 0.0 111.072 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -96.71 138.9 33.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.874 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 29.1 m -156.19 166.46 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.122 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.29 164.65 17.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.203 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -52.15 -50.51 61.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.841 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -57.14 -28.28 62.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.643 179.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 12.3 mmtt -79.65 -25.11 41.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.835 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 62.6 mt -84.25 159.64 20.93 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.874 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -142.22 101.51 3.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.82 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.9 143.39 51.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.983 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 22.4 mt -112.36 146.59 16.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.101 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.44 124.68 45.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.892 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.2 t -167.59 126.58 1.31 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.962 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 80.82 155.71 12.62 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.511 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.73 62.96 2.34 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.6 2.2 . . . . 0.0 112.311 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -90.38 -47.16 7.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.916 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.3 p -117.42 178.0 4.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.873 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.348 -1.251 . . . . 0.0 112.506 -179.993 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.448 HG22 HG21 ' A' ' 29' ' ' VAL . 19.4 mt . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.85 0.357 . . . . 0.0 111.048 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -140.0 179.58 6.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.3 t -60.3 129.18 22.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 86.28 43.93 6.08 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.476 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.629 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -144.21 137.04 13.66 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.635 0.255 . . . . 0.0 110.929 -179.902 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.22 132.31 12.47 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.466 2.111 . . . . 0.0 112.324 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.549 HG12 ' HA ' ' A' ' 87' ' ' LEU . 13.7 m -155.55 145.79 12.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.211 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.534 ' CG ' HD11 ' A' ' 88' ' ' ILE . 59.4 mttt -81.34 127.43 32.73 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.89 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.994 HG13 HG21 ' A' ' 80' ' ' VAL . 21.2 t -109.98 131.03 62.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.08 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -97.02 113.62 25.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.881 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 58.7 mt -82.03 -44.27 16.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.91 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -98.33 179.29 4.78 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.931 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.8 m -82.4 87.77 6.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.922 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.43 54.91 30.66 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.54 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -115.37 -50.01 2.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.929 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 17.5 tt0 -176.62 126.87 0.18 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.1 mttt -96.03 116.68 29.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.826 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.433 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 30.0 m-85 -86.92 131.48 44.87 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -73.42 145.52 38.23 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.478 2.119 . . . . 0.0 112.265 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.3 154.59 24.59 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.605 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.485 HG13 ' HD3' ' A' ' 30' ' ' ARG . 12.3 p -91.65 135.53 26.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.798 0.333 . . . . 0.0 111.0 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 12' ' ' CYS . 21.0 t -65.17 132.26 30.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.196 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.485 ' HD3' HG13 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -113.5 -30.13 6.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.045 179.988 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -152.8 168.35 26.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.878 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.413 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 16.2 ttt-85 -155.81 123.95 5.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.847 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.64 142.47 3.71 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.465 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo . . . . . 0 C--N 1.345 0.357 0 C-N-CA 122.492 2.128 . . . . 0.0 112.252 179.989 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.1 mt . . . . . 0 C--O 1.232 0.179 0 CA-C-O 120.793 0.33 . . . . 0.0 111.053 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -86.47 136.1 33.22 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.526 ' CB ' HD11 ' A' ' 85' ' ' LEU . 10.8 m-85 -115.66 111.89 21.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.95 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -71.47 119.64 7.87 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.382 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.626 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.8 t -129.86 136.69 58.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.77 0.319 . . . . 0.0 110.978 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -92.34 119.1 31.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.576 HD13 ' HB2' ' A' ' 57' ' ' GLN . 19.5 mt -59.07 133.91 56.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.981 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.7 -179.9 7.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.816 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.7 -29.52 39.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.062 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -63.35 -55.01 28.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.831 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.433 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -110.87 32.24 6.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.413 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 8.3 ttt180 -68.72 135.6 51.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 110.98 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 94.02 37.35 5.46 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.576 ' HB2' HD13 ' A' ' 50' ' ' LEU . 64.0 mm-40 -140.89 33.25 1.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.843 0.354 . . . . 0.0 110.948 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -102.51 145.74 16.56 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.48 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 7.6 p90 -109.94 -50.58 2.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.322 . . . . 0.0 110.972 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.5 t -62.77 -41.84 99.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.911 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 11.4 t70 60.02 30.45 19.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.988 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 94.26 -17.3 59.18 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.753 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.9 p -119.15 138.8 48.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.828 0.347 . . . . 0.0 111.18 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 7.1 t80 -130.14 110.05 11.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.814 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 61.77 28.66 17.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.955 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 100.01 -27.78 18.7 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.568 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -80.27 114.65 19.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.789 0.328 . . . . 0.0 111.018 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 28.6 tp60 -81.36 92.11 6.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.903 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.57 HD12 ' CE2' ' A' ' 79' ' ' PHE . 48.1 mt -70.46 -46.61 63.48 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.972 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.413 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.5 p90 -144.24 168.96 18.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.945 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -111.85 130.1 55.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.892 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 1.2 m -149.93 172.06 15.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.905 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -68.78 -179.98 1.6 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -71.65 121.14 18.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.944 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 60.81 51.57 4.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.878 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 27.4 m -130.1 -46.75 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.994 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.419 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -67.17 141.71 39.92 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.612 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.626 HG22 ' O ' ' A' ' 48' ' ' VAL . 20.7 m -156.99 141.14 7.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.361 . . . . 0.0 111.112 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 69' ' ' LEU . 5.7 m-85 -110.42 134.14 52.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.994 HG21 HG13 ' A' ' 16' ' ' VAL . 18.4 m -156.9 156.6 4.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.083 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.53 154.34 42.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.062 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.416 ' CD1' HD12 ' A' ' 8' ' ' ILE . 6.5 tp -50.37 -43.86 54.47 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.917 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -56.57 -28.0 59.22 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.576 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.7 mttm -79.61 -27.11 41.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.787 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.715 ' CD2' HG22 ' A' ' 16' ' ' VAL . 92.6 mt -80.73 152.45 28.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.904 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -124.91 108.37 11.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.855 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.549 ' HA ' HG12 ' A' ' 14' ' ' VAL . 20.1 tp -59.88 124.31 19.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.534 HD11 ' CG ' ' A' ' 15' ' ' LYS . 31.1 mt . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.112 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.649 HD12 HD12 ' A' ' 82' ' ' LEU . 27.0 mt . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.814 0.34 . . . . 0.0 111.099 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -155.16 -177.8 6.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.826 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.511 ' HA ' HG12 ' A' ' 29' ' ' VAL . 37.7 t -61.7 124.23 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.085 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.14 42.34 5.3 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.437 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.635 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -138.95 138.81 21.88 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.623 0.249 . . . . 0.0 110.95 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.895 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.6 Cg_endo -77.37 117.56 4.38 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.502 2.134 . . . . 0.0 112.398 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.487 HG12 ' HA ' ' A' ' 87' ' ' LEU . 16.0 m -146.8 138.47 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.117 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.44 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 26.9 mttm -81.37 156.88 25.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.992 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.661 HG13 HG21 ' A' ' 80' ' ' VAL . 21.2 t -133.3 127.23 53.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.041 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -88.49 124.06 33.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.878 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 40.2 mt -102.92 -40.13 6.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -85.59 179.88 7.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.812 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 64.7 m -95.61 79.83 3.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 73.12 49.87 14.65 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.525 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -116.73 -69.51 0.85 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.757 0.313 . . . . 0.0 110.867 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -161.93 138.3 7.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.867 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 13.2 mttt -95.67 146.13 24.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -106.0 127.74 27.78 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.788 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.601 ' HB2' HD12 ' A' ' 51' ' ' LEU . 57.0 Cg_endo -70.28 137.84 34.83 Favored 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.461 2.107 . . . . 0.0 112.348 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.92 174.96 29.24 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.512 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.414 HG13 ' O ' ' A' ' 28' ' ' VAL . 10.3 p -120.38 125.66 74.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.827 0.346 . . . . 0.0 111.017 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.635 HG23 ' O ' ' A' ' 12' ' ' CYS . 18.4 t -59.27 123.55 11.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.164 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.5 mmt180 -112.07 -31.91 6.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.889 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -144.62 166.26 25.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.428 ' HD3' ' CE2' ' A' ' 46' ' ' PHE . 38.5 ttp85 -156.77 124.3 5.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.842 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 166.6 145.17 4.36 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.419 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.497 ' HD3' HG23 ' A' ' 44' ' ' ILE . 50.6 Cg_exo . . . . . 0 C--N 1.345 0.357 0 C-N-CA 122.511 2.14 . . . . 0.0 112.356 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.497 HG23 ' HD3' ' A' ' 34' ' ' PRO . 13.8 mm . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.834 0.349 . . . . 0.0 111.076 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -104.36 121.35 43.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.48 ' HB2' HD11 ' A' ' 85' ' ' LEU . 13.6 m-85 -101.55 119.11 38.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.964 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.402 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -83.85 117.74 4.52 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.428 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.498 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -122.84 131.99 72.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.808 0.337 . . . . 0.0 111.092 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -85.18 117.73 24.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.885 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 14.0 mt -60.24 134.87 57.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.937 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.601 HD12 ' HB2' ' A' ' 26' ' ' PRO . 16.5 mt -80.01 -179.96 7.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.863 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -54.36 -29.66 49.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.05 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -60.36 -51.33 69.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.855 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -117.95 35.39 4.08 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.378 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -73.59 145.86 45.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 0.0 110.901 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.4 27.99 28.7 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.466 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -134.17 31.04 3.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.842 0.354 . . . . 0.0 110.89 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.17 149.81 18.46 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.519 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 13.4 p90 -109.94 -49.88 3.04 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.737 0.303 . . . . 0.0 110.928 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.419 HG23 ' N ' ' A' ' 61' ' ' ASP . 6.0 t -62.21 -48.25 80.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.856 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.419 ' N ' HG23 ' A' ' 60' ' ' THR . 11.7 m-20 58.17 37.04 26.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.97 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.42 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.94 -24.09 32.72 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.512 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.8 p -119.43 132.03 70.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.786 0.327 . . . . 0.0 111.132 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -118.55 113.62 21.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.815 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 60.08 28.7 18.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.976 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.07 -24.08 32.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.571 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.95 114.07 21.43 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.821 0.343 . . . . 0.0 110.989 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 6.9 tp60 -78.47 116.42 18.86 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.855 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.462 HD12 ' CE2' ' A' ' 79' ' ' PHE . 72.1 mt -98.92 -37.71 9.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.879 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.42 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 1.8 p90 -154.41 172.68 17.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.93 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -105.29 111.44 24.17 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.001 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.44 167.88 15.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.907 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.8 175.27 3.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.911 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -72.53 117.89 14.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.924 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 60.83 49.5 6.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.841 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 28.5 m -130.0 -49.97 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.912 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.414 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -67.06 146.23 47.66 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.531 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.498 HG22 ' O ' ' A' ' 48' ' ' VAL . 25.8 m -156.78 142.23 9.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.778 0.323 . . . . 0.0 111.179 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.462 ' CE2' HD12 ' A' ' 69' ' ' LEU . 14.8 m-85 -109.89 131.89 54.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.917 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.661 HG21 HG13 ' A' ' 16' ' ' VAL . 30.6 m -152.61 158.05 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.112 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.94 156.61 38.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.132 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.649 HD12 HD12 ' A' ' 8' ' ' ILE . 12.9 tp -51.15 -45.41 61.68 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -57.07 -28.22 62.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.638 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -81.17 -27.02 35.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.865 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.624 ' CD2' HG22 ' A' ' 16' ' ' VAL . 84.9 mt -84.11 130.28 34.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.902 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 57.0 tt0 -113.78 114.01 25.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.899 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.487 ' HA ' HG12 ' A' ' 14' ' ' VAL . 8.5 tp -63.48 142.68 58.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.893 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.895 HD12 ' HB2' ' A' ' 13' ' ' PRO . 20.6 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.094 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.763 HD12 HD12 ' A' ' 82' ' ' LEU . 5.2 mt . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.767 0.318 . . . . 0.0 111.04 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -131.78 -177.94 4.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.927 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.9 t -67.53 135.67 28.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.141 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.38 46.25 7.57 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.451 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.637 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.09 145.75 28.23 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 120.757 0.313 . . . . 0.0 110.962 -179.989 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.489 ' O ' HG13 ' A' ' 14' ' ' VAL . 74.2 Cg_endo -75.09 130.02 12.79 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.579 2.186 . . . . 0.0 112.269 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.598 HG11 HG21 ' A' ' 8' ' ' ILE . 11.8 m -158.02 138.51 4.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.14 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 47.1 mttm -79.23 140.45 37.65 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.05 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.758 HG13 HG21 ' A' ' 80' ' ' VAL . 18.4 t -115.91 135.87 54.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.062 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -97.25 110.07 22.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.857 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 83.0 mt -84.99 -56.26 3.65 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.97 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -75.06 171.99 13.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.944 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.4 m -78.01 80.26 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.885 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.62 55.49 26.84 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -120.45 -58.16 1.86 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 110.838 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -154.08 151.92 29.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.818 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -121.49 135.8 55.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.442 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 37.8 m-85 -106.11 136.49 19.32 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.838 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.545 ' HB2' HD12 ' A' ' 51' ' ' LEU . 63.1 Cg_endo -73.09 143.22 35.64 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.438 2.092 . . . . 0.0 112.431 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.98 156.58 27.98 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.526 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.2 p -95.52 126.52 48.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.771 0.32 . . . . 0.0 111.044 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.637 HG23 ' O ' ' A' ' 12' ' ' CYS . 18.6 t -59.87 135.84 24.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.119 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -119.46 -38.41 3.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.01 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.427 ' CE2' HD22 ' A' ' 69' ' ' LEU . 23.4 t80 -140.82 169.09 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.889 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.416 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 3.5 ttt180 -160.94 124.34 3.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.905 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 165.54 144.97 4.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.478 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo . . . . . 0 C--N 1.344 0.335 0 C-N-CA 122.537 2.158 . . . . 0.0 112.349 179.986 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.5 mt . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.763 0.316 . . . . 0.0 111.077 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -90.37 128.57 36.51 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.921 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.447 ' HB3' HD11 ' A' ' 85' ' ' LEU . 4.8 m-85 -111.74 109.9 19.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.875 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.46 122.68 11.01 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.344 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.624 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.9 t -137.9 130.94 41.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.805 0.336 . . . . 0.0 111.092 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -86.39 121.02 28.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.857 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.52 HD13 ' HB2' ' A' ' 57' ' ' GLN . 30.9 mt -60.45 141.27 56.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.049 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.545 HD12 ' HB2' ' A' ' 26' ' ' PRO . 13.3 mt -88.77 -179.88 6.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.83 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.06 -27.24 43.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.18 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -64.92 -41.57 95.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.966 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.442 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -132.13 38.67 1.86 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.47 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -74.31 161.33 29.99 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.851 0.358 . . . . 0.0 110.859 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.0 29.82 68.56 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.52 ' HB2' HD13 ' A' ' 50' ' ' LEU . 3.5 mm100 -135.86 34.14 2.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.816 0.341 . . . . 0.0 110.927 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.4 147.67 16.86 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.499 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -109.85 -47.78 3.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.813 0.34 . . . . 0.0 110.813 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.571 HG22 ' HA ' ' A' ' 78' ' ' VAL . 5.4 t -62.2 -47.93 82.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.943 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.414 ' N ' HG23 ' A' ' 60' ' ' THR . 0.7 OUTLIER 59.76 32.53 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.964 179.848 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.428 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.1 -24.82 28.32 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.564 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.7 p -120.85 133.28 68.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.864 0.364 . . . . 0.0 111.133 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 12.5 t80 -116.88 110.4 18.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.852 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 13.3 mt-30 60.45 31.01 20.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 98.04 -26.61 22.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.55 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.9 tptm -75.15 110.72 9.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.797 0.332 . . . . 0.0 110.904 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 24.2 tp60 -79.83 95.24 5.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.835 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.61 HD12 ' CE2' ' A' ' 79' ' ' PHE . 75.4 mt -81.65 -36.56 28.69 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.989 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.428 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.7 p90 -156.38 166.94 31.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.957 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -102.4 116.08 31.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.909 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -132.27 176.34 8.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.914 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -79.39 -179.94 7.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -77.69 121.35 23.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 59.7 48.04 9.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.005 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 26.6 m -129.93 -58.34 1.08 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.902 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.48 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -62.71 149.6 48.82 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.419 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.624 HG22 ' O ' ' A' ' 48' ' ' VAL . 15.3 m -158.0 146.54 9.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.873 0.368 . . . . 0.0 111.15 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.61 ' CE2' HD12 ' A' ' 69' ' ' LEU . 9.7 m-85 -108.95 131.8 54.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.758 HG21 HG13 ' A' ' 16' ' ' VAL . 13.2 m -151.01 160.35 3.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.073 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ALA . . . . . 0.416 ' HB3' ' HG3' ' A' ' 84' ' ' LYS . . . -75.86 153.46 36.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.054 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.763 HD12 HD12 ' A' ' 8' ' ' ILE . 11.0 tp -49.73 -44.3 48.32 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.904 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.9 t0 -58.27 -30.96 66.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.602 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.416 ' HG3' ' HB3' ' A' ' 81' ' ' ALA . 9.6 mtmt -78.08 -25.3 47.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.837 179.651 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.447 HD11 ' HB3' ' A' ' 46' ' ' PHE . 32.9 mt -81.7 130.87 35.21 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.14 105.21 14.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.963 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 27.3 tp -62.14 139.59 58.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.467 HD12 ' HB2' ' A' ' 13' ' ' PRO . 16.0 mt . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.074 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.643 HD13 HG11 ' A' ' 14' ' ' VAL . 31.4 mt . . . . . 0 N--CA 1.458 -0.044 0 CA-C-O 120.851 0.358 . . . . 0.0 111.063 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 54.2 m-20 -124.75 -174.91 3.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.4 t -65.14 136.88 25.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.037 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.19 46.56 6.94 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.475 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.659 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -140.49 136.89 17.0 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.618 0.247 . . . . 0.0 110.908 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.705 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.6 Cg_endo -76.47 117.03 4.45 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.45 2.1 . . . . 0.0 112.308 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.643 HG11 HD13 ' A' ' 8' ' ' ILE . 16.3 m -141.99 138.3 30.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.154 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 30.3 mttp -81.4 132.46 35.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.665 HG22 HD23 ' A' ' 85' ' ' LEU . 21.6 t -113.3 131.71 64.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.047 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -87.07 112.94 22.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.443 ' HA ' HD23 ' A' ' 18' ' ' LEU . 15.0 mt -93.83 -44.98 7.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.19 179.59 7.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.3 p -75.24 76.51 2.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.9 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.4 35.2 84.17 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.489 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.92 -62.42 1.47 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.802 0.334 . . . . 0.0 110.895 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.22 142.25 19.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.915 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 18.3 mttm -98.26 115.56 28.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.782 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -75.71 128.12 84.32 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.831 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.434 ' HB2' HD12 ' A' ' 51' ' ' LEU . 64.3 Cg_endo -73.05 139.35 29.66 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.423 2.082 . . . . 0.0 112.311 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.49 157.91 29.62 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.614 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.1 p -95.86 136.05 28.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.774 0.321 . . . . 0.0 111.01 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 12' ' ' CYS . 23.9 t -70.0 130.69 34.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.078 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.427 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 24.9 mmt180 -114.52 -29.42 6.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.209 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -148.49 167.2 25.97 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.881 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.428 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 7.2 ttp180 -162.93 131.73 4.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.857 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.27 150.28 5.66 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.572 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.408 ' HD3' HG23 ' A' ' 44' ' ' ILE . 48.6 Cg_exo . . . . . 0 C--N 1.345 0.354 0 C-N-CA 122.613 2.209 . . . . 0.0 112.333 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.408 HG23 ' HD3' ' A' ' 34' ' ' PRO . 4.2 mp . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.797 0.332 . . . . 0.0 111.089 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -82.95 139.24 33.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.869 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.633 ' CB ' HD11 ' A' ' 85' ' ' LEU . 7.6 m-85 -117.93 113.66 22.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.986 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -78.21 117.49 4.68 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.596 HG21 HD22 ' A' ' 85' ' ' LEU . 20.2 t -123.49 143.37 36.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.766 0.317 . . . . 0.0 111.09 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -97.72 115.0 27.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.93 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.9 mt -59.07 128.29 36.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.032 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.434 HD12 ' HB2' ' A' ' 26' ' ' PRO . 7.2 mt -80.54 -179.93 7.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.867 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -54.85 -29.28 54.77 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.067 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.99 -41.81 99.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.892 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.04 34.64 3.05 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.563 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.9 ttt180 -71.99 144.59 48.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.773 0.321 . . . . 0.0 110.926 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 90.2 31.02 11.2 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.464 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -137.12 32.57 2.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.847 0.356 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.28 143.52 15.67 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.443 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.6 p90 -109.99 -47.92 3.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.824 0.345 . . . . 0.0 110.991 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -66.47 -42.81 86.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.973 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.1 t0 60.03 29.2 18.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.088 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.417 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 85.55 26.25 36.34 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.61 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.53 HG23 ' C ' ' A' ' 67' ' ' LYS . 12.1 p -164.04 133.29 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.775 0.322 . . . . 0.0 111.123 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 17.9 t80 -123.76 117.09 24.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 61.27 29.16 18.52 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.869 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.71 -26.86 21.44 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.547 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.53 ' C ' HG23 ' A' ' 63' ' ' VAL . 22.2 tptt -76.87 111.93 12.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.84 0.352 . . . . 0.0 110.879 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 10.9 tp60 -80.99 108.4 14.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.841 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.648 HD12 ' CE2' ' A' ' 79' ' ' PHE . 44.9 mt -86.63 -31.16 21.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.046 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.427 ' CD2' ' HB2' ' A' ' 30' ' ' ARG . 7.1 p90 -161.35 163.2 30.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -99.0 132.63 44.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.939 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -150.48 170.61 18.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.808 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -70.24 179.96 2.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.806 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -74.35 118.71 17.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 61.17 52.06 4.11 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.97 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 36.1 m -130.06 -51.79 1.12 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.967 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -64.17 138.05 41.1 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.519 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 17.7 m -150.29 140.35 16.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.761 0.315 . . . . 0.0 111.207 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.648 ' CE2' HD12 ' A' ' 69' ' ' LEU . 3.4 m-85 -104.13 122.4 45.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.838 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.617 HG21 HG13 ' A' ' 16' ' ' VAL . 4.5 m -145.85 164.73 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.208 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -76.68 155.94 32.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.189 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.536 HD12 HD12 ' A' ' 8' ' ' ILE . 13.2 tp -50.42 -40.84 51.29 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.737 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.8 t0 -58.45 -29.97 66.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.55 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.1 mmtt -78.83 -23.41 45.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.866 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.665 HD23 HG22 ' A' ' 16' ' ' VAL . 78.7 mt -82.75 143.59 30.77 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.93 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -130.29 97.59 4.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.814 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.633 ' HA ' HG12 ' A' ' 14' ' ' VAL . 19.6 tp -58.69 130.72 48.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.969 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.705 HD12 ' HB2' ' A' ' 13' ' ' PRO . 18.7 mt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.091 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.581 HG12 HD13 ' A' ' 87' ' ' LEU . 21.5 mt . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.824 0.345 . . . . 0.0 111.142 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -131.72 173.03 11.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.783 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.2 t -59.65 141.81 15.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.102 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 73.35 48.39 19.06 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.45 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.525 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.06 141.52 17.34 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.69 0.281 . . . . 0.0 110.954 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.618 ' HB2' HD12 ' A' ' 88' ' ' ILE . 73.3 Cg_endo -75.87 121.81 6.45 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.622 2.215 . . . . 0.0 112.418 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.69 HG12 ' HA ' ' A' ' 87' ' ' LEU . 16.7 m -153.2 138.36 10.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.101 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.3 mttt -75.01 138.03 41.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.949 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.932 HG13 HG21 ' A' ' 80' ' ' VAL . 18.6 t -119.17 136.02 57.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.12 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -90.84 112.62 24.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.972 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.453 HD13 ' HB3' ' A' ' 57' ' ' GLN . 23.3 mt -83.62 -66.27 0.91 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -73.77 172.83 10.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.874 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -76.1 85.76 2.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 61.74 54.09 38.26 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.443 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -112.5 -61.52 1.71 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.798 0.333 . . . . 0.0 110.849 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -162.78 133.09 4.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -95.23 121.9 37.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.858 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.424 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 50.0 m-85 -97.96 142.15 24.12 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.819 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.16 148.37 55.94 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.463 2.109 . . . . 0.0 112.36 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -167.24 154.42 24.7 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.509 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -98.36 127.15 51.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.834 0.349 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 12' ' ' CYS . 11.2 t -59.98 131.91 24.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.999 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -116.41 -30.64 5.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.181 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -146.79 166.0 27.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.866 0.365 . . . . 0.0 111.005 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.422 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.1 ttp180 -165.79 141.28 4.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.831 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 142.73 134.75 2.96 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.548 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo . . . . . 0 C--N 1.346 0.416 0 C-N-CA 122.508 2.139 . . . . 0.0 112.245 -179.976 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.7 mt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.828 0.347 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -100.09 149.85 23.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.978 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.569 ' CB ' HD11 ' A' ' 85' ' ' LEU . 12.6 m-85 -127.8 116.98 21.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.925 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.66 120.67 5.27 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.41 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.597 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -133.6 129.2 55.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.868 0.366 . . . . 0.0 111.134 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -84.28 121.32 27.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.896 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.527 HD12 ' HA ' ' A' ' 76' ' ' CYS . 5.2 mt -59.99 150.23 29.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -96.71 -179.86 4.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.876 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -52.66 -30.02 29.56 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.143 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -62.86 -44.1 97.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.811 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.424 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -124.63 36.4 2.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.453 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt180 -75.48 140.49 42.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.898 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.8 29.85 11.27 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.518 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.453 ' HB3' HD13 ' A' ' 18' ' ' LEU . 48.4 mm-40 -137.21 36.25 2.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.866 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.41 142.43 15.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.576 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -105.65 -45.83 4.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.778 0.323 . . . . 0.0 110.864 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -63.38 -44.02 95.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.969 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.1 t0 57.72 33.73 23.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.928 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.42 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.72 -24.84 27.76 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.533 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.1 p -113.0 135.35 52.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.8 0.334 . . . . 0.0 111.098 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 4.0 t80 -116.82 110.43 18.36 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 77.6 mt-30 60.25 30.88 20.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.841 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.96 -26.3 23.96 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.604 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -81.85 114.11 20.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 110.968 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 31.7 tp60 -74.68 98.76 3.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.813 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.432 HD12 ' CE2' ' A' ' 79' ' ' PHE . 55.3 mt -79.79 -40.46 28.61 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.938 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.42 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -152.64 175.01 13.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.994 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.39 113.97 24.47 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 11.9 p -131.0 -180.0 5.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.01 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -65.65 179.95 0.76 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.96 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.12 118.84 22.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.034 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 59.56 50.04 7.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.023 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' CYS . . . . . 0.527 ' HA ' HD12 ' A' ' 50' ' ' LEU . 43.1 m -129.98 -45.54 1.15 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.983 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.466 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -60.91 146.39 47.53 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.563 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.597 HG22 ' O ' ' A' ' 48' ' ' VAL . 16.1 m -157.63 138.3 4.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.731 0.301 . . . . 0.0 111.074 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.432 ' CE2' HD12 ' A' ' 69' ' ' LEU . 11.2 m-85 -109.23 127.73 54.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.93 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.932 HG21 HG13 ' A' ' 16' ' ' VAL . 31.0 m -150.22 165.68 2.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.117 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.15 156.9 35.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.058 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 11.0 tp -49.55 -43.88 46.21 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.893 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -57.01 -29.85 63.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.55 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 12.5 mmtt -76.43 -25.64 54.64 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.814 179.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.904 ' CD2' HG22 ' A' ' 16' ' ' VAL . 79.2 mt -90.39 137.69 32.15 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.911 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.2 tm-20 -111.65 109.1 18.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.69 ' HA ' HG12 ' A' ' 14' ' ' VAL . 23.8 tp -64.56 128.24 34.92 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.965 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.618 HD12 ' HB2' ' A' ' 13' ' ' PRO . 22.1 mt . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.07 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.675 HD12 HD12 ' A' ' 82' ' ' LEU . 23.1 mt . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.82 0.343 . . . . 0.0 111.092 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -156.84 -172.14 3.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.846 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 t -60.67 136.83 23.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.212 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 75.03 46.58 15.93 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.59 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.797 ' O ' HG23 ' A' ' 29' ' ' VAL . 3.0 t -144.32 131.74 10.49 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.604 0.24 . . . . 0.0 110.969 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.08 122.97 6.97 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.479 2.119 . . . . 0.0 112.386 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.662 HG21 HD13 ' A' ' 85' ' ' LEU . 6.6 m -148.48 138.86 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.0 mttt -76.17 139.46 41.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.902 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.694 ' CG1' HG11 ' A' ' 80' ' ' VAL . 21.4 t -118.28 141.67 36.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.115 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -98.84 115.7 29.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.932 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 39.9 mt -98.39 -59.74 1.69 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 19.0 mtt85 -60.35 168.54 2.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.869 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.9 p -74.3 75.75 1.85 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.82 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.26 55.7 26.27 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.537 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -119.51 -67.25 1.0 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -147.9 154.51 40.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -112.31 152.09 28.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.865 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -116.69 135.63 23.0 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.491 ' HB2' HD12 ' A' ' 51' ' ' LEU . 61.6 Cg_endo -73.01 140.32 31.26 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.477 2.118 . . . . 0.0 112.312 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.79 148.51 16.06 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.635 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.453 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.3 p -89.83 140.66 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.737 0.303 . . . . 0.0 110.979 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.797 HG23 ' O ' ' A' ' 12' ' ' CYS . 11.9 t -72.34 131.17 35.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.098 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.453 ' HD3' HG13 ' A' ' 28' ' ' VAL . 5.8 mmm180 -112.83 -30.8 6.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.126 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -152.5 167.41 28.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.907 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.411 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 0.0 OUTLIER -154.72 130.04 9.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.755 179.931 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.33 151.12 6.14 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.507 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo . . . . . 0 C--N 1.344 0.326 0 C-N-CA 122.61 2.207 . . . . 0.0 112.29 179.993 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.434 HG22 ' N ' ' A' ' 45' ' ' PHE . 3.7 mp . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.829 0.347 . . . . 0.0 111.096 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.434 ' N ' HG22 ' A' ' 44' ' ' ILE . 18.6 m-85 -125.82 156.9 38.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.949 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.411 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 11.7 m-85 -126.78 109.89 12.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.95 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.517 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -66.98 132.73 31.26 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.356 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.618 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.7 t -144.12 130.53 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.899 0.38 . . . . 0.0 111.22 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -88.13 116.73 26.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.827 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 29.3 mt -59.97 131.96 52.48 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.491 HD12 ' HB2' ' A' ' 26' ' ' PRO . 12.0 mt -77.61 -179.89 6.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -53.41 -29.79 36.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.149 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -61.04 -55.47 32.39 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.914 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -112.05 32.44 6.33 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.514 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 8.8 ttt180 -72.83 135.26 45.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.913 0.387 . . . . 0.0 110.866 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 98.61 31.97 6.17 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.526 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 64.4 mm-40 -143.4 33.39 1.31 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.858 0.361 . . . . 0.0 110.932 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -99.8 147.99 18.4 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.521 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 23.7 p90 -109.51 -50.35 3.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.747 0.308 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.446 HG23 ' N ' ' A' ' 61' ' ' ASP . 8.7 t -68.84 -48.57 63.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.887 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.446 ' N ' HG23 ' A' ' 60' ' ' THR . 8.7 m-20 53.89 30.48 11.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.089 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.41 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 106.3 -26.38 20.46 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.506 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.446 HG23 ' C ' ' A' ' 67' ' ' LYS . 11.5 p -120.82 132.8 69.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 111.087 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -119.06 113.77 21.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.932 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 61.26 24.87 14.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.072 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 104.54 -27.9 17.2 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.555 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.446 ' C ' HG23 ' A' ' 63' ' ' VAL . 1.2 tpmp? -79.24 117.59 20.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.923 0.392 . . . . 0.0 110.913 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 8.6 tp60 -85.1 106.0 16.25 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.884 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.452 HD12 ' CE2' ' A' ' 79' ' ' PHE . 91.6 mt -91.01 -34.45 15.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.41 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 7.4 p90 -153.95 171.21 19.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 4.9 mm100 -102.77 121.15 41.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.922 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -136.52 172.85 12.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.807 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.93 173.78 10.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.905 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -65.53 118.67 9.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.991 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 59.55 52.15 5.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.852 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 87.0 m -130.07 -63.93 0.88 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -58.87 137.03 50.75 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.488 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.618 HG22 ' O ' ' A' ' 48' ' ' VAL . 5.7 m -148.07 129.79 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.792 0.329 . . . . 0.0 111.208 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.452 ' CE2' HD12 ' A' ' 69' ' ' LEU . 4.3 m-85 -93.02 129.77 38.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.785 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.694 HG11 ' CG1' ' A' ' 16' ' ' VAL . 4.6 m -150.32 164.56 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.235 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.7 162.58 20.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.176 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.675 HD12 HD12 ' A' ' 8' ' ' ILE . 12.8 tp -52.35 -47.99 65.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.805 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -57.64 -29.0 64.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.604 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 1.7 mttp -79.49 -25.35 41.87 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.809 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.662 HD13 HG21 ' A' ' 14' ' ' VAL . 52.5 mt -87.57 128.02 35.26 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.864 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -114.0 111.35 21.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.836 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.508 ' HA ' HG12 ' A' ' 14' ' ' VAL . 17.4 tp -60.04 134.13 56.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.957 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 29.3 mt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.105 -179.952 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.581 HD13 HG11 ' A' ' 14' ' ' VAL . 29.2 mt . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.761 0.315 . . . . 0.0 111.142 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.421 ' N ' HG22 ' A' ' 8' ' ' ILE . 1.0 OUTLIER -153.35 -168.94 3.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 179.964 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.408 ' HA ' ' CG1' ' A' ' 29' ' ' VAL . 24.9 t -70.16 135.27 28.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.125 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.9 46.17 7.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.408 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.684 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -144.73 137.42 13.6 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.677 0.275 . . . . 0.0 110.99 -179.965 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.1 118.07 4.61 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.477 2.118 . . . . 0.0 112.364 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.609 HG12 ' HA ' ' A' ' 87' ' ' LEU . 24.1 m -146.68 138.32 18.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.196 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.2 mttm -77.06 129.87 36.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.967 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 1.022 HG13 HG21 ' A' ' 80' ' ' VAL . 23.3 t -106.16 128.03 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.002 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 14.6 tt0 -97.24 110.32 22.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.912 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 88.9 mt -80.99 -45.55 16.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.835 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.28 -174.3 5.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.968 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.51 84.25 4.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.82 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.05 55.2 29.41 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.539 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 -117.25 -65.69 1.16 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.776 0.322 . . . . 0.0 110.892 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -158.43 123.07 4.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.866 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 24.2 mttt -90.57 144.06 26.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.419 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 74.0 m-85 -107.98 127.54 27.46 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.864 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -68.39 131.84 24.2 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.397 2.064 . . . . 0.0 112.262 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.66 163.38 30.35 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 28' ' ' VAL . 11.9 p -102.6 125.95 56.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.822 0.344 . . . . 0.0 110.97 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.684 HG23 ' O ' ' A' ' 12' ' ' CYS . 10.3 t -59.88 126.91 18.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -114.38 -31.79 6.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.054 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.558 ' CE2' HD22 ' A' ' 69' ' ' LEU . 28.0 t80 -142.58 167.43 22.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.934 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 13.5 ttp180 -159.22 129.47 5.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.72 148.34 5.15 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.505 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.456 ' HD3' HG23 ' A' ' 44' ' ' ILE . 58.1 Cg_endo . . . . . 0 C--N 1.344 0.338 0 C-N-CA 122.561 2.174 . . . . 0.0 112.274 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.456 HG23 ' HD3' ' A' ' 34' ' ' PRO . 23.2 mt . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.775 0.321 . . . . 0.0 111.18 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -106.99 150.39 26.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.98 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.421 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 9.5 m-85 -123.34 114.9 20.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.971 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.424 ' N ' ' CD1' ' A' ' 79' ' ' PHE . . . -74.93 121.84 6.77 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.48 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.573 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -129.95 133.76 64.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.823 0.344 . . . . 0.0 111.113 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -90.02 115.91 27.65 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.457 HD13 ' HB2' ' A' ' 57' ' ' GLN . 37.3 mt -58.88 133.59 56.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.993 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -81.55 -179.89 7.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.921 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -53.14 -29.63 32.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.106 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -60.86 -58.35 8.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.419 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -111.12 32.72 6.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.465 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -69.74 133.06 47.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.769 0.319 . . . . 0.0 110.907 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.46 35.8 4.56 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.53 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.457 ' HB2' HD13 ' A' ' 50' ' ' LEU . 4.8 mt-30 -141.47 31.36 1.69 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.342 . . . . 0.0 110.877 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.72 147.39 16.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.513 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -108.56 -49.23 3.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.75 0.31 . . . . 0.0 110.863 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.3 t -59.43 -43.78 93.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.957 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.0 t0 59.82 29.38 18.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.052 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.422 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.47 -19.57 53.62 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.69 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.537 HG23 ' C ' ' A' ' 67' ' ' LYS . 11.2 p -124.22 140.38 47.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.865 0.364 . . . . 0.0 111.178 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -122.85 109.96 14.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.923 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER 60.22 26.6 16.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.001 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.12 -30.27 9.54 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.592 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.537 ' C ' HG23 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -77.34 117.93 19.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.951 0.405 . . . . 0.0 110.925 -179.988 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 2.9 tp60 -84.91 92.69 8.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.861 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.558 HD22 ' CE2' ' A' ' 31' ' ' PHE . 71.1 mt -69.49 -44.57 70.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.912 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.422 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.9 p90 -147.77 177.78 9.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.961 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -113.83 123.92 50.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.885 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 17.7 p -150.0 163.06 39.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.891 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -60.12 178.51 0.18 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.936 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -75.71 124.55 27.45 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 60.79 49.86 5.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.909 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 53.7 m -129.99 -45.93 1.14 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.907 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -69.41 132.17 24.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.519 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 48' ' ' VAL . 7.7 m -142.15 131.16 22.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.886 0.374 . . . . 0.0 111.094 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.454 ' CE2' HD12 ' A' ' 69' ' ' LEU . 9.1 m-85 -101.53 127.06 48.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.93 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 1.022 HG21 HG13 ' A' ' 16' ' ' VAL . 31.5 m -151.71 164.15 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.159 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -81.13 162.38 23.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.204 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -51.9 -49.57 62.78 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.887 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -56.89 -28.33 61.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.672 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.0 mtmm -80.03 -25.86 40.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.815 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.795 ' CD2' HG22 ' A' ' 16' ' ' VAL . 80.3 mt -82.86 161.05 22.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.913 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -137.97 104.59 5.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.84 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.609 ' HA ' HG12 ' A' ' 14' ' ' VAL . 19.8 tp -59.68 137.71 57.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.984 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 32.3 mt . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.117 179.973 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.563 HD12 ' CD1' ' A' ' 82' ' ' LEU . 46.0 mt . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -143.1 -172.02 3.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.881 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.526 HG13 ' O ' ' A' ' 30' ' ' ARG . 29.2 t -64.48 127.78 25.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.038 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 87.84 43.28 5.77 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.537 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.649 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -141.44 137.04 16.12 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 120.617 0.246 . . . . 0.0 110.952 -179.961 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -76.34 116.84 4.43 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.526 2.151 . . . . 0.0 112.343 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.618 HG12 ' HA ' ' A' ' 87' ' ' LEU . 6.8 m -144.34 138.74 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.169 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 2.3 mttt -80.42 141.23 35.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.071 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.854 HG13 HG21 ' A' ' 80' ' ' VAL . 31.9 t -115.63 133.6 61.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.053 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -94.52 121.54 36.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.915 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.404 HD12 ' HE2' ' A' ' 25' ' ' PHE . 57.4 mt -101.93 -54.48 2.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.919 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.8 -174.78 0.05 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.839 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 51.7 p -93.0 48.37 1.34 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.918 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 95.51 57.89 1.16 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.469 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -121.43 -51.93 2.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.818 0.342 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -170.02 152.4 4.32 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 10.8 mttt -107.74 138.29 44.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.414 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 26.5 m-85 -95.08 123.14 58.21 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.769 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.634 ' HB2' HD12 ' A' ' 51' ' ' LEU . 37.8 Cg_endo -65.97 138.86 54.22 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.464 2.109 . . . . 0.0 112.263 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -166.74 146.6 11.02 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.571 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.2 p -83.37 145.83 7.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.803 0.335 . . . . 0.0 110.961 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.705 HG13 ' O ' ' A' ' 47' ' ' GLY . 21.7 t -77.86 138.87 19.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.158 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.526 ' O ' HG13 ' A' ' 10' ' ' VAL . 0.7 OUTLIER -117.78 -40.19 3.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.804 179.988 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.411 ' CD2' ' N ' ' A' ' 32' ' ' ARG . 58.1 t80 -140.05 163.8 31.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.793 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.413 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 22.5 ttp85 -158.99 140.79 13.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.911 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.83 161.33 9.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.482 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo . . . . . 0 C--N 1.344 0.292 0 C-N-CA 122.556 2.171 . . . . 0.0 112.287 179.974 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.2 mp . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.82 0.343 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -117.96 146.58 43.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.918 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.413 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 7.0 m-85 -118.28 112.94 20.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.924 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.705 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -68.44 141.4 37.02 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.589 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.443 ' O ' HG22 ' A' ' 78' ' ' VAL . 25.7 t -153.52 140.92 13.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.792 0.329 . . . . 0.0 111.006 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -98.79 113.94 26.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.871 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.456 HD12 ' HA ' ' A' ' 76' ' ' CYS . 3.4 mt -57.76 128.6 37.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.056 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.634 HD12 ' HB2' ' A' ' 26' ' ' PRO . 19.8 mt -78.0 -179.9 6.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.54 -30.03 52.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.079 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -60.64 -48.68 80.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.846 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.414 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -121.57 37.13 3.03 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.488 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.1 ttt180 -74.1 151.89 40.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.802 0.334 . . . . 0.0 110.9 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 84.3 27.91 35.07 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.492 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 68.5 mm-40 -133.92 36.69 3.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.837 0.351 . . . . 0.0 110.918 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.41 145.86 15.99 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.456 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -109.98 -47.38 3.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.821 0.343 . . . . 0.0 110.921 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.3 t -69.98 -40.47 75.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.831 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.6 t0 58.43 29.46 18.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.043 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.414 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 99.01 -20.25 51.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.67 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.9 p -118.56 134.59 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.867 0.365 . . . . 0.0 111.124 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.413 ' CE1' ' HG3' ' A' ' 65' ' ' GLN . 50.4 t80 -122.59 110.02 15.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.858 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.413 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 28.8 mt-30 58.94 26.54 15.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.037 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 105.72 -28.05 15.57 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.568 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.0 118.08 21.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.83 0.348 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 7.7 tp60 -84.08 90.08 7.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.913 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 84.7 mt -71.36 -31.78 67.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.825 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.1 p90 -161.49 164.82 29.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.858 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -112.0 119.42 38.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.887 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 1.3 m -137.17 179.95 6.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.907 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -71.69 179.96 2.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.885 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -72.33 123.24 22.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.001 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 60.02 50.59 6.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' CYS . . . . . 0.456 ' HA ' HD12 ' A' ' 50' ' ' LEU . 27.9 m -130.04 -49.28 1.11 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.983 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -62.65 127.14 38.77 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.558 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.443 HG22 ' O ' ' A' ' 48' ' ' VAL . 21.3 m -146.11 156.23 12.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.748 0.309 . . . . 0.0 111.128 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.429 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 7.9 m-85 -124.47 136.61 54.16 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.889 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.854 HG21 HG13 ' A' ' 16' ' ' VAL . 28.6 m -156.59 160.04 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.11 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ALA . . . . . 0.527 ' HB3' ' OD1' ' A' ' 83' ' ' ASP . . . -73.3 157.48 36.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.116 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.563 ' CD1' HD12 ' A' ' 8' ' ' ILE . 14.8 tp -51.14 -46.41 61.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.845 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ASP . . . . . 0.527 ' OD1' ' HB3' ' A' ' 81' ' ' ALA . 27.6 p-10 -57.16 -28.94 63.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.599 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 5.0 mmtt -79.28 -25.21 42.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.745 ' CD2' HG22 ' A' ' 16' ' ' VAL . 43.7 mt -83.17 154.98 24.0 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.02 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -141.45 104.66 4.62 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.853 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.618 ' HA ' HG12 ' A' ' 14' ' ' VAL . 19.0 tp -59.51 135.14 57.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.002 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.3 mt . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.113 -179.991 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.688 HG21 HG11 ' A' ' 14' ' ' VAL . 4.1 mt . . . . . 0 N--CA 1.458 -0.049 0 CA-C-O 120.918 0.39 . . . . 0.0 111.059 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -138.82 179.77 6.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.842 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.2 t -64.04 133.13 29.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.011 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 84.36 45.53 6.15 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.383 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.496 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -149.87 143.63 16.89 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 120.663 0.268 . . . . 0.0 110.953 -179.948 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.498 ' O ' HG13 ' A' ' 14' ' ' VAL . 74.4 Cg_endo -75.3 138.14 21.96 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.582 2.188 . . . . 0.0 112.267 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.688 HG11 HG21 ' A' ' 8' ' ' ILE . 11.3 m -158.49 138.69 4.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.232 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.3 mttt -82.82 125.94 31.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.948 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.838 HG22 ' CD2' ' A' ' 85' ' ' LEU . 22.0 t -104.49 138.46 29.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.03 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -102.96 112.09 24.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.939 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -85.78 -40.12 16.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.866 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -84.31 -176.3 6.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 71.8 p -100.04 48.26 0.93 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.874 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 105.71 56.89 0.66 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.553 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.95 -60.45 1.08 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.803 0.335 . . . . 0.0 110.904 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -161.63 146.18 13.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.863 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 14.8 mttt -109.21 150.62 27.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.435 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 27.3 m-85 -113.63 127.26 27.03 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.838 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.18 146.17 40.37 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.436 2.091 . . . . 0.0 112.318 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.82 153.4 21.53 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.489 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.8 p -93.27 138.85 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.772 0.32 . . . . 0.0 111.066 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.605 HG22 HG22 ' A' ' 48' ' ' VAL . 19.3 t -72.78 133.32 31.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.098 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 20.0 mmt180 -115.91 -30.45 6.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.038 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -142.78 168.3 20.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.948 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.428 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 24.3 ttp180 -161.23 123.53 3.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.858 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 168.37 145.7 4.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.545 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.532 ' HD3' HG23 ' A' ' 44' ' ' ILE . 53.0 Cg_exo . . . . . 0 C--N 1.344 0.338 0 C-N-CA 122.583 2.189 . . . . 0.0 112.25 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.532 HG23 ' HD3' ' A' ' 34' ' ' PRO . 32.9 mt . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.794 0.331 . . . . 0.0 111.095 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -90.39 147.81 23.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.952 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.428 ' CZ ' ' HD2' ' A' ' 32' ' ' ARG . 12.1 m-85 -117.12 111.95 20.21 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.67 110.27 2.99 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.498 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.605 HG22 HG22 ' A' ' 29' ' ' VAL . 21.8 t -116.97 132.13 67.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.846 0.355 . . . . 0.0 111.039 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -88.53 117.54 27.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.574 HD13 ' HB2' ' A' ' 57' ' ' GLN . 52.8 mt -59.15 135.19 57.56 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.993 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -79.78 -179.93 7.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.821 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -55.13 -30.2 59.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.079 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -63.01 -60.1 3.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.79 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.435 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -101.58 30.86 9.47 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.442 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -69.74 137.87 52.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.79 0.328 . . . . 0.0 110.88 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.01 34.06 6.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.47 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.574 ' HB2' HD13 ' A' ' 50' ' ' LEU . 31.1 mm-40 -140.9 43.84 1.81 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.906 0.384 . . . . 0.0 110.918 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -108.1 143.15 16.05 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.525 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -110.03 -32.1 7.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.87 0.367 . . . . 0.0 110.932 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -85.76 -42.31 14.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.899 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.6 t0 57.08 31.19 19.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.999 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.433 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 93.1 -16.8 59.65 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.676 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.7 p -123.01 142.1 40.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.856 0.36 . . . . 0.0 111.141 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 13.4 t80 -129.09 110.24 11.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.873 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 61.67 24.54 14.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.154 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.18 -27.81 14.7 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.566 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.6 119.53 23.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.947 0.403 . . . . 0.0 110.948 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -82.87 95.61 8.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 78.5 mt -70.83 -51.13 28.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.433 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -144.99 166.1 26.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.913 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.32 124.24 46.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.881 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 9.3 p -149.58 177.1 10.05 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -71.89 175.93 5.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.877 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -78.82 127.79 32.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 60.5 41.22 16.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.902 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 23.7 m -127.53 -46.66 1.45 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.909 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -68.32 132.25 27.67 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.538 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 12.4 m -148.44 135.96 13.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.806 0.336 . . . . 0.0 111.158 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -102.18 130.01 48.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.587 HG21 HG13 ' A' ' 16' ' ' VAL . 4.2 m -150.15 166.74 2.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.148 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.98 158.76 21.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.137 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.457 ' CD1' HD12 ' A' ' 8' ' ' ILE . 9.3 tp -50.55 -44.05 56.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.899 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -57.82 -28.82 64.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.603 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.4 mttt -82.6 -24.85 33.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.86 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.838 ' CD2' HG22 ' A' ' 16' ' ' VAL . 52.7 mt -88.88 128.45 35.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.013 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.9 tm-20 -114.89 107.95 16.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.81 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 13.7 tp -57.74 138.54 55.41 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.997 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 27.3 mt . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 -179.997 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.707 HD13 HG11 ' A' ' 14' ' ' VAL . 20.2 mt . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.828 0.346 . . . . 0.0 111.02 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -120.57 -179.59 4.03 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.3 t -66.86 137.33 25.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.027 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.75 46.82 7.02 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.399 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.581 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -140.72 140.96 23.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.623 0.249 . . . . 0.0 110.955 -179.965 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.473 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.5 Cg_endo -76.51 117.17 4.49 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.566 2.177 . . . . 0.0 112.343 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.707 HG11 HD13 ' A' ' 8' ' ' ILE . 4.9 m -144.38 138.9 23.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.129 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -87.38 140.98 28.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.886 HG22 HD23 ' A' ' 85' ' ' LEU . 19.5 t -121.0 140.4 45.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.095 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -97.96 110.06 22.7 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.442 HD23 ' HA ' ' A' ' 18' ' ' LEU . 14.6 mt -84.57 -58.69 2.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.89 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.42 -174.99 0.74 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.83 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -83.77 68.72 10.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 69.18 45.35 62.09 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.536 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -99.48 -44.72 6.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 0.0 110.916 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -176.66 131.56 0.2 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -88.29 124.85 34.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.825 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -89.84 128.06 51.67 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.832 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.693 ' HB2' HD12 ' A' ' 51' ' ' LEU . 60.4 Cg_endo -72.33 139.4 31.89 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.445 2.097 . . . . 0.0 112.328 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -154.82 167.05 32.6 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.515 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.446 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.6 p -108.73 124.0 64.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.75 0.31 . . . . 0.0 111.014 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 12' ' ' CYS . 16.7 t -59.46 128.55 20.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.13 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -115.73 -29.92 6.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.112 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 40.5 t80 -148.74 165.96 29.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.914 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 15.1 ttp180 -158.46 135.66 9.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.984 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.68 137.32 2.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo . . . . . 0 C--N 1.346 0.435 0 C-N-CA 122.516 2.144 . . . . 0.0 112.339 -179.992 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 16.2 mt . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.795 0.331 . . . . 0.0 111.099 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -120.2 138.92 53.36 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.939 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.475 ' CB ' HD11 ' A' ' 85' ' ' LEU . 6.4 m-85 -120.84 109.91 15.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.845 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.18 119.93 9.07 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.485 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.477 HG22 HG22 ' A' ' 29' ' ' VAL . 22.3 t -134.04 130.83 55.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.774 0.321 . . . . 0.0 111.03 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -83.62 119.06 24.28 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.932 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.9 mt -62.26 141.95 57.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.014 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.693 HD12 ' HB2' ' A' ' 26' ' ' PRO . 7.7 mt -86.73 -179.93 6.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.854 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -54.42 -30.03 51.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.037 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -61.73 -47.06 86.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.871 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.43 38.38 2.39 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.482 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -77.09 151.83 35.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.819 0.342 . . . . 0.0 110.869 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.18 28.13 37.99 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.543 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -135.35 46.55 2.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.804 0.335 . . . . 0.0 110.859 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -118.15 150.44 18.19 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.556 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -110.09 -50.55 2.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.433 HG23 ' N ' ' A' ' 61' ' ' ASP . 7.7 t -69.03 -48.07 63.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.962 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.433 ' N ' HG23 ' A' ' 60' ' ' THR . 18.3 m-20 55.54 32.74 19.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.044 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 105.1 -25.41 25.26 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.545 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 63' ' ' VAL . 10.7 p -121.93 126.54 74.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.807 0.336 . . . . 0.0 111.103 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -116.03 113.89 23.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.86 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 12.9 mt-30 62.39 26.8 16.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.943 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.83 -24.39 32.35 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.616 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 12.2 tptm -81.67 114.56 20.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.882 0.372 . . . . 0.0 110.903 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.8 tp60 -82.64 97.24 8.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.924 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.476 HD12 ' CE2' ' A' ' 79' ' ' PHE . 79.0 mt -80.87 -34.74 33.46 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.012 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.411 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -156.39 169.81 23.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.986 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -103.47 124.74 49.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.889 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -140.61 173.84 11.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.823 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -76.43 179.96 5.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -76.96 120.52 22.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 60.2 41.71 16.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.885 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 78.2 m -125.18 -52.83 1.63 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.945 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -64.62 130.14 36.84 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.454 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 48' ' ' VAL . 5.6 m -142.33 143.46 26.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.853 0.359 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.476 ' CE2' HD12 ' A' ' 69' ' ' LEU . 4.5 m-85 -105.87 124.69 49.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.867 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.814 HG11 HG11 ' A' ' 16' ' ' VAL . 29.4 m -146.65 155.77 11.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.15 155.67 40.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.2 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.471 HD12 HD12 ' A' ' 8' ' ' ILE . 8.9 tp -50.57 -44.51 56.76 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.927 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -56.48 -27.03 55.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.663 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 11.8 mmtt -81.52 -26.75 34.86 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.838 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.886 HD23 HG22 ' A' ' 16' ' ' VAL . 90.2 mt -79.3 140.91 37.43 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.823 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -115.75 103.34 10.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.846 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.529 ' HA ' HG12 ' A' ' 14' ' ' VAL . 23.4 tp -59.54 130.38 46.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.473 HD12 ' HB2' ' A' ' 13' ' ' PRO . 13.6 mt . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.007 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.777 HD12 HD12 ' A' ' 82' ' ' LEU . 30.0 mt . . . . . 0 N--CA 1.457 -0.095 0 CA-C-O 120.82 0.343 . . . . 0.0 111.1 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -134.75 -177.84 4.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.971 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 26.6 t -60.98 135.68 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.133 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.43 46.15 7.04 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.466 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -141.66 138.82 17.65 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.668 0.27 . . . . 0.0 110.865 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.43 ' O ' HD12 ' A' ' 87' ' ' LEU . 71.3 Cg_endo -74.48 117.25 4.89 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 122.503 2.136 . . . . 0.0 112.383 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.759 HG21 HD13 ' A' ' 85' ' ' LEU . 14.9 m -142.99 138.55 27.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.12 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 27.0 mttt -83.63 142.89 30.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.978 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.899 HG22 ' CD2' ' A' ' 85' ' ' LEU . 19.0 t -123.43 132.03 72.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -93.27 118.93 31.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.622 HD11 ' O ' ' A' ' 57' ' ' GLN . 18.1 mt -95.07 -55.8 2.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.98 -170.27 0.22 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.877 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 69.0 m -88.75 79.16 7.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.871 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.83 44.22 98.29 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.523 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -101.62 -66.54 0.91 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.798 0.333 . . . . 0.0 110.836 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -152.92 142.39 21.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.938 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.7 mtpt -103.73 133.13 49.25 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.826 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.424 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 25.8 m-85 -92.84 129.76 38.87 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.78 133.87 17.49 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.427 2.085 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.16 155.39 26.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.594 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -94.52 132.95 37.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.822 0.344 . . . . 0.0 111.067 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.4 t -63.75 133.83 29.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.097 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.28 -36.4 4.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.005 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 52.9 t80 -143.19 164.34 30.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.921 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.408 ' HG3' ' CE2' ' A' ' 46' ' ' PHE . 4.3 ttt180 -154.29 135.91 14.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 160.04 126.82 0.86 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.455 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.714 ' CD ' HG23 ' A' ' 44' ' ' ILE . 52.3 Cg_exo . . . . . 0 C--N 1.346 0.421 0 C-N-CA 122.435 2.09 . . . . 0.0 112.295 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.714 HG23 ' CD ' ' A' ' 34' ' ' PRO . 3.0 mt . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.75 0.309 . . . . 0.0 111.072 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -102.28 134.94 44.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.841 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.408 ' CE2' ' HG3' ' A' ' 32' ' ' ARG . 8.7 m-85 -121.69 113.01 19.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.446 ' N ' ' CD1' ' A' ' 79' ' ' PHE . . . -73.08 118.21 6.26 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.358 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.508 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.6 t -125.73 131.42 71.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 111.124 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -90.55 114.81 27.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.839 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.3 mt -58.32 135.99 57.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.073 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -82.28 -179.97 7.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.896 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.72 -29.66 54.04 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.09 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -61.33 -50.49 72.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.902 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.424 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -121.84 37.59 2.87 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.479 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.57 145.34 41.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.794 0.33 . . . . 0.0 110.911 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 85.95 33.13 15.98 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.539 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.622 ' O ' HD11 ' A' ' 18' ' ' LEU . 7.7 mm-40 -137.3 30.86 2.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.862 0.363 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.38 154.41 18.99 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.502 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -109.47 -49.79 3.07 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.799 0.333 . . . . 0.0 110.869 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.7 t -62.31 -46.26 89.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.946 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 57.51 35.37 25.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.003 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.407 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.49 -27.56 16.89 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.469 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.434 ' O ' HG13 ' A' ' 63' ' ' VAL . 10.8 p -117.46 124.83 73.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 0.0 111.053 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 37.3 t80 -111.91 115.05 28.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.96 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 30.7 mt-30 59.37 25.77 14.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.137 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.84 24.66 22.47 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.61 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.65 109.82 10.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.83 0.348 . . . . 0.0 110.859 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -75.71 97.01 3.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.946 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.443 HD12 ' CE2' ' A' ' 79' ' ' PHE . 79.0 mt -82.65 -30.81 29.1 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.858 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.407 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.9 p90 -152.82 174.64 13.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.938 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.79 110.02 19.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 26.5 p -133.17 174.71 10.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -72.55 179.97 3.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.881 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -74.78 119.31 18.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.975 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 60.75 51.25 4.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.906 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 47.6 m -129.98 -49.34 1.12 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.916 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -71.65 134.63 22.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.502 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 48' ' ' VAL . 8.1 m -141.9 132.61 25.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.805 0.336 . . . . 0.0 111.113 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 47' ' ' GLY . 7.9 m-85 -100.83 118.34 36.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.897 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.515 HG21 HG13 ' A' ' 16' ' ' VAL . 27.4 m -145.3 161.92 12.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.109 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.66 156.05 35.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.127 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.777 HD12 HD12 ' A' ' 8' ' ' ILE . 6.5 tp -50.43 -43.97 55.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.825 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -57.57 -29.27 64.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.573 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 22.6 mmtm -80.62 -27.02 37.41 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.79 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.899 ' CD2' HG22 ' A' ' 16' ' ' VAL . 39.4 mt -84.33 146.59 27.64 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.985 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -131.46 110.96 11.38 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.912 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.43 HD12 ' O ' ' A' ' 13' ' ' PRO . 34.5 tp -62.6 136.14 57.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.99 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 26.9 mt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.183 179.944 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.504 HG21 HG11 ' A' ' 14' ' ' VAL . 20.2 mt . . . . . 0 N--CA 1.457 -0.088 0 CA-C-O 120.755 0.312 . . . . 0.0 111.172 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -157.91 -176.65 6.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.592 HG13 ' O ' ' A' ' 30' ' ' ARG . 39.7 t -58.89 138.93 19.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.146 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 72.06 47.33 31.52 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.512 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.726 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -147.31 136.38 11.52 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.585 0.231 . . . . 0.0 110.893 179.985 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -76.19 130.2 11.91 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.512 2.141 . . . . 0.0 112.298 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.504 HG11 HG21 ' A' ' 8' ' ' ILE . 7.3 m -151.67 138.75 13.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.156 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -81.89 135.21 35.43 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.753 HG22 HD23 ' A' ' 85' ' ' LEU . 21.4 t -116.83 139.9 41.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.14 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -103.26 116.29 32.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.937 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 50.6 mt -89.72 -44.65 9.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.954 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -86.38 172.17 10.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.87 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 43.2 t -76.43 76.22 3.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.11 69.2 1.39 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.509 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -133.38 -57.7 0.89 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.887 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -156.12 132.7 10.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.847 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -102.87 128.1 49.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.874 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.402 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 42.6 m-85 -93.18 129.56 38.88 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.817 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.63 ' HB2' HD12 ' A' ' 51' ' ' LEU . 72.9 Cg_endo -76.06 138.59 20.73 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.435 2.09 . . . . 0.0 112.282 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.27 151.49 22.8 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.552 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.0 p -92.38 130.94 40.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.791 0.329 . . . . 0.0 111.018 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.726 HG23 ' O ' ' A' ' 12' ' ' CYS . 22.1 t -64.77 140.54 19.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.051 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.592 ' O ' HG13 ' A' ' 10' ' ' VAL . 11.3 mmt180 -122.22 -41.07 2.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.042 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -138.25 164.47 29.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.947 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 3.3 ttp180 -158.11 141.94 15.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.857 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.04 149.18 4.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.478 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo . . . . . 0 C--N 1.344 0.294 0 C-N-CA 122.604 2.203 . . . . 0.0 112.339 -179.99 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.6 mt . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.749 0.309 . . . . 0.0 111.063 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -136.71 147.23 46.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.941 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.448 ' HB2' HD11 ' A' ' 85' ' ' LEU . 9.6 m-85 -123.99 109.89 14.1 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.855 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.31 120.68 9.49 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.477 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.529 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -133.21 133.11 58.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.874 0.368 . . . . 0.0 111.107 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -90.24 116.93 28.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.881 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.469 HD21 HG21 ' A' ' 78' ' ' VAL . 63.6 mt -60.43 145.33 48.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.941 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.63 HD12 ' HB2' ' A' ' 26' ' ' PRO . 3.6 mt -86.44 -179.85 6.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.923 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -53.24 -29.35 32.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.111 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.09 -51.95 65.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.884 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.402 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -112.21 29.64 8.22 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.514 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -68.17 144.97 54.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.888 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.67 39.24 14.59 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.519 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -145.4 35.19 1.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.774 0.321 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.05 152.09 19.26 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -110.0 -43.87 3.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 0.0 110.979 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.4 t -77.61 -40.38 42.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.899 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 51.12 26.83 3.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.302 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.417 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 106.31 -31.74 8.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.622 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -111.78 128.79 68.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.89 0.376 . . . . 0.0 111.091 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.428 ' CE1' ' HG3' ' A' ' 65' ' ' GLN . 30.9 t80 -113.28 110.01 19.68 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.896 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLN . . . . . 0.428 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 9.9 mt-30 57.72 28.84 16.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.034 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 102.22 -26.81 22.97 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.498 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.6 tmtt? -82.17 116.82 21.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.918 0.39 . . . . 0.0 110.952 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 19.5 tp60 -78.96 98.91 6.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.832 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 79.0 mt -81.13 -37.86 28.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.949 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.417 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.0 p90 -155.96 173.3 16.99 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.936 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -107.72 123.36 48.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.889 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -139.58 177.2 8.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.911 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -76.05 179.92 5.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.886 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -73.52 114.01 11.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.913 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 42.2 m-20 60.83 45.21 10.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.912 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 62.6 m -125.63 -46.17 1.74 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.894 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -65.1 135.82 37.36 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.525 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 48' ' ' VAL . 8.6 m -148.49 138.86 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.803 0.335 . . . . 0.0 111.164 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -105.15 134.52 48.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.559 ' CG2' HD21 ' A' ' 85' ' ' LEU . 30.5 m -155.79 168.56 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.182 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -87.39 161.24 17.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.191 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 7.0 tp -49.99 -44.3 50.87 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -55.82 -27.1 49.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.665 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 16.1 mmtt -95.86 19.65 11.1 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.934 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.753 HD23 HG22 ' A' ' 16' ' ' VAL . 88.2 mt -129.18 126.71 39.82 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.93 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -107.8 110.39 22.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.963 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.435 ' HA ' HG12 ' A' ' 14' ' ' VAL . 12.2 tp -67.14 117.47 9.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.996 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.0 mp . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.152 179.923 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.455 HG21 HG11 ' A' ' 14' ' ' VAL . 8.7 mt . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.769 0.318 . . . . 0.0 111.058 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.65 -175.54 3.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.924 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.401 ' HA ' ' CG1' ' A' ' 29' ' ' VAL . 28.3 t -64.42 128.86 27.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.018 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 88.47 43.92 5.4 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.444 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.701 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -145.63 139.21 14.6 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.643 0.259 . . . . 0.0 110.963 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.622 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.2 Cg_endo -76.72 130.03 11.27 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.513 2.142 . . . . 0.0 112.303 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.455 HG11 HG21 ' A' ' 8' ' ' ILE . 12.6 m -151.1 138.8 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.141 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 50.2 mttt -82.21 127.49 33.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.962 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.725 HG13 HG21 ' A' ' 80' ' ' VAL . 21.4 t -108.69 137.01 42.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.029 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -92.98 121.41 34.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.971 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.1 mt -100.41 -42.49 6.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.956 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.9 mtt85 -79.68 -178.22 6.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.81 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -80.49 73.54 7.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.825 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.75 41.21 99.88 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.491 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -101.94 -61.86 1.33 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.747 0.308 . . . . 0.0 110.865 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -148.43 159.6 43.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.902 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 2.0 mttm -125.3 126.38 45.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -89.65 137.31 28.72 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.766 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.414 ' HB2' HD12 ' A' ' 51' ' ' LEU . 67.4 Cg_endo -73.88 146.15 37.23 Favored 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.424 2.082 . . . . 0.0 112.331 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -163.29 152.21 22.16 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.502 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.5 p -94.1 129.16 44.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.324 . . . . 0.0 111.138 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 12' ' ' CYS . 18.7 t -62.3 126.58 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.07 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 40.0 mmt180 -112.11 -31.05 7.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.012 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -148.25 167.73 24.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.976 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 9.6 ttp180 -160.85 119.39 2.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.865 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.52 156.34 11.8 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.55 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo . . . . . 0 C--N 1.344 0.325 0 C-N-CA 122.586 2.19 . . . . 0.0 112.357 -179.981 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.9 mp . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.794 0.33 . . . . 0.0 111.153 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -85.5 124.24 31.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.421 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 5.8 m-85 -98.16 120.0 37.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.999 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.444 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -83.56 131.64 10.52 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.418 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.679 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -139.35 126.39 24.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.876 0.37 . . . . 0.0 111.161 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -83.0 117.14 22.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.845 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.445 HD13 ' HB2' ' A' ' 57' ' ' GLN . 13.1 mt -58.62 130.15 45.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.934 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.414 HD12 ' HB2' ' A' ' 26' ' ' PRO . 5.1 mt -76.67 -179.94 5.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.867 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -53.88 -29.2 40.56 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.134 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -61.87 -43.6 98.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.946 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.24 35.33 2.86 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.528 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -72.61 143.44 48.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.779 0.323 . . . . 0.0 110.889 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.48 34.48 11.86 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.475 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.445 ' HB2' HD13 ' A' ' 50' ' ' LEU . 30.5 mm-40 -141.69 37.63 1.65 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.83 0.348 . . . . 0.0 110.843 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -110.16 155.22 16.21 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.521 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -109.92 -50.55 2.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.775 0.321 . . . . 0.0 110.929 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.431 HG23 ' N ' ' A' ' 61' ' ' ASP . 7.2 t -64.61 -48.21 75.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.929 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.431 ' N ' HG23 ' A' ' 60' ' ' THR . 6.0 m-20 56.64 27.8 13.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.154 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.414 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 107.35 -27.05 16.61 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.571 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.494 HG23 ' C ' ' A' ' 67' ' ' LYS . 12.6 p -117.69 138.12 49.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 111.158 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -121.44 109.97 15.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.911 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 17.1 mt-30 61.29 25.17 15.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.091 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.45 -29.27 10.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.571 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.494 ' C ' HG23 ' A' ' 63' ' ' VAL . 6.1 tmtt? -79.27 119.15 21.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.864 0.364 . . . . 0.0 110.984 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 17.9 tp60 -82.13 97.09 8.02 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.91 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.49 HD12 ' CE2' ' A' ' 79' ' ' PHE . 80.5 mt -76.85 -43.92 34.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.958 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.2 p90 -151.46 170.92 18.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.89 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.02 134.45 44.0 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -156.85 165.81 35.15 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -66.92 173.71 3.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -72.68 121.66 20.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 60.38 49.41 6.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.91 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 60.4 m -129.96 -51.65 1.13 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -66.56 142.83 42.99 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.487 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.679 HG22 ' O ' ' A' ' 48' ' ' VAL . 21.0 m -151.37 143.67 16.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.834 0.349 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.49 ' CE2' HD12 ' A' ' 69' ' ' LEU . 12.5 m-85 -109.74 128.39 55.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.881 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.725 HG21 HG13 ' A' ' 16' ' ' VAL . 30.5 m -149.85 154.93 8.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.101 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.52 156.24 33.19 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.092 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.406 ' CD1' HD12 ' A' ' 8' ' ' ILE . 16.2 tp -50.89 -47.7 60.55 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.939 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -55.84 -28.58 57.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.545 179.664 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.2 mmmp? -75.85 -26.32 57.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.727 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.577 ' CD2' HG22 ' A' ' 16' ' ' VAL . 77.7 mt -84.16 137.68 33.4 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.852 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -124.62 108.03 11.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.453 HD13 HG12 ' A' ' 8' ' ' ILE . 10.1 tp -60.91 142.54 56.26 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.88 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.622 HD12 ' HB2' ' A' ' 13' ' ' PRO . 21.5 mt . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.169 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.604 HG21 HG11 ' A' ' 14' ' ' VAL . 31.1 mt . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.819 0.342 . . . . 0.0 111.142 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -122.39 -175.75 3.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.924 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.3 t -66.09 135.17 28.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.077 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.75 45.85 7.05 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.514 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.646 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -143.62 139.8 16.7 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.64 0.257 . . . . 0.0 110.877 -179.974 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -74.77 122.8 7.55 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.427 2.085 . . . . 0.0 112.234 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.681 ' CG2' HD22 ' A' ' 85' ' ' LEU . 15.8 m -147.13 138.39 18.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.154 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 20.3 mttm -84.69 133.43 34.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.036 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.851 HG22 HD23 ' A' ' 85' ' ' LEU . 18.0 t -114.22 139.57 39.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.106 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -91.16 122.28 33.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.888 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 45.9 mt -104.59 -52.2 2.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.965 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.6 mtt85 -68.45 -175.86 0.7 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.2 p -94.7 70.21 3.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.82 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 81.06 47.54 6.5 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -111.92 -68.8 0.91 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.804 0.335 . . . . 0.0 110.888 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -157.57 163.09 38.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 17.0 mttm -114.72 112.29 22.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.902 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -72.25 133.41 83.42 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.746 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.575 ' HB2' HD12 ' A' ' 51' ' ' LEU . 73.0 Cg_endo -74.57 143.95 31.3 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.36 2.04 . . . . 0.0 112.392 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -162.76 156.3 27.95 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.487 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.3 p -95.12 131.47 41.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.346 . . . . 0.0 111.046 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.646 HG23 ' O ' ' A' ' 12' ' ' CYS . 22.0 t -65.9 129.75 30.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.039 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.414 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 5.1 mmt180 -114.88 -29.92 6.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -147.37 166.65 26.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.883 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.422 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 6.3 ttp180 -164.38 141.43 6.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.885 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.86 147.99 4.81 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.483 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo . . . . . 0 C--N 1.344 0.299 0 C-N-CA 122.568 2.179 . . . . 0.0 112.336 179.921 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.7 mp . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.878 0.37 . . . . 0.0 111.065 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -95.1 137.13 34.57 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.892 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.667 ' CB ' HD11 ' A' ' 85' ' ' LEU . 5.3 m-85 -114.59 109.92 18.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.408 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -70.97 118.85 7.73 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.297 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.571 HG21 ' CD2' ' A' ' 85' ' ' LEU . 24.2 t -130.99 131.61 64.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.863 0.363 . . . . 0.0 111.139 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -89.71 116.76 28.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.801 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.668 HD13 ' O ' ' A' ' 54' ' ' GLY . 91.8 mt -57.14 145.57 30.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.149 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.575 HD12 ' HB2' ' A' ' 26' ' ' PRO . 13.3 mt -90.08 -179.88 5.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.836 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -53.19 -27.83 23.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.145 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -63.1 -54.92 30.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.862 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.668 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -116.59 35.65 4.12 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.3 mtt85 -74.69 123.87 25.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.818 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 113.58 25.49 4.28 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.726 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 39.2 mm-40 -135.45 45.72 2.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.847 0.356 . . . . 0.0 110.929 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.62 148.34 18.4 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.47 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 16.3 p90 -109.91 -49.95 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.794 0.33 . . . . 0.0 110.981 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -59.26 -46.2 89.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.0 t0 59.45 26.98 16.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.119 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.409 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.21 -25.49 23.92 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.712 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.6 p -114.18 147.92 17.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.809 0.337 . . . . 0.0 111.161 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 31.7 t80 -132.08 110.01 10.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 53.4 mt-30 60.21 29.62 19.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.914 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.49 -28.33 15.98 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.475 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 8.7 tmtt? -79.66 114.58 18.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.792 0.33 . . . . 0.0 110.932 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 24.5 tp60 -71.51 99.64 2.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.942 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 73.0 mt -78.08 -39.05 42.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CD2' ' HB2' ' A' ' 30' ' ' ARG . 2.3 p90 -163.71 167.9 20.47 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.86 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 17.4 mm-40 -93.82 129.36 40.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.942 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.64 173.96 12.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.91 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -83.27 167.62 17.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.799 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -66.04 118.35 9.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 60.56 44.34 11.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.946 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 86.8 m -127.61 -55.84 1.31 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.94 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.17 135.42 51.75 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.546 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.499 HG22 ' O ' ' A' ' 48' ' ' VAL . 6.1 m -143.73 143.84 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.803 0.335 . . . . 0.0 111.107 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.408 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 3.8 m-85 -109.68 131.48 55.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.762 HG21 HG13 ' A' ' 16' ' ' VAL . 20.4 m -155.96 157.72 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.082 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ALA . . . . . 0.411 ' HB3' ' HG3' ' A' ' 84' ' ' LYS . . . -70.54 155.12 41.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.999 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 10.2 tp -50.4 -45.8 55.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -57.26 -29.54 63.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.606 179.759 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.411 ' HG3' ' HB3' ' A' ' 81' ' ' ALA . 14.2 mttm -77.9 -24.68 48.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.902 179.716 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.851 HD23 HG22 ' A' ' 16' ' ' VAL . 66.6 mt -81.82 158.09 24.2 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.908 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -142.99 109.31 5.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.92 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.455 ' HA ' HG12 ' A' ' 14' ' ' VAL . 34.6 tp -61.8 135.81 57.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.965 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.4 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.052 -179.995 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.505 HD12 HD12 ' A' ' 82' ' ' LEU . 32.1 mt . . . . . 0 N--CA 1.457 -0.096 0 CA-C-O 120.83 0.348 . . . . 0.0 111.109 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -122.51 172.93 8.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.888 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.423 HG13 ' C ' ' A' ' 30' ' ' ARG . 37.2 t -60.65 133.08 26.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.117 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 85.5 45.14 5.91 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.455 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.494 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.44 139.26 14.75 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 120.638 0.256 . . . . 0.0 110.908 -179.94 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -74.17 133.33 17.76 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.486 2.124 . . . . 0.0 112.253 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.468 ' CG2' HD22 ' A' ' 85' ' ' LEU . 6.2 m -153.83 138.87 10.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.139 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -84.02 131.16 34.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.968 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.802 HG22 HD23 ' A' ' 85' ' ' LEU . 16.8 t -113.26 132.4 62.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.102 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -91.59 116.02 28.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.957 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.564 HD12 ' CE2' ' A' ' 25' ' ' PHE . 36.7 mt -91.56 -57.33 2.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -70.44 -172.11 0.56 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.941 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 t -84.5 79.52 9.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.5 39.04 94.43 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.486 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -95.03 -61.97 1.39 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.858 0.361 . . . . 0.0 110.905 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -155.54 144.58 20.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 21.3 mttt -106.72 124.84 50.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.862 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.564 ' CE2' HD12 ' A' ' 18' ' ' LEU . 61.3 m-85 -87.84 132.59 39.79 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.77 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.416 ' HB2' HD12 ' A' ' 51' ' ' LEU . 65.8 Cg_endo -73.72 141.64 31.02 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.426 2.084 . . . . 0.0 112.34 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.67 147.83 14.67 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.557 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.531 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.9 p -90.47 133.13 33.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.771 0.32 . . . . 0.0 110.984 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.494 HG23 ' O ' ' A' ' 12' ' ' CYS . 23.4 t -65.07 136.68 26.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.138 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.531 ' HD3' HG13 ' A' ' 28' ' ' VAL . 13.9 mmm180 -117.68 -38.04 3.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.021 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -143.11 166.27 25.13 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.877 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.429 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.8 ttp180 -159.6 133.84 7.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.81 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 155.3 151.45 5.87 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.511 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 C--N 1.344 0.319 0 C-N-CA 122.56 2.173 . . . . 0.0 112.233 -179.973 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.9 mm . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.827 0.346 . . . . 0.0 111.034 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -114.87 139.38 49.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.429 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 7.6 m-85 -120.85 109.93 15.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.414 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -72.06 128.82 14.58 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.414 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.52 HG21 HD21 ' A' ' 85' ' ' LEU . 21.5 t -137.12 136.78 47.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.796 0.331 . . . . 0.0 111.065 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -94.19 115.4 27.67 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.553 HD13 ' O ' ' A' ' 54' ' ' GLY . 65.2 mt -59.17 130.94 49.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.918 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.416 HD12 ' HB2' ' A' ' 26' ' ' PRO . 12.5 mt -77.5 -179.94 6.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.852 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.05 -29.8 45.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.067 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -61.79 -42.97 99.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.958 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.553 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -123.89 34.46 3.57 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.445 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -75.74 132.54 40.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.864 0.364 . . . . 0.0 110.874 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.04 29.96 6.94 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.524 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -140.97 33.38 1.76 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.802 0.334 . . . . 0.0 110.888 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -99.51 152.67 19.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.529 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -109.98 -50.95 2.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.853 0.358 . . . . 0.0 110.941 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.453 HG22 ' HA ' ' A' ' 78' ' ' VAL . 6.1 t -66.58 -48.56 69.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.947 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.425 ' N ' HG23 ' A' ' 60' ' ' THR . 18.4 t70 60.36 23.77 13.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.203 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.427 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 103.81 -31.96 8.09 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.671 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -103.7 133.73 46.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.861 0.362 . . . . 0.0 111.199 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -118.95 109.98 16.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.879 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 60.21 28.11 17.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.956 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.37 23.82 25.72 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.596 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 5.6 tttm -132.3 109.95 10.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.861 0.363 . . . . 0.0 110.88 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 11.9 tp60 -69.72 95.56 0.89 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 83.0 mt -82.32 -37.53 25.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.92 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.427 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.5 p90 -149.0 165.45 31.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -98.25 128.36 44.66 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.907 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.39 164.51 32.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.781 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.89 174.24 9.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -62.84 113.17 2.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.888 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 60.33 54.63 3.85 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.858 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 68.7 m -129.57 -56.47 1.14 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.441 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -59.57 140.28 48.08 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.511 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.453 ' HA ' HG22 ' A' ' 60' ' ' THR . 6.0 m -156.61 127.84 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.754 0.311 . . . . 0.0 111.157 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -90.4 130.31 36.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.848 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.526 HG11 ' CG1' ' A' ' 16' ' ' VAL . 6.1 m -150.41 164.86 2.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.181 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.87 157.4 22.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.128 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.505 HD12 HD12 ' A' ' 8' ' ' ILE . 11.3 tp -50.39 -44.21 54.81 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.848 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -57.39 -28.75 63.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.571 179.698 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.448 ' HE3' HG12 ' A' ' 80' ' ' VAL . 5.2 mtmt -81.4 -26.67 35.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.813 179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.802 HD23 HG22 ' A' ' 16' ' ' VAL . 83.8 mt -85.42 146.16 27.11 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.891 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -133.35 107.89 8.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.925 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 12.4 tp -60.07 121.65 12.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.92 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 1.9 mp . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.162 179.864 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.438 HG21 HG11 ' A' ' 14' ' ' VAL . 11.3 mt . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.799 0.333 . . . . 0.0 111.051 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -150.72 -177.83 6.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.402 ' HA ' HG12 ' A' ' 29' ' ' VAL . 40.3 t -59.71 127.66 19.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.027 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 84.89 43.59 6.7 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.478 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.675 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -139.51 139.32 22.12 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.66 0.267 . . . . 0.0 110.923 -179.897 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.544 ' HB2' HD12 ' A' ' 88' ' ' ILE . 75.3 Cg_endo -77.38 117.38 4.33 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.516 2.144 . . . . 0.0 112.427 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.472 HG12 ' HA ' ' A' ' 87' ' ' LEU . 13.7 m -145.67 138.52 20.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.075 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.414 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 13.3 mttm -84.16 141.19 31.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.072 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.677 HG22 HD23 ' A' ' 85' ' ' LEU . 21.9 t -117.29 134.84 59.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.067 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -92.79 110.1 21.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.946 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.425 HD12 ' CE2' ' A' ' 25' ' ' PHE . 71.2 mt -81.5 -47.05 13.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.801 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.53 145.8 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.957 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 30.2 t -74.57 86.75 2.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.958 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.83 67.8 1.44 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.437 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -149.46 -58.46 0.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.833 0.349 . . . . 0.0 110.984 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -175.97 164.09 2.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 40.6 mttt -117.11 160.36 21.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.896 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.44 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 56.6 m-85 -126.4 121.92 23.77 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.822 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.414 ' HA ' ' HA ' ' A' ' 15' ' ' LYS . 38.3 Cg_endo -66.04 140.6 60.66 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.513 2.142 . . . . 0.0 112.4 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.9 158.0 28.99 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.403 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.9 p -99.46 129.21 50.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.868 0.365 . . . . 0.0 111.098 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.675 HG23 ' O ' ' A' ' 12' ' ' CYS . 19.5 t -65.4 132.65 31.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.097 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.411 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 4.5 mmm180 -116.05 -35.55 4.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.006 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -146.37 169.45 18.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.931 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.426 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 9.6 ttt180 -157.54 120.76 4.01 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.879 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -178.86 146.94 7.53 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.492 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo . . . . . 0 C--N 1.344 0.326 0 C-N-CA 122.603 2.202 . . . . 0.0 112.252 -179.896 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.0 mt . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.758 0.313 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.439 ' HB3' ' CD1' ' A' ' 79' ' ' PHE . 82.8 m-85 -104.67 144.79 31.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.912 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.543 ' CB ' HD11 ' A' ' 85' ' ' LEU . 6.2 m-85 -119.46 109.93 16.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.87 119.86 8.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.58 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.4 t -132.03 133.09 61.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.869 0.366 . . . . 0.0 111.189 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -87.71 116.61 25.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.44 HD13 ' O ' ' A' ' 54' ' ' GLY . 94.5 mt -60.18 130.41 46.52 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.952 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 mt -78.82 -179.93 6.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.767 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.24 -30.06 48.96 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.057 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -61.43 -41.54 97.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.873 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.44 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -127.5 34.04 3.13 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.445 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 mtt180 -72.88 138.26 46.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.799 0.333 . . . . 0.0 110.868 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.42 29.52 8.79 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.513 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -141.51 43.42 1.75 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.792 0.33 . . . . 0.0 110.898 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -113.18 150.18 18.5 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.525 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 5.6 p90 -110.06 -51.22 2.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.78 0.324 . . . . 0.0 110.879 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.445 HG23 ' N ' ' A' ' 61' ' ' ASP . 9.3 t -69.72 -48.32 59.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.835 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.445 ' N ' HG23 ' A' ' 60' ' ' THR . 8.6 m-20 53.91 36.22 23.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.09 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.422 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 97.97 -26.15 24.6 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.555 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.472 HG23 ' C ' ' A' ' 67' ' ' LYS . 12.0 p -118.51 137.23 53.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.809 0.337 . . . . 0.0 111.104 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 3.1 t80 -122.68 111.13 16.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.945 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 62.18 27.15 16.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.037 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 103.04 -28.43 15.85 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.526 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.472 ' C ' HG23 ' A' ' 63' ' ' VAL . 0.5 OUTLIER -79.44 116.63 19.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.871 0.367 . . . . 0.0 110.956 179.998 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 21.7 tp60 -80.31 99.5 7.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.42 HD12 ' HE2' ' A' ' 79' ' ' PHE . 88.0 mt -79.21 -44.93 20.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.853 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.422 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.8 p90 -146.81 176.45 9.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.93 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 2.5 mm-40 -99.37 128.6 45.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -152.05 165.59 34.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -80.66 171.94 14.38 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 -68.9 126.21 29.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 59.02 43.79 17.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 37.5 m -129.87 -60.84 1.02 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -58.6 135.66 51.74 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.535 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 48' ' ' VAL . 22.1 m -148.05 141.28 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.788 0.328 . . . . 0.0 111.131 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.439 ' CD1' ' HB3' ' A' ' 45' ' ' PHE . 3.0 m-85 -104.99 126.82 52.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.842 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.671 HG11 ' CG1' ' A' ' 16' ' ' VAL . 28.9 m -150.22 164.24 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.105 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.26 158.04 29.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.113 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.406 HD12 HD12 ' A' ' 8' ' ' ILE . 8.6 tp -50.68 -44.41 57.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.867 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -57.42 -29.27 63.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.591 179.668 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.26 -26.03 42.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.763 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.677 HD23 HG22 ' A' ' 16' ' ' VAL . 89.0 mt -82.19 125.04 30.45 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.954 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 5.2 tm-20 -112.05 107.48 16.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.472 ' HA ' HG12 ' A' ' 14' ' ' VAL . 31.6 tp -60.36 131.19 50.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.906 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.544 HD12 ' HB2' ' A' ' 13' ' ' PRO . 4.9 mt . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.109 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.53 HG12 HD13 ' A' ' 87' ' ' LEU . 30.8 mt . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.82 0.343 . . . . 0.0 111.115 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -144.58 -172.52 3.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.812 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 30' ' ' ARG . 33.9 t -65.42 144.49 14.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.152 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 68.88 49.11 44.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.506 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.608 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.89 139.91 15.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 120.662 0.268 . . . . 0.0 111.002 179.899 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.09 126.7 8.8 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.544 2.163 . . . . 0.0 112.293 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.413 HG21 HD22 ' A' ' 85' ' ' LEU . 13.3 m -154.04 138.27 9.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.153 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.408 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 39.3 mttt -88.32 138.11 31.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.005 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.777 HG22 HD23 ' A' ' 85' ' ' LEU . 26.2 t -117.35 141.57 35.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.997 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.0 tt0 -103.11 110.03 21.82 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.881 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.1 mt -80.78 -51.07 9.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.02 -169.84 1.72 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.9 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -104.75 87.09 2.59 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.865 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 67.96 56.6 10.38 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.452 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.03 -52.86 1.75 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.36 . . . . 0.0 110.935 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -176.06 139.89 0.39 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.913 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -100.96 122.79 44.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.91 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.44 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 46.6 m-85 -87.67 129.84 49.29 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.821 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.412 ' HB2' HD12 ' A' ' 51' ' ' LEU . 63.0 Cg_endo -73.0 141.02 32.34 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.503 2.135 . . . . 0.0 112.301 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.47 150.22 20.09 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.51 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.628 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.7 p -93.78 133.75 33.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.836 0.35 . . . . 0.0 111.085 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 47' ' ' GLY . 15.8 t -67.96 136.23 26.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.11 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.628 ' HD3' HG13 ' A' ' 28' ' ' VAL . 1.7 mmm180 -118.86 -38.75 3.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.984 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -139.88 165.98 25.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.408 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 36.9 ttp85 -160.49 127.55 4.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.33 146.56 4.67 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.45 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo . . . . . 0 C--N 1.345 0.356 0 C-N-CA 122.504 2.136 . . . . 0.0 112.325 179.967 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.5 mt . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.835 0.35 . . . . 0.0 111.191 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -119.44 139.96 51.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.494 ' CB ' HD11 ' A' ' 85' ' ' LEU . 6.5 m-85 -118.56 109.95 16.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.92 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.635 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -69.09 140.9 34.96 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.557 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.426 HG21 ' CD2' ' A' ' 85' ' ' LEU . 21.9 t -152.37 134.64 6.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.844 0.355 . . . . 0.0 111.109 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -92.62 116.34 28.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.435 HD13 ' O ' ' A' ' 54' ' ' GLY . 74.7 mt -60.03 136.55 58.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.986 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.412 HD12 ' HB2' ' A' ' 26' ' ' PRO . 0.9 OUTLIER -81.08 -179.94 7.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.902 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -53.8 -30.04 43.19 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.141 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -62.26 -47.48 84.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.847 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.44 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -120.12 35.76 3.67 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.444 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -76.88 133.84 39.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.774 0.321 . . . . 0.0 110.898 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.28 30.26 6.71 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.586 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -140.68 38.84 1.84 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 0.0 110.936 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.57 150.31 17.17 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.456 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 10.5 p90 -109.35 -45.73 3.67 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.747 0.308 . . . . 0.0 110.852 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.595 HG22 ' HA ' ' A' ' 78' ' ' VAL . 8.8 t -71.0 -48.45 53.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.927 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.43 ' N ' HG23 ' A' ' 60' ' ' THR . 14.6 m-20 56.05 28.6 13.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.126 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.15 -24.88 28.14 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.702 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -117.59 129.95 73.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.865 0.364 . . . . 0.0 111.151 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 62.4 t80 -114.95 110.01 18.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.946 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 59.37 24.71 13.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.113 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.13 23.66 16.74 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.558 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -125.37 109.81 13.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.89 0.376 . . . . 0.0 110.812 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 17.5 tp60 -71.47 95.25 1.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.906 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.404 HD12 ' HE2' ' A' ' 79' ' ' PHE . 44.1 mt -84.5 -38.09 20.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CD1' ' N ' ' A' ' 70' ' ' PHE . 3.0 p90 -152.25 171.54 17.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.843 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -101.01 112.63 25.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -137.85 170.07 16.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.913 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -78.96 172.3 13.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.925 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -72.14 123.4 22.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.922 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 60.34 37.91 19.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.885 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 34.7 m -121.46 -64.61 1.21 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.939 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.14 144.62 44.94 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.502 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.595 ' HA ' HG22 ' A' ' 60' ' ' THR . 15.3 m -152.41 142.78 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.347 . . . . 0.0 111.201 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.404 ' HE2' HD12 ' A' ' 69' ' ' LEU . 2.8 m-85 -104.24 119.52 39.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.837 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.453 HG11 HG11 ' A' ' 16' ' ' VAL . 27.1 m -142.77 163.59 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.239 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -76.31 161.27 28.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.241 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.494 HD12 HD12 ' A' ' 8' ' ' ILE . 13.6 tp -51.55 -47.46 63.41 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.912 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -56.5 -27.23 56.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.711 179.719 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -80.91 -5.26 57.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.232 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.777 HD23 HG22 ' A' ' 16' ' ' VAL . 43.8 mt -104.58 140.43 38.01 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.894 0.378 . . . . 0.0 111.032 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -122.02 110.16 15.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.802 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.53 HD13 HG12 ' A' ' 8' ' ' ILE . 7.9 tp -59.16 138.52 57.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.05 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 5.3 mt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.037 179.982 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.508 HD13 HG11 ' A' ' 14' ' ' VAL . 33.4 mt . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.782 0.325 . . . . 0.0 111.142 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -144.77 -177.58 5.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.931 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.405 HG13 ' C ' ' A' ' 30' ' ' ARG . 38.3 t -67.04 129.71 31.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.132 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 88.04 43.9 5.53 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.482 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.688 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.35 140.36 18.95 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.584 0.23 . . . . 0.0 110.893 179.986 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.652 ' HB2' HD12 ' A' ' 88' ' ' ILE . 71.9 Cg_endo -77.14 118.87 4.83 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.528 2.152 . . . . 0.0 112.366 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.508 HG11 HD13 ' A' ' 8' ' ' ILE . 4.5 m -141.8 138.92 31.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.135 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 0.1 OUTLIER -84.01 126.44 33.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.996 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.608 HG22 ' CD2' ' A' ' 85' ' ' LEU . 29.8 t -102.24 128.81 54.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.997 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -89.31 131.65 35.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.947 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -111.37 -56.84 2.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.812 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -67.65 171.3 6.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.932 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.2 m -72.71 78.4 1.11 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.923 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.17 62.24 6.42 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.535 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -122.44 -65.09 1.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.811 0.339 . . . . 0.0 110.84 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -143.39 162.51 35.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.891 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.5 mttt -127.03 113.06 15.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.887 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -76.89 127.72 83.21 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.823 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 15' ' ' LYS . 59.0 Cg_endo -71.32 149.99 58.0 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.452 2.102 . . . . 0.0 112.34 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.507 ' HA2' HD12 ' A' ' 51' ' ' LEU . . . -170.59 149.93 13.44 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.521 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.7 p -88.36 132.71 32.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.826 0.346 . . . . 0.0 111.072 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.688 HG23 ' O ' ' A' ' 12' ' ' CYS . 28.4 t -67.96 132.2 32.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.018 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.405 ' C ' HG13 ' A' ' 10' ' ' VAL . 1.0 OUTLIER -114.59 -37.0 4.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.959 179.975 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -136.93 166.74 22.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.934 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -164.36 120.34 1.55 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.882 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.54 154.04 7.56 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.51 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo . . . . . 0 C--N 1.343 0.262 0 C-N-CA 122.616 2.211 . . . . 0.0 112.328 -179.999 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.409 HG22 ' N ' ' A' ' 45' ' ' PHE . 25.2 mt . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 120.834 0.35 . . . . 0.0 111.139 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.409 ' N ' HG22 ' A' ' 44' ' ' ILE . 85.9 m-85 -124.24 142.59 51.12 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.858 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.622 ' CB ' HD11 ' A' ' 85' ' ' LEU . 10.4 m-85 -123.92 111.05 15.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.848 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -75.76 117.73 5.24 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.438 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.567 HG22 HG22 ' A' ' 29' ' ' VAL . 21.3 t -130.31 127.22 62.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.811 0.339 . . . . 0.0 111.132 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -84.14 118.84 24.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.913 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 18.8 mt -58.93 139.26 56.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.095 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.507 HD12 ' HA2' ' A' ' 27' ' ' GLY . 0.0 OUTLIER -84.52 -179.84 7.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.827 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -50.63 -28.8 9.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.188 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.04 -61.56 2.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.854 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -108.58 29.0 10.44 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.459 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt180 -64.76 126.3 27.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.855 0.359 . . . . 0.0 110.933 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.8 36.26 4.31 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.485 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -141.08 32.57 1.75 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.835 0.35 . . . . 0.0 110.924 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -92.47 150.56 20.17 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.485 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -110.04 -33.63 6.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.739 0.304 . . . . 0.0 110.945 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.7 t -83.34 -44.36 14.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.941 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.0 t0 54.93 30.21 13.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.069 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.41 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.44 -28.02 14.92 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.438 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.456 HG13 ' O ' ' A' ' 63' ' ' VAL . 11.0 p -115.09 122.99 70.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.749 0.309 . . . . 0.0 111.107 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -108.1 114.11 27.77 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.941 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 43.0 mt-30 59.55 26.08 15.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.057 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.08 24.94 23.48 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.601 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -134.15 109.92 9.23 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.866 0.365 . . . . 0.0 110.89 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -67.3 121.28 15.37 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.876 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 95.3 mt -108.89 -32.38 7.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.41 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -156.71 170.48 22.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.838 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.66 116.93 32.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.803 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 5.0 p -139.55 175.31 9.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.69 170.4 15.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.83 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -66.84 116.39 7.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.932 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 60.79 46.0 9.34 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 65.7 m -125.56 -45.93 1.77 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.896 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -68.85 139.75 33.47 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.541 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.538 HG22 ' O ' ' A' ' 48' ' ' VAL . 6.3 m -150.56 131.5 4.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.789 0.328 . . . . 0.0 111.175 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 14.1 m-85 -99.99 119.93 39.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.835 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.568 HG21 HG13 ' A' ' 16' ' ' VAL . 29.1 m -142.2 168.77 14.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.124 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -81.56 159.69 24.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.194 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 6.3 tp -50.06 -43.18 51.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.894 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -57.02 -28.06 62.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.595 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -81.79 -27.07 33.89 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.792 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.622 HD11 ' CB ' ' A' ' 46' ' ' PHE . 91.1 mt -88.7 142.41 27.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.922 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -133.43 112.93 11.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.885 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.45 140.09 56.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.652 HD12 ' HB2' ' A' ' 13' ' ' PRO . 6.2 mt . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.063 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.49 HD12 HD12 ' A' ' 82' ' ' LEU . 22.5 mt . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.864 0.364 . . . . 0.0 111.138 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -133.55 -169.27 2.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.846 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 26.1 t -74.28 135.4 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.063 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.32 45.9 7.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.509 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.555 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -143.26 136.84 14.21 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 120.561 0.22 . . . . 0.0 110.927 -179.974 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.526 ' HB2' HD12 ' A' ' 88' ' ' ILE . 70.5 Cg_endo -74.58 118.4 5.31 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.54 2.16 . . . . 0.0 112.327 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.629 HG12 ' HA ' ' A' ' 87' ' ' LEU . 17.9 m -145.66 138.46 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.15 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.0 mtpt -74.36 133.63 42.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.907 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 1.049 HG13 HG21 ' A' ' 80' ' ' VAL . 23.5 t -111.07 139.63 34.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.012 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -98.69 129.45 45.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.6 mt -100.1 -52.46 3.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.35 171.94 10.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 65.2 p -68.27 74.4 0.23 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.837 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.89 66.35 2.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.492 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.8 tt0 -124.79 -47.19 1.82 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.816 0.341 . . . . 0.0 110.921 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -167.27 132.75 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.836 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 4.9 mttt -104.06 129.41 51.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.96 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -96.33 135.05 22.74 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.781 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.603 ' HB2' HD12 ' A' ' 51' ' ' LEU . 58.8 Cg_endo -71.82 140.78 35.96 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.432 2.088 . . . . 0.0 112.328 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.85 146.47 10.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.506 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.2 p -85.1 143.06 12.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 111.025 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.555 HG23 ' O ' ' A' ' 12' ' ' CYS . 23.2 t -72.99 136.81 24.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.022 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -116.93 -32.45 5.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.21 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 30.8 t80 -150.39 167.84 25.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.8 0.333 . . . . 0.0 111.003 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CE2' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -153.38 125.51 7.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.923 179.924 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.62 158.0 18.31 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.473 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo . . . . . 0 C--N 1.344 0.325 0 C-N-CA 122.479 2.119 . . . . 0.0 112.301 -179.98 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.5 mt . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.838 0.351 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -103.24 174.01 6.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.947 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.705 ' CB ' HD11 ' A' ' 85' ' ' LEU . 28.6 m-85 -145.89 109.93 4.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.9 118.35 8.14 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.457 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.602 HG21 ' CD2' ' A' ' 85' ' ' LEU . 21.0 t -126.37 140.08 49.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.743 0.306 . . . . 0.0 111.069 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -99.19 114.47 27.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.866 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.501 HD13 ' HB2' ' A' ' 57' ' ' GLN . 34.4 mt -57.49 138.27 55.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.038 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.603 HD12 ' HB2' ' A' ' 26' ' ' PRO . 1.8 mt -80.41 -179.9 7.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.802 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -54.48 -29.96 51.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.046 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -61.14 -60.46 3.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.816 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -103.26 28.5 15.42 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.488 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -67.67 131.06 44.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 110.919 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.55 33.57 4.42 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.522 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.501 ' HB2' HD13 ' A' ' 50' ' ' LEU . 99.6 mm-40 -140.25 34.54 1.89 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.85 0.357 . . . . 0.0 110.916 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.1 146.52 16.09 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.49 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 32.3 p90 -109.88 -49.23 3.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.749 0.309 . . . . 0.0 110.912 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.423 HG23 ' N ' ' A' ' 61' ' ' ASP . 6.9 t -63.51 -48.49 77.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.898 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.423 ' N ' HG23 ' A' ' 60' ' ' THR . 9.1 m-20 55.38 29.96 14.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.083 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.417 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 98.35 -28.78 13.24 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.35 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -110.72 128.24 67.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.864 0.364 . . . . 0.0 111.102 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -116.29 112.02 20.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.946 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 58.95 26.93 15.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.103 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.93 21.35 33.64 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.564 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 3.4 tptp -126.46 109.82 12.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.834 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 18.4 tp60 -68.08 89.99 0.31 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.856 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 16.8 mt -78.16 -42.29 32.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.888 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.417 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.0 p90 -151.15 169.52 21.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.918 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.43 134.22 40.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.918 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -159.49 165.57 32.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -72.26 176.24 5.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.89 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -75.2 120.97 21.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 60.7 47.63 7.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.971 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 84.8 m -130.03 -58.8 1.07 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.851 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.3 139.63 48.54 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.616 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 27.3 m -151.54 125.68 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 111.049 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -89.45 127.86 35.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.952 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 1.049 HG21 HG13 ' A' ' 16' ' ' VAL . 31.0 m -148.65 157.89 7.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.079 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.02 156.99 38.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.101 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.49 HD12 HD12 ' A' ' 8' ' ' ILE . 6.6 tp -51.17 -46.55 62.13 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -56.88 -28.86 62.37 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.651 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 17.1 mmtt -77.78 -24.27 48.94 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.879 179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.705 HD11 ' CB ' ' A' ' 46' ' ' PHE . 62.1 mt -83.48 151.59 25.36 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.989 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -135.37 105.86 6.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.839 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.629 ' HA ' HG12 ' A' ' 14' ' ' VAL . 16.8 tp -61.09 133.8 56.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.975 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.526 HD12 ' HB2' ' A' ' 13' ' ' PRO . 28.0 mt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.12 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.625 ' CG2' HG11 ' A' ' 14' ' ' VAL . 19.7 mt . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.5 -176.94 3.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.903 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.3 t -66.43 138.69 22.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.018 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.65 38.63 13.7 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.552 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.621 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -135.12 139.4 31.73 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-O 120.658 0.266 . . . . 0.0 110.929 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.3 118.5 5.21 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.548 2.165 . . . . 0.0 112.304 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.625 HG11 ' CG2' ' A' ' 8' ' ' ILE . 16.4 m -144.76 138.5 22.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.209 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 35.6 mttt -77.87 126.33 30.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.934 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.733 HG13 HG21 ' A' ' 80' ' ' VAL . 26.3 t -105.46 137.68 34.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.049 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.0 tt0 -99.06 112.24 24.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.915 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 88.4 mt -73.77 -58.4 3.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.95 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 8.0 ttt-85 -83.96 168.91 15.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.888 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.8 m -80.13 61.07 3.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.852 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 103.61 64.22 0.69 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.499 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -130.0 -66.4 0.79 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.782 0.325 . . . . 0.0 110.883 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -164.96 130.04 2.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.2 mttt -95.33 111.45 23.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.918 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.425 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 38.4 m-85 -86.56 138.87 33.56 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.759 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -68.79 148.85 72.11 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.496 2.13 . . . . 0.0 112.43 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.83 148.05 11.47 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.519 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.446 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.9 p -88.76 132.45 33.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.79 0.328 . . . . 0.0 111.142 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 12' ' ' CYS . 19.6 t -66.18 135.17 28.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.114 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.446 ' HD3' HG13 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -118.28 -36.09 3.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 -179.914 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -141.16 166.0 25.99 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.917 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.415 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 5.1 ttt180 -158.7 114.91 2.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.875 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.46 145.46 5.63 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.447 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.628 ' HD3' HG23 ' A' ' 44' ' ' ILE . 52.3 Cg_exo . . . . . 0 C--N 1.345 0.391 0 C-N-CA 122.527 2.152 . . . . 0.0 112.287 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.628 HG23 ' HD3' ' A' ' 34' ' ' PRO . 35.4 mt . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.761 0.315 . . . . 0.0 111.11 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 14.5 m-85 -91.08 144.97 25.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.843 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.415 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 6.4 m-85 -119.34 123.88 45.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.996 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.556 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -87.48 131.5 10.64 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.323 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.611 ' HB ' HG21 ' A' ' 16' ' ' VAL . 21.7 t -139.37 127.5 26.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.758 0.313 . . . . 0.0 111.209 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -85.89 116.66 24.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.764 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.429 HD13 ' O ' ' A' ' 54' ' ' GLY . 60.1 mt -55.98 140.32 43.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.19 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -87.55 -179.89 6.42 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.85 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -51.97 -29.71 21.74 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.207 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -60.24 -51.34 69.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.889 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.429 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -122.31 38.96 2.42 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.468 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.6 ttt180 -76.52 133.15 39.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.843 0.354 . . . . 0.0 110.931 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.57 23.36 8.9 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.681 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 -130.75 45.37 2.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.861 0.362 . . . . 0.0 110.818 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -107.86 148.45 16.62 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.576 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -110.05 -47.98 3.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.771 0.32 . . . . 0.0 110.908 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.4 t -65.29 -44.84 86.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.994 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.3 t0 57.28 30.6 18.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.061 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.43 -28.17 14.33 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.426 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.431 ' O ' HG13 ' A' ' 63' ' ' VAL . 11.8 p -113.47 125.02 70.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.819 0.342 . . . . 0.0 111.063 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 51.7 t80 -111.25 110.09 20.42 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 58.46 28.45 16.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.084 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.28 24.38 22.04 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.492 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.8 tptt -131.55 109.89 10.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.795 0.331 . . . . 0.0 110.805 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 15.3 tp60 -71.07 89.92 0.83 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.939 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 9.0 mt -75.24 -30.73 60.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.915 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -161.89 166.98 25.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -103.28 119.21 38.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.897 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 6.8 p -144.28 176.26 9.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.959 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -72.16 176.21 5.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.9 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -75.59 119.71 20.01 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 60.72 36.5 19.38 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.918 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 86.6 m -118.21 -38.98 3.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.952 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.55 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -79.09 146.87 29.77 Favored Glycine 0 N--CA 1.452 -0.233 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.473 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.55 HG13 ' O ' ' A' ' 77' ' ' GLY . 5.2 m -159.4 134.4 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.842 0.353 . . . . 0.0 111.072 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -96.71 138.9 33.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.874 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.733 HG21 HG13 ' A' ' 16' ' ' VAL . 29.1 m -156.19 166.46 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.122 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.29 164.65 17.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.203 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -52.15 -50.51 61.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.841 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -57.14 -28.28 62.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.643 179.75 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 12.3 mmtt -79.65 -25.11 41.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.835 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.597 ' CD2' HG22 ' A' ' 16' ' ' VAL . 62.6 mt -84.25 159.64 20.93 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.874 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -142.22 101.51 3.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.82 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.605 ' HA ' HG12 ' A' ' 14' ' ' VAL . 8.9 tp -59.9 143.39 51.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.983 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 22.4 mt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.101 179.944 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.183 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 m -135.0 64.97 1.58 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.924 0.392 . . . . 0.0 110.865 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 37.5 m -82.04 -31.47 30.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 131.02 43.14 0.19 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.536 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.3 m -127.06 -67.06 0.86 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.848 0.356 . . . . 0.0 110.982 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 18.6 m 60.17 -172.89 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.927 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 161.97 103.56 0.18 Allowed Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.521 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.448 HG22 HG21 ' A' ' 29' ' ' VAL . 19.4 mt -102.12 137.14 31.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.85 0.357 . . . . 0.0 111.048 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -140.0 179.58 6.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.3 t -60.3 129.18 22.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 86.28 43.93 6.08 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.476 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.629 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -144.21 137.04 13.66 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.635 0.255 . . . . 0.0 110.929 -179.902 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.22 132.31 12.47 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.466 2.111 . . . . 0.0 112.324 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.549 HG12 ' HA ' ' A' ' 87' ' ' LEU . 13.7 m -155.55 145.79 12.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.211 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.534 ' CG ' HD11 ' A' ' 88' ' ' ILE . 59.4 mttt -81.34 127.43 32.73 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.89 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.994 HG13 HG21 ' A' ' 80' ' ' VAL . 21.2 t -109.98 131.03 62.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.08 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -97.02 113.62 25.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.881 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 58.7 mt -82.03 -44.27 16.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.91 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -98.33 179.29 4.78 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.931 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.8 m -82.4 87.77 6.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.922 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.43 54.91 30.66 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.54 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -115.37 -50.01 2.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.929 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 17.5 tt0 -176.62 126.87 0.18 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.1 mttt -96.03 116.68 29.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.826 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.433 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 30.0 m-85 -86.92 131.48 44.87 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -73.42 145.52 38.23 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.478 2.119 . . . . 0.0 112.265 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.3 154.59 24.59 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.605 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.485 HG13 ' HD3' ' A' ' 30' ' ' ARG . 12.3 p -91.65 135.53 26.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.798 0.333 . . . . 0.0 111.0 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 12' ' ' CYS . 21.0 t -65.17 132.26 30.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.196 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.485 ' HD3' HG13 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -113.5 -30.13 6.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.045 179.988 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -152.8 168.35 26.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.878 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.413 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 16.2 ttt-85 -155.81 123.95 5.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.847 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.64 142.47 3.71 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.465 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -56.67 -173.16 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.492 2.128 . . . . 0.0 112.252 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.502 HD13 ' CZ ' ' A' ' 64' ' ' TYR . 96.2 mt -148.57 -61.29 0.24 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 9.8 mp -83.16 -178.41 7.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.89 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -152.06 92.5 1.72 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.132 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 59.32 33.06 22.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.973 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 3.1 mtm180 -103.85 -31.46 9.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.839 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 37.4 m -141.09 -61.49 0.48 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.903 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.0 p -156.46 138.96 6.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.095 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 13.9 m -80.73 94.64 6.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -148.99 134.93 5.18 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.567 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.1 mt -75.49 130.23 36.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.793 0.33 . . . . 0.0 111.053 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -86.47 136.1 33.22 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.526 ' CB ' HD11 ' A' ' 85' ' ' LEU . 10.8 m-85 -115.66 111.89 21.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.95 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -71.47 119.64 7.87 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.382 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.626 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.8 t -129.86 136.69 58.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.77 0.319 . . . . 0.0 110.978 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -92.34 119.1 31.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.576 HD13 ' HB2' ' A' ' 57' ' ' GLN . 19.5 mt -59.07 133.91 56.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.981 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.7 -179.9 7.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.816 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.7 -29.52 39.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.062 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -63.35 -55.01 28.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.831 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.433 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -110.87 32.24 6.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.413 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 8.3 ttt180 -68.72 135.6 51.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 110.98 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 94.02 37.35 5.46 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.576 ' HB2' HD13 ' A' ' 50' ' ' LEU . 64.0 mm-40 -140.89 33.25 1.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.843 0.354 . . . . 0.0 110.948 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -102.51 145.74 16.56 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.48 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 7.6 p90 -109.94 -50.58 2.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.322 . . . . 0.0 110.972 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.5 t -62.77 -41.84 99.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.911 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 11.4 t70 60.02 30.45 19.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.988 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 94.26 -17.3 59.18 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.753 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.9 p -119.15 138.8 48.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.828 0.347 . . . . 0.0 111.18 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.502 ' CZ ' HD13 ' A' ' 35' ' ' LEU . 7.1 t80 -130.14 110.05 11.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.814 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 61.77 28.66 17.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.955 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 100.01 -27.78 18.7 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.568 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -80.27 114.65 19.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.789 0.328 . . . . 0.0 111.018 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 28.6 tp60 -81.36 92.11 6.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.903 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.57 HD12 ' CE2' ' A' ' 79' ' ' PHE . 48.1 mt -70.46 -46.61 63.48 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.972 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.413 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.5 p90 -144.24 168.96 18.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.945 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -111.85 130.1 55.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.892 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 1.2 m -149.93 172.06 15.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.905 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -68.78 -179.98 1.6 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -71.65 121.14 18.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.944 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 60.81 51.57 4.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.878 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 27.4 m -130.1 -46.75 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.994 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.419 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -67.17 141.71 39.92 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.612 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.626 HG22 ' O ' ' A' ' 48' ' ' VAL . 20.7 m -156.99 141.14 7.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.361 . . . . 0.0 111.112 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 69' ' ' LEU . 5.7 m-85 -110.42 134.14 52.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.994 HG21 HG13 ' A' ' 16' ' ' VAL . 18.4 m -156.9 156.6 4.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.083 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.53 154.34 42.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.062 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.416 ' CD1' HD12 ' A' ' 8' ' ' ILE . 6.5 tp -50.37 -43.86 54.47 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.917 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -56.57 -28.0 59.22 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.576 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.7 mttm -79.61 -27.11 41.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.787 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.715 ' CD2' HG22 ' A' ' 16' ' ' VAL . 92.6 mt -80.73 152.45 28.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.904 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -124.91 108.37 11.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.855 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.549 ' HA ' HG12 ' A' ' 14' ' ' VAL . 20.1 tp -59.88 124.31 19.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.534 HD11 ' CG ' ' A' ' 15' ' ' LYS . 31.1 mt -112.05 138.61 40.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.112 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -65.73 141.46 58.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.895 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 9.4 t -98.4 35.45 1.79 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.866 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -139.53 66.13 0.52 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.541 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.27 -41.68 64.64 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.573 2.182 . . . . 0.0 112.28 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 81.0 p -102.59 117.91 35.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.853 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 82.2 p -148.95 127.47 12.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.947 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.34 -1.255 . . . . 0.0 112.511 -179.992 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.235 0 N-CA-C 112.529 -0.228 . . . . 0.0 112.529 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -140.97 157.07 45.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.858 0.361 . . . . 0.0 110.859 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.2 100.98 0.66 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.929 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 105.33 159.13 23.1 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.496 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.6 m -160.84 145.13 13.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.77 0.319 . . . . 0.0 110.895 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.5 m -79.33 -77.62 0.17 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.894 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 112.85 103.74 2.65 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.457 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.649 HD12 HD12 ' A' ' 82' ' ' LEU . 27.0 mt -87.07 145.89 7.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.814 0.34 . . . . 0.0 111.099 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -155.16 -177.8 6.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.826 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.511 ' HA ' HG12 ' A' ' 29' ' ' VAL . 37.7 t -61.7 124.23 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.085 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.14 42.34 5.3 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.437 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.635 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -138.95 138.81 21.88 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.623 0.249 . . . . 0.0 110.95 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.895 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.6 Cg_endo -77.37 117.56 4.38 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.502 2.134 . . . . 0.0 112.398 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.487 HG12 ' HA ' ' A' ' 87' ' ' LEU . 16.0 m -146.8 138.47 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.117 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.44 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 26.9 mttm -81.37 156.88 25.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.992 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.661 HG13 HG21 ' A' ' 80' ' ' VAL . 21.2 t -133.3 127.23 53.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.041 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -88.49 124.06 33.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.878 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 40.2 mt -102.92 -40.13 6.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -85.59 179.88 7.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.812 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 64.7 m -95.61 79.83 3.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 73.12 49.87 14.65 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.525 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -116.73 -69.51 0.85 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.757 0.313 . . . . 0.0 110.867 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -161.93 138.3 7.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.867 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 13.2 mttt -95.67 146.13 24.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -106.0 127.74 27.78 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.788 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.601 ' HB2' HD12 ' A' ' 51' ' ' LEU . 57.0 Cg_endo -70.28 137.84 34.83 Favored 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.461 2.107 . . . . 0.0 112.348 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.92 174.96 29.24 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.512 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.414 HG13 ' O ' ' A' ' 28' ' ' VAL . 10.3 p -120.38 125.66 74.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.827 0.346 . . . . 0.0 111.017 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.635 HG23 ' O ' ' A' ' 12' ' ' CYS . 18.4 t -59.27 123.55 11.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.164 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.5 mmt180 -112.07 -31.91 6.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.889 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -144.62 166.26 25.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.428 ' HD3' ' CE2' ' A' ' 46' ' ' PHE . 38.5 ttp85 -156.77 124.3 5.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.842 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 166.6 145.17 4.36 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.419 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.497 ' HD3' HG23 ' A' ' 44' ' ' ILE . 50.6 Cg_exo -53.72 -176.98 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.511 2.14 . . . . 0.0 112.356 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.463 HD21 ' CE2' ' A' ' 64' ' ' TYR . 19.4 mt -95.73 -63.58 1.14 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.838 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -90.49 -174.8 4.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.774 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -121.32 31.32 6.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.083 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 53.5 mm-40 -80.45 157.27 26.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.933 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 18.0 mtt180 -66.75 -31.83 72.73 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.86 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.8 t -103.5 117.35 34.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.91 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.484 HG22 ' H ' ' A' ' 43' ' ' GLY . 11.0 p -131.38 145.75 34.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.044 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.8 p -74.53 -38.63 62.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.81 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.484 ' H ' HG22 ' A' ' 41' ' ' VAL . . . -179.99 173.07 44.66 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.478 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.497 HG23 ' HD3' ' A' ' 34' ' ' PRO . 13.8 mm -87.17 148.8 4.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.834 0.349 . . . . 0.0 111.076 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -104.36 121.35 43.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.48 ' HB2' HD11 ' A' ' 85' ' ' LEU . 13.6 m-85 -101.55 119.11 38.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.964 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.402 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -83.85 117.74 4.52 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.428 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.498 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -122.84 131.99 72.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.808 0.337 . . . . 0.0 111.092 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -85.18 117.73 24.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.885 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 14.0 mt -60.24 134.87 57.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.937 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.601 HD12 ' HB2' ' A' ' 26' ' ' PRO . 16.5 mt -80.01 -179.96 7.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.863 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -54.36 -29.66 49.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.05 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -60.36 -51.33 69.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.855 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -117.95 35.39 4.08 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.378 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -73.59 145.86 45.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 0.0 110.901 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.4 27.99 28.7 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.466 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -134.17 31.04 3.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.842 0.354 . . . . 0.0 110.89 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.17 149.81 18.46 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.519 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 13.4 p90 -109.94 -49.88 3.04 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.737 0.303 . . . . 0.0 110.928 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.419 HG23 ' N ' ' A' ' 61' ' ' ASP . 6.0 t -62.21 -48.25 80.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.856 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.419 ' N ' HG23 ' A' ' 60' ' ' THR . 11.7 m-20 58.17 37.04 26.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.97 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.42 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.94 -24.09 32.72 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.512 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.8 p -119.43 132.03 70.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.786 0.327 . . . . 0.0 111.132 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.463 ' CE2' HD21 ' A' ' 35' ' ' LEU . 0.3 OUTLIER -118.55 113.62 21.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.815 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 60.08 28.7 18.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.976 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.07 -24.08 32.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.571 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.95 114.07 21.43 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.821 0.343 . . . . 0.0 110.989 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 6.9 tp60 -78.47 116.42 18.86 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.855 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.462 HD12 ' CE2' ' A' ' 79' ' ' PHE . 72.1 mt -98.92 -37.71 9.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.879 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.42 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 1.8 p90 -154.41 172.68 17.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.93 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -105.29 111.44 24.17 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.001 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.44 167.88 15.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.907 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.8 175.27 3.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.911 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -72.53 117.89 14.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.924 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 60.83 49.5 6.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.841 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 28.5 m -130.0 -49.97 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.912 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.414 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -67.06 146.23 47.66 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.531 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.498 HG22 ' O ' ' A' ' 48' ' ' VAL . 25.8 m -156.78 142.23 9.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.778 0.323 . . . . 0.0 111.179 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.462 ' CE2' HD12 ' A' ' 69' ' ' LEU . 14.8 m-85 -109.89 131.89 54.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.917 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.661 HG21 HG13 ' A' ' 16' ' ' VAL . 30.6 m -152.61 158.05 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.112 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.94 156.61 38.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.132 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.649 HD12 HD12 ' A' ' 8' ' ' ILE . 12.9 tp -51.15 -45.41 61.68 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -57.07 -28.22 62.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.638 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -81.17 -27.02 35.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.865 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.624 ' CD2' HG22 ' A' ' 16' ' ' VAL . 84.9 mt -84.11 130.28 34.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.902 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 57.0 tt0 -113.78 114.01 25.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.899 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.487 ' HA ' HG12 ' A' ' 14' ' ' VAL . 8.5 tp -63.48 142.68 58.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.893 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.895 HD12 ' HB2' ' A' ' 13' ' ' PRO . 20.6 mt -95.51 146.82 6.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.094 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -112.63 159.42 18.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.8 t 56.28 96.38 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.961 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -77.55 163.83 51.77 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.467 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.27 -61.47 0.5 Allowed 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.596 2.198 . . . . 0.0 112.325 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.2 m -98.89 88.5 4.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.931 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.4 p -129.94 131.96 46.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.923 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.399 -1.223 . . . . 0.0 112.48 -179.992 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.201 0 N-CA-C 112.527 -0.229 . . . . 0.0 112.527 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 m -84.57 -32.36 23.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.749 0.309 . . . . 0.0 110.827 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 33.7 t -143.79 157.86 44.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.932 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -111.65 -156.46 13.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.519 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.9 m -147.98 145.43 28.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.775 0.321 . . . . 0.0 110.95 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.8 m -117.76 -171.35 2.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.956 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.97 114.64 1.12 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.429 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.763 HD12 HD12 ' A' ' 82' ' ' LEU . 5.2 mt -122.09 138.84 50.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.767 0.318 . . . . 0.0 111.04 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -131.78 -177.94 4.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.927 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.9 t -67.53 135.67 28.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.141 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.38 46.25 7.57 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.451 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.637 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.09 145.75 28.23 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 120.757 0.313 . . . . 0.0 110.962 -179.989 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.489 ' O ' HG13 ' A' ' 14' ' ' VAL . 74.2 Cg_endo -75.09 130.02 12.79 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.579 2.186 . . . . 0.0 112.269 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.598 HG11 HG21 ' A' ' 8' ' ' ILE . 11.8 m -158.02 138.51 4.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.14 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 47.1 mttm -79.23 140.45 37.65 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.05 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.758 HG13 HG21 ' A' ' 80' ' ' VAL . 18.4 t -115.91 135.87 54.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.062 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -97.25 110.07 22.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.857 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 83.0 mt -84.99 -56.26 3.65 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.97 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -75.06 171.99 13.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.944 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.4 m -78.01 80.26 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.885 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.62 55.49 26.84 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -120.45 -58.16 1.86 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 110.838 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -154.08 151.92 29.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.818 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -121.49 135.8 55.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.442 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 37.8 m-85 -106.11 136.49 19.32 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.838 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.545 ' HB2' HD12 ' A' ' 51' ' ' LEU . 63.1 Cg_endo -73.09 143.22 35.64 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.438 2.092 . . . . 0.0 112.431 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.98 156.58 27.98 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.526 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.2 p -95.52 126.52 48.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.771 0.32 . . . . 0.0 111.044 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.637 HG23 ' O ' ' A' ' 12' ' ' CYS . 18.6 t -59.87 135.84 24.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.119 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -119.46 -38.41 3.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.01 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.427 ' CE2' HD22 ' A' ' 69' ' ' LEU . 23.4 t80 -140.82 169.09 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.889 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.416 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 3.5 ttt180 -160.94 124.34 3.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.905 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 165.54 144.97 4.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.478 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -73.34 177.68 7.59 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.537 2.158 . . . . 0.0 112.349 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.444 HD13 ' CE1' ' A' ' 64' ' ' TYR . 60.9 mt -124.1 -66.52 0.98 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.838 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -169.47 -178.08 2.98 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.831 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.03 178.51 5.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.055 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -137.03 -70.28 0.45 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.904 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.5 mmt85 -145.45 -46.83 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.978 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.6 m -161.07 35.42 0.14 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.926 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 12.2 p -130.37 135.99 59.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.054 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.3 t -141.02 116.12 9.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.951 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -157.43 157.95 28.56 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.527 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.5 mt -94.37 136.65 25.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.763 0.316 . . . . 0.0 111.077 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -90.37 128.57 36.51 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.921 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.447 ' HB3' HD11 ' A' ' 85' ' ' LEU . 4.8 m-85 -111.74 109.9 19.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.875 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.46 122.68 11.01 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.344 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.624 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.9 t -137.9 130.94 41.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.805 0.336 . . . . 0.0 111.092 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -86.39 121.02 28.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.857 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.52 HD13 ' HB2' ' A' ' 57' ' ' GLN . 30.9 mt -60.45 141.27 56.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.049 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.545 HD12 ' HB2' ' A' ' 26' ' ' PRO . 13.3 mt -88.77 -179.88 6.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.83 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.06 -27.24 43.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.18 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -64.92 -41.57 95.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.966 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.442 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -132.13 38.67 1.86 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.47 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -74.31 161.33 29.99 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.851 0.358 . . . . 0.0 110.859 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.0 29.82 68.56 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.52 ' HB2' HD13 ' A' ' 50' ' ' LEU . 3.5 mm100 -135.86 34.14 2.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.816 0.341 . . . . 0.0 110.927 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.4 147.67 16.86 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.499 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -109.85 -47.78 3.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.813 0.34 . . . . 0.0 110.813 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.571 HG22 ' HA ' ' A' ' 78' ' ' VAL . 5.4 t -62.2 -47.93 82.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.943 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.414 ' N ' HG23 ' A' ' 60' ' ' THR . 0.7 OUTLIER 59.76 32.53 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.964 179.848 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.428 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.1 -24.82 28.32 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.564 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.7 p -120.85 133.28 68.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.864 0.364 . . . . 0.0 111.133 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.444 ' CE1' HD13 ' A' ' 35' ' ' LEU . 12.5 t80 -116.88 110.4 18.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.852 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 13.3 mt-30 60.45 31.01 20.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 98.04 -26.61 22.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.55 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.9 tptm -75.15 110.72 9.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.797 0.332 . . . . 0.0 110.904 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 24.2 tp60 -79.83 95.24 5.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.835 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.61 HD12 ' CE2' ' A' ' 79' ' ' PHE . 75.4 mt -81.65 -36.56 28.69 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.989 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.428 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.7 p90 -156.38 166.94 31.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.957 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -102.4 116.08 31.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.909 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -132.27 176.34 8.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.914 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -79.39 -179.94 7.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -77.69 121.35 23.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 59.7 48.04 9.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.005 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 26.6 m -129.93 -58.34 1.08 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.902 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.48 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -62.71 149.6 48.82 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.419 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.624 HG22 ' O ' ' A' ' 48' ' ' VAL . 15.3 m -158.0 146.54 9.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.873 0.368 . . . . 0.0 111.15 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.61 ' CE2' HD12 ' A' ' 69' ' ' LEU . 9.7 m-85 -108.95 131.8 54.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.758 HG21 HG13 ' A' ' 16' ' ' VAL . 13.2 m -151.01 160.35 3.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.073 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.416 ' HB3' ' HG3' ' A' ' 84' ' ' LYS . . . -75.86 153.46 36.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.054 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.763 HD12 HD12 ' A' ' 8' ' ' ILE . 11.0 tp -49.73 -44.3 48.32 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.904 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.9 t0 -58.27 -30.96 66.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.602 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.416 ' HG3' ' HB3' ' A' ' 81' ' ' ALA . 9.6 mtmt -78.08 -25.3 47.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.837 179.651 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.447 HD11 ' HB3' ' A' ' 46' ' ' PHE . 32.9 mt -81.7 130.87 35.21 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.14 105.21 14.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.963 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 27.3 tp -62.14 139.59 58.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.467 HD12 ' HB2' ' A' ' 13' ' ' PRO . 16.0 mt -102.26 128.04 55.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.074 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -120.96 -176.34 3.24 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.892 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 60.3 p -78.9 -34.32 44.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.873 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -67.24 146.12 47.19 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.503 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.59 142.84 33.26 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.582 2.188 . . . . 0.0 112.354 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 59.61 172.63 0.08 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.94 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -152.55 119.0 5.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.342 -1.255 . . . . 0.0 112.507 179.95 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.247 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -170.36 126.94 0.8 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.816 0.341 . . . . 0.0 110.911 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.4 m -135.38 128.23 31.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.887 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.25 75.81 0.19 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.486 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 83.3 p -119.33 -68.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.804 0.335 . . . . 0.0 110.912 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -155.27 -45.89 0.08 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.94 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 76.17 105.02 0.13 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.516 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.643 HD13 HG11 ' A' ' 14' ' ' VAL . 31.4 mt -112.3 128.68 68.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.851 0.358 . . . . 0.0 111.063 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 54.2 m-20 -124.75 -174.91 3.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.4 t -65.14 136.88 25.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.037 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.19 46.56 6.94 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.475 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.659 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -140.49 136.89 17.0 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.618 0.247 . . . . 0.0 110.908 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.705 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.6 Cg_endo -76.47 117.03 4.45 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.45 2.1 . . . . 0.0 112.308 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.643 HG11 HD13 ' A' ' 8' ' ' ILE . 16.3 m -141.99 138.3 30.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.154 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 30.3 mttp -81.4 132.46 35.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.665 HG22 HD23 ' A' ' 85' ' ' LEU . 21.6 t -113.3 131.71 64.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.047 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -87.07 112.94 22.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.443 ' HA ' HD23 ' A' ' 18' ' ' LEU . 15.0 mt -93.83 -44.98 7.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.19 179.59 7.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.3 p -75.24 76.51 2.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.9 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.4 35.2 84.17 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.489 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.92 -62.42 1.47 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.802 0.334 . . . . 0.0 110.895 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.22 142.25 19.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.915 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 18.3 mttm -98.26 115.56 28.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.782 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -75.71 128.12 84.32 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.831 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.434 ' HB2' HD12 ' A' ' 51' ' ' LEU . 64.3 Cg_endo -73.05 139.35 29.66 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.423 2.082 . . . . 0.0 112.311 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.49 157.91 29.62 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.614 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.1 p -95.86 136.05 28.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.774 0.321 . . . . 0.0 111.01 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 12' ' ' CYS . 23.9 t -70.0 130.69 34.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.078 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.427 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 24.9 mmt180 -114.52 -29.42 6.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.209 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -148.49 167.2 25.97 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.881 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.428 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 7.2 ttp180 -162.93 131.73 4.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.857 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.27 150.28 5.66 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.572 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.408 ' HD3' HG23 ' A' ' 44' ' ' ILE . 48.6 Cg_exo -55.68 160.31 9.75 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.613 2.209 . . . . 0.0 112.333 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.423 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 10.3 mt -121.02 -55.41 1.98 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.801 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.8 mt -143.0 151.42 40.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.808 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -143.62 33.03 1.29 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -110.07 110.16 20.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.89 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 6.8 mtm180 60.26 32.6 20.84 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.808 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.6 t -166.41 136.89 3.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.935 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 12.2 p -125.11 128.81 73.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.135 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.25 -48.15 0.2 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.944 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 123.72 -145.54 16.04 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.515 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.434 ' H ' HD12 ' A' ' 44' ' ' ILE . 4.2 mp -92.62 128.29 44.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.797 0.332 . . . . 0.0 111.089 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.423 ' CE1' ' HB2' ' A' ' 35' ' ' LEU . 66.1 m-85 -82.95 139.24 33.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.869 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.633 ' CB ' HD11 ' A' ' 85' ' ' LEU . 7.6 m-85 -117.93 113.66 22.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.986 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -78.21 117.49 4.68 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.596 HG21 HD22 ' A' ' 85' ' ' LEU . 20.2 t -123.49 143.37 36.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.766 0.317 . . . . 0.0 111.09 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -97.72 115.0 27.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.93 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.9 mt -59.07 128.29 36.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.032 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.434 HD12 ' HB2' ' A' ' 26' ' ' PRO . 7.2 mt -80.54 -179.93 7.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.867 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -54.85 -29.28 54.77 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.067 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.99 -41.81 99.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.892 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.04 34.64 3.05 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.563 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.9 ttt180 -71.99 144.59 48.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.773 0.321 . . . . 0.0 110.926 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 90.2 31.02 11.2 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.464 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -137.12 32.57 2.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.847 0.356 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.28 143.52 15.67 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.443 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.6 p90 -109.99 -47.92 3.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.824 0.345 . . . . 0.0 110.991 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -66.47 -42.81 86.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.973 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.1 t0 60.03 29.2 18.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.088 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.417 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 85.55 26.25 36.34 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.61 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.53 HG23 ' C ' ' A' ' 67' ' ' LYS . 12.1 p -164.04 133.29 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.775 0.322 . . . . 0.0 111.123 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 17.9 t80 -123.76 117.09 24.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 61.27 29.16 18.52 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.869 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.71 -26.86 21.44 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.547 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.53 ' C ' HG23 ' A' ' 63' ' ' VAL . 22.2 tptt -76.87 111.93 12.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.84 0.352 . . . . 0.0 110.879 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 10.9 tp60 -80.99 108.4 14.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.841 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.648 HD12 ' CE2' ' A' ' 79' ' ' PHE . 44.9 mt -86.63 -31.16 21.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.046 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.427 ' CD2' ' HB2' ' A' ' 30' ' ' ARG . 7.1 p90 -161.35 163.2 30.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -99.0 132.63 44.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.939 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -150.48 170.61 18.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.808 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -70.24 179.96 2.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.806 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -74.35 118.71 17.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 61.17 52.06 4.11 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.97 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 36.1 m -130.06 -51.79 1.12 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.967 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -64.17 138.05 41.1 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.519 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 17.7 m -150.29 140.35 16.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.761 0.315 . . . . 0.0 111.207 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.648 ' CE2' HD12 ' A' ' 69' ' ' LEU . 3.4 m-85 -104.13 122.4 45.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.838 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.617 HG21 HG13 ' A' ' 16' ' ' VAL . 4.5 m -145.85 164.73 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.208 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -76.68 155.94 32.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.189 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.536 HD12 HD12 ' A' ' 8' ' ' ILE . 13.2 tp -50.42 -40.84 51.29 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.737 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.8 t0 -58.45 -29.97 66.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.55 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.1 mmtt -78.83 -23.41 45.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.866 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.665 HD23 HG22 ' A' ' 16' ' ' VAL . 78.7 mt -82.75 143.59 30.77 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.93 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -130.29 97.59 4.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.814 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.633 ' HA ' HG12 ' A' ' 14' ' ' VAL . 19.6 tp -58.69 130.72 48.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.969 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.705 HD12 ' HB2' ' A' ' 13' ' ' PRO . 18.7 mt -82.97 151.71 4.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.091 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -114.03 139.24 49.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.928 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.5 p -72.72 110.6 7.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -107.15 144.27 15.9 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.504 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo -74.0 167.65 26.7 Favored 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.572 2.181 . . . . 0.0 112.32 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 23.2 t -80.28 129.11 34.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.916 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.1 m -140.2 122.95 16.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.899 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.438 -1.201 . . . . 0.0 112.464 -179.971 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.182 0 N-CA-C 112.577 -0.209 . . . . 0.0 112.577 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.2 m -127.9 31.68 5.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.757 0.313 . . . . 0.0 110.836 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -109.51 130.12 55.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.934 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -70.22 -174.68 15.27 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.533 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 42.3 t -67.18 -42.59 83.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.833 0.349 . . . . 0.0 110.948 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -166.73 172.3 10.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.904 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.5 -42.48 3.4 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.479 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.581 HG12 HD13 ' A' ' 87' ' ' LEU . 21.5 mt -103.29 139.83 23.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.824 0.345 . . . . 0.0 111.142 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -131.72 173.03 11.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.783 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.2 t -59.65 141.81 15.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.102 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 73.35 48.39 19.06 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.45 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.525 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.06 141.52 17.34 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.69 0.281 . . . . 0.0 110.954 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.618 ' HB2' HD12 ' A' ' 88' ' ' ILE . 73.3 Cg_endo -75.87 121.81 6.45 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.622 2.215 . . . . 0.0 112.418 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.69 HG12 ' HA ' ' A' ' 87' ' ' LEU . 16.7 m -153.2 138.36 10.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.101 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.3 mttt -75.01 138.03 41.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.949 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.932 HG13 HG21 ' A' ' 80' ' ' VAL . 18.6 t -119.17 136.02 57.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.12 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -90.84 112.62 24.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.972 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.453 HD13 ' HB3' ' A' ' 57' ' ' GLN . 23.3 mt -83.62 -66.27 0.91 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -73.77 172.83 10.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.874 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -76.1 85.76 2.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 61.74 54.09 38.26 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.443 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -112.5 -61.52 1.71 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.798 0.333 . . . . 0.0 110.849 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -162.78 133.09 4.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -95.23 121.9 37.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.858 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.424 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 50.0 m-85 -97.96 142.15 24.12 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.819 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.16 148.37 55.94 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.463 2.109 . . . . 0.0 112.36 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -167.24 154.42 24.7 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.509 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -98.36 127.15 51.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.834 0.349 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 12' ' ' CYS . 11.2 t -59.98 131.91 24.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.999 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -116.41 -30.64 5.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.181 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -146.79 166.0 27.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.866 0.365 . . . . 0.0 111.005 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.422 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.1 ttp180 -165.79 141.28 4.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.831 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 142.73 134.75 2.96 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.548 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -55.27 158.55 11.93 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.508 2.139 . . . . 0.0 112.245 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 61.6 mt -105.55 -56.9 2.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.795 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.505 HD12 ' HD3' ' A' ' 39' ' ' ARG . 4.0 mm? -108.21 143.48 36.98 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.784 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -146.26 48.02 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.075 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -177.68 -40.59 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.951 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.505 ' HD3' HD12 ' A' ' 36' ' ' LEU . 9.7 mpt_? -77.14 65.25 2.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.911 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 65.9 m 62.87 -78.95 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.021 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.0 m -56.91 142.47 12.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.212 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.3 t -168.73 109.75 0.51 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -160.86 156.96 28.41 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.568 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.7 mt -82.42 119.66 32.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.828 0.347 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -100.09 149.85 23.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.978 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.569 ' CB ' HD11 ' A' ' 85' ' ' LEU . 12.6 m-85 -127.8 116.98 21.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.925 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.66 120.67 5.27 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.41 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.597 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -133.6 129.2 55.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.868 0.366 . . . . 0.0 111.134 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -84.28 121.32 27.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.896 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.527 HD12 ' HA ' ' A' ' 76' ' ' CYS . 5.2 mt -59.99 150.23 29.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -96.71 -179.86 4.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.876 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -52.66 -30.02 29.56 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.143 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -62.86 -44.1 97.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.811 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.424 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -124.63 36.4 2.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.453 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt180 -75.48 140.49 42.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.898 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.8 29.85 11.27 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.518 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.453 ' HB3' HD13 ' A' ' 18' ' ' LEU . 48.4 mm-40 -137.21 36.25 2.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.866 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.41 142.43 15.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.576 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -105.65 -45.83 4.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.778 0.323 . . . . 0.0 110.864 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -63.38 -44.02 95.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.969 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.1 t0 57.72 33.73 23.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.928 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.42 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.72 -24.84 27.76 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.533 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.1 p -113.0 135.35 52.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.8 0.334 . . . . 0.0 111.098 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 4.0 t80 -116.82 110.43 18.36 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 77.6 mt-30 60.25 30.88 20.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.841 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.96 -26.3 23.96 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.604 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -81.85 114.11 20.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 110.968 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 31.7 tp60 -74.68 98.76 3.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.813 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.432 HD12 ' CE2' ' A' ' 79' ' ' PHE . 55.3 mt -79.79 -40.46 28.61 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.938 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.42 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -152.64 175.01 13.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.994 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.39 113.97 24.47 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 11.9 p -131.0 -180.0 5.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.01 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -65.65 179.95 0.76 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.96 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.12 118.84 22.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.034 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 59.56 50.04 7.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.023 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' CYS . . . . . 0.527 ' HA ' HD12 ' A' ' 50' ' ' LEU . 43.1 m -129.98 -45.54 1.15 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.983 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.466 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -60.91 146.39 47.53 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.563 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.597 HG22 ' O ' ' A' ' 48' ' ' VAL . 16.1 m -157.63 138.3 4.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.731 0.301 . . . . 0.0 111.074 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.432 ' CE2' HD12 ' A' ' 69' ' ' LEU . 11.2 m-85 -109.23 127.73 54.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.93 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.932 HG21 HG13 ' A' ' 16' ' ' VAL . 31.0 m -150.22 165.68 2.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.117 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.15 156.9 35.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.058 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 11.0 tp -49.55 -43.88 46.21 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.893 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -57.01 -29.85 63.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.55 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 12.5 mmtt -76.43 -25.64 54.64 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.814 179.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.904 ' CD2' HG22 ' A' ' 16' ' ' VAL . 79.2 mt -90.39 137.69 32.15 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.911 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.2 tm-20 -111.65 109.1 18.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.69 ' HA ' HG12 ' A' ' 14' ' ' VAL . 23.8 tp -64.56 128.24 34.92 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.965 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.618 HD12 ' HB2' ' A' ' 13' ' ' PRO . 22.1 mt -88.81 139.79 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.07 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -101.26 136.28 41.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.969 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.3 -41.32 2.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.831 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.402 ' N ' ' CD ' ' A' ' 92' ' ' PRO . . . 90.87 51.87 2.55 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.604 180.0 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 91' ' ' GLY . 57.0 Cg_endo -70.92 -178.51 2.82 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.536 2.158 . . . . 0.0 112.29 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -177.01 152.33 0.9 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.964 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 54.4 p -85.81 171.06 11.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.142 0 CA-C-O 118.456 -1.191 . . . . 0.0 112.49 -179.987 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.1 m -154.38 155.68 35.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 0.0 110.88 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 t -164.54 -177.6 4.92 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.832 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.85 166.59 20.73 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.497 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.8 t -149.48 104.12 3.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.871 0.367 . . . . 0.0 110.881 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.6 m -89.38 -177.59 5.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.925 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.61 -92.03 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.461 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.675 HD12 HD12 ' A' ' 82' ' ' LEU . 23.1 mt -89.52 147.62 5.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.82 0.343 . . . . 0.0 111.092 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -156.84 -172.14 3.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.846 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 t -60.67 136.83 23.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.212 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 75.03 46.58 15.93 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.59 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.797 ' O ' HG23 ' A' ' 29' ' ' VAL . 3.0 t -144.32 131.74 10.49 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.604 0.24 . . . . 0.0 110.969 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.08 122.97 6.97 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.479 2.119 . . . . 0.0 112.386 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.662 HG21 HD13 ' A' ' 85' ' ' LEU . 6.6 m -148.48 138.86 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.0 mttt -76.17 139.46 41.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.902 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.694 ' CG1' HG11 ' A' ' 80' ' ' VAL . 21.4 t -118.28 141.67 36.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.115 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -98.84 115.7 29.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.932 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 39.9 mt -98.39 -59.74 1.69 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 19.0 mtt85 -60.35 168.54 2.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.869 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.9 p -74.3 75.75 1.85 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.82 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.26 55.7 26.27 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.537 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -119.51 -67.25 1.0 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -147.9 154.51 40.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -112.31 152.09 28.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.865 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -116.69 135.63 23.0 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.491 ' HB2' HD12 ' A' ' 51' ' ' LEU . 61.6 Cg_endo -73.01 140.32 31.26 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.477 2.118 . . . . 0.0 112.312 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.79 148.51 16.06 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.635 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.453 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.3 p -89.83 140.66 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.737 0.303 . . . . 0.0 110.979 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.797 HG23 ' O ' ' A' ' 12' ' ' CYS . 11.9 t -72.34 131.17 35.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.098 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.453 ' HD3' HG13 ' A' ' 28' ' ' VAL . 5.8 mmm180 -112.83 -30.8 6.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.126 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -152.5 167.41 28.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.907 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.411 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 0.0 OUTLIER -154.72 130.04 9.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.755 179.931 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.33 151.12 6.14 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.507 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.04 -177.95 1.86 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.61 2.207 . . . . 0.0 112.29 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.748 HD13 ' CE1' ' A' ' 64' ' ' TYR . 4.7 mt -117.66 -50.04 2.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.924 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.5 mt -118.04 -179.51 3.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.703 ' HB1' ' O ' ' A' ' 40' ' ' THR . . . 60.66 79.01 0.26 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.134 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -85.6 -31.61 22.52 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 8.2 mmm180 -74.92 -33.13 61.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.865 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.703 ' O ' ' HB1' ' A' ' 37' ' ' ALA . 1.9 m -142.09 126.75 17.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.884 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.515 ' O ' HG13 ' A' ' 41' ' ' VAL . 11.6 p -69.56 118.26 13.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.116 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.4 t -110.12 -40.51 4.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.897 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -158.86 115.78 0.68 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.483 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.449 HD11 HG21 ' A' ' 41' ' ' VAL . 3.7 mp -92.21 156.02 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.829 0.347 . . . . 0.0 111.096 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.434 ' N ' HG22 ' A' ' 44' ' ' ILE . 18.6 m-85 -125.82 156.9 38.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.949 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.411 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 11.7 m-85 -126.78 109.89 12.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.95 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.517 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -66.98 132.73 31.26 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.356 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.618 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.7 t -144.12 130.53 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.899 0.38 . . . . 0.0 111.22 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -88.13 116.73 26.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.827 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 29.3 mt -59.97 131.96 52.48 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.491 HD12 ' HB2' ' A' ' 26' ' ' PRO . 12.0 mt -77.61 -179.89 6.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -53.41 -29.79 36.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.149 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -61.04 -55.47 32.39 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.914 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -112.05 32.44 6.33 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.514 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 8.8 ttt180 -72.83 135.26 45.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.913 0.387 . . . . 0.0 110.866 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 98.61 31.97 6.17 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.526 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 64.4 mm-40 -143.4 33.39 1.31 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.858 0.361 . . . . 0.0 110.932 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -99.8 147.99 18.4 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.521 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 23.7 p90 -109.51 -50.35 3.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.747 0.308 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.446 HG23 ' N ' ' A' ' 61' ' ' ASP . 8.7 t -68.84 -48.57 63.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.887 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.446 ' N ' HG23 ' A' ' 60' ' ' THR . 8.7 m-20 53.89 30.48 11.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.089 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.41 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 106.3 -26.38 20.46 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.506 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.446 HG23 ' C ' ' A' ' 67' ' ' LYS . 11.5 p -120.82 132.8 69.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 111.087 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.748 ' CE1' HD13 ' A' ' 35' ' ' LEU . 40.2 t80 -119.06 113.77 21.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.932 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 61.26 24.87 14.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.072 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 104.54 -27.9 17.2 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.555 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.446 ' C ' HG23 ' A' ' 63' ' ' VAL . 1.2 tpmp? -79.24 117.59 20.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.923 0.392 . . . . 0.0 110.913 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 8.6 tp60 -85.1 106.0 16.25 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.884 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.452 HD12 ' CE2' ' A' ' 79' ' ' PHE . 91.6 mt -91.01 -34.45 15.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.41 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 7.4 p90 -153.95 171.21 19.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 4.9 mm100 -102.77 121.15 41.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.922 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -136.52 172.85 12.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.807 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.93 173.78 10.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.905 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -65.53 118.67 9.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.991 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 59.55 52.15 5.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.852 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 87.0 m -130.07 -63.93 0.88 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -58.87 137.03 50.75 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.488 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.618 HG22 ' O ' ' A' ' 48' ' ' VAL . 5.7 m -148.07 129.79 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.792 0.329 . . . . 0.0 111.208 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.452 ' CE2' HD12 ' A' ' 69' ' ' LEU . 4.3 m-85 -93.02 129.77 38.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.785 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.694 HG11 ' CG1' ' A' ' 16' ' ' VAL . 4.6 m -150.32 164.56 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.235 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.7 162.58 20.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.176 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.675 HD12 HD12 ' A' ' 8' ' ' ILE . 12.8 tp -52.35 -47.99 65.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.805 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -57.64 -29.0 64.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.604 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 1.7 mttp -79.49 -25.35 41.87 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.809 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.662 HD13 HG21 ' A' ' 14' ' ' VAL . 52.5 mt -87.57 128.02 35.26 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.864 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -114.0 111.35 21.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.836 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.508 ' HA ' HG12 ' A' ' 14' ' ' VAL . 17.4 tp -60.04 134.13 56.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.957 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 29.3 mt -93.46 128.86 44.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.105 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -83.54 152.82 24.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.915 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 3.0 t -161.01 49.31 0.23 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -148.46 92.47 0.15 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.493 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.98 149.88 72.33 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.561 2.174 . . . . 0.0 112.22 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 15.9 t -119.99 112.13 18.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.935 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 49.4 m -81.77 -31.58 31.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.903 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.116 0 CA-C-O 118.35 -1.25 . . . . 0.0 112.461 179.957 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.176 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.6 p -165.1 176.41 8.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.825 0.345 . . . . 0.0 110.944 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.0 m -156.71 124.59 5.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.82 -69.01 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.412 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.9 m -163.28 -45.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.877 0.37 . . . . 0.0 110.912 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -162.2 171.1 17.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.911 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -120.91 -39.1 0.61 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.444 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.581 HD13 HG11 ' A' ' 14' ' ' VAL . 29.2 mt -113.08 155.13 14.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.761 0.315 . . . . 0.0 111.142 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.421 ' N ' HG22 ' A' ' 8' ' ' ILE . 1.0 OUTLIER -153.35 -168.94 3.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 179.964 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.408 ' HA ' ' CG1' ' A' ' 29' ' ' VAL . 24.9 t -70.16 135.27 28.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.125 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.9 46.17 7.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.408 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.684 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -144.73 137.42 13.6 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.677 0.275 . . . . 0.0 110.99 -179.965 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.1 118.07 4.61 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.477 2.118 . . . . 0.0 112.364 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.609 HG12 ' HA ' ' A' ' 87' ' ' LEU . 24.1 m -146.68 138.32 18.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.196 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.2 mttm -77.06 129.87 36.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.967 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 1.022 HG13 HG21 ' A' ' 80' ' ' VAL . 23.3 t -106.16 128.03 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.002 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 14.6 tt0 -97.24 110.32 22.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.912 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 88.9 mt -80.99 -45.55 16.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.835 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.28 -174.3 5.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.968 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.51 84.25 4.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.82 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.05 55.2 29.41 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.539 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 -117.25 -65.69 1.16 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.776 0.322 . . . . 0.0 110.892 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -158.43 123.07 4.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.866 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 24.2 mttt -90.57 144.06 26.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.419 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 74.0 m-85 -107.98 127.54 27.46 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.864 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -68.39 131.84 24.2 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.397 2.064 . . . . 0.0 112.262 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.66 163.38 30.35 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 28' ' ' VAL . 11.9 p -102.6 125.95 56.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.822 0.344 . . . . 0.0 110.97 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.684 HG23 ' O ' ' A' ' 12' ' ' CYS . 10.3 t -59.88 126.91 18.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -114.38 -31.79 6.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.054 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.558 ' CE2' HD22 ' A' ' 69' ' ' LEU . 28.0 t80 -142.58 167.43 22.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.934 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 13.5 ttp180 -159.22 129.47 5.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.72 148.34 5.15 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.505 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.456 ' HD3' HG23 ' A' ' 44' ' ' ILE . 58.1 Cg_endo -71.61 147.36 51.2 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.561 2.174 . . . . 0.0 112.274 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.404 HD22 ' CD1' ' A' ' 64' ' ' TYR . 8.0 mt -86.51 -67.73 0.79 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.867 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.432 ' O ' HD12 ' A' ' 36' ' ' LEU . 0.9 OUTLIER -88.84 93.57 9.63 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.815 -179.962 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -121.3 31.62 6.26 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.098 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.54 -50.05 6.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.895 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -104.02 85.45 2.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.968 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 96.9 m 57.06 97.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.908 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.2 p -72.0 141.56 16.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.095 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.4 t -167.88 35.18 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.908 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -164.1 89.36 0.1 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.513 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.456 HG23 ' HD3' ' A' ' 34' ' ' PRO . 23.2 mt -82.72 135.43 24.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.775 0.321 . . . . 0.0 111.18 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -106.99 150.39 26.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.98 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.421 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 9.5 m-85 -123.34 114.9 20.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.971 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.424 ' N ' ' CD1' ' A' ' 79' ' ' PHE . . . -74.93 121.84 6.77 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.48 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.573 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -129.95 133.76 64.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.823 0.344 . . . . 0.0 111.113 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -90.02 115.91 27.65 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.457 HD13 ' HB2' ' A' ' 57' ' ' GLN . 37.3 mt -58.88 133.59 56.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.993 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -81.55 -179.89 7.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.921 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -53.14 -29.63 32.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.106 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -60.86 -58.35 8.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.419 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -111.12 32.72 6.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.465 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -69.74 133.06 47.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.769 0.319 . . . . 0.0 110.907 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.46 35.8 4.56 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.53 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.457 ' HB2' HD13 ' A' ' 50' ' ' LEU . 4.8 mt-30 -141.47 31.36 1.69 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.342 . . . . 0.0 110.877 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.72 147.39 16.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.513 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -108.56 -49.23 3.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.75 0.31 . . . . 0.0 110.863 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.3 t -59.43 -43.78 93.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.957 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.0 t0 59.82 29.38 18.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.052 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.422 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.47 -19.57 53.62 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.69 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.537 HG23 ' C ' ' A' ' 67' ' ' LYS . 11.2 p -124.22 140.38 47.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.865 0.364 . . . . 0.0 111.178 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.404 ' CD1' HD22 ' A' ' 35' ' ' LEU . 52.7 t80 -122.85 109.96 14.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.923 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER 60.22 26.6 16.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.001 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.12 -30.27 9.54 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.592 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.537 ' C ' HG23 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -77.34 117.93 19.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.951 0.405 . . . . 0.0 110.925 -179.988 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 2.9 tp60 -84.91 92.69 8.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.861 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.558 HD22 ' CE2' ' A' ' 31' ' ' PHE . 71.1 mt -69.49 -44.57 70.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.912 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.422 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.9 p90 -147.77 177.78 9.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.961 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -113.83 123.92 50.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.885 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 17.7 p -150.0 163.06 39.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.891 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -60.12 178.51 0.18 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.936 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -75.71 124.55 27.45 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 60.79 49.86 5.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.909 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 53.7 m -129.99 -45.93 1.14 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.907 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -69.41 132.17 24.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.519 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 48' ' ' VAL . 7.7 m -142.15 131.16 22.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.886 0.374 . . . . 0.0 111.094 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.454 ' CE2' HD12 ' A' ' 69' ' ' LEU . 9.1 m-85 -101.53 127.06 48.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.93 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 1.022 HG21 HG13 ' A' ' 16' ' ' VAL . 31.5 m -151.71 164.15 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.159 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -81.13 162.38 23.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.204 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -51.9 -49.57 62.78 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.887 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -56.89 -28.33 61.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.672 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.0 mtmm -80.03 -25.86 40.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.815 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.795 ' CD2' HG22 ' A' ' 16' ' ' VAL . 80.3 mt -82.86 161.05 22.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.913 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -137.97 104.59 5.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.84 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.609 ' HA ' HG12 ' A' ' 14' ' ' VAL . 19.8 tp -59.68 137.71 57.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.984 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.427 HG22 ' N ' ' A' ' 89' ' ' GLU . 32.3 mt -106.69 155.62 7.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.117 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLU . . . . . 0.427 ' N ' HG22 ' A' ' 88' ' ' ILE . 24.5 mt-10 -125.53 -48.77 1.67 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.966 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 92.3 p -115.35 -40.96 3.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.9 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.23 -148.83 16.52 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.461 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.85 145.19 61.6 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.502 2.135 . . . . 0.0 112.328 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.4 m -109.83 -42.23 4.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.978 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 38.4 m -84.61 130.54 34.71 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.968 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.128 0 CA-C-O 118.361 -1.244 . . . . 0.0 112.459 -179.963 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.163 0 N-CA-C 112.499 -0.24 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.5 t 61.26 153.77 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.831 0.348 . . . . 0.0 110.904 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.5 p 58.18 179.6 0.06 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.4 91.93 1.28 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.516 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.1 m -140.35 -170.95 3.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.854 0.359 . . . . 0.0 110.901 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 74.4 m -134.46 136.34 43.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.872 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.91 -94.62 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.521 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.563 HD12 ' CD1' ' A' ' 82' ' ' LEU . 46.0 mt -100.85 125.75 54.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -143.1 -172.02 3.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.881 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.526 HG13 ' O ' ' A' ' 30' ' ' ARG . 29.2 t -64.48 127.78 25.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.038 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 87.84 43.28 5.77 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.537 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.649 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -141.44 137.04 16.12 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 120.617 0.246 . . . . 0.0 110.952 -179.961 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -76.34 116.84 4.43 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.526 2.151 . . . . 0.0 112.343 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.618 HG12 ' HA ' ' A' ' 87' ' ' LEU . 6.8 m -144.34 138.74 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.169 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 2.3 mttt -80.42 141.23 35.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.071 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.854 HG13 HG21 ' A' ' 80' ' ' VAL . 31.9 t -115.63 133.6 61.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.053 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -94.52 121.54 36.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.915 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.404 HD12 ' HE2' ' A' ' 25' ' ' PHE . 57.4 mt -101.93 -54.48 2.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.919 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.8 -174.78 0.05 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.839 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 51.7 p -93.0 48.37 1.34 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.918 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 95.51 57.89 1.16 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.469 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -121.43 -51.93 2.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.818 0.342 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -170.02 152.4 4.32 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 10.8 mttt -107.74 138.29 44.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.414 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 26.5 m-85 -95.08 123.14 58.21 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.769 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.634 ' HB2' HD12 ' A' ' 51' ' ' LEU . 37.8 Cg_endo -65.97 138.86 54.22 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.464 2.109 . . . . 0.0 112.263 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -166.74 146.6 11.02 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.571 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.2 p -83.37 145.83 7.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.803 0.335 . . . . 0.0 110.961 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.705 HG13 ' O ' ' A' ' 47' ' ' GLY . 21.7 t -77.86 138.87 19.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.158 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.526 ' O ' HG13 ' A' ' 10' ' ' VAL . 0.7 OUTLIER -117.78 -40.19 3.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.804 179.988 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.411 ' CD2' ' N ' ' A' ' 32' ' ' ARG . 58.1 t80 -140.05 163.8 31.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.793 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.413 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 22.5 ttp85 -158.99 140.79 13.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.911 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.83 161.33 9.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.482 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.9 136.09 31.75 Favored 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.556 2.171 . . . . 0.0 112.287 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.527 HD13 ' CZ ' ' A' ' 64' ' ' TYR . 72.2 mt -62.95 -64.93 0.77 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.918 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.46 HD22 ' O ' ' A' ' 35' ' ' LEU . 3.4 mm? -122.89 156.87 33.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.843 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.36 153.76 40.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.11 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -149.88 161.37 42.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.867 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.4 -31.38 7.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.886 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.631 HG23 HG12 ' A' ' 41' ' ' VAL . 7.7 t -91.11 -34.64 14.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.919 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.631 HG12 HG23 ' A' ' 40' ' ' THR . 11.6 p -169.47 124.79 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 31.1 t -98.91 96.36 7.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -62.38 116.51 9.47 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.467 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.2 mp -93.42 135.62 27.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 111.064 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -117.96 146.58 43.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.918 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.413 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 7.0 m-85 -118.28 112.94 20.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.924 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.705 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -68.44 141.4 37.02 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.589 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.443 ' O ' HG22 ' A' ' 78' ' ' VAL . 25.7 t -153.52 140.92 13.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.792 0.329 . . . . 0.0 111.006 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -98.79 113.94 26.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.871 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.456 HD12 ' HA ' ' A' ' 76' ' ' CYS . 3.4 mt -57.76 128.6 37.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.056 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.634 HD12 ' HB2' ' A' ' 26' ' ' PRO . 19.8 mt -78.0 -179.9 6.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.54 -30.03 52.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.079 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -60.64 -48.68 80.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.846 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.414 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -121.57 37.13 3.03 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.488 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.1 ttt180 -74.1 151.89 40.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.802 0.334 . . . . 0.0 110.9 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 84.3 27.91 35.07 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.492 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 68.5 mm-40 -133.92 36.69 3.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.837 0.351 . . . . 0.0 110.918 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.41 145.86 15.99 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.456 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -109.98 -47.38 3.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.821 0.343 . . . . 0.0 110.921 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.3 t -69.98 -40.47 75.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.831 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.6 t0 58.43 29.46 18.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.043 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.414 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 99.01 -20.25 51.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.67 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.9 p -118.56 134.59 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.867 0.365 . . . . 0.0 111.124 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.527 ' CZ ' HD13 ' A' ' 35' ' ' LEU . 50.4 t80 -122.59 110.02 15.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.858 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.413 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 28.8 mt-30 58.94 26.54 15.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.037 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 105.72 -28.05 15.57 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.568 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.0 118.08 21.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.83 0.348 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 7.7 tp60 -84.08 90.08 7.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.913 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 84.7 mt -71.36 -31.78 67.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.825 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.1 p90 -161.49 164.82 29.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.858 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -112.0 119.42 38.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.887 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 1.3 m -137.17 179.95 6.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.907 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -71.69 179.96 2.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.885 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -72.33 123.24 22.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.001 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 60.02 50.59 6.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' CYS . . . . . 0.456 ' HA ' HD12 ' A' ' 50' ' ' LEU . 27.9 m -130.04 -49.28 1.11 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.983 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -62.65 127.14 38.77 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.558 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.443 HG22 ' O ' ' A' ' 48' ' ' VAL . 21.3 m -146.11 156.23 12.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.748 0.309 . . . . 0.0 111.128 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.429 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 7.9 m-85 -124.47 136.61 54.16 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.889 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.854 HG21 HG13 ' A' ' 16' ' ' VAL . 28.6 m -156.59 160.04 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.11 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.527 ' HB3' ' OD1' ' A' ' 83' ' ' ASP . . . -73.3 157.48 36.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.116 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.563 ' CD1' HD12 ' A' ' 8' ' ' ILE . 14.8 tp -51.14 -46.41 61.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.845 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.527 ' OD1' ' HB3' ' A' ' 81' ' ' ALA . 27.6 p-10 -57.16 -28.94 63.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.599 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 5.0 mmtt -79.28 -25.21 42.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.745 ' CD2' HG22 ' A' ' 16' ' ' VAL . 43.7 mt -83.17 154.98 24.0 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.02 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -141.45 104.66 4.62 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.853 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.618 ' HA ' HG12 ' A' ' 14' ' ' VAL . 19.0 tp -59.51 135.14 57.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.002 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.3 mt -93.61 126.57 46.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.113 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -119.68 -38.49 2.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.024 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 7.6 p 61.49 41.51 12.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.926 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 122.29 161.16 11.18 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.458 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -68.49 124.62 11.81 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.615 2.21 . . . . 0.0 112.3 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 23.1 t -79.09 121.25 24.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.889 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.42 -31.12 53.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.903 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.411 -1.216 . . . . 0.0 112.542 179.968 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.166 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.2 m 60.43 95.45 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.792 0.33 . . . . 0.0 110.89 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.5 m -158.08 160.44 37.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.927 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 132.21 174.4 13.62 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.472 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 99.3 p -98.82 31.5 2.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.838 0.351 . . . . 0.0 110.93 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 m -100.59 178.16 4.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.75 -51.86 1.25 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.533 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.688 HG21 HG11 ' A' ' 14' ' ' VAL . 4.1 mt -127.4 143.69 39.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.918 0.39 . . . . 0.0 111.059 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -138.82 179.77 6.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.842 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.2 t -64.04 133.13 29.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.011 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 84.36 45.53 6.15 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.383 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.496 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -149.87 143.63 16.89 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 120.663 0.268 . . . . 0.0 110.953 -179.948 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.498 ' O ' HG13 ' A' ' 14' ' ' VAL . 74.4 Cg_endo -75.3 138.14 21.96 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.582 2.188 . . . . 0.0 112.267 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.688 HG11 HG21 ' A' ' 8' ' ' ILE . 11.3 m -158.49 138.69 4.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.232 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.3 mttt -82.82 125.94 31.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.948 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.838 HG22 ' CD2' ' A' ' 85' ' ' LEU . 22.0 t -104.49 138.46 29.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.03 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -102.96 112.09 24.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.939 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -85.78 -40.12 16.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.866 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -84.31 -176.3 6.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 71.8 p -100.04 48.26 0.93 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.874 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 105.71 56.89 0.66 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.553 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.95 -60.45 1.08 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.803 0.335 . . . . 0.0 110.904 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -161.63 146.18 13.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.863 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 14.8 mttt -109.21 150.62 27.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.435 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 27.3 m-85 -113.63 127.26 27.03 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.838 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.18 146.17 40.37 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.436 2.091 . . . . 0.0 112.318 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.82 153.4 21.53 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.489 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.8 p -93.27 138.85 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.772 0.32 . . . . 0.0 111.066 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.605 HG22 HG22 ' A' ' 48' ' ' VAL . 19.3 t -72.78 133.32 31.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.098 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 20.0 mmt180 -115.91 -30.45 6.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.038 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -142.78 168.3 20.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.948 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.428 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 24.3 ttp180 -161.23 123.53 3.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.858 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 168.37 145.7 4.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.545 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.532 ' HD3' HG23 ' A' ' 44' ' ' ILE . 53.0 Cg_exo -54.96 -169.31 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.583 2.189 . . . . 0.0 112.25 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.419 ' HG ' ' CD2' ' A' ' 45' ' ' PHE . 12.9 mt -118.21 -64.06 1.34 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.5 mp -130.74 139.08 50.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.7 77.42 0.12 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.085 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -93.56 -38.32 11.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.897 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 26.8 mtm180 -110.92 -33.31 6.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.939 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.8 m -151.39 147.6 27.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.886 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.7 p -77.55 146.36 8.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.084 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 13.0 t -107.07 -67.43 0.95 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.888 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -176.18 145.6 7.63 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.515 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.532 HG23 ' HD3' ' A' ' 34' ' ' PRO . 32.9 mt -81.17 123.36 37.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.794 0.331 . . . . 0.0 111.095 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.419 ' CD2' ' HG ' ' A' ' 35' ' ' LEU . 52.7 m-85 -90.39 147.81 23.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.952 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.428 ' CZ ' ' HD2' ' A' ' 32' ' ' ARG . 12.1 m-85 -117.12 111.95 20.21 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.67 110.27 2.99 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.498 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.605 HG22 HG22 ' A' ' 29' ' ' VAL . 21.8 t -116.97 132.13 67.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.846 0.355 . . . . 0.0 111.039 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -88.53 117.54 27.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.574 HD13 ' HB2' ' A' ' 57' ' ' GLN . 52.8 mt -59.15 135.19 57.56 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.993 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -79.78 -179.93 7.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.821 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -55.13 -30.2 59.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.079 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -63.01 -60.1 3.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.79 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.435 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -101.58 30.86 9.47 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.442 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -69.74 137.87 52.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.79 0.328 . . . . 0.0 110.88 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.01 34.06 6.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.47 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.574 ' HB2' HD13 ' A' ' 50' ' ' LEU . 31.1 mm-40 -140.9 43.84 1.81 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.906 0.384 . . . . 0.0 110.918 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -108.1 143.15 16.05 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.525 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -110.03 -32.1 7.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.87 0.367 . . . . 0.0 110.932 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -85.76 -42.31 14.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.899 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.6 t0 57.08 31.19 19.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.999 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.433 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 93.1 -16.8 59.65 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.676 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.7 p -123.01 142.1 40.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.856 0.36 . . . . 0.0 111.141 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 13.4 t80 -129.09 110.24 11.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.873 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 61.67 24.54 14.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.154 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.18 -27.81 14.7 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.566 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.6 119.53 23.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.947 0.403 . . . . 0.0 110.948 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -82.87 95.61 8.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 78.5 mt -70.83 -51.13 28.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.433 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -144.99 166.1 26.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.913 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.32 124.24 46.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.881 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 9.3 p -149.58 177.1 10.05 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -71.89 175.93 5.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.877 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -78.82 127.79 32.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 60.5 41.22 16.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.902 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 23.7 m -127.53 -46.66 1.45 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.909 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -68.32 132.25 27.67 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.538 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 12.4 m -148.44 135.96 13.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.806 0.336 . . . . 0.0 111.158 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -102.18 130.01 48.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.587 HG21 HG13 ' A' ' 16' ' ' VAL . 4.2 m -150.15 166.74 2.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.148 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.98 158.76 21.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.137 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.457 ' CD1' HD12 ' A' ' 8' ' ' ILE . 9.3 tp -50.55 -44.05 56.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.899 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -57.82 -28.82 64.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.603 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.4 mttt -82.6 -24.85 33.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.86 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.838 ' CD2' HG22 ' A' ' 16' ' ' VAL . 52.7 mt -88.88 128.45 35.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.013 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.9 tm-20 -114.89 107.95 16.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.81 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 13.7 tp -57.74 138.54 55.41 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.997 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 27.3 mt -94.19 133.53 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.3 mt-10 -136.18 103.75 5.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -64.63 121.23 13.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.903 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -158.38 -96.74 0.12 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.49 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -73.5 145.12 37.23 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.542 2.161 . . . . 0.0 112.285 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 69.3 p -161.06 -63.87 0.06 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.958 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.5 m -88.21 -51.5 5.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.941 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.313 -1.271 . . . . 0.0 112.509 -179.995 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.217 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -103.5 144.6 31.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.886 0.374 . . . . 0.0 110.85 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.1 m -157.4 120.31 3.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.858 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 148.84 158.36 8.01 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.462 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.3 t -170.82 -51.02 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.813 0.34 . . . . 0.0 110.927 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.6 m 60.31 166.88 0.08 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.28 104.19 2.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.506 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.707 HD13 HG11 ' A' ' 14' ' ' VAL . 20.2 mt -128.15 138.26 55.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.828 0.346 . . . . 0.0 111.02 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -120.57 -179.59 4.03 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.3 t -66.86 137.33 25.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.027 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.75 46.82 7.02 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.399 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.581 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -140.72 140.96 23.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.623 0.249 . . . . 0.0 110.955 -179.965 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.473 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.5 Cg_endo -76.51 117.17 4.49 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.566 2.177 . . . . 0.0 112.343 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.707 HG11 HD13 ' A' ' 8' ' ' ILE . 4.9 m -144.38 138.9 23.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.129 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -87.38 140.98 28.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.886 HG22 HD23 ' A' ' 85' ' ' LEU . 19.5 t -121.0 140.4 45.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.095 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -97.96 110.06 22.7 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.442 HD23 ' HA ' ' A' ' 18' ' ' LEU . 14.6 mt -84.57 -58.69 2.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.89 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.42 -174.99 0.74 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.83 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -83.77 68.72 10.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 69.18 45.35 62.09 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.536 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -99.48 -44.72 6.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 0.0 110.916 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -176.66 131.56 0.2 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -88.29 124.85 34.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.825 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -89.84 128.06 51.67 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.832 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.693 ' HB2' HD12 ' A' ' 51' ' ' LEU . 60.4 Cg_endo -72.33 139.4 31.89 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.445 2.097 . . . . 0.0 112.328 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -154.82 167.05 32.6 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.515 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.446 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.6 p -108.73 124.0 64.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.75 0.31 . . . . 0.0 111.014 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 12' ' ' CYS . 16.7 t -59.46 128.55 20.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.13 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -115.73 -29.92 6.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.112 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 40.5 t80 -148.74 165.96 29.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.914 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 15.1 ttp180 -158.46 135.66 9.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.984 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.68 137.32 2.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.96 164.5 2.47 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.516 2.144 . . . . 0.0 112.339 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 13.7 mt -125.28 69.34 1.15 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.806 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 mt 59.92 176.96 0.09 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.82 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -171.3 124.37 0.6 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.157 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -128.73 103.43 7.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 9.5 mtt180 60.77 36.18 19.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.894 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.5 t -143.34 159.44 42.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.834 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.0 p -64.19 143.29 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.093 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.0 p -67.9 103.57 1.5 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.868 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -112.44 115.0 3.64 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.55 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 16.2 mt -73.45 146.99 9.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.795 0.331 . . . . 0.0 111.099 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -120.2 138.92 53.36 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.939 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.475 ' CB ' HD11 ' A' ' 85' ' ' LEU . 6.4 m-85 -120.84 109.91 15.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.845 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.18 119.93 9.07 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.485 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.477 HG22 HG22 ' A' ' 29' ' ' VAL . 22.3 t -134.04 130.83 55.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.774 0.321 . . . . 0.0 111.03 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -83.62 119.06 24.28 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.932 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.9 mt -62.26 141.95 57.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.014 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.693 HD12 ' HB2' ' A' ' 26' ' ' PRO . 7.7 mt -86.73 -179.93 6.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.854 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -54.42 -30.03 51.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.037 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -61.73 -47.06 86.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.871 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.43 38.38 2.39 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.482 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -77.09 151.83 35.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.819 0.342 . . . . 0.0 110.869 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.18 28.13 37.99 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.543 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -135.35 46.55 2.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.804 0.335 . . . . 0.0 110.859 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -118.15 150.44 18.19 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.556 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -110.09 -50.55 2.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.433 HG23 ' N ' ' A' ' 61' ' ' ASP . 7.7 t -69.03 -48.07 63.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.962 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.433 ' N ' HG23 ' A' ' 60' ' ' THR . 18.3 m-20 55.54 32.74 19.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.044 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 105.1 -25.41 25.26 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.545 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 63' ' ' VAL . 10.7 p -121.93 126.54 74.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.807 0.336 . . . . 0.0 111.103 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -116.03 113.89 23.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.86 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 12.9 mt-30 62.39 26.8 16.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.943 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.83 -24.39 32.35 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.616 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 12.2 tptm -81.67 114.56 20.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.882 0.372 . . . . 0.0 110.903 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.8 tp60 -82.64 97.24 8.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.924 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.476 HD12 ' CE2' ' A' ' 79' ' ' PHE . 79.0 mt -80.87 -34.74 33.46 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.012 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.411 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -156.39 169.81 23.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.986 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -103.47 124.74 49.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.889 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -140.61 173.84 11.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.823 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -76.43 179.96 5.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -76.96 120.52 22.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 60.2 41.71 16.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.885 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 78.2 m -125.18 -52.83 1.63 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.945 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -64.62 130.14 36.84 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.454 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 48' ' ' VAL . 5.6 m -142.33 143.46 26.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.853 0.359 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.476 ' CE2' HD12 ' A' ' 69' ' ' LEU . 4.5 m-85 -105.87 124.69 49.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.867 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.814 HG11 HG11 ' A' ' 16' ' ' VAL . 29.4 m -146.65 155.77 11.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.15 155.67 40.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.2 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.471 HD12 HD12 ' A' ' 8' ' ' ILE . 8.9 tp -50.57 -44.51 56.76 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.927 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -56.48 -27.03 55.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.663 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 11.8 mmtt -81.52 -26.75 34.86 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.838 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.886 HD23 HG22 ' A' ' 16' ' ' VAL . 90.2 mt -79.3 140.91 37.43 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.823 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -115.75 103.34 10.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.846 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.529 ' HA ' HG12 ' A' ' 14' ' ' VAL . 23.4 tp -59.54 130.38 46.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.473 HD12 ' HB2' ' A' ' 13' ' ' PRO . 13.6 mt -103.04 153.5 5.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.007 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLU . . . . . 0.404 ' N ' HG22 ' A' ' 88' ' ' ILE . 7.0 mt-10 -139.08 150.99 46.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.917 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -140.61 -68.52 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.44 94.9 0.93 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.529 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -68.14 -41.74 6.84 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.539 2.159 . . . . 0.0 112.322 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.8 m -103.45 151.42 22.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.0 m -161.98 89.42 0.72 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.422 -1.21 . . . . 0.0 112.506 -179.984 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 112.545 -0.222 . . . . 0.0 112.545 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.42 176.65 0.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.802 0.334 . . . . 0.0 110.902 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.5 t -90.33 -65.85 0.98 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.874 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 132.15 77.67 0.14 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.537 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.9 m -88.41 -61.34 1.73 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.845 0.355 . . . . 0.0 110.895 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.1 m -92.01 -78.0 0.42 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.874 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.66 103.17 2.21 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.61 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.777 HD12 HD12 ' A' ' 82' ' ' LEU . 30.0 mt -105.7 132.44 52.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.82 0.343 . . . . 0.0 111.1 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -134.75 -177.84 4.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.971 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 26.6 t -60.98 135.68 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.133 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.43 46.15 7.04 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.466 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -141.66 138.82 17.65 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.668 0.27 . . . . 0.0 110.865 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.43 ' O ' HD12 ' A' ' 87' ' ' LEU . 71.3 Cg_endo -74.48 117.25 4.89 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 122.503 2.136 . . . . 0.0 112.383 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.759 HG21 HD13 ' A' ' 85' ' ' LEU . 14.9 m -142.99 138.55 27.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.12 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 27.0 mttt -83.63 142.89 30.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.978 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.899 HG22 ' CD2' ' A' ' 85' ' ' LEU . 19.0 t -123.43 132.03 72.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -93.27 118.93 31.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.622 HD11 ' O ' ' A' ' 57' ' ' GLN . 18.1 mt -95.07 -55.8 2.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.98 -170.27 0.22 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.877 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 69.0 m -88.75 79.16 7.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.871 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.83 44.22 98.29 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.523 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -101.62 -66.54 0.91 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.798 0.333 . . . . 0.0 110.836 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -152.92 142.39 21.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.938 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.7 mtpt -103.73 133.13 49.25 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.826 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.424 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 25.8 m-85 -92.84 129.76 38.87 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.78 133.87 17.49 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.427 2.085 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.16 155.39 26.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.594 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -94.52 132.95 37.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.822 0.344 . . . . 0.0 111.067 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.4 t -63.75 133.83 29.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.097 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.28 -36.4 4.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.005 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 52.9 t80 -143.19 164.34 30.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.921 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.408 ' HG3' ' CE2' ' A' ' 46' ' ' PHE . 4.3 ttt180 -154.29 135.91 14.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 160.04 126.82 0.86 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.455 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.714 ' CD ' HG23 ' A' ' 44' ' ' ILE . 52.3 Cg_exo -54.74 -174.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.435 2.09 . . . . 0.0 112.295 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.441 HD12 ' CE1' ' A' ' 45' ' ' PHE . 21.5 mt -144.74 91.45 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.881 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.0 mt 60.74 34.06 19.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.981 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -88.08 132.98 34.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.083 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -67.15 -74.97 0.1 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.941 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -131.14 -78.24 0.52 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.882 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.9 t -138.36 28.78 2.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.9 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 3.2 m -103.3 32.09 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.115 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -160.01 -60.64 0.06 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.885 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.28 130.44 5.84 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.473 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.714 HG23 ' CD ' ' A' ' 34' ' ' PRO . 3.0 mt -59.48 149.26 6.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.75 0.309 . . . . 0.0 111.072 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.441 ' CE1' HD12 ' A' ' 35' ' ' LEU . 77.5 m-85 -102.28 134.94 44.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.841 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.408 ' CE2' ' HG3' ' A' ' 32' ' ' ARG . 8.7 m-85 -121.69 113.01 19.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.446 ' N ' ' CD1' ' A' ' 79' ' ' PHE . . . -73.08 118.21 6.26 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.358 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.508 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.6 t -125.73 131.42 71.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 111.124 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -90.55 114.81 27.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.839 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.3 mt -58.32 135.99 57.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.073 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -82.28 -179.97 7.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.896 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.72 -29.66 54.04 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.09 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -61.33 -50.49 72.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.902 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.424 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -121.84 37.59 2.87 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.479 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.57 145.34 41.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.794 0.33 . . . . 0.0 110.911 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 85.95 33.13 15.98 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.539 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.622 ' O ' HD11 ' A' ' 18' ' ' LEU . 7.7 mm-40 -137.3 30.86 2.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.862 0.363 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.38 154.41 18.99 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.502 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -109.47 -49.79 3.07 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.799 0.333 . . . . 0.0 110.869 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.7 t -62.31 -46.26 89.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.946 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 57.51 35.37 25.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.003 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.407 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.49 -27.56 16.89 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.469 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.434 ' O ' HG13 ' A' ' 63' ' ' VAL . 10.8 p -117.46 124.83 73.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 0.0 111.053 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.437 ' CE2' HD13 ' A' ' 35' ' ' LEU . 37.3 t80 -111.91 115.05 28.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.96 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 30.7 mt-30 59.37 25.77 14.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.137 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.84 24.66 22.47 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.61 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.65 109.82 10.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.83 0.348 . . . . 0.0 110.859 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -75.71 97.01 3.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.946 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.443 HD12 ' CE2' ' A' ' 79' ' ' PHE . 79.0 mt -82.65 -30.81 29.1 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.858 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.407 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.9 p90 -152.82 174.64 13.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.938 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.79 110.02 19.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 26.5 p -133.17 174.71 10.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -72.55 179.97 3.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.881 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -74.78 119.31 18.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.975 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 60.75 51.25 4.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.906 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 47.6 m -129.98 -49.34 1.12 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.916 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -71.65 134.63 22.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.502 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 48' ' ' VAL . 8.1 m -141.9 132.61 25.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.805 0.336 . . . . 0.0 111.113 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 47' ' ' GLY . 7.9 m-85 -100.83 118.34 36.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.897 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.515 HG21 HG13 ' A' ' 16' ' ' VAL . 27.4 m -145.3 161.92 12.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.109 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.66 156.05 35.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.127 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.777 HD12 HD12 ' A' ' 8' ' ' ILE . 6.5 tp -50.43 -43.97 55.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.825 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -57.57 -29.27 64.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.573 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 22.6 mmtm -80.62 -27.02 37.41 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.79 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.899 ' CD2' HG22 ' A' ' 16' ' ' VAL . 39.4 mt -84.33 146.59 27.64 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.985 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -131.46 110.96 11.38 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.912 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.43 HD12 ' O ' ' A' ' 13' ' ' PRO . 34.5 tp -62.6 136.14 57.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.99 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 26.9 mt -79.57 130.86 35.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.183 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -118.31 144.25 45.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.893 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 p -95.5 -47.43 6.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.919 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -177.91 89.81 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.511 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.08 95.47 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.547 2.165 . . . . 0.0 112.32 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 68.7 m -105.82 177.38 4.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.887 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.2 m -149.01 -48.09 0.14 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.332 -1.26 . . . . 0.0 112.51 179.993 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 112.462 -0.255 . . . . 0.0 112.462 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.4 m -93.43 154.25 18.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.825 0.345 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 90.5 p -91.04 -46.9 7.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.917 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.69 124.15 3.78 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.443 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 p -120.88 62.48 0.87 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.931 0.396 . . . . 0.0 110.852 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.8 m 59.84 -176.78 0.1 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.977 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -161.34 -81.44 0.04 OUTLIER Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.533 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.504 HG21 HG11 ' A' ' 14' ' ' VAL . 20.2 mt -126.93 150.08 32.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.755 0.312 . . . . 0.0 111.172 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -157.91 -176.65 6.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.592 HG13 ' O ' ' A' ' 30' ' ' ARG . 39.7 t -58.89 138.93 19.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.146 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 72.06 47.33 31.52 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.512 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.726 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -147.31 136.38 11.52 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.585 0.231 . . . . 0.0 110.893 179.985 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -76.19 130.2 11.91 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.512 2.141 . . . . 0.0 112.298 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.504 HG11 HG21 ' A' ' 8' ' ' ILE . 7.3 m -151.67 138.75 13.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.156 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -81.89 135.21 35.43 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.753 HG22 HD23 ' A' ' 85' ' ' LEU . 21.4 t -116.83 139.9 41.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.14 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -103.26 116.29 32.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.937 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 50.6 mt -89.72 -44.65 9.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.954 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -86.38 172.17 10.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.87 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 43.2 t -76.43 76.22 3.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.11 69.2 1.39 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.509 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -133.38 -57.7 0.89 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.887 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -156.12 132.7 10.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.847 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -102.87 128.1 49.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.874 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.402 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 42.6 m-85 -93.18 129.56 38.88 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.817 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.63 ' HB2' HD12 ' A' ' 51' ' ' LEU . 72.9 Cg_endo -76.06 138.59 20.73 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.435 2.09 . . . . 0.0 112.282 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.27 151.49 22.8 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.552 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.0 p -92.38 130.94 40.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.791 0.329 . . . . 0.0 111.018 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.726 HG23 ' O ' ' A' ' 12' ' ' CYS . 22.1 t -64.77 140.54 19.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.051 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.592 ' O ' HG13 ' A' ' 10' ' ' VAL . 11.3 mmt180 -122.22 -41.07 2.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.042 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -138.25 164.47 29.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.947 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 3.3 ttp180 -158.11 141.94 15.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.857 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.04 149.18 4.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.478 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.71 154.16 64.14 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.604 2.203 . . . . 0.0 112.339 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.541 HD12 ' CE1' ' A' ' 45' ' ' PHE . 9.7 mt -84.47 58.01 4.62 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.9 mt 59.8 172.9 0.08 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.949 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.561 ' HB1' ' O ' ' A' ' 40' ' ' THR . . . -157.88 163.01 38.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.188 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -91.59 -67.08 0.88 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.874 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.67 -33.24 6.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.013 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.561 ' O ' ' HB1' ' A' ' 37' ' ' ALA . 2.0 t -133.05 141.51 48.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.443 HG23 ' O ' ' A' ' 41' ' ' VAL . 11.8 m -83.55 76.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.071 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.3 m -113.1 92.65 4.08 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.972 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 149.95 76.72 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.51 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.6 mt -90.9 150.73 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.749 0.309 . . . . 0.0 111.063 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.541 ' CE1' HD12 ' A' ' 35' ' ' LEU . 83.0 m-85 -136.71 147.23 46.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.941 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.448 ' HB2' HD11 ' A' ' 85' ' ' LEU . 9.6 m-85 -123.99 109.89 14.1 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.855 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.31 120.68 9.49 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.477 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.529 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -133.21 133.11 58.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.874 0.368 . . . . 0.0 111.107 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -90.24 116.93 28.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.881 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.469 HD21 HG21 ' A' ' 78' ' ' VAL . 63.6 mt -60.43 145.33 48.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.941 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.63 HD12 ' HB2' ' A' ' 26' ' ' PRO . 3.6 mt -86.44 -179.85 6.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.923 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -53.24 -29.35 32.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.111 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.09 -51.95 65.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.884 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.402 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -112.21 29.64 8.22 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.514 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -68.17 144.97 54.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.888 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.67 39.24 14.59 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.519 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -145.4 35.19 1.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.774 0.321 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.05 152.09 19.26 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -110.0 -43.87 3.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 0.0 110.979 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.4 t -77.61 -40.38 42.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.899 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 51.12 26.83 3.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.302 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.417 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 106.31 -31.74 8.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.622 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -111.78 128.79 68.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.89 0.376 . . . . 0.0 111.091 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.428 ' CE1' ' HG3' ' A' ' 65' ' ' GLN . 30.9 t80 -113.28 110.01 19.68 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.896 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLN . . . . . 0.428 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 9.9 mt-30 57.72 28.84 16.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.034 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 102.22 -26.81 22.97 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.498 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.6 tmtt? -82.17 116.82 21.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.918 0.39 . . . . 0.0 110.952 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 19.5 tp60 -78.96 98.91 6.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.832 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 79.0 mt -81.13 -37.86 28.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.949 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.417 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.0 p90 -155.96 173.3 16.99 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.936 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -107.72 123.36 48.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.889 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -139.58 177.2 8.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.911 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -76.05 179.92 5.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.886 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -73.52 114.01 11.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.913 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 42.2 m-20 60.83 45.21 10.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.912 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 62.6 m -125.63 -46.17 1.74 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.894 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -65.1 135.82 37.36 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.525 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 48' ' ' VAL . 8.6 m -148.49 138.86 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.803 0.335 . . . . 0.0 111.164 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -105.15 134.52 48.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.559 ' CG2' HD21 ' A' ' 85' ' ' LEU . 30.5 m -155.79 168.56 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.182 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -87.39 161.24 17.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.191 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 7.0 tp -49.99 -44.3 50.87 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -55.82 -27.1 49.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.665 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 16.1 mmtt -95.86 19.65 11.1 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.934 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.753 HD23 HG22 ' A' ' 16' ' ' VAL . 88.2 mt -129.18 126.71 39.82 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.93 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -107.8 110.39 22.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.963 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.435 ' HA ' HG12 ' A' ' 14' ' ' VAL . 12.2 tp -67.14 117.47 9.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.996 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.474 HG22 ' N ' ' A' ' 89' ' ' GLU . 2.0 mp -86.17 158.23 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.152 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLU . . . . . 0.474 ' N ' HG22 ' A' ' 88' ' ' ILE . 2.5 tt0 -146.8 161.75 40.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.931 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.75 113.91 9.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.878 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -134.25 -146.35 5.42 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.473 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.37 -26.73 40.94 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.524 2.149 . . . . 0.0 112.366 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.3 m -66.51 99.52 0.58 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 m 60.9 178.91 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.345 -1.253 . . . . 0.0 112.433 179.981 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 112.484 -0.247 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.0 t -174.81 178.28 1.88 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.834 0.349 . . . . 0.0 110.888 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.3 t -159.82 -45.33 0.05 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.922 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.01 177.18 48.34 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.516 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 60.0 p -150.26 -50.38 0.13 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.816 0.341 . . . . 0.0 110.917 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.5 m -112.92 153.92 27.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.912 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 121.18 104.99 1.95 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.456 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.455 HG21 HG11 ' A' ' 14' ' ' VAL . 8.7 mt -102.11 125.85 56.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.769 0.318 . . . . 0.0 111.058 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.65 -175.54 3.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.924 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.401 ' HA ' ' CG1' ' A' ' 29' ' ' VAL . 28.3 t -64.42 128.86 27.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.018 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 88.47 43.92 5.4 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.444 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.701 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -145.63 139.21 14.6 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.643 0.259 . . . . 0.0 110.963 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.622 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.2 Cg_endo -76.72 130.03 11.27 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.513 2.142 . . . . 0.0 112.303 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.455 HG11 HG21 ' A' ' 8' ' ' ILE . 12.6 m -151.1 138.8 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.141 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 50.2 mttt -82.21 127.49 33.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.962 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.725 HG13 HG21 ' A' ' 80' ' ' VAL . 21.4 t -108.69 137.01 42.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.029 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -92.98 121.41 34.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.971 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.1 mt -100.41 -42.49 6.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.956 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.9 mtt85 -79.68 -178.22 6.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.81 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -80.49 73.54 7.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.825 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.75 41.21 99.88 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.491 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -101.94 -61.86 1.33 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.747 0.308 . . . . 0.0 110.865 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -148.43 159.6 43.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.902 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 2.0 mttm -125.3 126.38 45.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -89.65 137.31 28.72 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.766 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.414 ' HB2' HD12 ' A' ' 51' ' ' LEU . 67.4 Cg_endo -73.88 146.15 37.23 Favored 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.424 2.082 . . . . 0.0 112.331 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -163.29 152.21 22.16 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.502 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.5 p -94.1 129.16 44.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.324 . . . . 0.0 111.138 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 12' ' ' CYS . 18.7 t -62.3 126.58 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.07 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 40.0 mmt180 -112.11 -31.05 7.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.012 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -148.25 167.73 24.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.976 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 9.6 ttp180 -160.85 119.39 2.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.865 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.52 156.34 11.8 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.55 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.08 174.53 9.65 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.586 2.19 . . . . 0.0 112.357 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.502 HD11 ' CZ ' ' A' ' 45' ' ' PHE . 4.6 mt -98.78 -33.21 10.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.919 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.5 mp -138.89 147.65 42.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.886 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -164.38 87.92 0.49 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.061 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -115.43 -73.07 0.66 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.954 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 5.2 mtp180 -86.57 -36.07 19.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.937 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.3 m -162.35 150.22 14.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.955 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 10.0 m -88.08 142.81 12.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.135 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 5.1 m -98.8 -36.22 9.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.845 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -175.98 -157.26 16.78 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.468 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.9 mp -142.54 117.02 4.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.794 0.33 . . . . 0.0 111.153 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.502 ' CZ ' HD11 ' A' ' 35' ' ' LEU . 33.5 m-85 -85.5 124.24 31.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.421 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 5.8 m-85 -98.16 120.0 37.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.999 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.444 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -83.56 131.64 10.52 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.418 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.679 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -139.35 126.39 24.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.876 0.37 . . . . 0.0 111.161 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -83.0 117.14 22.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.845 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.445 HD13 ' HB2' ' A' ' 57' ' ' GLN . 13.1 mt -58.62 130.15 45.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.934 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.414 HD12 ' HB2' ' A' ' 26' ' ' PRO . 5.1 mt -76.67 -179.94 5.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.867 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -53.88 -29.2 40.56 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.134 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -61.87 -43.6 98.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.946 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.24 35.33 2.86 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.528 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -72.61 143.44 48.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.779 0.323 . . . . 0.0 110.889 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.48 34.48 11.86 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.475 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.445 ' HB2' HD13 ' A' ' 50' ' ' LEU . 30.5 mm-40 -141.69 37.63 1.65 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.83 0.348 . . . . 0.0 110.843 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -110.16 155.22 16.21 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.521 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -109.92 -50.55 2.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.775 0.321 . . . . 0.0 110.929 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.431 HG23 ' N ' ' A' ' 61' ' ' ASP . 7.2 t -64.61 -48.21 75.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.929 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.431 ' N ' HG23 ' A' ' 60' ' ' THR . 6.0 m-20 56.64 27.8 13.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.154 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.414 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 107.35 -27.05 16.61 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.571 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.494 HG23 ' C ' ' A' ' 67' ' ' LYS . 12.6 p -117.69 138.12 49.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 111.158 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -121.44 109.97 15.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.911 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 17.1 mt-30 61.29 25.17 15.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.091 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.45 -29.27 10.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.571 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.494 ' C ' HG23 ' A' ' 63' ' ' VAL . 6.1 tmtt? -79.27 119.15 21.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.864 0.364 . . . . 0.0 110.984 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 17.9 tp60 -82.13 97.09 8.02 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.91 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.49 HD12 ' CE2' ' A' ' 79' ' ' PHE . 80.5 mt -76.85 -43.92 34.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.958 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.2 p90 -151.46 170.92 18.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.89 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.02 134.45 44.0 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -156.85 165.81 35.15 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -66.92 173.71 3.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -72.68 121.66 20.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 60.38 49.41 6.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.91 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 60.4 m -129.96 -51.65 1.13 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -66.56 142.83 42.99 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.487 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.679 HG22 ' O ' ' A' ' 48' ' ' VAL . 21.0 m -151.37 143.67 16.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.834 0.349 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.49 ' CE2' HD12 ' A' ' 69' ' ' LEU . 12.5 m-85 -109.74 128.39 55.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.881 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.725 HG21 HG13 ' A' ' 16' ' ' VAL . 30.5 m -149.85 154.93 8.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.101 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.52 156.24 33.19 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.092 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.406 ' CD1' HD12 ' A' ' 8' ' ' ILE . 16.2 tp -50.89 -47.7 60.55 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.939 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -55.84 -28.58 57.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.545 179.664 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.2 mmmp? -75.85 -26.32 57.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.727 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.577 ' CD2' HG22 ' A' ' 16' ' ' VAL . 77.7 mt -84.16 137.68 33.4 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.852 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -124.62 108.03 11.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.453 HD13 HG12 ' A' ' 8' ' ' ILE . 10.1 tp -60.91 142.54 56.26 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.88 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.852 HG21 ' HD3' ' A' ' 92' ' ' PRO . 21.5 mt -98.11 133.48 40.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.169 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.69 -36.08 4.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.923 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.3 p -92.89 -75.25 0.5 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.966 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.82 122.43 0.73 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.422 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.852 ' HD3' HG21 ' A' ' 88' ' ' ILE . 68.1 Cg_endo -74.27 -44.21 0.45 Allowed 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.43 2.087 . . . . 0.0 112.37 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 27.2 m -113.73 124.34 52.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.915 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -142.72 118.12 10.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.897 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.393 -1.226 . . . . 0.0 112.521 -179.995 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.259 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.9 p -99.34 34.35 2.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.892 0.377 . . . . 0.0 110.939 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.0 t -64.51 177.11 0.94 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.839 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.91 124.49 1.33 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.543 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.97 120.35 27.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.788 0.328 . . . . 0.0 110.956 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.5 m -91.48 146.19 24.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.98 -95.05 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.529 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.604 HG21 HG11 ' A' ' 14' ' ' VAL . 31.1 mt -120.32 119.64 60.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.819 0.342 . . . . 0.0 111.142 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -122.39 -175.75 3.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.924 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.3 t -66.09 135.17 28.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.077 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.75 45.85 7.05 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.514 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.646 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -143.62 139.8 16.7 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.64 0.257 . . . . 0.0 110.877 -179.974 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -74.77 122.8 7.55 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.427 2.085 . . . . 0.0 112.234 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.681 ' CG2' HD22 ' A' ' 85' ' ' LEU . 15.8 m -147.13 138.39 18.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.154 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 20.3 mttm -84.69 133.43 34.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.036 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.851 HG22 HD23 ' A' ' 85' ' ' LEU . 18.0 t -114.22 139.57 39.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.106 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -91.16 122.28 33.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.888 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 45.9 mt -104.59 -52.2 2.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.965 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.6 mtt85 -68.45 -175.86 0.7 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.2 p -94.7 70.21 3.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.82 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 81.06 47.54 6.5 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -111.92 -68.8 0.91 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.804 0.335 . . . . 0.0 110.888 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -157.57 163.09 38.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 17.0 mttm -114.72 112.29 22.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.902 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -72.25 133.41 83.42 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.746 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.575 ' HB2' HD12 ' A' ' 51' ' ' LEU . 73.0 Cg_endo -74.57 143.95 31.3 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.36 2.04 . . . . 0.0 112.392 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -162.76 156.3 27.95 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.487 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.3 p -95.12 131.47 41.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.346 . . . . 0.0 111.046 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.646 HG23 ' O ' ' A' ' 12' ' ' CYS . 22.0 t -65.9 129.75 30.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.039 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.414 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 5.1 mmt180 -114.88 -29.92 6.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -147.37 166.65 26.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.883 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.422 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 6.3 ttp180 -164.38 141.43 6.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.885 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.86 147.99 4.81 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.483 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -71.02 152.13 62.51 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.568 2.179 . . . . 0.0 112.336 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.407 ' C ' HD12 ' A' ' 36' ' ' LEU . 27.6 mt -62.01 -45.81 91.97 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.906 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.407 HD12 ' C ' ' A' ' 35' ' ' LEU . 9.3 mp -118.13 160.94 20.68 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.932 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -122.08 90.16 3.25 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.035 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.617 ' HB3' HG22 ' A' ' 40' ' ' THR . 4.6 mt-10 -112.16 -14.87 13.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.29 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.7 mtt180 62.7 43.96 6.95 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.946 0.403 . . . . 0.0 110.737 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.617 HG22 ' HB3' ' A' ' 38' ' ' GLU . 2.8 t -154.16 -47.81 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.81 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.7 m -71.85 177.86 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.102 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 9.7 t -141.47 86.74 2.03 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -148.12 61.99 0.44 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.509 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.513 ' H ' HD12 ' A' ' 44' ' ' ILE . 3.7 mp -79.33 118.05 26.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.878 0.37 . . . . 0.0 111.065 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -95.1 137.13 34.57 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.892 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.667 ' CB ' HD11 ' A' ' 85' ' ' LEU . 5.3 m-85 -114.59 109.92 18.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.408 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -70.97 118.85 7.73 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.297 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.571 HG21 ' CD2' ' A' ' 85' ' ' LEU . 24.2 t -130.99 131.61 64.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.863 0.363 . . . . 0.0 111.139 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -89.71 116.76 28.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.801 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.668 HD13 ' O ' ' A' ' 54' ' ' GLY . 91.8 mt -57.14 145.57 30.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.149 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.575 HD12 ' HB2' ' A' ' 26' ' ' PRO . 13.3 mt -90.08 -179.88 5.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.836 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -53.19 -27.83 23.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.145 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -63.1 -54.92 30.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.862 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.668 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -116.59 35.65 4.12 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.3 mtt85 -74.69 123.87 25.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.818 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 113.58 25.49 4.28 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.726 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 39.2 mm-40 -135.45 45.72 2.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.847 0.356 . . . . 0.0 110.929 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.62 148.34 18.4 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.47 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 16.3 p90 -109.91 -49.95 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.794 0.33 . . . . 0.0 110.981 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -59.26 -46.2 89.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.0 t0 59.45 26.98 16.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.119 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.409 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.21 -25.49 23.92 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.712 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.6 p -114.18 147.92 17.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.809 0.337 . . . . 0.0 111.161 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 31.7 t80 -132.08 110.01 10.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 53.4 mt-30 60.21 29.62 19.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.914 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.49 -28.33 15.98 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.475 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 8.7 tmtt? -79.66 114.58 18.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.792 0.33 . . . . 0.0 110.932 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 24.5 tp60 -71.51 99.64 2.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.942 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 73.0 mt -78.08 -39.05 42.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CD2' ' HB2' ' A' ' 30' ' ' ARG . 2.3 p90 -163.71 167.9 20.47 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.86 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 17.4 mm-40 -93.82 129.36 40.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.942 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.64 173.96 12.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.91 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -83.27 167.62 17.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.799 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -66.04 118.35 9.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 60.56 44.34 11.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.946 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 86.8 m -127.61 -55.84 1.31 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.94 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.17 135.42 51.75 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.546 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.499 HG22 ' O ' ' A' ' 48' ' ' VAL . 6.1 m -143.73 143.84 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.803 0.335 . . . . 0.0 111.107 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.408 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 3.8 m-85 -109.68 131.48 55.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.762 HG21 HG13 ' A' ' 16' ' ' VAL . 20.4 m -155.96 157.72 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.082 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ALA . . . . . 0.411 ' HB3' ' HG3' ' A' ' 84' ' ' LYS . . . -70.54 155.12 41.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.999 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 10.2 tp -50.4 -45.8 55.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -57.26 -29.54 63.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.606 179.759 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.411 ' HG3' ' HB3' ' A' ' 81' ' ' ALA . 14.2 mttm -77.9 -24.68 48.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.902 179.716 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.851 HD23 HG22 ' A' ' 16' ' ' VAL . 66.6 mt -81.82 158.09 24.2 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.908 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -142.99 109.31 5.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.92 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.455 ' HA ' HG12 ' A' ' 14' ' ' VAL . 34.6 tp -61.8 135.81 57.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.965 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.4 mt -103.1 140.33 21.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.052 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -134.71 173.55 11.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.954 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 p -72.79 117.41 14.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.933 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -168.6 76.74 0.11 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.515 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.18 133.91 48.71 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.528 2.152 . . . . 0.0 112.347 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.9 p -152.08 160.58 43.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 44.7 p -68.38 120.67 14.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.913 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.389 -1.228 . . . . 0.0 112.559 -179.918 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.163 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.37 -37.26 4.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.863 0.363 . . . . 0.0 110.894 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -98.26 -169.97 1.89 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.899 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.59 158.4 19.23 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.509 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 m -100.26 -31.76 11.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.842 0.354 . . . . 0.0 110.94 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.8 m -119.61 178.04 4.71 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.916 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 120.4 106.1 2.08 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.53 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.505 HD12 HD12 ' A' ' 82' ' ' LEU . 32.1 mt -97.07 125.77 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.83 0.348 . . . . 0.0 111.109 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -122.51 172.93 8.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.888 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.423 HG13 ' C ' ' A' ' 30' ' ' ARG . 37.2 t -60.65 133.08 26.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.117 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 85.5 45.14 5.91 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.455 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.494 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.44 139.26 14.75 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 120.638 0.256 . . . . 0.0 110.908 -179.94 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -74.17 133.33 17.76 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.486 2.124 . . . . 0.0 112.253 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.468 ' CG2' HD22 ' A' ' 85' ' ' LEU . 6.2 m -153.83 138.87 10.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.139 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -84.02 131.16 34.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.968 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.802 HG22 HD23 ' A' ' 85' ' ' LEU . 16.8 t -113.26 132.4 62.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.102 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -91.59 116.02 28.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.957 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.564 HD12 ' CE2' ' A' ' 25' ' ' PHE . 36.7 mt -91.56 -57.33 2.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -70.44 -172.11 0.56 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.941 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 t -84.5 79.52 9.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.5 39.04 94.43 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.486 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -95.03 -61.97 1.39 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.858 0.361 . . . . 0.0 110.905 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -155.54 144.58 20.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 21.3 mttt -106.72 124.84 50.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.862 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.564 ' CE2' HD12 ' A' ' 18' ' ' LEU . 61.3 m-85 -87.84 132.59 39.79 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.77 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.416 ' HB2' HD12 ' A' ' 51' ' ' LEU . 65.8 Cg_endo -73.72 141.64 31.02 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.426 2.084 . . . . 0.0 112.34 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.67 147.83 14.67 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.557 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.531 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.9 p -90.47 133.13 33.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.771 0.32 . . . . 0.0 110.984 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.494 HG23 ' O ' ' A' ' 12' ' ' CYS . 23.4 t -65.07 136.68 26.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.138 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.531 ' HD3' HG13 ' A' ' 28' ' ' VAL . 13.9 mmm180 -117.68 -38.04 3.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.021 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -143.11 166.27 25.13 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.877 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.429 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.8 ttp180 -159.6 133.84 7.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.81 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 155.3 151.45 5.87 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.511 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -54.33 157.29 11.83 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.56 2.173 . . . . 0.0 112.233 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.423 ' HG ' ' CD1' ' A' ' 45' ' ' PHE . 71.0 mt -127.06 80.9 1.98 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.804 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.449 HD23 ' H ' ' A' ' 37' ' ' ALA . 0.3 OUTLIER -113.48 152.72 29.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.987 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.449 ' H ' HD23 ' A' ' 36' ' ' LEU . . . -167.87 33.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.984 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -170.33 -65.72 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.956 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.439 ' C ' HD21 ' A' ' 36' ' ' LEU . 0.2 OUTLIER -176.13 -68.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.866 179.958 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.9 t -59.08 161.79 4.87 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.962 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.2 p -167.45 150.63 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.027 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 9.1 t -91.23 -38.22 12.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 154.58 -157.39 27.52 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.532 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.9 mm -75.56 141.37 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.827 0.346 . . . . 0.0 111.034 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.423 ' CD1' ' HG ' ' A' ' 35' ' ' LEU . 83.5 m-85 -114.87 139.38 49.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.429 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 7.6 m-85 -120.85 109.93 15.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.414 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -72.06 128.82 14.58 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.414 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.52 HG21 HD21 ' A' ' 85' ' ' LEU . 21.5 t -137.12 136.78 47.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.796 0.331 . . . . 0.0 111.065 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -94.19 115.4 27.67 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.553 HD13 ' O ' ' A' ' 54' ' ' GLY . 65.2 mt -59.17 130.94 49.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.918 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.416 HD12 ' HB2' ' A' ' 26' ' ' PRO . 12.5 mt -77.5 -179.94 6.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.852 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.05 -29.8 45.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.067 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -61.79 -42.97 99.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.958 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.553 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -123.89 34.46 3.57 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.445 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -75.74 132.54 40.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.864 0.364 . . . . 0.0 110.874 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.04 29.96 6.94 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.524 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -140.97 33.38 1.76 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.802 0.334 . . . . 0.0 110.888 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -99.51 152.67 19.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.529 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -109.98 -50.95 2.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.853 0.358 . . . . 0.0 110.941 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.453 HG22 ' HA ' ' A' ' 78' ' ' VAL . 6.1 t -66.58 -48.56 69.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.947 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.425 ' N ' HG23 ' A' ' 60' ' ' THR . 18.4 t70 60.36 23.77 13.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.203 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.427 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 103.81 -31.96 8.09 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.671 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -103.7 133.73 46.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.861 0.362 . . . . 0.0 111.199 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -118.95 109.98 16.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.879 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 60.21 28.11 17.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.956 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.37 23.82 25.72 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.596 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 5.6 tttm -132.3 109.95 10.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.861 0.363 . . . . 0.0 110.88 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 11.9 tp60 -69.72 95.56 0.89 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 83.0 mt -82.32 -37.53 25.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.92 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.427 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.5 p90 -149.0 165.45 31.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -98.25 128.36 44.66 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.907 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.39 164.51 32.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.781 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.89 174.24 9.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -62.84 113.17 2.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.888 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 60.33 54.63 3.85 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.858 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 68.7 m -129.57 -56.47 1.14 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.441 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -59.57 140.28 48.08 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.511 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.453 ' HA ' HG22 ' A' ' 60' ' ' THR . 6.0 m -156.61 127.84 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.754 0.311 . . . . 0.0 111.157 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -90.4 130.31 36.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.848 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.526 HG11 ' CG1' ' A' ' 16' ' ' VAL . 6.1 m -150.41 164.86 2.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.181 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.87 157.4 22.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.128 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.505 HD12 HD12 ' A' ' 8' ' ' ILE . 11.3 tp -50.39 -44.21 54.81 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.848 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -57.39 -28.75 63.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.571 179.698 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.448 ' HE3' HG12 ' A' ' 80' ' ' VAL . 5.2 mtmt -81.4 -26.67 35.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.813 179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.802 HD23 HG22 ' A' ' 16' ' ' VAL . 83.8 mt -85.42 146.16 27.11 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.891 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -133.35 107.89 8.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.925 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 12.4 tp -60.07 121.65 12.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.92 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 1.9 mp -81.26 135.91 24.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.162 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -70.48 -174.69 0.9 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.881 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.8 p -77.96 -51.82 9.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.876 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -167.55 170.61 41.78 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.515 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -54.15 -171.78 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.595 2.197 . . . . 0.0 112.248 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.68 164.97 25.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.921 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.8 m -60.77 -73.11 0.1 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.428 -179.939 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.217 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -119.32 35.67 4.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.844 0.354 . . . . 0.0 110.864 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 p -131.14 132.75 44.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.931 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 169.65 172.97 36.77 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.52 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 44.1 m -96.34 -64.79 1.02 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.779 0.323 . . . . 0.0 110.907 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.44 -172.21 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.843 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.85 -31.88 0.22 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.505 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.438 HG21 HG11 ' A' ' 14' ' ' VAL . 11.3 mt -118.01 145.23 24.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.799 0.333 . . . . 0.0 111.051 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -150.72 -177.83 6.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.402 ' HA ' HG12 ' A' ' 29' ' ' VAL . 40.3 t -59.71 127.66 19.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.027 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 84.89 43.59 6.7 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.478 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.675 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -139.51 139.32 22.12 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.66 0.267 . . . . 0.0 110.923 -179.897 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.544 ' HB2' HD12 ' A' ' 88' ' ' ILE . 75.3 Cg_endo -77.38 117.38 4.33 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.516 2.144 . . . . 0.0 112.427 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.472 HG12 ' HA ' ' A' ' 87' ' ' LEU . 13.7 m -145.67 138.52 20.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.075 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.414 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 13.3 mttm -84.16 141.19 31.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.072 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.677 HG22 HD23 ' A' ' 85' ' ' LEU . 21.9 t -117.29 134.84 59.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.067 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -92.79 110.1 21.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.946 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.425 HD12 ' CE2' ' A' ' 25' ' ' PHE . 71.2 mt -81.5 -47.05 13.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.801 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.53 145.8 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.957 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 30.2 t -74.57 86.75 2.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.958 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.83 67.8 1.44 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.437 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -149.46 -58.46 0.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.833 0.349 . . . . 0.0 110.984 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -175.97 164.09 2.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 40.6 mttt -117.11 160.36 21.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.896 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.44 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 56.6 m-85 -126.4 121.92 23.77 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.822 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.414 ' HA ' ' HA ' ' A' ' 15' ' ' LYS . 38.3 Cg_endo -66.04 140.6 60.66 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.513 2.142 . . . . 0.0 112.4 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.9 158.0 28.99 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.403 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.9 p -99.46 129.21 50.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.868 0.365 . . . . 0.0 111.098 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.675 HG23 ' O ' ' A' ' 12' ' ' CYS . 19.5 t -65.4 132.65 31.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.097 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.411 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 4.5 mmm180 -116.05 -35.55 4.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.006 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -146.37 169.45 18.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.931 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.426 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 9.6 ttt180 -157.54 120.76 4.01 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.879 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -178.86 146.94 7.53 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.492 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -73.1 177.13 8.18 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.603 2.202 . . . . 0.0 112.252 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 84.0 mt -132.08 31.18 4.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.926 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 24.8 mt 60.62 -176.21 0.11 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -129.29 108.37 10.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.119 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 59.0 mm-40 -97.29 -67.44 0.85 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.818 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.68 31.75 3.35 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.92 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.3 t -158.93 173.9 15.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.839 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 4.7 m -97.64 33.78 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.186 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.6 p -59.9 127.18 30.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.965 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -102.71 -146.76 18.04 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.487 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.0 mt -70.05 134.33 30.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.758 0.313 . . . . 0.0 111.168 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.439 ' HB3' ' CD1' ' A' ' 79' ' ' PHE . 82.8 m-85 -104.67 144.79 31.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.912 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.543 ' CB ' HD11 ' A' ' 85' ' ' LEU . 6.2 m-85 -119.46 109.93 16.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.87 119.86 8.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.58 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.4 t -132.03 133.09 61.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.869 0.366 . . . . 0.0 111.189 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -87.71 116.61 25.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.44 HD13 ' O ' ' A' ' 54' ' ' GLY . 94.5 mt -60.18 130.41 46.52 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.952 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 mt -78.82 -179.93 6.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.767 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.24 -30.06 48.96 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.057 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -61.43 -41.54 97.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.873 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.44 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -127.5 34.04 3.13 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.445 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 mtt180 -72.88 138.26 46.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.799 0.333 . . . . 0.0 110.868 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.42 29.52 8.79 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.513 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -141.51 43.42 1.75 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.792 0.33 . . . . 0.0 110.898 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -113.18 150.18 18.5 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.525 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 5.6 p90 -110.06 -51.22 2.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.78 0.324 . . . . 0.0 110.879 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.445 HG23 ' N ' ' A' ' 61' ' ' ASP . 9.3 t -69.72 -48.32 59.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.835 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.445 ' N ' HG23 ' A' ' 60' ' ' THR . 8.6 m-20 53.91 36.22 23.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.09 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.422 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 97.97 -26.15 24.6 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.555 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.472 HG23 ' C ' ' A' ' 67' ' ' LYS . 12.0 p -118.51 137.23 53.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.809 0.337 . . . . 0.0 111.104 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 3.1 t80 -122.68 111.13 16.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.945 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 62.18 27.15 16.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.037 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 103.04 -28.43 15.85 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.526 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.472 ' C ' HG23 ' A' ' 63' ' ' VAL . 0.5 OUTLIER -79.44 116.63 19.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.871 0.367 . . . . 0.0 110.956 179.998 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 21.7 tp60 -80.31 99.5 7.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.42 HD12 ' HE2' ' A' ' 79' ' ' PHE . 88.0 mt -79.21 -44.93 20.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.853 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.422 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.8 p90 -146.81 176.45 9.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.93 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 2.5 mm-40 -99.37 128.6 45.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -152.05 165.59 34.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -80.66 171.94 14.38 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 -68.9 126.21 29.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 59.02 43.79 17.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 37.5 m -129.87 -60.84 1.02 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -58.6 135.66 51.74 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.535 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 48' ' ' VAL . 22.1 m -148.05 141.28 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.788 0.328 . . . . 0.0 111.131 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.439 ' CD1' ' HB3' ' A' ' 45' ' ' PHE . 3.0 m-85 -104.99 126.82 52.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.842 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.671 HG11 ' CG1' ' A' ' 16' ' ' VAL . 28.9 m -150.22 164.24 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.105 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.26 158.04 29.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.113 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.406 HD12 HD12 ' A' ' 8' ' ' ILE . 8.6 tp -50.68 -44.41 57.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.867 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -57.42 -29.27 63.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.591 179.668 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.26 -26.03 42.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.763 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.677 HD23 HG22 ' A' ' 16' ' ' VAL . 89.0 mt -82.19 125.04 30.45 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.954 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 5.2 tm-20 -112.05 107.48 16.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.472 ' HA ' HG12 ' A' ' 14' ' ' VAL . 31.6 tp -60.36 131.19 50.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.906 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.544 HD12 ' HB2' ' A' ' 13' ' ' PRO . 4.9 mt -86.46 140.93 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.109 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -152.73 129.49 10.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.842 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 47.9 t -86.47 -46.5 10.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -166.13 -161.2 14.64 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.473 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.2 -41.12 67.41 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.587 2.191 . . . . 0.0 112.358 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -124.19 105.04 9.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.845 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 15.4 p -175.92 -43.61 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.867 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.423 -1.209 . . . . 0.0 112.457 -179.989 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.203 0 N-CA-C 112.469 -0.253 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.29 31.89 20.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.875 0.369 . . . . 0.0 110.961 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.34 31.2 5.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.989 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -118.91 129.54 8.17 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.527 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.2 m -113.36 104.84 12.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.751 0.31 . . . . 0.0 110.902 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.1 m -141.79 150.73 42.08 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.73 -69.03 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.529 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.53 HG12 HD13 ' A' ' 87' ' ' LEU . 30.8 mt -123.61 136.65 59.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.82 0.343 . . . . 0.0 111.115 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -144.58 -172.52 3.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.812 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 30' ' ' ARG . 33.9 t -65.42 144.49 14.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.152 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 68.88 49.11 44.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.506 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.608 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.89 139.91 15.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 120.662 0.268 . . . . 0.0 111.002 179.899 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.09 126.7 8.8 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.544 2.163 . . . . 0.0 112.293 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.413 HG21 HD22 ' A' ' 85' ' ' LEU . 13.3 m -154.04 138.27 9.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.153 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.408 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 39.3 mttt -88.32 138.11 31.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.005 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.777 HG22 HD23 ' A' ' 85' ' ' LEU . 26.2 t -117.35 141.57 35.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.997 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.0 tt0 -103.11 110.03 21.82 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.881 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.1 mt -80.78 -51.07 9.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.02 -169.84 1.72 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.9 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -104.75 87.09 2.59 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.865 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 67.96 56.6 10.38 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.452 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.03 -52.86 1.75 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.36 . . . . 0.0 110.935 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -176.06 139.89 0.39 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.913 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -100.96 122.79 44.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.91 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.44 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 46.6 m-85 -87.67 129.84 49.29 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.821 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.412 ' HB2' HD12 ' A' ' 51' ' ' LEU . 63.0 Cg_endo -73.0 141.02 32.34 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.503 2.135 . . . . 0.0 112.301 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.47 150.22 20.09 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.51 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.628 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.7 p -93.78 133.75 33.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.836 0.35 . . . . 0.0 111.085 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 47' ' ' GLY . 15.8 t -67.96 136.23 26.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.11 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.628 ' HD3' HG13 ' A' ' 28' ' ' VAL . 1.7 mmm180 -118.86 -38.75 3.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.984 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -139.88 165.98 25.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.408 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 36.9 ttp85 -160.49 127.55 4.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.33 146.56 4.67 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.45 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -54.04 169.78 0.59 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.504 2.136 . . . . 0.0 112.325 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.633 ' HB3' HD12 ' A' ' 36' ' ' LEU . 6.9 mt -120.08 -60.97 1.65 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.817 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.633 HD12 ' HB3' ' A' ' 35' ' ' LEU . 4.6 mp -121.31 124.93 45.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.881 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -162.25 111.69 1.47 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.137 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -160.81 -58.71 0.05 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.867 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.04 -33.09 6.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.928 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.6 t -127.83 121.95 31.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.821 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.4 m -67.71 132.78 32.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.164 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 19.6 m -113.06 -50.44 2.88 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.877 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 130.6 161.3 10.3 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.45 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.5 mt -77.52 150.93 5.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.835 0.35 . . . . 0.0 111.191 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -119.44 139.96 51.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.494 ' CB ' HD11 ' A' ' 85' ' ' LEU . 6.5 m-85 -118.56 109.95 16.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.92 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.635 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -69.09 140.9 34.96 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.557 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.426 HG21 ' CD2' ' A' ' 85' ' ' LEU . 21.9 t -152.37 134.64 6.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.844 0.355 . . . . 0.0 111.109 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -92.62 116.34 28.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.435 HD13 ' O ' ' A' ' 54' ' ' GLY . 74.7 mt -60.03 136.55 58.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.986 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.412 HD12 ' HB2' ' A' ' 26' ' ' PRO . 0.9 OUTLIER -81.08 -179.94 7.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.902 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -53.8 -30.04 43.19 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.141 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -62.26 -47.48 84.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.847 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.44 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -120.12 35.76 3.67 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.444 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -76.88 133.84 39.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.774 0.321 . . . . 0.0 110.898 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.28 30.26 6.71 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.586 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -140.68 38.84 1.84 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 0.0 110.936 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.57 150.31 17.17 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.456 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 10.5 p90 -109.35 -45.73 3.67 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.747 0.308 . . . . 0.0 110.852 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.595 HG22 ' HA ' ' A' ' 78' ' ' VAL . 8.8 t -71.0 -48.45 53.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.927 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.43 ' N ' HG23 ' A' ' 60' ' ' THR . 14.6 m-20 56.05 28.6 13.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.126 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.15 -24.88 28.14 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.702 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -117.59 129.95 73.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.865 0.364 . . . . 0.0 111.151 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.457 ' CZ ' HD13 ' A' ' 35' ' ' LEU . 62.4 t80 -114.95 110.01 18.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.946 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 59.37 24.71 13.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.113 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.13 23.66 16.74 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.558 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -125.37 109.81 13.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.89 0.376 . . . . 0.0 110.812 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 17.5 tp60 -71.47 95.25 1.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.906 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.404 HD12 ' HE2' ' A' ' 79' ' ' PHE . 44.1 mt -84.5 -38.09 20.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CD1' ' N ' ' A' ' 70' ' ' PHE . 3.0 p90 -152.25 171.54 17.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.843 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -101.01 112.63 25.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -137.85 170.07 16.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.913 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -78.96 172.3 13.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.925 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -72.14 123.4 22.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.922 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 60.34 37.91 19.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.885 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 34.7 m -121.46 -64.61 1.21 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.939 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.14 144.62 44.94 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.502 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.595 ' HA ' HG22 ' A' ' 60' ' ' THR . 15.3 m -152.41 142.78 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.347 . . . . 0.0 111.201 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.404 ' HE2' HD12 ' A' ' 69' ' ' LEU . 2.8 m-85 -104.24 119.52 39.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.837 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.453 HG11 HG11 ' A' ' 16' ' ' VAL . 27.1 m -142.77 163.59 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.239 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -76.31 161.27 28.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.241 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.494 HD12 HD12 ' A' ' 8' ' ' ILE . 13.6 tp -51.55 -47.46 63.41 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.912 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -56.5 -27.23 56.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.711 179.719 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -80.91 -5.26 57.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.232 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.777 HD23 HG22 ' A' ' 16' ' ' VAL . 43.8 mt -104.58 140.43 38.01 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.894 0.378 . . . . 0.0 111.032 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -122.02 110.16 15.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.802 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.53 HD13 HG12 ' A' ' 8' ' ' ILE . 7.9 tp -59.16 138.52 57.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.05 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.489 HG22 ' N ' ' A' ' 89' ' ' GLU . 5.3 mt -109.28 158.53 9.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.037 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLU . . . . . 0.489 ' N ' HG22 ' A' ' 88' ' ' ILE . 2.3 mm-40 -85.34 102.46 13.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.87 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 20.8 p -109.35 103.18 12.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 177.01 -60.2 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.587 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -71.96 -178.56 3.23 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.605 2.203 . . . . 0.0 112.316 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 66.9 m -105.23 91.08 3.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.88 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.1 t -155.82 -54.87 0.09 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.915 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.101 0 CA-C-O 118.36 -1.245 . . . . 0.0 112.473 -179.997 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.176 0 N-CA-C 112.526 -0.229 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 m -82.66 -43.43 16.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.892 0.377 . . . . 0.0 110.944 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 56.5 m -69.53 106.42 3.0 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.874 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 132.66 87.66 0.35 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.531 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.4 t -159.09 31.95 0.21 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.844 0.354 . . . . 0.0 110.95 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.2 m -166.08 177.5 6.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.36 -63.91 0.26 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.518 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.508 HD13 HG11 ' A' ' 14' ' ' VAL . 33.4 mt -81.4 146.47 7.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.782 0.325 . . . . 0.0 111.142 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -144.77 -177.58 5.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.931 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.405 HG13 ' C ' ' A' ' 30' ' ' ARG . 38.3 t -67.04 129.71 31.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.132 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 88.04 43.9 5.53 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.482 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.688 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.35 140.36 18.95 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.584 0.23 . . . . 0.0 110.893 179.986 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.652 ' HB2' HD12 ' A' ' 88' ' ' ILE . 71.9 Cg_endo -77.14 118.87 4.83 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.528 2.152 . . . . 0.0 112.366 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.508 HG11 HD13 ' A' ' 8' ' ' ILE . 4.5 m -141.8 138.92 31.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.135 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 0.1 OUTLIER -84.01 126.44 33.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.996 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.608 HG22 ' CD2' ' A' ' 85' ' ' LEU . 29.8 t -102.24 128.81 54.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.997 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -89.31 131.65 35.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.947 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -111.37 -56.84 2.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.812 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -67.65 171.3 6.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.932 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.2 m -72.71 78.4 1.11 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.923 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.17 62.24 6.42 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.535 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -122.44 -65.09 1.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.811 0.339 . . . . 0.0 110.84 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -143.39 162.51 35.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.891 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.5 mttt -127.03 113.06 15.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.887 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -76.89 127.72 83.21 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.823 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 15' ' ' LYS . 59.0 Cg_endo -71.32 149.99 58.0 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.452 2.102 . . . . 0.0 112.34 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.507 ' HA2' HD12 ' A' ' 51' ' ' LEU . . . -170.59 149.93 13.44 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.521 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.7 p -88.36 132.71 32.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.826 0.346 . . . . 0.0 111.072 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.688 HG23 ' O ' ' A' ' 12' ' ' CYS . 28.4 t -67.96 132.2 32.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.018 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.405 ' C ' HG13 ' A' ' 10' ' ' VAL . 1.0 OUTLIER -114.59 -37.0 4.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.959 179.975 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -136.93 166.74 22.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.934 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -164.36 120.34 1.55 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.882 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.54 154.04 7.56 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.51 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.88 146.48 53.4 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.616 2.211 . . . . 0.0 112.328 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.422 ' HG ' ' CD2' ' A' ' 45' ' ' PHE . 74.0 mt -74.85 -68.88 0.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.82 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 mt -161.4 163.68 30.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.868 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -134.6 119.61 18.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.054 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -130.31 -68.43 0.7 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -120.41 -40.18 2.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.984 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.0 t -66.69 173.08 3.68 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.478 HG22 ' N ' ' A' ' 42' ' ' SER . 11.0 p -66.33 158.33 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.068 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.478 ' N ' HG22 ' A' ' 41' ' ' VAL . 40.6 t -92.8 95.8 9.75 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.993 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -107.82 -169.5 21.67 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.542 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.409 HG22 ' N ' ' A' ' 45' ' ' PHE . 25.2 mt -129.11 154.43 40.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.834 0.35 . . . . 0.0 111.139 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.422 ' CD2' ' HG ' ' A' ' 35' ' ' LEU . 85.9 m-85 -124.24 142.59 51.12 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.858 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.622 ' CB ' HD11 ' A' ' 85' ' ' LEU . 10.4 m-85 -123.92 111.05 15.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.848 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -75.76 117.73 5.24 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.438 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.567 HG22 HG22 ' A' ' 29' ' ' VAL . 21.3 t -130.31 127.22 62.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.811 0.339 . . . . 0.0 111.132 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -84.14 118.84 24.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.913 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 18.8 mt -58.93 139.26 56.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.095 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.507 HD12 ' HA2' ' A' ' 27' ' ' GLY . 0.0 OUTLIER -84.52 -179.84 7.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.827 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -50.63 -28.8 9.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.188 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.04 -61.56 2.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.854 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -108.58 29.0 10.44 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.459 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt180 -64.76 126.3 27.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.855 0.359 . . . . 0.0 110.933 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.8 36.26 4.31 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.485 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -141.08 32.57 1.75 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.835 0.35 . . . . 0.0 110.924 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -92.47 150.56 20.17 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.485 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -110.04 -33.63 6.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.739 0.304 . . . . 0.0 110.945 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.7 t -83.34 -44.36 14.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.941 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.0 t0 54.93 30.21 13.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.069 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.41 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.44 -28.02 14.92 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.438 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.456 ' O ' HG13 ' A' ' 63' ' ' VAL . 11.0 p -115.09 122.99 70.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.749 0.309 . . . . 0.0 111.107 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -108.1 114.11 27.77 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.941 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 43.0 mt-30 59.55 26.08 15.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.057 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.08 24.94 23.48 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.601 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -134.15 109.92 9.23 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.866 0.365 . . . . 0.0 110.89 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -67.3 121.28 15.37 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.876 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 95.3 mt -108.89 -32.38 7.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.41 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -156.71 170.48 22.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.838 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.66 116.93 32.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.803 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 5.0 p -139.55 175.31 9.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.69 170.4 15.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.83 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -66.84 116.39 7.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.932 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 60.79 46.0 9.34 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 65.7 m -125.56 -45.93 1.77 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.896 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -68.85 139.75 33.47 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.541 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.538 HG22 ' O ' ' A' ' 48' ' ' VAL . 6.3 m -150.56 131.5 4.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.789 0.328 . . . . 0.0 111.175 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 14.1 m-85 -99.99 119.93 39.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.835 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.568 HG21 HG13 ' A' ' 16' ' ' VAL . 29.1 m -142.2 168.77 14.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.124 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -81.56 159.69 24.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.194 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 6.3 tp -50.06 -43.18 51.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.894 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -57.02 -28.06 62.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.595 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -81.79 -27.07 33.89 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.792 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.622 HD11 ' CB ' ' A' ' 46' ' ' PHE . 91.1 mt -88.7 142.41 27.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.922 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -133.43 112.93 11.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.885 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.45 140.09 56.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.652 HD12 ' HB2' ' A' ' 13' ' ' PRO . 6.2 mt -103.2 148.88 7.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.063 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 79.8 mt-10 -121.36 -69.51 0.83 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.2 t -176.86 -40.17 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 110.57 -168.06 12.84 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.487 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -52.16 -49.31 17.81 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.621 2.214 . . . . 0.0 112.329 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -88.29 132.98 34.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.27 87.35 7.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.883 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.368 -1.24 . . . . 0.0 112.565 179.98 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -113.91 116.11 28.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.831 0.348 . . . . 0.0 110.831 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.8 m 61.35 113.24 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.961 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.42 -174.47 29.63 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.508 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.7 m -137.02 177.98 7.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.831 0.348 . . . . 0.0 110.848 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -156.64 163.91 38.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.988 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.49 111.25 2.72 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.617 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.49 HD12 HD12 ' A' ' 82' ' ' LEU . 22.5 mt -95.39 136.91 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.864 0.364 . . . . 0.0 111.138 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -133.55 -169.27 2.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.846 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 26.1 t -74.28 135.4 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.063 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.32 45.9 7.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.509 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.555 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -143.26 136.84 14.21 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 120.561 0.22 . . . . 0.0 110.927 -179.974 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.526 ' HB2' HD12 ' A' ' 88' ' ' ILE . 70.5 Cg_endo -74.58 118.4 5.31 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.54 2.16 . . . . 0.0 112.327 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.629 HG12 ' HA ' ' A' ' 87' ' ' LEU . 17.9 m -145.66 138.46 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.15 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.0 mtpt -74.36 133.63 42.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.907 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 1.049 HG13 HG21 ' A' ' 80' ' ' VAL . 23.5 t -111.07 139.63 34.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.012 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -98.69 129.45 45.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.6 mt -100.1 -52.46 3.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.35 171.94 10.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 65.2 p -68.27 74.4 0.23 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.837 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.89 66.35 2.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.492 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.8 tt0 -124.79 -47.19 1.82 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.816 0.341 . . . . 0.0 110.921 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -167.27 132.75 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.836 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 4.9 mttt -104.06 129.41 51.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.96 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -96.33 135.05 22.74 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.781 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.603 ' HB2' HD12 ' A' ' 51' ' ' LEU . 58.8 Cg_endo -71.82 140.78 35.96 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.432 2.088 . . . . 0.0 112.328 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.85 146.47 10.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.506 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.2 p -85.1 143.06 12.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 111.025 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.555 HG23 ' O ' ' A' ' 12' ' ' CYS . 23.2 t -72.99 136.81 24.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.022 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -116.93 -32.45 5.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.21 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 30.8 t80 -150.39 167.84 25.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.8 0.333 . . . . 0.0 111.003 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CE2' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -153.38 125.51 7.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.923 179.924 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.62 158.0 18.31 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.473 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.97 163.46 38.36 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.479 2.119 . . . . 0.0 112.301 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 28.1 mt -153.01 -71.99 0.14 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.9 mt -120.25 145.79 46.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.968 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -106.51 95.41 5.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.11 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -102.15 133.28 47.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 60.8 mtt85 62.85 -79.61 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.088 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.02 146.49 31.96 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.962 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 10.9 p -78.67 134.95 26.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.091 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 15.2 t 60.21 100.73 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.9 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -129.22 131.84 6.91 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.483 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.5 mt -93.25 135.3 28.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.838 0.351 . . . . 0.0 111.152 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -103.24 174.01 6.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.947 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.705 ' CB ' HD11 ' A' ' 85' ' ' LEU . 28.6 m-85 -145.89 109.93 4.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.9 118.35 8.14 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.457 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.602 HG21 ' CD2' ' A' ' 85' ' ' LEU . 21.0 t -126.37 140.08 49.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.743 0.306 . . . . 0.0 111.069 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -99.19 114.47 27.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.866 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.501 HD13 ' HB2' ' A' ' 57' ' ' GLN . 34.4 mt -57.49 138.27 55.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.038 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.603 HD12 ' HB2' ' A' ' 26' ' ' PRO . 1.8 mt -80.41 -179.9 7.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.802 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -54.48 -29.96 51.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.046 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -61.14 -60.46 3.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.816 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -103.26 28.5 15.42 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.488 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -67.67 131.06 44.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 110.919 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.55 33.57 4.42 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.522 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.501 ' HB2' HD13 ' A' ' 50' ' ' LEU . 99.6 mm-40 -140.25 34.54 1.89 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.85 0.357 . . . . 0.0 110.916 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.1 146.52 16.09 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.49 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 32.3 p90 -109.88 -49.23 3.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.749 0.309 . . . . 0.0 110.912 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.423 HG23 ' N ' ' A' ' 61' ' ' ASP . 6.9 t -63.51 -48.49 77.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.898 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.423 ' N ' HG23 ' A' ' 60' ' ' THR . 9.1 m-20 55.38 29.96 14.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.083 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.417 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 98.35 -28.78 13.24 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.35 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -110.72 128.24 67.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.864 0.364 . . . . 0.0 111.102 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -116.29 112.02 20.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.946 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 58.95 26.93 15.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.103 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.93 21.35 33.64 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.564 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 3.4 tptp -126.46 109.82 12.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.834 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 18.4 tp60 -68.08 89.99 0.31 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.856 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 16.8 mt -78.16 -42.29 32.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.888 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.417 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.0 p90 -151.15 169.52 21.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.918 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.43 134.22 40.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.918 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -159.49 165.57 32.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -72.26 176.24 5.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.89 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -75.2 120.97 21.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 60.7 47.63 7.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.971 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 84.8 m -130.03 -58.8 1.07 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.851 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.3 139.63 48.54 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.616 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 27.3 m -151.54 125.68 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 111.049 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -89.45 127.86 35.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.952 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 1.049 HG21 HG13 ' A' ' 16' ' ' VAL . 31.0 m -148.65 157.89 7.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.079 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.02 156.99 38.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.101 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.49 HD12 HD12 ' A' ' 8' ' ' ILE . 6.6 tp -51.17 -46.55 62.13 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -56.88 -28.86 62.37 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.651 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 17.1 mmtt -77.78 -24.27 48.94 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.879 179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.705 HD11 ' CB ' ' A' ' 46' ' ' PHE . 62.1 mt -83.48 151.59 25.36 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.989 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -135.37 105.86 6.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.839 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.629 ' HA ' HG12 ' A' ' 14' ' ' VAL . 16.8 tp -61.09 133.8 56.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.975 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.526 HD12 ' HB2' ' A' ' 13' ' ' PRO . 28.0 mt -91.23 134.61 29.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.12 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -161.65 122.45 2.7 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.888 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 10.3 p 59.78 110.6 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.95 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 155.32 99.75 0.17 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.525 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.7 176.47 5.06 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.499 2.132 . . . . 0.0 112.253 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.73 158.86 18.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.2 t -97.47 -39.95 8.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.933 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.427 -1.207 . . . . 0.0 112.574 179.979 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.2 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 76.7 p -163.39 130.14 3.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.854 0.359 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.36 30.82 4.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.879 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.44 58.08 0.62 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.513 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -168.73 -69.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.779 0.323 . . . . 0.0 110.876 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -60.41 -173.3 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.864 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 118.46 24.45 3.17 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.897 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.625 ' CG2' HG11 ' A' ' 14' ' ' VAL . 19.7 mt -68.39 94.95 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.5 -176.94 3.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.903 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.3 t -66.43 138.69 22.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.018 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.65 38.63 13.7 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.552 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.621 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -135.12 139.4 31.73 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-O 120.658 0.266 . . . . 0.0 110.929 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.3 118.5 5.21 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.548 2.165 . . . . 0.0 112.304 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.625 HG11 ' CG2' ' A' ' 8' ' ' ILE . 16.4 m -144.76 138.5 22.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.209 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 35.6 mttt -77.87 126.33 30.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.934 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.733 HG13 HG21 ' A' ' 80' ' ' VAL . 26.3 t -105.46 137.68 34.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.049 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.0 tt0 -99.06 112.24 24.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.915 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 88.4 mt -73.77 -58.4 3.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.95 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 8.0 ttt-85 -83.96 168.91 15.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.888 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.8 m -80.13 61.07 3.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.852 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 103.61 64.22 0.69 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.499 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -130.0 -66.4 0.79 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.782 0.325 . . . . 0.0 110.883 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -164.96 130.04 2.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.2 mttt -95.33 111.45 23.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.918 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.425 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 38.4 m-85 -86.56 138.87 33.56 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.759 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -68.79 148.85 72.11 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.496 2.13 . . . . 0.0 112.43 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.83 148.05 11.47 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.519 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.446 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.9 p -88.76 132.45 33.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.79 0.328 . . . . 0.0 111.142 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 12' ' ' CYS . 19.6 t -66.18 135.17 28.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.114 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.446 ' HD3' HG13 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -118.28 -36.09 3.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 -179.914 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -141.16 166.0 25.99 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.917 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.415 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 5.1 ttt180 -158.7 114.91 2.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.875 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.46 145.46 5.63 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.447 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.628 ' HD3' HG23 ' A' ' 44' ' ' ILE . 52.3 Cg_exo -54.76 -170.26 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.527 2.152 . . . . 0.0 112.287 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.402 HD13 ' CZ ' ' A' ' 64' ' ' TYR . 82.4 mt -115.94 -71.67 0.73 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.881 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.28 171.66 11.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.871 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -120.63 113.78 20.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.106 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.566 ' HB3' HG22 ' A' ' 41' ' ' VAL . 4.7 tt0 -163.03 169.74 19.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.862 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.39 -30.9 11.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.435 HG23 ' N ' ' A' ' 41' ' ' VAL . 7.8 t -61.33 -47.5 85.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.912 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.566 HG22 ' HB3' ' A' ' 38' ' ' GLU . 18.5 m -77.75 177.58 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.156 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.4 t -176.39 68.63 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -138.88 124.11 2.75 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.541 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.628 HG23 ' HD3' ' A' ' 34' ' ' PRO . 35.4 mt -97.43 129.11 48.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.761 0.315 . . . . 0.0 111.11 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 14.5 m-85 -91.08 144.97 25.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.843 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.415 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 6.4 m-85 -119.34 123.88 45.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.996 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.556 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -87.48 131.5 10.64 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.323 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.611 ' HB ' HG21 ' A' ' 16' ' ' VAL . 21.7 t -139.37 127.5 26.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.758 0.313 . . . . 0.0 111.209 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -85.89 116.66 24.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.764 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.429 HD13 ' O ' ' A' ' 54' ' ' GLY . 60.1 mt -55.98 140.32 43.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.19 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -87.55 -179.89 6.42 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.85 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -51.97 -29.71 21.74 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.207 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -60.24 -51.34 69.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.889 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.429 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -122.31 38.96 2.42 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.468 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.6 ttt180 -76.52 133.15 39.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.843 0.354 . . . . 0.0 110.931 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.57 23.36 8.9 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.681 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 -130.75 45.37 2.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.861 0.362 . . . . 0.0 110.818 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -107.86 148.45 16.62 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.576 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -110.05 -47.98 3.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.771 0.32 . . . . 0.0 110.908 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.4 t -65.29 -44.84 86.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.994 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.3 t0 57.28 30.6 18.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.061 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.43 -28.17 14.33 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.426 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.431 ' O ' HG13 ' A' ' 63' ' ' VAL . 11.8 p -113.47 125.02 70.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.819 0.342 . . . . 0.0 111.063 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.402 ' CZ ' HD13 ' A' ' 35' ' ' LEU . 51.7 t80 -111.25 110.09 20.42 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 58.46 28.45 16.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.084 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.28 24.38 22.04 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.492 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.8 tptt -131.55 109.89 10.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.795 0.331 . . . . 0.0 110.805 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 15.3 tp60 -71.07 89.92 0.83 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.939 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 9.0 mt -75.24 -30.73 60.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.915 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -161.89 166.98 25.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -103.28 119.21 38.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.897 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 6.8 p -144.28 176.26 9.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.959 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -72.16 176.21 5.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.9 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -75.59 119.71 20.01 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 60.72 36.5 19.38 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.918 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 86.6 m -118.21 -38.98 3.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.952 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.55 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -79.09 146.87 29.77 Favored Glycine 0 N--CA 1.452 -0.233 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.473 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.55 HG13 ' O ' ' A' ' 77' ' ' GLY . 5.2 m -159.4 134.4 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.842 0.353 . . . . 0.0 111.072 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -96.71 138.9 33.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.874 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.733 HG21 HG13 ' A' ' 16' ' ' VAL . 29.1 m -156.19 166.46 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.122 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.29 164.65 17.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.203 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -52.15 -50.51 61.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.841 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -57.14 -28.28 62.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.643 179.75 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 12.3 mmtt -79.65 -25.11 41.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.835 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.597 ' CD2' HG22 ' A' ' 16' ' ' VAL . 62.6 mt -84.25 159.64 20.93 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.874 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -142.22 101.51 3.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.82 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.605 ' HA ' HG12 ' A' ' 14' ' ' VAL . 8.9 tp -59.9 143.39 51.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.983 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 22.4 mt -112.36 146.59 16.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.101 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.44 124.68 45.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.892 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.2 t -167.59 126.58 1.31 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.962 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 80.82 155.71 12.62 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.511 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.73 62.96 2.34 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.6 2.2 . . . . 0.0 112.311 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -90.38 -47.16 7.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.916 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.3 p -117.42 178.0 4.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.873 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.348 -1.251 . . . . 0.0 112.506 -179.993 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.448 HG22 HG21 ' A' ' 29' ' ' VAL . 19.4 mt . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.85 0.357 . . . . 0.0 111.048 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -140.0 179.58 6.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.3 t -60.3 129.18 22.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 86.28 43.93 6.08 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.476 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.629 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -144.21 137.04 13.66 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.635 0.255 . . . . 0.0 110.929 -179.902 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.22 132.31 12.47 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.466 2.111 . . . . 0.0 112.324 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.549 HG12 ' HA ' ' A' ' 87' ' ' LEU . 13.7 m -155.55 145.79 12.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.211 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.534 ' CG ' HD11 ' A' ' 88' ' ' ILE . 59.4 mttt -81.34 127.43 32.73 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.89 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.994 HG13 HG21 ' A' ' 80' ' ' VAL . 21.2 t -109.98 131.03 62.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.08 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -97.02 113.62 25.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.881 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 58.7 mt -82.03 -44.27 16.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.91 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -98.33 179.29 4.78 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.931 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.8 m -82.4 87.77 6.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.922 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.43 54.91 30.66 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.54 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -115.37 -50.01 2.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.929 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 17.5 tt0 -176.62 126.87 0.18 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.1 mttt -96.03 116.68 29.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.826 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.433 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 30.0 m-85 -86.92 131.48 44.87 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -73.42 145.52 38.23 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.478 2.119 . . . . 0.0 112.265 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.3 154.59 24.59 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.605 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.485 HG13 ' HD3' ' A' ' 30' ' ' ARG . 12.3 p -91.65 135.53 26.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.798 0.333 . . . . 0.0 111.0 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 12' ' ' CYS . 21.0 t -65.17 132.26 30.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.196 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.485 ' HD3' HG13 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -113.5 -30.13 6.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.045 179.988 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -152.8 168.35 26.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.878 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.413 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 16.2 ttt-85 -155.81 123.95 5.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.847 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.64 142.47 3.71 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.465 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo . . . . . 0 C--N 1.345 0.357 0 C-N-CA 122.492 2.128 . . . . 0.0 112.252 179.989 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.1 mt . . . . . 0 C--O 1.232 0.179 0 CA-C-O 120.793 0.33 . . . . 0.0 111.053 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -86.47 136.1 33.22 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.526 ' CB ' HD11 ' A' ' 85' ' ' LEU . 10.8 m-85 -115.66 111.89 21.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.95 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -71.47 119.64 7.87 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.382 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.626 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.8 t -129.86 136.69 58.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.77 0.319 . . . . 0.0 110.978 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -92.34 119.1 31.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.576 HD13 ' HB2' ' A' ' 57' ' ' GLN . 19.5 mt -59.07 133.91 56.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.981 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.7 -179.9 7.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.816 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.7 -29.52 39.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.062 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -63.35 -55.01 28.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.831 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.433 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -110.87 32.24 6.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.413 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 8.3 ttt180 -68.72 135.6 51.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 110.98 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 94.02 37.35 5.46 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.576 ' HB2' HD13 ' A' ' 50' ' ' LEU . 64.0 mm-40 -140.89 33.25 1.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.843 0.354 . . . . 0.0 110.948 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -102.51 145.74 16.56 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.48 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 7.6 p90 -109.94 -50.58 2.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.322 . . . . 0.0 110.972 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.5 t -62.77 -41.84 99.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.911 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 11.4 t70 60.02 30.45 19.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.988 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 94.26 -17.3 59.18 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.753 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.9 p -119.15 138.8 48.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.828 0.347 . . . . 0.0 111.18 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 7.1 t80 -130.14 110.05 11.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.814 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 61.77 28.66 17.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.955 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 100.01 -27.78 18.7 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.568 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -80.27 114.65 19.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.789 0.328 . . . . 0.0 111.018 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 28.6 tp60 -81.36 92.11 6.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.903 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.57 HD12 ' CE2' ' A' ' 79' ' ' PHE . 48.1 mt -70.46 -46.61 63.48 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.972 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.413 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.5 p90 -144.24 168.96 18.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.945 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.85 130.1 55.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.892 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 1.2 m -149.93 172.06 15.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.905 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -68.78 -179.98 1.6 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -71.65 121.14 18.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.944 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 60.81 51.57 4.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.878 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 27.4 m -130.1 -46.75 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.994 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.419 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -67.17 141.71 39.92 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.612 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.626 HG22 ' O ' ' A' ' 48' ' ' VAL . 20.7 m -156.99 141.14 7.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.361 . . . . 0.0 111.112 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 69' ' ' LEU . 5.7 m-85 -110.42 134.14 52.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.994 HG21 HG13 ' A' ' 16' ' ' VAL . 18.4 m -156.9 156.6 4.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.083 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.53 154.34 42.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.062 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.416 ' CD1' HD12 ' A' ' 8' ' ' ILE . 6.5 tp -50.37 -43.86 54.47 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.917 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -56.57 -28.0 59.22 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.576 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.7 mttm -79.61 -27.11 41.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.787 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.715 ' CD2' HG22 ' A' ' 16' ' ' VAL . 92.6 mt -80.73 152.45 28.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.904 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -124.91 108.37 11.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.855 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.549 ' HA ' HG12 ' A' ' 14' ' ' VAL . 20.1 tp -59.88 124.31 19.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.534 HD11 ' CG ' ' A' ' 15' ' ' LYS . 31.1 mt . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.112 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.649 HD12 HD12 ' A' ' 82' ' ' LEU . 27.0 mt . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.814 0.34 . . . . 0.0 111.099 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -155.16 -177.8 6.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.826 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.511 ' HA ' HG12 ' A' ' 29' ' ' VAL . 37.7 t -61.7 124.23 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.085 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.14 42.34 5.3 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.437 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.635 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -138.95 138.81 21.88 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.623 0.249 . . . . 0.0 110.95 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.895 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.6 Cg_endo -77.37 117.56 4.38 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.502 2.134 . . . . 0.0 112.398 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.487 HG12 ' HA ' ' A' ' 87' ' ' LEU . 16.0 m -146.8 138.47 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.117 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.44 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 26.9 mttm -81.37 156.88 25.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.992 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.661 HG13 HG21 ' A' ' 80' ' ' VAL . 21.2 t -133.3 127.23 53.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.041 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -88.49 124.06 33.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.878 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 40.2 mt -102.92 -40.13 6.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -85.59 179.88 7.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.812 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 64.7 m -95.61 79.83 3.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 73.12 49.87 14.65 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.525 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -116.73 -69.51 0.85 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.757 0.313 . . . . 0.0 110.867 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -161.93 138.3 7.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.867 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 13.2 mttt -95.67 146.13 24.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -106.0 127.74 27.78 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.788 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.601 ' HB2' HD12 ' A' ' 51' ' ' LEU . 57.0 Cg_endo -70.28 137.84 34.83 Favored 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.461 2.107 . . . . 0.0 112.348 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.92 174.96 29.24 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.512 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.414 HG13 ' O ' ' A' ' 28' ' ' VAL . 10.3 p -120.38 125.66 74.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.827 0.346 . . . . 0.0 111.017 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.635 HG23 ' O ' ' A' ' 12' ' ' CYS . 18.4 t -59.27 123.55 11.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.164 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.5 mmt180 -112.07 -31.91 6.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.889 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -144.62 166.26 25.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.428 ' HD3' ' CE2' ' A' ' 46' ' ' PHE . 38.5 ttp85 -156.77 124.3 5.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.842 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 166.6 145.17 4.36 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.419 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.497 ' HD3' HG23 ' A' ' 44' ' ' ILE . 50.6 Cg_exo . . . . . 0 C--N 1.345 0.357 0 C-N-CA 122.511 2.14 . . . . 0.0 112.356 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.497 HG23 ' HD3' ' A' ' 34' ' ' PRO . 13.8 mm . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.834 0.349 . . . . 0.0 111.076 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -104.36 121.35 43.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.48 ' HB2' HD11 ' A' ' 85' ' ' LEU . 13.6 m-85 -101.55 119.11 38.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.964 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.402 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -83.85 117.74 4.52 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.428 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.498 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -122.84 131.99 72.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.808 0.337 . . . . 0.0 111.092 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -85.18 117.73 24.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.885 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 14.0 mt -60.24 134.87 57.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.937 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.601 HD12 ' HB2' ' A' ' 26' ' ' PRO . 16.5 mt -80.01 -179.96 7.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.863 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -54.36 -29.66 49.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.05 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -60.36 -51.33 69.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.855 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -117.95 35.39 4.08 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.378 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -73.59 145.86 45.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 0.0 110.901 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.4 27.99 28.7 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.466 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -134.17 31.04 3.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.842 0.354 . . . . 0.0 110.89 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.17 149.81 18.46 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.519 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 13.4 p90 -109.94 -49.88 3.04 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.737 0.303 . . . . 0.0 110.928 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.419 HG23 ' N ' ' A' ' 61' ' ' ASP . 6.0 t -62.21 -48.25 80.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.856 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.419 ' N ' HG23 ' A' ' 60' ' ' THR . 11.7 m-20 58.17 37.04 26.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.97 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.42 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.94 -24.09 32.72 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.512 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.8 p -119.43 132.03 70.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.786 0.327 . . . . 0.0 111.132 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -118.55 113.62 21.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.815 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 60.08 28.7 18.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.976 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.07 -24.08 32.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.571 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.95 114.07 21.43 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.821 0.343 . . . . 0.0 110.989 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 6.9 tp60 -78.47 116.42 18.86 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.855 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.462 HD12 ' CE2' ' A' ' 79' ' ' PHE . 72.1 mt -98.92 -37.71 9.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.879 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.42 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 1.8 p90 -154.41 172.68 17.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.93 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -105.29 111.44 24.17 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.001 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.44 167.88 15.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.907 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.8 175.27 3.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.911 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -72.53 117.89 14.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.924 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 60.83 49.5 6.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.841 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 28.5 m -130.0 -49.97 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.912 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.414 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -67.06 146.23 47.66 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.531 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.498 HG22 ' O ' ' A' ' 48' ' ' VAL . 25.8 m -156.78 142.23 9.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.778 0.323 . . . . 0.0 111.179 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.462 ' CE2' HD12 ' A' ' 69' ' ' LEU . 14.8 m-85 -109.89 131.89 54.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.917 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.661 HG21 HG13 ' A' ' 16' ' ' VAL . 30.6 m -152.61 158.05 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.112 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.94 156.61 38.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.132 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.649 HD12 HD12 ' A' ' 8' ' ' ILE . 12.9 tp -51.15 -45.41 61.68 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -57.07 -28.22 62.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.638 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -81.17 -27.02 35.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.865 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.624 ' CD2' HG22 ' A' ' 16' ' ' VAL . 84.9 mt -84.11 130.28 34.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.902 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 57.0 tt0 -113.78 114.01 25.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.899 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.487 ' HA ' HG12 ' A' ' 14' ' ' VAL . 8.5 tp -63.48 142.68 58.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.893 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.895 HD12 ' HB2' ' A' ' 13' ' ' PRO . 20.6 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.094 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.763 HD12 HD12 ' A' ' 82' ' ' LEU . 5.2 mt . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.767 0.318 . . . . 0.0 111.04 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -131.78 -177.94 4.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.927 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.9 t -67.53 135.67 28.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.141 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.38 46.25 7.57 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.451 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.637 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.09 145.75 28.23 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 120.757 0.313 . . . . 0.0 110.962 -179.989 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.489 ' O ' HG13 ' A' ' 14' ' ' VAL . 74.2 Cg_endo -75.09 130.02 12.79 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.579 2.186 . . . . 0.0 112.269 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.598 HG11 HG21 ' A' ' 8' ' ' ILE . 11.8 m -158.02 138.51 4.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.14 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 47.1 mttm -79.23 140.45 37.65 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.05 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.758 HG13 HG21 ' A' ' 80' ' ' VAL . 18.4 t -115.91 135.87 54.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.062 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -97.25 110.07 22.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.857 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 83.0 mt -84.99 -56.26 3.65 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.97 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -75.06 171.99 13.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.944 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.4 m -78.01 80.26 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.885 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.62 55.49 26.84 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -120.45 -58.16 1.86 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 110.838 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -154.08 151.92 29.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.818 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -121.49 135.8 55.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.442 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 37.8 m-85 -106.11 136.49 19.32 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.838 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.545 ' HB2' HD12 ' A' ' 51' ' ' LEU . 63.1 Cg_endo -73.09 143.22 35.64 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.438 2.092 . . . . 0.0 112.431 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.98 156.58 27.98 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.526 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.2 p -95.52 126.52 48.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.771 0.32 . . . . 0.0 111.044 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.637 HG23 ' O ' ' A' ' 12' ' ' CYS . 18.6 t -59.87 135.84 24.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.119 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -119.46 -38.41 3.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.01 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.427 ' CE2' HD22 ' A' ' 69' ' ' LEU . 23.4 t80 -140.82 169.09 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.889 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.416 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 3.5 ttt180 -160.94 124.34 3.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.905 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 165.54 144.97 4.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.478 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo . . . . . 0 C--N 1.344 0.335 0 C-N-CA 122.537 2.158 . . . . 0.0 112.349 179.986 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.5 mt . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.763 0.316 . . . . 0.0 111.077 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -90.37 128.57 36.51 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.921 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.447 ' HB3' HD11 ' A' ' 85' ' ' LEU . 4.8 m-85 -111.74 109.9 19.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.875 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.46 122.68 11.01 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.344 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.624 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.9 t -137.9 130.94 41.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.805 0.336 . . . . 0.0 111.092 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -86.39 121.02 28.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.857 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.52 HD13 ' HB2' ' A' ' 57' ' ' GLN . 30.9 mt -60.45 141.27 56.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.049 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.545 HD12 ' HB2' ' A' ' 26' ' ' PRO . 13.3 mt -88.77 -179.88 6.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.83 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.06 -27.24 43.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.18 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -64.92 -41.57 95.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.966 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.442 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -132.13 38.67 1.86 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.47 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -74.31 161.33 29.99 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.851 0.358 . . . . 0.0 110.859 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.0 29.82 68.56 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.52 ' HB2' HD13 ' A' ' 50' ' ' LEU . 3.5 mm100 -135.86 34.14 2.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.816 0.341 . . . . 0.0 110.927 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.4 147.67 16.86 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.499 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -109.85 -47.78 3.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.813 0.34 . . . . 0.0 110.813 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.571 HG22 ' HA ' ' A' ' 78' ' ' VAL . 5.4 t -62.2 -47.93 82.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.943 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.414 ' N ' HG23 ' A' ' 60' ' ' THR . 0.7 OUTLIER 59.76 32.53 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.964 179.848 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.428 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.1 -24.82 28.32 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.564 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.7 p -120.85 133.28 68.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.864 0.364 . . . . 0.0 111.133 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 12.5 t80 -116.88 110.4 18.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.852 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 13.3 mt-30 60.45 31.01 20.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 98.04 -26.61 22.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.55 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.9 tptm -75.15 110.72 9.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.797 0.332 . . . . 0.0 110.904 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 24.2 tp60 -79.83 95.24 5.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.835 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.61 HD12 ' CE2' ' A' ' 79' ' ' PHE . 75.4 mt -81.65 -36.56 28.69 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.989 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.428 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.7 p90 -156.38 166.94 31.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.957 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -102.4 116.08 31.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.909 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -132.27 176.34 8.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.914 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -79.39 -179.94 7.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -77.69 121.35 23.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 59.7 48.04 9.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.005 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 26.6 m -129.93 -58.34 1.08 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.902 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.48 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -62.71 149.6 48.82 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.419 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.624 HG22 ' O ' ' A' ' 48' ' ' VAL . 15.3 m -158.0 146.54 9.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.873 0.368 . . . . 0.0 111.15 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.61 ' CE2' HD12 ' A' ' 69' ' ' LEU . 9.7 m-85 -108.95 131.8 54.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.758 HG21 HG13 ' A' ' 16' ' ' VAL . 13.2 m -151.01 160.35 3.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.073 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . 0.416 ' HB3' ' HG3' ' A' ' 84' ' ' LYS . . . -75.86 153.46 36.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.054 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.763 HD12 HD12 ' A' ' 8' ' ' ILE . 11.0 tp -49.73 -44.3 48.32 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.904 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.9 t0 -58.27 -30.96 66.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.602 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.416 ' HG3' ' HB3' ' A' ' 81' ' ' ALA . 9.6 mtmt -78.08 -25.3 47.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.837 179.651 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.447 HD11 ' HB3' ' A' ' 46' ' ' PHE . 32.9 mt -81.7 130.87 35.21 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.14 105.21 14.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.963 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 27.3 tp -62.14 139.59 58.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.467 HD12 ' HB2' ' A' ' 13' ' ' PRO . 16.0 mt . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.074 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.643 HD13 HG11 ' A' ' 14' ' ' VAL . 31.4 mt . . . . . 0 N--CA 1.458 -0.044 0 CA-C-O 120.851 0.358 . . . . 0.0 111.063 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 54.2 m-20 -124.75 -174.91 3.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.4 t -65.14 136.88 25.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.037 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.19 46.56 6.94 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.475 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.659 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -140.49 136.89 17.0 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.618 0.247 . . . . 0.0 110.908 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.705 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.6 Cg_endo -76.47 117.03 4.45 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.45 2.1 . . . . 0.0 112.308 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.643 HG11 HD13 ' A' ' 8' ' ' ILE . 16.3 m -141.99 138.3 30.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.154 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 30.3 mttp -81.4 132.46 35.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.665 HG22 HD23 ' A' ' 85' ' ' LEU . 21.6 t -113.3 131.71 64.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.047 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -87.07 112.94 22.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.443 ' HA ' HD23 ' A' ' 18' ' ' LEU . 15.0 mt -93.83 -44.98 7.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.19 179.59 7.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.3 p -75.24 76.51 2.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.9 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.4 35.2 84.17 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.489 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.92 -62.42 1.47 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.802 0.334 . . . . 0.0 110.895 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.22 142.25 19.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.915 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 18.3 mttm -98.26 115.56 28.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.782 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -75.71 128.12 84.32 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.831 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.434 ' HB2' HD12 ' A' ' 51' ' ' LEU . 64.3 Cg_endo -73.05 139.35 29.66 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.423 2.082 . . . . 0.0 112.311 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.49 157.91 29.62 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.614 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.1 p -95.86 136.05 28.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.774 0.321 . . . . 0.0 111.01 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 12' ' ' CYS . 23.9 t -70.0 130.69 34.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.078 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.427 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 24.9 mmt180 -114.52 -29.42 6.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.209 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -148.49 167.2 25.97 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.881 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.428 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 7.2 ttp180 -162.93 131.73 4.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.857 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.27 150.28 5.66 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.572 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.408 ' HD3' HG23 ' A' ' 44' ' ' ILE . 48.6 Cg_exo . . . . . 0 C--N 1.345 0.354 0 C-N-CA 122.613 2.209 . . . . 0.0 112.333 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.408 HG23 ' HD3' ' A' ' 34' ' ' PRO . 4.2 mp . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.797 0.332 . . . . 0.0 111.089 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -82.95 139.24 33.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.869 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.633 ' CB ' HD11 ' A' ' 85' ' ' LEU . 7.6 m-85 -117.93 113.66 22.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.986 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -78.21 117.49 4.68 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.596 HG21 HD22 ' A' ' 85' ' ' LEU . 20.2 t -123.49 143.37 36.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.766 0.317 . . . . 0.0 111.09 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -97.72 115.0 27.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.93 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.9 mt -59.07 128.29 36.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.032 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.434 HD12 ' HB2' ' A' ' 26' ' ' PRO . 7.2 mt -80.54 -179.93 7.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.867 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -54.85 -29.28 54.77 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.067 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.99 -41.81 99.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.892 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.04 34.64 3.05 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.563 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.9 ttt180 -71.99 144.59 48.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.773 0.321 . . . . 0.0 110.926 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 90.2 31.02 11.2 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.464 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -137.12 32.57 2.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.847 0.356 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.28 143.52 15.67 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.443 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.6 p90 -109.99 -47.92 3.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.824 0.345 . . . . 0.0 110.991 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -66.47 -42.81 86.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.973 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.1 t0 60.03 29.2 18.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.088 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.417 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 85.55 26.25 36.34 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.61 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.53 HG23 ' C ' ' A' ' 67' ' ' LYS . 12.1 p -164.04 133.29 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.775 0.322 . . . . 0.0 111.123 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 17.9 t80 -123.76 117.09 24.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 61.27 29.16 18.52 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.869 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.71 -26.86 21.44 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.547 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.53 ' C ' HG23 ' A' ' 63' ' ' VAL . 22.2 tptt -76.87 111.93 12.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.84 0.352 . . . . 0.0 110.879 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 10.9 tp60 -80.99 108.4 14.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.841 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.648 HD12 ' CE2' ' A' ' 79' ' ' PHE . 44.9 mt -86.63 -31.16 21.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.046 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.427 ' CD2' ' HB2' ' A' ' 30' ' ' ARG . 7.1 p90 -161.35 163.2 30.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -99.0 132.63 44.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.939 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -150.48 170.61 18.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.808 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -70.24 179.96 2.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.806 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -74.35 118.71 17.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 61.17 52.06 4.11 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.97 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 36.1 m -130.06 -51.79 1.12 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.967 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -64.17 138.05 41.1 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.519 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 17.7 m -150.29 140.35 16.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.761 0.315 . . . . 0.0 111.207 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.648 ' CE2' HD12 ' A' ' 69' ' ' LEU . 3.4 m-85 -104.13 122.4 45.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.838 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.617 HG21 HG13 ' A' ' 16' ' ' VAL . 4.5 m -145.85 164.73 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.208 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -76.68 155.94 32.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.189 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.536 HD12 HD12 ' A' ' 8' ' ' ILE . 13.2 tp -50.42 -40.84 51.29 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.737 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.8 t0 -58.45 -29.97 66.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.55 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.1 mmtt -78.83 -23.41 45.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.866 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.665 HD23 HG22 ' A' ' 16' ' ' VAL . 78.7 mt -82.75 143.59 30.77 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.93 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -130.29 97.59 4.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.814 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.633 ' HA ' HG12 ' A' ' 14' ' ' VAL . 19.6 tp -58.69 130.72 48.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.969 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.705 HD12 ' HB2' ' A' ' 13' ' ' PRO . 18.7 mt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.091 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.581 HG12 HD13 ' A' ' 87' ' ' LEU . 21.5 mt . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.824 0.345 . . . . 0.0 111.142 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -131.72 173.03 11.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.783 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.2 t -59.65 141.81 15.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.102 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 73.35 48.39 19.06 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.45 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.525 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.06 141.52 17.34 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.69 0.281 . . . . 0.0 110.954 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.618 ' HB2' HD12 ' A' ' 88' ' ' ILE . 73.3 Cg_endo -75.87 121.81 6.45 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.622 2.215 . . . . 0.0 112.418 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.69 HG12 ' HA ' ' A' ' 87' ' ' LEU . 16.7 m -153.2 138.36 10.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.101 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.3 mttt -75.01 138.03 41.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.949 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.932 HG13 HG21 ' A' ' 80' ' ' VAL . 18.6 t -119.17 136.02 57.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.12 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -90.84 112.62 24.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.972 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.453 HD13 ' HB3' ' A' ' 57' ' ' GLN . 23.3 mt -83.62 -66.27 0.91 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -73.77 172.83 10.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.874 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -76.1 85.76 2.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 61.74 54.09 38.26 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.443 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -112.5 -61.52 1.71 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.798 0.333 . . . . 0.0 110.849 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -162.78 133.09 4.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -95.23 121.9 37.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.858 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.424 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 50.0 m-85 -97.96 142.15 24.12 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.819 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.16 148.37 55.94 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.463 2.109 . . . . 0.0 112.36 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -167.24 154.42 24.7 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.509 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -98.36 127.15 51.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.834 0.349 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 12' ' ' CYS . 11.2 t -59.98 131.91 24.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.999 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -116.41 -30.64 5.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.181 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -146.79 166.0 27.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.866 0.365 . . . . 0.0 111.005 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.422 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.1 ttp180 -165.79 141.28 4.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.831 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 142.73 134.75 2.96 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.548 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo . . . . . 0 C--N 1.346 0.416 0 C-N-CA 122.508 2.139 . . . . 0.0 112.245 -179.976 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.7 mt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.828 0.347 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -100.09 149.85 23.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.978 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.569 ' CB ' HD11 ' A' ' 85' ' ' LEU . 12.6 m-85 -127.8 116.98 21.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.925 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.66 120.67 5.27 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.41 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.597 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -133.6 129.2 55.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.868 0.366 . . . . 0.0 111.134 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -84.28 121.32 27.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.896 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.527 HD12 ' HA ' ' A' ' 76' ' ' CYS . 5.2 mt -59.99 150.23 29.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -96.71 -179.86 4.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.876 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -52.66 -30.02 29.56 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.143 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -62.86 -44.1 97.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.811 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.424 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -124.63 36.4 2.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.453 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt180 -75.48 140.49 42.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.898 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.8 29.85 11.27 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.518 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.453 ' HB3' HD13 ' A' ' 18' ' ' LEU . 48.4 mm-40 -137.21 36.25 2.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.866 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.41 142.43 15.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.576 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -105.65 -45.83 4.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.778 0.323 . . . . 0.0 110.864 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -63.38 -44.02 95.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.969 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.1 t0 57.72 33.73 23.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.928 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.42 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.72 -24.84 27.76 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.533 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.1 p -113.0 135.35 52.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.8 0.334 . . . . 0.0 111.098 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 4.0 t80 -116.82 110.43 18.36 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 77.6 mt-30 60.25 30.88 20.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.841 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.96 -26.3 23.96 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.604 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -81.85 114.11 20.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 110.968 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 31.7 tp60 -74.68 98.76 3.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.813 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.432 HD12 ' CE2' ' A' ' 79' ' ' PHE . 55.3 mt -79.79 -40.46 28.61 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.938 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.42 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -152.64 175.01 13.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.994 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.39 113.97 24.47 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 11.9 p -131.0 -180.0 5.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.01 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -65.65 179.95 0.76 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.96 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.12 118.84 22.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.034 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 59.56 50.04 7.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.023 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . 0.527 ' HA ' HD12 ' A' ' 50' ' ' LEU . 43.1 m -129.98 -45.54 1.15 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.983 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.466 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -60.91 146.39 47.53 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.563 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.597 HG22 ' O ' ' A' ' 48' ' ' VAL . 16.1 m -157.63 138.3 4.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.731 0.301 . . . . 0.0 111.074 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.432 ' CE2' HD12 ' A' ' 69' ' ' LEU . 11.2 m-85 -109.23 127.73 54.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.93 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.932 HG21 HG13 ' A' ' 16' ' ' VAL . 31.0 m -150.22 165.68 2.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.117 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.15 156.9 35.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.058 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 11.0 tp -49.55 -43.88 46.21 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.893 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -57.01 -29.85 63.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.55 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 12.5 mmtt -76.43 -25.64 54.64 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.814 179.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.904 ' CD2' HG22 ' A' ' 16' ' ' VAL . 79.2 mt -90.39 137.69 32.15 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.911 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.2 tm-20 -111.65 109.1 18.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.69 ' HA ' HG12 ' A' ' 14' ' ' VAL . 23.8 tp -64.56 128.24 34.92 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.965 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.618 HD12 ' HB2' ' A' ' 13' ' ' PRO . 22.1 mt . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.07 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.675 HD12 HD12 ' A' ' 82' ' ' LEU . 23.1 mt . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.82 0.343 . . . . 0.0 111.092 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -156.84 -172.14 3.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.846 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 t -60.67 136.83 23.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.212 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 75.03 46.58 15.93 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.59 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.797 ' O ' HG23 ' A' ' 29' ' ' VAL . 3.0 t -144.32 131.74 10.49 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.604 0.24 . . . . 0.0 110.969 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.08 122.97 6.97 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.479 2.119 . . . . 0.0 112.386 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.662 HG21 HD13 ' A' ' 85' ' ' LEU . 6.6 m -148.48 138.86 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.0 mttt -76.17 139.46 41.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.902 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.694 ' CG1' HG11 ' A' ' 80' ' ' VAL . 21.4 t -118.28 141.67 36.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.115 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -98.84 115.7 29.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.932 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 39.9 mt -98.39 -59.74 1.69 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 19.0 mtt85 -60.35 168.54 2.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.869 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.9 p -74.3 75.75 1.85 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.82 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.26 55.7 26.27 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.537 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -119.51 -67.25 1.0 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -147.9 154.51 40.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -112.31 152.09 28.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.865 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -116.69 135.63 23.0 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.491 ' HB2' HD12 ' A' ' 51' ' ' LEU . 61.6 Cg_endo -73.01 140.32 31.26 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.477 2.118 . . . . 0.0 112.312 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.79 148.51 16.06 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.635 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.453 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.3 p -89.83 140.66 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.737 0.303 . . . . 0.0 110.979 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.797 HG23 ' O ' ' A' ' 12' ' ' CYS . 11.9 t -72.34 131.17 35.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.098 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.453 ' HD3' HG13 ' A' ' 28' ' ' VAL . 5.8 mmm180 -112.83 -30.8 6.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.126 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -152.5 167.41 28.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.907 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.411 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 0.0 OUTLIER -154.72 130.04 9.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.755 179.931 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.33 151.12 6.14 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.507 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo . . . . . 0 C--N 1.344 0.326 0 C-N-CA 122.61 2.207 . . . . 0.0 112.29 179.993 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.434 HG22 ' N ' ' A' ' 45' ' ' PHE . 3.7 mp . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.829 0.347 . . . . 0.0 111.096 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.434 ' N ' HG22 ' A' ' 44' ' ' ILE . 18.6 m-85 -125.82 156.9 38.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.949 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.411 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 11.7 m-85 -126.78 109.89 12.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.95 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.517 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -66.98 132.73 31.26 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.356 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.618 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.7 t -144.12 130.53 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.899 0.38 . . . . 0.0 111.22 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -88.13 116.73 26.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.827 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 29.3 mt -59.97 131.96 52.48 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.491 HD12 ' HB2' ' A' ' 26' ' ' PRO . 12.0 mt -77.61 -179.89 6.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -53.41 -29.79 36.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.149 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -61.04 -55.47 32.39 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.914 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -112.05 32.44 6.33 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.514 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 8.8 ttt180 -72.83 135.26 45.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.913 0.387 . . . . 0.0 110.866 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 98.61 31.97 6.17 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.526 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 64.4 mm-40 -143.4 33.39 1.31 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.858 0.361 . . . . 0.0 110.932 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -99.8 147.99 18.4 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.521 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 23.7 p90 -109.51 -50.35 3.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.747 0.308 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.446 HG23 ' N ' ' A' ' 61' ' ' ASP . 8.7 t -68.84 -48.57 63.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.887 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.446 ' N ' HG23 ' A' ' 60' ' ' THR . 8.7 m-20 53.89 30.48 11.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.089 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.41 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 106.3 -26.38 20.46 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.506 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.446 HG23 ' C ' ' A' ' 67' ' ' LYS . 11.5 p -120.82 132.8 69.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 111.087 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -119.06 113.77 21.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.932 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 61.26 24.87 14.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.072 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 104.54 -27.9 17.2 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.555 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.446 ' C ' HG23 ' A' ' 63' ' ' VAL . 1.2 tpmp? -79.24 117.59 20.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.923 0.392 . . . . 0.0 110.913 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 8.6 tp60 -85.1 106.0 16.25 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.884 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.452 HD12 ' CE2' ' A' ' 79' ' ' PHE . 91.6 mt -91.01 -34.45 15.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.41 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 7.4 p90 -153.95 171.21 19.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 4.9 mm100 -102.77 121.15 41.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.922 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -136.52 172.85 12.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.807 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.93 173.78 10.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.905 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -65.53 118.67 9.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.991 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 59.55 52.15 5.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.852 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 87.0 m -130.07 -63.93 0.88 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -58.87 137.03 50.75 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.488 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.618 HG22 ' O ' ' A' ' 48' ' ' VAL . 5.7 m -148.07 129.79 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.792 0.329 . . . . 0.0 111.208 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.452 ' CE2' HD12 ' A' ' 69' ' ' LEU . 4.3 m-85 -93.02 129.77 38.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.785 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.694 HG11 ' CG1' ' A' ' 16' ' ' VAL . 4.6 m -150.32 164.56 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.235 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.7 162.58 20.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.176 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.675 HD12 HD12 ' A' ' 8' ' ' ILE . 12.8 tp -52.35 -47.99 65.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.805 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -57.64 -29.0 64.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.604 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 1.7 mttp -79.49 -25.35 41.87 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.809 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.662 HD13 HG21 ' A' ' 14' ' ' VAL . 52.5 mt -87.57 128.02 35.26 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.864 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -114.0 111.35 21.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.836 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.508 ' HA ' HG12 ' A' ' 14' ' ' VAL . 17.4 tp -60.04 134.13 56.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.957 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 29.3 mt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.105 -179.952 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.581 HD13 HG11 ' A' ' 14' ' ' VAL . 29.2 mt . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.761 0.315 . . . . 0.0 111.142 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.421 ' N ' HG22 ' A' ' 8' ' ' ILE . 1.0 OUTLIER -153.35 -168.94 3.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 179.964 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.408 ' HA ' ' CG1' ' A' ' 29' ' ' VAL . 24.9 t -70.16 135.27 28.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.125 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.9 46.17 7.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.408 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.684 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -144.73 137.42 13.6 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.677 0.275 . . . . 0.0 110.99 -179.965 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.1 118.07 4.61 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.477 2.118 . . . . 0.0 112.364 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.609 HG12 ' HA ' ' A' ' 87' ' ' LEU . 24.1 m -146.68 138.32 18.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.196 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.2 mttm -77.06 129.87 36.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.967 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 1.022 HG13 HG21 ' A' ' 80' ' ' VAL . 23.3 t -106.16 128.03 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.002 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 30.2 tt0 -97.24 110.32 22.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.912 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 88.9 mt -80.99 -45.55 16.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.835 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.28 -174.3 5.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.968 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.51 84.25 4.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.82 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.05 55.2 29.41 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.539 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 -117.25 -65.69 1.16 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.776 0.322 . . . . 0.0 110.892 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -158.43 123.07 4.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.866 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 24.2 mttt -90.57 144.06 26.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.419 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 74.0 m-85 -107.98 127.54 27.46 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.864 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -68.39 131.84 24.2 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.397 2.064 . . . . 0.0 112.262 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.66 163.38 30.35 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 28' ' ' VAL . 11.9 p -102.6 125.95 56.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.822 0.344 . . . . 0.0 110.97 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.684 HG23 ' O ' ' A' ' 12' ' ' CYS . 10.3 t -59.88 126.91 18.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -114.38 -31.79 6.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.054 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.558 ' CE2' HD22 ' A' ' 69' ' ' LEU . 28.0 t80 -142.58 167.43 22.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.934 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 13.5 ttp180 -159.22 129.47 5.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.72 148.34 5.15 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.505 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.456 ' HD3' HG23 ' A' ' 44' ' ' ILE . 58.1 Cg_endo . . . . . 0 C--N 1.344 0.338 0 C-N-CA 122.561 2.174 . . . . 0.0 112.274 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.456 HG23 ' HD3' ' A' ' 34' ' ' PRO . 23.2 mt . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.775 0.321 . . . . 0.0 111.18 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -106.99 150.39 26.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.98 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.421 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 9.5 m-85 -123.34 114.9 20.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.971 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.424 ' N ' ' CD1' ' A' ' 79' ' ' PHE . . . -74.93 121.84 6.77 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.48 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.573 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -129.95 133.76 64.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.823 0.344 . . . . 0.0 111.113 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -90.02 115.91 27.65 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.457 HD13 ' HB2' ' A' ' 57' ' ' GLN . 37.3 mt -58.88 133.59 56.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.993 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -81.55 -179.89 7.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.921 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -53.14 -29.63 32.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.106 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -60.86 -58.35 8.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.419 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -111.12 32.72 6.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.465 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -69.74 133.06 47.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.769 0.319 . . . . 0.0 110.907 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.46 35.8 4.56 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.53 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.457 ' HB2' HD13 ' A' ' 50' ' ' LEU . 4.8 mt-30 -141.47 31.36 1.69 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.342 . . . . 0.0 110.877 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.72 147.39 16.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.513 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -108.56 -49.23 3.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.75 0.31 . . . . 0.0 110.863 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.3 t -59.43 -43.78 93.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.957 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.0 t0 59.82 29.38 18.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.052 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.422 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.47 -19.57 53.62 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.69 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.537 HG23 ' C ' ' A' ' 67' ' ' LYS . 11.2 p -124.22 140.38 47.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.865 0.364 . . . . 0.0 111.178 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -122.85 109.96 14.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.923 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER 60.22 26.6 16.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.001 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.12 -30.27 9.54 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.592 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.537 ' C ' HG23 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -77.34 117.93 19.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.951 0.405 . . . . 0.0 110.925 -179.988 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 2.9 tp60 -84.91 92.69 8.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.861 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.558 HD22 ' CE2' ' A' ' 31' ' ' PHE . 71.1 mt -69.49 -44.57 70.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.912 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.422 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.9 p90 -147.77 177.78 9.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.961 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -113.83 123.92 50.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.885 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 17.7 p -150.0 163.06 39.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.891 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -60.12 178.51 0.18 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.936 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -75.71 124.55 27.45 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 60.79 49.86 5.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.909 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 53.7 m -129.99 -45.93 1.14 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.907 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -69.41 132.17 24.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.519 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 48' ' ' VAL . 7.7 m -142.15 131.16 22.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.886 0.374 . . . . 0.0 111.094 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.454 ' CE2' HD12 ' A' ' 69' ' ' LEU . 9.1 m-85 -101.53 127.06 48.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.93 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 1.022 HG21 HG13 ' A' ' 16' ' ' VAL . 31.5 m -151.71 164.15 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.159 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -81.13 162.38 23.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.204 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -51.9 -49.57 62.78 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.887 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -56.89 -28.33 61.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.672 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.0 mtmm -80.03 -25.86 40.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.815 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.795 ' CD2' HG22 ' A' ' 16' ' ' VAL . 80.3 mt -82.86 161.05 22.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.913 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -137.97 104.59 5.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.84 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.609 ' HA ' HG12 ' A' ' 14' ' ' VAL . 19.8 tp -59.68 137.71 57.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.984 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 32.3 mt . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.117 179.973 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.563 HD12 ' CD1' ' A' ' 82' ' ' LEU . 46.0 mt . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -143.1 -172.02 3.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.881 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.526 HG13 ' O ' ' A' ' 30' ' ' ARG . 29.2 t -64.48 127.78 25.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.038 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 87.84 43.28 5.77 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.537 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.649 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -141.44 137.04 16.12 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 120.617 0.246 . . . . 0.0 110.952 -179.961 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -76.34 116.84 4.43 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.526 2.151 . . . . 0.0 112.343 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.618 HG12 ' HA ' ' A' ' 87' ' ' LEU . 6.8 m -144.34 138.74 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.169 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 2.3 mttt -80.42 141.23 35.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.071 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.854 HG13 HG21 ' A' ' 80' ' ' VAL . 31.9 t -115.63 133.6 61.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.053 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -94.52 121.54 36.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.915 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.404 HD12 ' HE2' ' A' ' 25' ' ' PHE . 57.4 mt -101.93 -54.48 2.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.919 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.8 -174.78 0.05 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.839 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 51.7 p -93.0 48.37 1.34 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.918 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 95.51 57.89 1.16 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.469 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -121.43 -51.93 2.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.818 0.342 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -170.02 152.4 4.32 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 10.8 mttt -107.74 138.29 44.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.414 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 26.5 m-85 -95.08 123.14 58.21 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.769 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.634 ' HB2' HD12 ' A' ' 51' ' ' LEU . 37.8 Cg_endo -65.97 138.86 54.22 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.464 2.109 . . . . 0.0 112.263 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -166.74 146.6 11.02 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.571 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.2 p -83.37 145.83 7.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.803 0.335 . . . . 0.0 110.961 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.705 HG13 ' O ' ' A' ' 47' ' ' GLY . 21.7 t -77.86 138.87 19.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.158 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.526 ' O ' HG13 ' A' ' 10' ' ' VAL . 0.7 OUTLIER -117.78 -40.19 3.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.804 179.988 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.411 ' CD2' ' N ' ' A' ' 32' ' ' ARG . 58.1 t80 -140.05 163.8 31.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.793 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.413 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 22.5 ttp85 -158.99 140.79 13.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.911 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.83 161.33 9.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.482 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo . . . . . 0 C--N 1.344 0.292 0 C-N-CA 122.556 2.171 . . . . 0.0 112.287 179.974 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.2 mp . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.82 0.343 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -117.96 146.58 43.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.918 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.413 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 7.0 m-85 -118.28 112.94 20.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.924 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.705 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -68.44 141.4 37.02 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.589 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.443 ' O ' HG22 ' A' ' 78' ' ' VAL . 25.7 t -153.52 140.92 13.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.792 0.329 . . . . 0.0 111.006 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -98.79 113.94 26.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.871 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.456 HD12 ' HA ' ' A' ' 76' ' ' CYS . 3.4 mt -57.76 128.6 37.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.056 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.634 HD12 ' HB2' ' A' ' 26' ' ' PRO . 19.8 mt -78.0 -179.9 6.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.54 -30.03 52.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.079 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -60.64 -48.68 80.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.846 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.414 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -121.57 37.13 3.03 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.488 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.1 ttt180 -74.1 151.89 40.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.802 0.334 . . . . 0.0 110.9 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 84.3 27.91 35.07 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.492 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 68.5 mm-40 -133.92 36.69 3.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.837 0.351 . . . . 0.0 110.918 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.41 145.86 15.99 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.456 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -109.98 -47.38 3.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.821 0.343 . . . . 0.0 110.921 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.3 t -69.98 -40.47 75.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.831 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.6 t0 58.43 29.46 18.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.043 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.414 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 99.01 -20.25 51.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.67 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.9 p -118.56 134.59 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.867 0.365 . . . . 0.0 111.124 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.413 ' CE1' ' HG3' ' A' ' 65' ' ' GLN . 50.4 t80 -122.59 110.02 15.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.858 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.413 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 28.8 mt-30 58.94 26.54 15.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.037 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 105.72 -28.05 15.57 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.568 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.0 118.08 21.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.83 0.348 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 7.7 tp60 -84.08 90.08 7.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.913 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 84.7 mt -71.36 -31.78 67.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.825 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.1 p90 -161.49 164.82 29.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.858 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -112.0 119.42 38.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.887 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 1.3 m -137.17 179.95 6.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.907 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -71.69 179.96 2.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.885 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -72.33 123.24 22.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.001 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 60.02 50.59 6.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . 0.456 ' HA ' HD12 ' A' ' 50' ' ' LEU . 27.9 m -130.04 -49.28 1.11 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.983 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -62.65 127.14 38.77 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.558 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.443 HG22 ' O ' ' A' ' 48' ' ' VAL . 21.3 m -146.11 156.23 12.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.748 0.309 . . . . 0.0 111.128 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.429 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 7.9 m-85 -124.47 136.61 54.16 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.889 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.854 HG21 HG13 ' A' ' 16' ' ' VAL . 28.6 m -156.59 160.04 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.11 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . 0.527 ' HB3' ' OD1' ' A' ' 83' ' ' ASP . . . -73.3 157.48 36.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.116 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.563 ' CD1' HD12 ' A' ' 8' ' ' ILE . 14.8 tp -51.14 -46.41 61.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.845 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . 0.527 ' OD1' ' HB3' ' A' ' 81' ' ' ALA . 27.6 p-10 -57.16 -28.94 63.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.599 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 5.0 mmtt -79.28 -25.21 42.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.745 ' CD2' HG22 ' A' ' 16' ' ' VAL . 43.7 mt -83.17 154.98 24.0 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.02 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -141.45 104.66 4.62 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.853 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.618 ' HA ' HG12 ' A' ' 14' ' ' VAL . 19.0 tp -59.51 135.14 57.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.002 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.3 mt . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.113 -179.991 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.688 HG21 HG11 ' A' ' 14' ' ' VAL . 4.1 mt . . . . . 0 N--CA 1.458 -0.049 0 CA-C-O 120.918 0.39 . . . . 0.0 111.059 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -138.82 179.77 6.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.842 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.2 t -64.04 133.13 29.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.011 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 84.36 45.53 6.15 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.383 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.496 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -149.87 143.63 16.89 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 120.663 0.268 . . . . 0.0 110.953 -179.948 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.498 ' O ' HG13 ' A' ' 14' ' ' VAL . 74.4 Cg_endo -75.3 138.14 21.96 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.582 2.188 . . . . 0.0 112.267 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.688 HG11 HG21 ' A' ' 8' ' ' ILE . 11.3 m -158.49 138.69 4.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.232 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.3 mttt -82.82 125.94 31.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.948 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.838 HG22 ' CD2' ' A' ' 85' ' ' LEU . 22.0 t -104.49 138.46 29.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.03 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -102.96 112.09 24.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.939 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -85.78 -40.12 16.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.866 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -84.31 -176.3 6.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 71.8 p -100.04 48.26 0.93 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.874 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 105.71 56.89 0.66 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.553 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.95 -60.45 1.08 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.803 0.335 . . . . 0.0 110.904 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -161.63 146.18 13.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.863 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 14.8 mttt -109.21 150.62 27.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.435 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 27.3 m-85 -113.63 127.26 27.03 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.838 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.18 146.17 40.37 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.436 2.091 . . . . 0.0 112.318 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.82 153.4 21.53 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.489 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.8 p -93.27 138.85 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.772 0.32 . . . . 0.0 111.066 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.605 HG22 HG22 ' A' ' 48' ' ' VAL . 19.3 t -72.78 133.32 31.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.098 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 20.0 mmt180 -115.91 -30.45 6.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.038 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -142.78 168.3 20.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.948 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.428 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 24.3 ttp180 -161.23 123.53 3.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.858 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 168.37 145.7 4.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.545 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.532 ' HD3' HG23 ' A' ' 44' ' ' ILE . 53.0 Cg_exo . . . . . 0 C--N 1.344 0.338 0 C-N-CA 122.583 2.189 . . . . 0.0 112.25 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.532 HG23 ' HD3' ' A' ' 34' ' ' PRO . 32.9 mt . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.794 0.331 . . . . 0.0 111.095 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -90.39 147.81 23.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.952 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.428 ' CZ ' ' HD2' ' A' ' 32' ' ' ARG . 12.1 m-85 -117.12 111.95 20.21 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.67 110.27 2.99 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.498 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.605 HG22 HG22 ' A' ' 29' ' ' VAL . 21.8 t -116.97 132.13 67.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.846 0.355 . . . . 0.0 111.039 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -88.53 117.54 27.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.574 HD13 ' HB2' ' A' ' 57' ' ' GLN . 52.8 mt -59.15 135.19 57.56 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.993 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -79.78 -179.93 7.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.821 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -55.13 -30.2 59.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.079 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -63.01 -60.1 3.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.79 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.435 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -101.58 30.86 9.47 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.442 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -69.74 137.87 52.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.79 0.328 . . . . 0.0 110.88 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.01 34.06 6.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.47 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.574 ' HB2' HD13 ' A' ' 50' ' ' LEU . 31.1 mm-40 -140.9 43.84 1.81 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.906 0.384 . . . . 0.0 110.918 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -108.1 143.15 16.05 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.525 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -110.03 -32.1 7.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.87 0.367 . . . . 0.0 110.932 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -85.76 -42.31 14.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.899 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.6 t0 57.08 31.19 19.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.999 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.433 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 93.1 -16.8 59.65 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.676 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.7 p -123.01 142.1 40.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.856 0.36 . . . . 0.0 111.141 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 13.4 t80 -129.09 110.24 11.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.873 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 61.67 24.54 14.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.154 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.18 -27.81 14.7 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.566 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.6 119.53 23.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.947 0.403 . . . . 0.0 110.948 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -82.87 95.61 8.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 78.5 mt -70.83 -51.13 28.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.433 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -144.99 166.1 26.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.913 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.32 124.24 46.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.881 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 9.3 p -149.58 177.1 10.05 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -71.89 175.93 5.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.877 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -78.82 127.79 32.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 60.5 41.22 16.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.902 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 23.7 m -127.53 -46.66 1.45 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.909 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -68.32 132.25 27.67 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.538 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 12.4 m -148.44 135.96 13.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.806 0.336 . . . . 0.0 111.158 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -102.18 130.01 48.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.587 HG21 HG13 ' A' ' 16' ' ' VAL . 4.2 m -150.15 166.74 2.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.148 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.98 158.76 21.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.137 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.457 ' CD1' HD12 ' A' ' 8' ' ' ILE . 9.3 tp -50.55 -44.05 56.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.899 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -57.82 -28.82 64.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.603 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.4 mttt -82.6 -24.85 33.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.86 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.838 ' CD2' HG22 ' A' ' 16' ' ' VAL . 52.7 mt -88.88 128.45 35.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.013 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.9 tm-20 -114.89 107.95 16.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.81 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 13.7 tp -57.74 138.54 55.41 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.997 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 27.3 mt . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 -179.997 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.707 HD13 HG11 ' A' ' 14' ' ' VAL . 20.2 mt . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.828 0.346 . . . . 0.0 111.02 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -120.57 -179.59 4.03 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.3 t -66.86 137.33 25.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.027 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.75 46.82 7.02 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.399 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.581 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -140.72 140.96 23.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.623 0.249 . . . . 0.0 110.955 -179.965 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.473 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.5 Cg_endo -76.51 117.17 4.49 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.566 2.177 . . . . 0.0 112.343 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.707 HG11 HD13 ' A' ' 8' ' ' ILE . 4.9 m -144.38 138.9 23.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.129 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -87.38 140.98 28.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.886 HG22 HD23 ' A' ' 85' ' ' LEU . 19.5 t -121.0 140.4 45.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.095 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -97.96 110.06 22.7 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.442 HD23 ' HA ' ' A' ' 18' ' ' LEU . 14.6 mt -84.57 -58.69 2.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.89 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.42 -174.99 0.74 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.83 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -83.77 68.72 10.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 69.18 45.35 62.09 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.536 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -99.48 -44.72 6.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 0.0 110.916 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -176.66 131.56 0.2 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -88.29 124.85 34.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.825 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -89.84 128.06 51.67 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.832 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.693 ' HB2' HD12 ' A' ' 51' ' ' LEU . 60.4 Cg_endo -72.33 139.4 31.89 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.445 2.097 . . . . 0.0 112.328 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -154.82 167.05 32.6 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.515 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.446 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.6 p -108.73 124.0 64.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.75 0.31 . . . . 0.0 111.014 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 12' ' ' CYS . 16.7 t -59.46 128.55 20.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.13 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -115.73 -29.92 6.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.112 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 40.5 t80 -148.74 165.96 29.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.914 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 15.1 ttp180 -158.46 135.66 9.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.984 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.68 137.32 2.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo . . . . . 0 C--N 1.346 0.435 0 C-N-CA 122.516 2.144 . . . . 0.0 112.339 -179.992 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 16.2 mt . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.795 0.331 . . . . 0.0 111.099 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -120.2 138.92 53.36 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.939 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.475 ' CB ' HD11 ' A' ' 85' ' ' LEU . 6.4 m-85 -120.84 109.91 15.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.845 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.18 119.93 9.07 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.485 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.477 HG22 HG22 ' A' ' 29' ' ' VAL . 22.3 t -134.04 130.83 55.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.774 0.321 . . . . 0.0 111.03 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -83.62 119.06 24.28 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.932 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.9 mt -62.26 141.95 57.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.014 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.693 HD12 ' HB2' ' A' ' 26' ' ' PRO . 7.7 mt -86.73 -179.93 6.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.854 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -54.42 -30.03 51.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.037 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -61.73 -47.06 86.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.871 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.43 38.38 2.39 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.482 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -77.09 151.83 35.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.819 0.342 . . . . 0.0 110.869 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.18 28.13 37.99 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.543 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -135.35 46.55 2.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.804 0.335 . . . . 0.0 110.859 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -118.15 150.44 18.19 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.556 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -110.09 -50.55 2.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.433 HG23 ' N ' ' A' ' 61' ' ' ASP . 7.7 t -69.03 -48.07 63.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.962 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.433 ' N ' HG23 ' A' ' 60' ' ' THR . 18.3 m-20 55.54 32.74 19.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.044 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 105.1 -25.41 25.26 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.545 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 63' ' ' VAL . 10.7 p -121.93 126.54 74.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.807 0.336 . . . . 0.0 111.103 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -116.03 113.89 23.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.86 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 12.9 mt-30 62.39 26.8 16.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.943 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.83 -24.39 32.35 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.616 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 12.2 tptm -81.67 114.56 20.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.882 0.372 . . . . 0.0 110.903 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.8 tp60 -82.64 97.24 8.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.924 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.476 HD12 ' CE2' ' A' ' 79' ' ' PHE . 79.0 mt -80.87 -34.74 33.46 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.012 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.411 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -156.39 169.81 23.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.986 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -103.47 124.74 49.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.889 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -140.61 173.84 11.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.823 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -76.43 179.96 5.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -76.96 120.52 22.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 60.2 41.71 16.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.885 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 78.2 m -125.18 -52.83 1.63 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.945 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -64.62 130.14 36.84 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.454 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 48' ' ' VAL . 5.6 m -142.33 143.46 26.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.853 0.359 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.476 ' CE2' HD12 ' A' ' 69' ' ' LEU . 4.5 m-85 -105.87 124.69 49.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.867 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.814 HG11 HG11 ' A' ' 16' ' ' VAL . 29.4 m -146.65 155.77 11.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.15 155.67 40.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.2 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.471 HD12 HD12 ' A' ' 8' ' ' ILE . 8.9 tp -50.57 -44.51 56.76 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.927 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -56.48 -27.03 55.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.663 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 11.8 mmtt -81.52 -26.75 34.86 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.838 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.886 HD23 HG22 ' A' ' 16' ' ' VAL . 90.2 mt -79.3 140.91 37.43 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.823 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -115.75 103.34 10.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.846 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.529 ' HA ' HG12 ' A' ' 14' ' ' VAL . 23.4 tp -59.54 130.38 46.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.473 HD12 ' HB2' ' A' ' 13' ' ' PRO . 13.6 mt . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.007 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.777 HD12 HD12 ' A' ' 82' ' ' LEU . 30.0 mt . . . . . 0 N--CA 1.457 -0.095 0 CA-C-O 120.82 0.343 . . . . 0.0 111.1 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -134.75 -177.84 4.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.971 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 26.6 t -60.98 135.68 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.133 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.43 46.15 7.04 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.466 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -141.66 138.82 17.65 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.668 0.27 . . . . 0.0 110.865 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.43 ' O ' HD12 ' A' ' 87' ' ' LEU . 71.3 Cg_endo -74.48 117.25 4.89 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 122.503 2.136 . . . . 0.0 112.383 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.759 HG21 HD13 ' A' ' 85' ' ' LEU . 14.9 m -142.99 138.55 27.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.12 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 27.0 mttt -83.63 142.89 30.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.978 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.899 HG22 ' CD2' ' A' ' 85' ' ' LEU . 19.0 t -123.43 132.03 72.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -93.27 118.93 31.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.622 HD11 ' O ' ' A' ' 57' ' ' GLN . 18.1 mt -95.07 -55.8 2.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.98 -170.27 0.22 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.877 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 69.0 m -88.75 79.16 7.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.871 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.83 44.22 98.29 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.523 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -101.62 -66.54 0.91 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.798 0.333 . . . . 0.0 110.836 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -152.92 142.39 21.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.938 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.7 mtpt -103.73 133.13 49.25 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.826 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.424 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 25.8 m-85 -92.84 129.76 38.87 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.78 133.87 17.49 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.427 2.085 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.16 155.39 26.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.594 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -94.52 132.95 37.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.822 0.344 . . . . 0.0 111.067 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.4 t -63.75 133.83 29.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.097 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.28 -36.4 4.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.005 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 52.9 t80 -143.19 164.34 30.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.921 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.408 ' HG3' ' CE2' ' A' ' 46' ' ' PHE . 4.3 ttt180 -154.29 135.91 14.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 160.04 126.82 0.86 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.455 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.714 ' CD ' HG23 ' A' ' 44' ' ' ILE . 52.3 Cg_exo . . . . . 0 C--N 1.346 0.421 0 C-N-CA 122.435 2.09 . . . . 0.0 112.295 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.714 HG23 ' CD ' ' A' ' 34' ' ' PRO . 3.0 mt . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.75 0.309 . . . . 0.0 111.072 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -102.28 134.94 44.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.841 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.408 ' CE2' ' HG3' ' A' ' 32' ' ' ARG . 8.7 m-85 -121.69 113.01 19.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.446 ' N ' ' CD1' ' A' ' 79' ' ' PHE . . . -73.08 118.21 6.26 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.358 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.508 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.6 t -125.73 131.42 71.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 111.124 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -90.55 114.81 27.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.839 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.3 mt -58.32 135.99 57.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.073 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -82.28 -179.97 7.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.896 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.72 -29.66 54.04 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.09 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -61.33 -50.49 72.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.902 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.424 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -121.84 37.59 2.87 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.479 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.57 145.34 41.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.794 0.33 . . . . 0.0 110.911 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 85.95 33.13 15.98 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.539 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.622 ' O ' HD11 ' A' ' 18' ' ' LEU . 7.7 mm-40 -137.3 30.86 2.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.862 0.363 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.38 154.41 18.99 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.502 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -109.47 -49.79 3.07 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.799 0.333 . . . . 0.0 110.869 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.7 t -62.31 -46.26 89.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.946 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 57.51 35.37 25.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.003 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.407 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.49 -27.56 16.89 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.469 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.434 ' O ' HG13 ' A' ' 63' ' ' VAL . 10.8 p -117.46 124.83 73.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 0.0 111.053 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 37.3 t80 -111.91 115.05 28.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.96 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 30.7 mt-30 59.37 25.77 14.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.137 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.84 24.66 22.47 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.61 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.65 109.82 10.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.83 0.348 . . . . 0.0 110.859 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -75.71 97.01 3.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.946 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.443 HD12 ' CE2' ' A' ' 79' ' ' PHE . 79.0 mt -82.65 -30.81 29.1 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.858 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.407 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.9 p90 -152.82 174.64 13.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.938 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.79 110.02 19.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 26.5 p -133.17 174.71 10.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -72.55 179.97 3.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.881 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -74.78 119.31 18.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.975 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 60.75 51.25 4.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.906 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 47.6 m -129.98 -49.34 1.12 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.916 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -71.65 134.63 22.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.502 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 48' ' ' VAL . 8.1 m -141.9 132.61 25.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.805 0.336 . . . . 0.0 111.113 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 47' ' ' GLY . 7.9 m-85 -100.83 118.34 36.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.897 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.515 HG21 HG13 ' A' ' 16' ' ' VAL . 27.4 m -145.3 161.92 12.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.109 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.66 156.05 35.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.127 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.777 HD12 HD12 ' A' ' 8' ' ' ILE . 6.5 tp -50.43 -43.97 55.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.825 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -57.57 -29.27 64.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.573 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 22.6 mmtm -80.62 -27.02 37.41 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.79 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.899 ' CD2' HG22 ' A' ' 16' ' ' VAL . 39.4 mt -84.33 146.59 27.64 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.985 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -131.46 110.96 11.38 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.912 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.43 HD12 ' O ' ' A' ' 13' ' ' PRO . 34.5 tp -62.6 136.14 57.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.99 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 26.9 mt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.183 179.944 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.504 HG21 HG11 ' A' ' 14' ' ' VAL . 20.2 mt . . . . . 0 N--CA 1.457 -0.088 0 CA-C-O 120.755 0.312 . . . . 0.0 111.172 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -157.91 -176.65 6.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.592 HG13 ' O ' ' A' ' 30' ' ' ARG . 39.7 t -58.89 138.93 19.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.146 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 72.06 47.33 31.52 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.512 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.726 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -147.31 136.38 11.52 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.585 0.231 . . . . 0.0 110.893 179.985 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -76.19 130.2 11.91 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.512 2.141 . . . . 0.0 112.298 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.504 HG11 HG21 ' A' ' 8' ' ' ILE . 7.3 m -151.67 138.75 13.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.156 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -81.89 135.21 35.43 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.753 HG22 HD23 ' A' ' 85' ' ' LEU . 21.4 t -116.83 139.9 41.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.14 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -103.26 116.29 32.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.937 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 50.6 mt -89.72 -44.65 9.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.954 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -86.38 172.17 10.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.87 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 43.2 t -76.43 76.22 3.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.11 69.2 1.39 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.509 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -133.38 -57.7 0.89 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.887 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -156.12 132.7 10.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.847 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -102.87 128.1 49.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.874 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.402 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 42.6 m-85 -93.18 129.56 38.88 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.817 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.63 ' HB2' HD12 ' A' ' 51' ' ' LEU . 72.9 Cg_endo -76.06 138.59 20.73 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.435 2.09 . . . . 0.0 112.282 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.27 151.49 22.8 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.552 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.0 p -92.38 130.94 40.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.791 0.329 . . . . 0.0 111.018 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.726 HG23 ' O ' ' A' ' 12' ' ' CYS . 22.1 t -64.77 140.54 19.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.051 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.592 ' O ' HG13 ' A' ' 10' ' ' VAL . 11.3 mmt180 -122.22 -41.07 2.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.042 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -138.25 164.47 29.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.947 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 3.3 ttp180 -158.11 141.94 15.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.857 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.04 149.18 4.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.478 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo . . . . . 0 C--N 1.344 0.294 0 C-N-CA 122.604 2.203 . . . . 0.0 112.339 -179.99 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.6 mt . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.749 0.309 . . . . 0.0 111.063 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -136.71 147.23 46.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.941 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.448 ' HB2' HD11 ' A' ' 85' ' ' LEU . 9.6 m-85 -123.99 109.89 14.1 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.855 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.31 120.68 9.49 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.477 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.529 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -133.21 133.11 58.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.874 0.368 . . . . 0.0 111.107 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -90.24 116.93 28.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.881 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.469 HD21 HG21 ' A' ' 78' ' ' VAL . 63.6 mt -60.43 145.33 48.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.941 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.63 HD12 ' HB2' ' A' ' 26' ' ' PRO . 3.6 mt -86.44 -179.85 6.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.923 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -53.24 -29.35 32.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.111 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.09 -51.95 65.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.884 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.402 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -112.21 29.64 8.22 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.514 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -68.17 144.97 54.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.888 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.67 39.24 14.59 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.519 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -145.4 35.19 1.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.774 0.321 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.05 152.09 19.26 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -110.0 -43.87 3.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 0.0 110.979 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.4 t -77.61 -40.38 42.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.899 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 51.12 26.83 3.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.302 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.417 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 106.31 -31.74 8.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.622 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -111.78 128.79 68.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.89 0.376 . . . . 0.0 111.091 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.428 ' CE1' ' HG3' ' A' ' 65' ' ' GLN . 30.9 t80 -113.28 110.01 19.68 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.896 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . 0.428 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 9.9 mt-30 57.72 28.84 16.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.034 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 102.22 -26.81 22.97 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.498 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.6 tmtt? -82.17 116.82 21.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.918 0.39 . . . . 0.0 110.952 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 19.5 tp60 -78.96 98.91 6.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.832 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 79.0 mt -81.13 -37.86 28.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.949 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.417 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.0 p90 -155.96 173.3 16.99 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.936 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -107.72 123.36 48.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.889 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -139.58 177.2 8.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.911 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -76.05 179.92 5.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.886 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -73.52 114.01 11.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.913 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 42.2 m-20 60.83 45.21 10.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.912 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 62.6 m -125.63 -46.17 1.74 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.894 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -65.1 135.82 37.36 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.525 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 48' ' ' VAL . 8.6 m -148.49 138.86 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.803 0.335 . . . . 0.0 111.164 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -105.15 134.52 48.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.559 ' CG2' HD21 ' A' ' 85' ' ' LEU . 30.5 m -155.79 168.56 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.182 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -87.39 161.24 17.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.191 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 7.0 tp -49.99 -44.3 50.87 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -55.82 -27.1 49.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.665 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 16.1 mmtt -95.86 19.65 11.1 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.934 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.753 HD23 HG22 ' A' ' 16' ' ' VAL . 88.2 mt -129.18 126.71 39.82 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.93 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -107.8 110.39 22.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.963 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.435 ' HA ' HG12 ' A' ' 14' ' ' VAL . 12.2 tp -67.14 117.47 9.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.996 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.0 mp . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.152 179.923 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.455 HG21 HG11 ' A' ' 14' ' ' VAL . 8.7 mt . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.769 0.318 . . . . 0.0 111.058 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.65 -175.54 3.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.924 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.401 ' HA ' ' CG1' ' A' ' 29' ' ' VAL . 28.3 t -64.42 128.86 27.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.018 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 88.47 43.92 5.4 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.444 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.701 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -145.63 139.21 14.6 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.643 0.259 . . . . 0.0 110.963 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.622 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.2 Cg_endo -76.72 130.03 11.27 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.513 2.142 . . . . 0.0 112.303 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.455 HG11 HG21 ' A' ' 8' ' ' ILE . 12.6 m -151.1 138.8 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.141 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 50.2 mttt -82.21 127.49 33.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.962 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.725 HG13 HG21 ' A' ' 80' ' ' VAL . 21.4 t -108.69 137.01 42.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.029 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -92.98 121.41 34.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.971 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.1 mt -100.41 -42.49 6.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.956 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.9 mtt85 -79.68 -178.22 6.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.81 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -80.49 73.54 7.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.825 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.75 41.21 99.88 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.491 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -101.94 -61.86 1.33 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.747 0.308 . . . . 0.0 110.865 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -148.43 159.6 43.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.902 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 2.0 mttm -125.3 126.38 45.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -89.65 137.31 28.72 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.766 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.414 ' HB2' HD12 ' A' ' 51' ' ' LEU . 67.4 Cg_endo -73.88 146.15 37.23 Favored 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.424 2.082 . . . . 0.0 112.331 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -163.29 152.21 22.16 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.502 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.5 p -94.1 129.16 44.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.324 . . . . 0.0 111.138 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 12' ' ' CYS . 18.7 t -62.3 126.58 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.07 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 40.0 mmt180 -112.11 -31.05 7.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.012 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -148.25 167.73 24.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.976 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 9.6 ttp180 -160.85 119.39 2.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.865 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.52 156.34 11.8 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.55 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo . . . . . 0 C--N 1.344 0.325 0 C-N-CA 122.586 2.19 . . . . 0.0 112.357 -179.981 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.9 mp . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.794 0.33 . . . . 0.0 111.153 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -85.5 124.24 31.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.421 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 5.8 m-85 -98.16 120.0 37.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.999 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.444 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -83.56 131.64 10.52 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.418 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.679 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -139.35 126.39 24.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.876 0.37 . . . . 0.0 111.161 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -83.0 117.14 22.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.845 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.445 HD13 ' HB2' ' A' ' 57' ' ' GLN . 13.1 mt -58.62 130.15 45.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.934 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.414 HD12 ' HB2' ' A' ' 26' ' ' PRO . 5.1 mt -76.67 -179.94 5.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.867 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -53.88 -29.2 40.56 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.134 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -61.87 -43.6 98.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.946 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.24 35.33 2.86 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.528 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -72.61 143.44 48.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.779 0.323 . . . . 0.0 110.889 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.48 34.48 11.86 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.475 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.445 ' HB2' HD13 ' A' ' 50' ' ' LEU . 30.5 mm-40 -141.69 37.63 1.65 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.83 0.348 . . . . 0.0 110.843 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -110.16 155.22 16.21 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.521 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -109.92 -50.55 2.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.775 0.321 . . . . 0.0 110.929 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.431 HG23 ' N ' ' A' ' 61' ' ' ASP . 7.2 t -64.61 -48.21 75.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.929 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.431 ' N ' HG23 ' A' ' 60' ' ' THR . 6.0 m-20 56.64 27.8 13.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.154 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.414 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 107.35 -27.05 16.61 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.571 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.494 HG23 ' C ' ' A' ' 67' ' ' LYS . 12.6 p -117.69 138.12 49.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 111.158 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -121.44 109.97 15.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.911 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 17.1 mt-30 61.29 25.17 15.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.091 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.45 -29.27 10.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.571 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.494 ' C ' HG23 ' A' ' 63' ' ' VAL . 6.1 tmtt? -79.27 119.15 21.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.864 0.364 . . . . 0.0 110.984 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 17.9 tp60 -82.13 97.09 8.02 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.91 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.49 HD12 ' CE2' ' A' ' 79' ' ' PHE . 80.5 mt -76.85 -43.92 34.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.958 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.2 p90 -151.46 170.92 18.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.89 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.02 134.45 44.0 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -156.85 165.81 35.15 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -66.92 173.71 3.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -72.68 121.66 20.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 60.38 49.41 6.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.91 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 60.4 m -129.96 -51.65 1.13 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -66.56 142.83 42.99 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.487 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.679 HG22 ' O ' ' A' ' 48' ' ' VAL . 21.0 m -151.37 143.67 16.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.834 0.349 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.49 ' CE2' HD12 ' A' ' 69' ' ' LEU . 12.5 m-85 -109.74 128.39 55.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.881 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.725 HG21 HG13 ' A' ' 16' ' ' VAL . 30.5 m -149.85 154.93 8.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.101 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.52 156.24 33.19 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.092 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.406 ' CD1' HD12 ' A' ' 8' ' ' ILE . 16.2 tp -50.89 -47.7 60.55 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.939 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -55.84 -28.58 57.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.545 179.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.2 mmmp? -75.85 -26.32 57.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.727 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.577 ' CD2' HG22 ' A' ' 16' ' ' VAL . 77.7 mt -84.16 137.68 33.4 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.852 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -124.62 108.03 11.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.453 HD13 HG12 ' A' ' 8' ' ' ILE . 10.1 tp -60.91 142.54 56.26 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.88 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.622 HD12 ' HB2' ' A' ' 13' ' ' PRO . 21.5 mt . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.169 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.604 HG21 HG11 ' A' ' 14' ' ' VAL . 31.1 mt . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.819 0.342 . . . . 0.0 111.142 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -122.39 -175.75 3.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.924 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.3 t -66.09 135.17 28.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.077 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.75 45.85 7.05 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.514 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.646 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -143.62 139.8 16.7 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.64 0.257 . . . . 0.0 110.877 -179.974 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -74.77 122.8 7.55 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.427 2.085 . . . . 0.0 112.234 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.681 ' CG2' HD22 ' A' ' 85' ' ' LEU . 15.8 m -147.13 138.39 18.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.154 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 20.3 mttm -84.69 133.43 34.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.036 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.851 HG22 HD23 ' A' ' 85' ' ' LEU . 18.0 t -114.22 139.57 39.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.106 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -91.16 122.28 33.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.888 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 45.9 mt -104.59 -52.2 2.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.965 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.6 mtt85 -68.45 -175.86 0.7 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.2 p -94.7 70.21 3.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.82 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 81.06 47.54 6.5 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -111.92 -68.8 0.91 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.804 0.335 . . . . 0.0 110.888 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -157.57 163.09 38.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 17.0 mttm -114.72 112.29 22.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.902 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -72.25 133.41 83.42 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.746 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.575 ' HB2' HD12 ' A' ' 51' ' ' LEU . 73.0 Cg_endo -74.57 143.95 31.3 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.36 2.04 . . . . 0.0 112.392 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -162.76 156.3 27.95 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.487 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.3 p -95.12 131.47 41.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.346 . . . . 0.0 111.046 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.646 HG23 ' O ' ' A' ' 12' ' ' CYS . 22.0 t -65.9 129.75 30.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.039 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.414 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 5.1 mmt180 -114.88 -29.92 6.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -147.37 166.65 26.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.883 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.422 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 6.3 ttp180 -164.38 141.43 6.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.885 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.86 147.99 4.81 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.483 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo . . . . . 0 C--N 1.344 0.299 0 C-N-CA 122.568 2.179 . . . . 0.0 112.336 179.921 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.7 mp . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.878 0.37 . . . . 0.0 111.065 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -95.1 137.13 34.57 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.892 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.667 ' CB ' HD11 ' A' ' 85' ' ' LEU . 5.3 m-85 -114.59 109.92 18.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.408 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -70.97 118.85 7.73 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.297 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.571 HG21 ' CD2' ' A' ' 85' ' ' LEU . 24.2 t -130.99 131.61 64.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.863 0.363 . . . . 0.0 111.139 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -89.71 116.76 28.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.801 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.668 HD13 ' O ' ' A' ' 54' ' ' GLY . 91.8 mt -57.14 145.57 30.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.149 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.575 HD12 ' HB2' ' A' ' 26' ' ' PRO . 13.3 mt -90.08 -179.88 5.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.836 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -53.19 -27.83 23.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.145 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -63.1 -54.92 30.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.862 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.668 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -116.59 35.65 4.12 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.3 mtt85 -74.69 123.87 25.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.818 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 113.58 25.49 4.28 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.726 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 39.2 mm-40 -135.45 45.72 2.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.847 0.356 . . . . 0.0 110.929 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.62 148.34 18.4 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.47 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 16.3 p90 -109.91 -49.95 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.794 0.33 . . . . 0.0 110.981 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -59.26 -46.2 89.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.0 t0 59.45 26.98 16.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.119 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.409 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.21 -25.49 23.92 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.712 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.6 p -114.18 147.92 17.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.809 0.337 . . . . 0.0 111.161 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 31.7 t80 -132.08 110.01 10.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 53.4 mt-30 60.21 29.62 19.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.914 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.49 -28.33 15.98 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.475 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 8.7 tmtt? -79.66 114.58 18.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.792 0.33 . . . . 0.0 110.932 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 24.5 tp60 -71.51 99.64 2.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.942 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 73.0 mt -78.08 -39.05 42.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CD2' ' HB2' ' A' ' 30' ' ' ARG . 2.3 p90 -163.71 167.9 20.47 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.86 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 17.4 mm-40 -93.82 129.36 40.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.942 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.64 173.96 12.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.91 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -83.27 167.62 17.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.799 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -66.04 118.35 9.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 60.56 44.34 11.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.946 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 86.8 m -127.61 -55.84 1.31 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.94 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.17 135.42 51.75 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.546 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.499 HG22 ' O ' ' A' ' 48' ' ' VAL . 6.1 m -143.73 143.84 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.803 0.335 . . . . 0.0 111.107 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.408 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 3.8 m-85 -109.68 131.48 55.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.762 HG21 HG13 ' A' ' 16' ' ' VAL . 20.4 m -155.96 157.72 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.082 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . 0.411 ' HB3' ' HG3' ' A' ' 84' ' ' LYS . . . -70.54 155.12 41.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.999 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 10.2 tp -50.4 -45.8 55.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -57.26 -29.54 63.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.606 179.759 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.411 ' HG3' ' HB3' ' A' ' 81' ' ' ALA . 14.2 mttm -77.9 -24.68 48.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.902 179.716 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.851 HD23 HG22 ' A' ' 16' ' ' VAL . 66.6 mt -81.82 158.09 24.2 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.908 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -142.99 109.31 5.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.92 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.455 ' HA ' HG12 ' A' ' 14' ' ' VAL . 34.6 tp -61.8 135.81 57.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.965 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.4 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.052 -179.995 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.505 HD12 HD12 ' A' ' 82' ' ' LEU . 32.1 mt . . . . . 0 N--CA 1.457 -0.096 0 CA-C-O 120.83 0.348 . . . . 0.0 111.109 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -122.51 172.93 8.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.888 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.423 HG13 ' C ' ' A' ' 30' ' ' ARG . 37.2 t -60.65 133.08 26.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.117 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 85.5 45.14 5.91 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.455 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.494 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.44 139.26 14.75 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 120.638 0.256 . . . . 0.0 110.908 -179.94 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -74.17 133.33 17.76 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.486 2.124 . . . . 0.0 112.253 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.468 ' CG2' HD22 ' A' ' 85' ' ' LEU . 6.2 m -153.83 138.87 10.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.139 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -84.02 131.16 34.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.968 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.802 HG22 HD23 ' A' ' 85' ' ' LEU . 16.8 t -113.26 132.4 62.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.102 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.59 116.02 28.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.957 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.564 HD12 ' CE2' ' A' ' 25' ' ' PHE . 36.7 mt -91.56 -57.33 2.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -70.44 -172.11 0.56 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.941 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 t -84.5 79.52 9.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.5 39.04 94.43 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.486 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -95.03 -61.97 1.39 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.858 0.361 . . . . 0.0 110.905 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -155.54 144.58 20.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 21.3 mttt -106.72 124.84 50.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.862 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.564 ' CE2' HD12 ' A' ' 18' ' ' LEU . 61.3 m-85 -87.84 132.59 39.79 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.77 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.416 ' HB2' HD12 ' A' ' 51' ' ' LEU . 65.8 Cg_endo -73.72 141.64 31.02 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.426 2.084 . . . . 0.0 112.34 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.67 147.83 14.67 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.557 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.531 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.9 p -90.47 133.13 33.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.771 0.32 . . . . 0.0 110.984 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.494 HG23 ' O ' ' A' ' 12' ' ' CYS . 23.4 t -65.07 136.68 26.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.138 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.531 ' HD3' HG13 ' A' ' 28' ' ' VAL . 13.9 mmm180 -117.68 -38.04 3.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.021 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -143.11 166.27 25.13 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.877 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.429 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.8 ttp180 -159.6 133.84 7.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.81 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 155.3 151.45 5.87 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.511 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 C--N 1.344 0.319 0 C-N-CA 122.56 2.173 . . . . 0.0 112.233 -179.973 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.9 mm . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.827 0.346 . . . . 0.0 111.034 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -114.87 139.38 49.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.429 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 7.6 m-85 -120.85 109.93 15.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.414 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -72.06 128.82 14.58 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.414 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.52 HG21 HD21 ' A' ' 85' ' ' LEU . 21.5 t -137.12 136.78 47.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.796 0.331 . . . . 0.0 111.065 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -94.19 115.4 27.67 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.553 HD13 ' O ' ' A' ' 54' ' ' GLY . 65.2 mt -59.17 130.94 49.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.918 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.416 HD12 ' HB2' ' A' ' 26' ' ' PRO . 12.5 mt -77.5 -179.94 6.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.852 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.05 -29.8 45.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.067 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -61.79 -42.97 99.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.958 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.553 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -123.89 34.46 3.57 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.445 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -75.74 132.54 40.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.864 0.364 . . . . 0.0 110.874 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.04 29.96 6.94 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.524 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -140.97 33.38 1.76 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.802 0.334 . . . . 0.0 110.888 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -99.51 152.67 19.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.529 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -109.98 -50.95 2.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.853 0.358 . . . . 0.0 110.941 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.453 HG22 ' HA ' ' A' ' 78' ' ' VAL . 6.1 t -66.58 -48.56 69.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.947 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.425 ' N ' HG23 ' A' ' 60' ' ' THR . 18.4 t70 60.36 23.77 13.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.203 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.427 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 103.81 -31.96 8.09 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.671 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -103.7 133.73 46.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.861 0.362 . . . . 0.0 111.199 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -118.95 109.98 16.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.879 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 60.21 28.11 17.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.956 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.37 23.82 25.72 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.596 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 5.6 tttm -132.3 109.95 10.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.861 0.363 . . . . 0.0 110.88 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 11.9 tp60 -69.72 95.56 0.89 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 83.0 mt -82.32 -37.53 25.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.92 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.427 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.5 p90 -149.0 165.45 31.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -98.25 128.36 44.66 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.907 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.39 164.51 32.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.781 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.89 174.24 9.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -62.84 113.17 2.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.888 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 60.33 54.63 3.85 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.858 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 68.7 m -129.57 -56.47 1.14 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.441 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -59.57 140.28 48.08 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.511 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.453 ' HA ' HG22 ' A' ' 60' ' ' THR . 6.0 m -156.61 127.84 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.754 0.311 . . . . 0.0 111.157 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -90.4 130.31 36.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.848 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.526 HG11 ' CG1' ' A' ' 16' ' ' VAL . 6.1 m -150.41 164.86 2.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.181 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.87 157.4 22.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.128 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.505 HD12 HD12 ' A' ' 8' ' ' ILE . 11.3 tp -50.39 -44.21 54.81 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.848 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -57.39 -28.75 63.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.571 179.698 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.448 ' HE3' HG12 ' A' ' 80' ' ' VAL . 5.2 mtmt -81.4 -26.67 35.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.813 179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.802 HD23 HG22 ' A' ' 16' ' ' VAL . 83.8 mt -85.42 146.16 27.11 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.891 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -133.35 107.89 8.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.925 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 12.4 tp -60.07 121.65 12.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.92 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 1.9 mp . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.162 179.864 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.438 HG21 HG11 ' A' ' 14' ' ' VAL . 11.3 mt . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.799 0.333 . . . . 0.0 111.051 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -150.72 -177.83 6.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.402 ' HA ' HG12 ' A' ' 29' ' ' VAL . 40.3 t -59.71 127.66 19.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.027 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 84.89 43.59 6.7 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.478 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.675 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -139.51 139.32 22.12 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.66 0.267 . . . . 0.0 110.923 -179.897 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.544 ' HB2' HD12 ' A' ' 88' ' ' ILE . 75.3 Cg_endo -77.38 117.38 4.33 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.516 2.144 . . . . 0.0 112.427 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.472 HG12 ' HA ' ' A' ' 87' ' ' LEU . 13.7 m -145.67 138.52 20.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.075 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.414 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 13.3 mttm -84.16 141.19 31.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.072 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.677 HG22 HD23 ' A' ' 85' ' ' LEU . 21.9 t -117.29 134.84 59.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.067 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -92.79 110.1 21.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.946 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.425 HD12 ' CE2' ' A' ' 25' ' ' PHE . 71.2 mt -81.5 -47.05 13.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.801 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.53 145.8 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.957 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 30.2 t -74.57 86.75 2.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.958 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.83 67.8 1.44 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.437 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -149.46 -58.46 0.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.833 0.349 . . . . 0.0 110.984 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -175.97 164.09 2.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 40.6 mttt -117.11 160.36 21.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.896 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.44 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 56.6 m-85 -126.4 121.92 23.77 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.822 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.414 ' HA ' ' HA ' ' A' ' 15' ' ' LYS . 38.3 Cg_endo -66.04 140.6 60.66 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.513 2.142 . . . . 0.0 112.4 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.9 158.0 28.99 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.403 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.9 p -99.46 129.21 50.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.868 0.365 . . . . 0.0 111.098 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.675 HG23 ' O ' ' A' ' 12' ' ' CYS . 19.5 t -65.4 132.65 31.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.097 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.411 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 4.5 mmm180 -116.05 -35.55 4.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.006 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -146.37 169.45 18.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.931 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.426 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 9.6 ttt180 -157.54 120.76 4.01 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.879 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -178.86 146.94 7.53 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.492 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo . . . . . 0 C--N 1.344 0.326 0 C-N-CA 122.603 2.202 . . . . 0.0 112.252 -179.896 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.0 mt . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.758 0.313 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.439 ' HB3' ' CD1' ' A' ' 79' ' ' PHE . 82.8 m-85 -104.67 144.79 31.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.912 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.543 ' CB ' HD11 ' A' ' 85' ' ' LEU . 6.2 m-85 -119.46 109.93 16.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.87 119.86 8.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.58 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.4 t -132.03 133.09 61.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.869 0.366 . . . . 0.0 111.189 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -87.71 116.61 25.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.44 HD13 ' O ' ' A' ' 54' ' ' GLY . 94.5 mt -60.18 130.41 46.52 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.952 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 mt -78.82 -179.93 6.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.767 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.24 -30.06 48.96 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.057 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -61.43 -41.54 97.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.873 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.44 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -127.5 34.04 3.13 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.445 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 mtt180 -72.88 138.26 46.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.799 0.333 . . . . 0.0 110.868 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.42 29.52 8.79 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.513 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -141.51 43.42 1.75 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.792 0.33 . . . . 0.0 110.898 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -113.18 150.18 18.5 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.525 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 5.6 p90 -110.06 -51.22 2.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.78 0.324 . . . . 0.0 110.879 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.445 HG23 ' N ' ' A' ' 61' ' ' ASP . 9.3 t -69.72 -48.32 59.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.835 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.445 ' N ' HG23 ' A' ' 60' ' ' THR . 8.6 m-20 53.91 36.22 23.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.09 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.422 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 97.97 -26.15 24.6 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.555 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.472 HG23 ' C ' ' A' ' 67' ' ' LYS . 12.0 p -118.51 137.23 53.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.809 0.337 . . . . 0.0 111.104 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 3.1 t80 -122.68 111.13 16.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.945 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 62.18 27.15 16.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.037 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 103.04 -28.43 15.85 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.526 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.472 ' C ' HG23 ' A' ' 63' ' ' VAL . 0.5 OUTLIER -79.44 116.63 19.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.871 0.367 . . . . 0.0 110.956 179.998 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 21.7 tp60 -80.31 99.5 7.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.42 HD12 ' HE2' ' A' ' 79' ' ' PHE . 88.0 mt -79.21 -44.93 20.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.853 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.422 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.8 p90 -146.81 176.45 9.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.93 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 2.5 mm-40 -99.37 128.6 45.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -152.05 165.59 34.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -80.66 171.94 14.38 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 -68.9 126.21 29.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 59.02 43.79 17.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 37.5 m -129.87 -60.84 1.02 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -58.6 135.66 51.74 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.535 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 48' ' ' VAL . 22.1 m -148.05 141.28 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.788 0.328 . . . . 0.0 111.131 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.439 ' CD1' ' HB3' ' A' ' 45' ' ' PHE . 3.0 m-85 -104.99 126.82 52.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.842 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.671 HG11 ' CG1' ' A' ' 16' ' ' VAL . 28.9 m -150.22 164.24 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.105 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.26 158.04 29.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.113 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.406 HD12 HD12 ' A' ' 8' ' ' ILE . 8.6 tp -50.68 -44.41 57.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.867 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -57.42 -29.27 63.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.591 179.668 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.26 -26.03 42.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.763 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.677 HD23 HG22 ' A' ' 16' ' ' VAL . 89.0 mt -82.19 125.04 30.45 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.954 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 5.2 tm-20 -112.05 107.48 16.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.472 ' HA ' HG12 ' A' ' 14' ' ' VAL . 31.6 tp -60.36 131.19 50.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.906 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.544 HD12 ' HB2' ' A' ' 13' ' ' PRO . 4.9 mt . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.109 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.53 HG12 HD13 ' A' ' 87' ' ' LEU . 30.8 mt . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.82 0.343 . . . . 0.0 111.115 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -144.58 -172.52 3.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.812 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 30' ' ' ARG . 33.9 t -65.42 144.49 14.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.152 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 68.88 49.11 44.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.506 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.608 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.89 139.91 15.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 120.662 0.268 . . . . 0.0 111.002 179.899 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.09 126.7 8.8 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.544 2.163 . . . . 0.0 112.293 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.413 HG21 HD22 ' A' ' 85' ' ' LEU . 13.3 m -154.04 138.27 9.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.153 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.408 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 39.3 mttt -88.32 138.11 31.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.005 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.777 HG22 HD23 ' A' ' 85' ' ' LEU . 26.2 t -117.35 141.57 35.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.997 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.0 tt0 -103.11 110.03 21.82 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.881 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.1 mt -80.78 -51.07 9.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.02 -169.84 1.72 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.9 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -104.75 87.09 2.59 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.865 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 67.96 56.6 10.38 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.452 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.03 -52.86 1.75 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.36 . . . . 0.0 110.935 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -176.06 139.89 0.39 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.913 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -100.96 122.79 44.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.91 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.44 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 46.6 m-85 -87.67 129.84 49.29 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.821 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.412 ' HB2' HD12 ' A' ' 51' ' ' LEU . 63.0 Cg_endo -73.0 141.02 32.34 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.503 2.135 . . . . 0.0 112.301 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.47 150.22 20.09 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.51 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.628 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.7 p -93.78 133.75 33.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.836 0.35 . . . . 0.0 111.085 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 47' ' ' GLY . 15.8 t -67.96 136.23 26.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.11 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.628 ' HD3' HG13 ' A' ' 28' ' ' VAL . 1.7 mmm180 -118.86 -38.75 3.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.984 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -139.88 165.98 25.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.408 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 36.9 ttp85 -160.49 127.55 4.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.33 146.56 4.67 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.45 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo . . . . . 0 C--N 1.345 0.356 0 C-N-CA 122.504 2.136 . . . . 0.0 112.325 179.967 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.5 mt . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.835 0.35 . . . . 0.0 111.191 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -119.44 139.96 51.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.494 ' CB ' HD11 ' A' ' 85' ' ' LEU . 6.5 m-85 -118.56 109.95 16.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.92 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.635 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -69.09 140.9 34.96 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.557 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.426 HG21 ' CD2' ' A' ' 85' ' ' LEU . 21.9 t -152.37 134.64 6.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.844 0.355 . . . . 0.0 111.109 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -92.62 116.34 28.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.435 HD13 ' O ' ' A' ' 54' ' ' GLY . 74.7 mt -60.03 136.55 58.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.986 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.412 HD12 ' HB2' ' A' ' 26' ' ' PRO . 0.9 OUTLIER -81.08 -179.94 7.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.902 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -53.8 -30.04 43.19 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.141 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -62.26 -47.48 84.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.847 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.44 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -120.12 35.76 3.67 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.444 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -76.88 133.84 39.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.774 0.321 . . . . 0.0 110.898 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.28 30.26 6.71 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.586 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -140.68 38.84 1.84 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 0.0 110.936 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.57 150.31 17.17 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.456 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 10.5 p90 -109.35 -45.73 3.67 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.747 0.308 . . . . 0.0 110.852 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.595 HG22 ' HA ' ' A' ' 78' ' ' VAL . 8.8 t -71.0 -48.45 53.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.927 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.43 ' N ' HG23 ' A' ' 60' ' ' THR . 14.6 m-20 56.05 28.6 13.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.126 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.15 -24.88 28.14 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.702 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -117.59 129.95 73.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.865 0.364 . . . . 0.0 111.151 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 62.4 t80 -114.95 110.01 18.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.946 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 59.37 24.71 13.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.113 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.13 23.66 16.74 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.558 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -125.37 109.81 13.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.89 0.376 . . . . 0.0 110.812 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 17.5 tp60 -71.47 95.25 1.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.906 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.404 HD12 ' HE2' ' A' ' 79' ' ' PHE . 44.1 mt -84.5 -38.09 20.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CD1' ' N ' ' A' ' 70' ' ' PHE . 3.0 p90 -152.25 171.54 17.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.843 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -101.01 112.63 25.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -137.85 170.07 16.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.913 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -78.96 172.3 13.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.925 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -72.14 123.4 22.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.922 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 60.34 37.91 19.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.885 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 34.7 m -121.46 -64.61 1.21 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.939 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.14 144.62 44.94 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.502 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.595 ' HA ' HG22 ' A' ' 60' ' ' THR . 15.3 m -152.41 142.78 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.347 . . . . 0.0 111.201 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.404 ' HE2' HD12 ' A' ' 69' ' ' LEU . 2.8 m-85 -104.24 119.52 39.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.837 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.453 HG11 HG11 ' A' ' 16' ' ' VAL . 27.1 m -142.77 163.59 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.239 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -76.31 161.27 28.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.241 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.494 HD12 HD12 ' A' ' 8' ' ' ILE . 13.6 tp -51.55 -47.46 63.41 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.912 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -56.5 -27.23 56.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.711 179.719 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -80.91 -5.26 57.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.232 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.777 HD23 HG22 ' A' ' 16' ' ' VAL . 43.8 mt -104.58 140.43 38.01 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.894 0.378 . . . . 0.0 111.032 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -122.02 110.16 15.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.802 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.53 HD13 HG12 ' A' ' 8' ' ' ILE . 7.9 tp -59.16 138.52 57.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.05 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 5.3 mt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.037 179.982 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.508 HD13 HG11 ' A' ' 14' ' ' VAL . 33.4 mt . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.782 0.325 . . . . 0.0 111.142 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -144.77 -177.58 5.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.931 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.405 HG13 ' C ' ' A' ' 30' ' ' ARG . 38.3 t -67.04 129.71 31.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.132 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 88.04 43.9 5.53 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.482 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.688 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.35 140.36 18.95 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.584 0.23 . . . . 0.0 110.893 179.986 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.652 ' HB2' HD12 ' A' ' 88' ' ' ILE . 71.9 Cg_endo -77.14 118.87 4.83 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.528 2.152 . . . . 0.0 112.366 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.508 HG11 HD13 ' A' ' 8' ' ' ILE . 4.5 m -141.8 138.92 31.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.135 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 0.1 OUTLIER -84.01 126.44 33.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.996 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.608 HG22 ' CD2' ' A' ' 85' ' ' LEU . 29.8 t -102.24 128.81 54.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.997 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -89.31 131.65 35.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.947 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -111.37 -56.84 2.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.812 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -67.65 171.3 6.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.932 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.2 m -72.71 78.4 1.11 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.923 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.17 62.24 6.42 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.535 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -122.44 -65.09 1.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.811 0.339 . . . . 0.0 110.84 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -143.39 162.51 35.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.891 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.5 mttt -127.03 113.06 15.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.887 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -76.89 127.72 83.21 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.823 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 15' ' ' LYS . 59.0 Cg_endo -71.32 149.99 58.0 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.452 2.102 . . . . 0.0 112.34 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.507 ' HA2' HD12 ' A' ' 51' ' ' LEU . . . -170.59 149.93 13.44 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.521 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.7 p -88.36 132.71 32.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.826 0.346 . . . . 0.0 111.072 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.688 HG23 ' O ' ' A' ' 12' ' ' CYS . 28.4 t -67.96 132.2 32.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.018 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.405 ' C ' HG13 ' A' ' 10' ' ' VAL . 1.0 OUTLIER -114.59 -37.0 4.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.959 179.975 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -136.93 166.74 22.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.934 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -164.36 120.34 1.55 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.882 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.54 154.04 7.56 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.51 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo . . . . . 0 C--N 1.343 0.262 0 C-N-CA 122.616 2.211 . . . . 0.0 112.328 -179.999 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.409 HG22 ' N ' ' A' ' 45' ' ' PHE . 25.2 mt . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 120.834 0.35 . . . . 0.0 111.139 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.409 ' N ' HG22 ' A' ' 44' ' ' ILE . 85.9 m-85 -124.24 142.59 51.12 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.858 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.622 ' CB ' HD11 ' A' ' 85' ' ' LEU . 10.4 m-85 -123.92 111.05 15.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.848 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -75.76 117.73 5.24 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.438 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.567 HG22 HG22 ' A' ' 29' ' ' VAL . 21.3 t -130.31 127.22 62.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.811 0.339 . . . . 0.0 111.132 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -84.14 118.84 24.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.913 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 18.8 mt -58.93 139.26 56.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.095 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.507 HD12 ' HA2' ' A' ' 27' ' ' GLY . 0.0 OUTLIER -84.52 -179.84 7.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.827 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -50.63 -28.8 9.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.188 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.04 -61.56 2.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.854 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -108.58 29.0 10.44 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.459 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt180 -64.76 126.3 27.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.855 0.359 . . . . 0.0 110.933 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.8 36.26 4.31 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.485 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -141.08 32.57 1.75 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.835 0.35 . . . . 0.0 110.924 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -92.47 150.56 20.17 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.485 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -110.04 -33.63 6.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.739 0.304 . . . . 0.0 110.945 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.7 t -83.34 -44.36 14.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.941 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.0 t0 54.93 30.21 13.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.069 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.41 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.44 -28.02 14.92 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.438 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.456 HG13 ' O ' ' A' ' 63' ' ' VAL . 11.0 p -115.09 122.99 70.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.749 0.309 . . . . 0.0 111.107 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -108.1 114.11 27.77 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.941 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 43.0 mt-30 59.55 26.08 15.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.057 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.08 24.94 23.48 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.601 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -134.15 109.92 9.23 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.866 0.365 . . . . 0.0 110.89 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -67.3 121.28 15.37 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.876 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 95.3 mt -108.89 -32.38 7.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.41 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -156.71 170.48 22.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.838 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.66 116.93 32.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.803 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 5.0 p -139.55 175.31 9.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.69 170.4 15.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.83 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -66.84 116.39 7.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.932 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 60.79 46.0 9.34 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 65.7 m -125.56 -45.93 1.77 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.896 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -68.85 139.75 33.47 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.541 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.538 HG22 ' O ' ' A' ' 48' ' ' VAL . 6.3 m -150.56 131.5 4.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.789 0.328 . . . . 0.0 111.175 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 14.1 m-85 -99.99 119.93 39.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.835 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.568 HG21 HG13 ' A' ' 16' ' ' VAL . 29.1 m -142.2 168.77 14.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.124 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -81.56 159.69 24.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.194 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 6.3 tp -50.06 -43.18 51.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.894 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -57.02 -28.06 62.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.595 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -81.79 -27.07 33.89 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.792 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.622 HD11 ' CB ' ' A' ' 46' ' ' PHE . 91.1 mt -88.7 142.41 27.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.922 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -133.43 112.93 11.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.885 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.45 140.09 56.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.652 HD12 ' HB2' ' A' ' 13' ' ' PRO . 6.2 mt . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.063 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.49 HD12 HD12 ' A' ' 82' ' ' LEU . 22.5 mt . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.864 0.364 . . . . 0.0 111.138 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -133.55 -169.27 2.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.846 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 26.1 t -74.28 135.4 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.063 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.32 45.9 7.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.509 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.555 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -143.26 136.84 14.21 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 120.561 0.22 . . . . 0.0 110.927 -179.974 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.526 ' HB2' HD12 ' A' ' 88' ' ' ILE . 70.5 Cg_endo -74.58 118.4 5.31 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.54 2.16 . . . . 0.0 112.327 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.629 HG12 ' HA ' ' A' ' 87' ' ' LEU . 17.9 m -145.66 138.46 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.15 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.0 mtpt -74.36 133.63 42.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.907 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 1.049 HG13 HG21 ' A' ' 80' ' ' VAL . 23.5 t -111.07 139.63 34.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.012 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -98.69 129.45 45.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.6 mt -100.1 -52.46 3.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.35 171.94 10.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 65.2 p -68.27 74.4 0.23 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.837 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.89 66.35 2.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.492 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.8 tt0 -124.79 -47.19 1.82 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.816 0.341 . . . . 0.0 110.921 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -167.27 132.75 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.836 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 4.9 mttt -104.06 129.41 51.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.96 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -96.33 135.05 22.74 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.781 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.603 ' HB2' HD12 ' A' ' 51' ' ' LEU . 58.8 Cg_endo -71.82 140.78 35.96 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.432 2.088 . . . . 0.0 112.328 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.85 146.47 10.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.506 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.2 p -85.1 143.06 12.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 111.025 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.555 HG23 ' O ' ' A' ' 12' ' ' CYS . 23.2 t -72.99 136.81 24.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.022 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -116.93 -32.45 5.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.21 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 30.8 t80 -150.39 167.84 25.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.8 0.333 . . . . 0.0 111.003 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CE2' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -153.38 125.51 7.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.923 179.924 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.62 158.0 18.31 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.473 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo . . . . . 0 C--N 1.344 0.325 0 C-N-CA 122.479 2.119 . . . . 0.0 112.301 -179.98 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.5 mt . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.838 0.351 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -103.24 174.01 6.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.947 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.705 ' CB ' HD11 ' A' ' 85' ' ' LEU . 28.6 m-85 -145.89 109.93 4.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.9 118.35 8.14 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.457 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.602 HG21 ' CD2' ' A' ' 85' ' ' LEU . 21.0 t -126.37 140.08 49.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.743 0.306 . . . . 0.0 111.069 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -99.19 114.47 27.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.866 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.501 HD13 ' HB2' ' A' ' 57' ' ' GLN . 34.4 mt -57.49 138.27 55.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.038 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.603 HD12 ' HB2' ' A' ' 26' ' ' PRO . 1.8 mt -80.41 -179.9 7.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.802 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -54.48 -29.96 51.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.046 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -61.14 -60.46 3.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.816 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -103.26 28.5 15.42 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.488 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -67.67 131.06 44.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 110.919 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.55 33.57 4.42 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.522 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.501 ' HB2' HD13 ' A' ' 50' ' ' LEU . 99.6 mm-40 -140.25 34.54 1.89 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.85 0.357 . . . . 0.0 110.916 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.1 146.52 16.09 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.49 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 32.3 p90 -109.88 -49.23 3.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.749 0.309 . . . . 0.0 110.912 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.423 HG23 ' N ' ' A' ' 61' ' ' ASP . 6.9 t -63.51 -48.49 77.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.898 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.423 ' N ' HG23 ' A' ' 60' ' ' THR . 9.1 m-20 55.38 29.96 14.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.083 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.417 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 98.35 -28.78 13.24 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.35 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -110.72 128.24 67.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.864 0.364 . . . . 0.0 111.102 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -116.29 112.02 20.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.946 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 58.95 26.93 15.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.103 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.93 21.35 33.64 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.564 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 3.4 tptp -126.46 109.82 12.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.834 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 18.4 tp60 -68.08 89.99 0.31 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.856 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 16.8 mt -78.16 -42.29 32.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.888 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.417 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.0 p90 -151.15 169.52 21.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.918 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.43 134.22 40.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.918 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -159.49 165.57 32.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -72.26 176.24 5.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.89 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -75.2 120.97 21.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 60.7 47.63 7.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.971 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 84.8 m -130.03 -58.8 1.07 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.851 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.3 139.63 48.54 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.616 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 27.3 m -151.54 125.68 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 111.049 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -89.45 127.86 35.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.952 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 1.049 HG21 HG13 ' A' ' 16' ' ' VAL . 31.0 m -148.65 157.89 7.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.079 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.02 156.99 38.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.101 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.49 HD12 HD12 ' A' ' 8' ' ' ILE . 6.6 tp -51.17 -46.55 62.13 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -56.88 -28.86 62.37 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.651 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 17.1 mmtt -77.78 -24.27 48.94 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.879 179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.705 HD11 ' CB ' ' A' ' 46' ' ' PHE . 62.1 mt -83.48 151.59 25.36 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.989 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -135.37 105.86 6.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.839 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.629 ' HA ' HG12 ' A' ' 14' ' ' VAL . 16.8 tp -61.09 133.8 56.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.975 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.526 HD12 ' HB2' ' A' ' 13' ' ' PRO . 28.0 mt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.12 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.625 ' CG2' HG11 ' A' ' 14' ' ' VAL . 19.7 mt . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.5 -176.94 3.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.903 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.3 t -66.43 138.69 22.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.018 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.65 38.63 13.7 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.552 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.621 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -135.12 139.4 31.73 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-O 120.658 0.266 . . . . 0.0 110.929 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.3 118.5 5.21 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.548 2.165 . . . . 0.0 112.304 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.625 HG11 ' CG2' ' A' ' 8' ' ' ILE . 16.4 m -144.76 138.5 22.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.209 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 35.6 mttt -77.87 126.33 30.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.934 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.733 HG13 HG21 ' A' ' 80' ' ' VAL . 26.3 t -105.46 137.68 34.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.049 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -99.06 112.24 24.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.915 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 88.4 mt -73.77 -58.4 3.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.95 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 8.0 ttt-85 -83.96 168.91 15.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.888 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.8 m -80.13 61.07 3.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.852 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 103.61 64.22 0.69 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.499 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -130.0 -66.4 0.79 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.782 0.325 . . . . 0.0 110.883 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -164.96 130.04 2.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.2 mttt -95.33 111.45 23.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.918 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.425 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 38.4 m-85 -86.56 138.87 33.56 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.759 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -68.79 148.85 72.11 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.496 2.13 . . . . 0.0 112.43 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.83 148.05 11.47 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.519 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.446 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.9 p -88.76 132.45 33.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.79 0.328 . . . . 0.0 111.142 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 12' ' ' CYS . 19.6 t -66.18 135.17 28.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.114 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.446 ' HD3' HG13 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -118.28 -36.09 3.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 -179.914 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -141.16 166.0 25.99 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.917 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.415 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 5.1 ttt180 -158.7 114.91 2.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.875 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.46 145.46 5.63 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.447 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.628 ' HD3' HG23 ' A' ' 44' ' ' ILE . 52.3 Cg_exo . . . . . 0 C--N 1.345 0.391 0 C-N-CA 122.527 2.152 . . . . 0.0 112.287 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.628 HG23 ' HD3' ' A' ' 34' ' ' PRO . 35.4 mt . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.761 0.315 . . . . 0.0 111.11 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 14.5 m-85 -91.08 144.97 25.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.843 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.415 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 6.4 m-85 -119.34 123.88 45.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.996 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.556 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -87.48 131.5 10.64 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.323 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.611 ' HB ' HG21 ' A' ' 16' ' ' VAL . 21.7 t -139.37 127.5 26.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.758 0.313 . . . . 0.0 111.209 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -85.89 116.66 24.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.764 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.429 HD13 ' O ' ' A' ' 54' ' ' GLY . 60.1 mt -55.98 140.32 43.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.19 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -87.55 -179.89 6.42 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.85 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -51.97 -29.71 21.74 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.207 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -60.24 -51.34 69.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.889 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.429 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -122.31 38.96 2.42 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.468 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.6 ttt180 -76.52 133.15 39.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.843 0.354 . . . . 0.0 110.931 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.57 23.36 8.9 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.681 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 -130.75 45.37 2.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.861 0.362 . . . . 0.0 110.818 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -107.86 148.45 16.62 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.576 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -110.05 -47.98 3.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.771 0.32 . . . . 0.0 110.908 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.4 t -65.29 -44.84 86.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.994 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.3 t0 57.28 30.6 18.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.061 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.43 -28.17 14.33 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.426 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.431 ' O ' HG13 ' A' ' 63' ' ' VAL . 11.8 p -113.47 125.02 70.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.819 0.342 . . . . 0.0 111.063 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 51.7 t80 -111.25 110.09 20.42 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 58.46 28.45 16.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.084 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.28 24.38 22.04 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.492 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.8 tptt -131.55 109.89 10.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.795 0.331 . . . . 0.0 110.805 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 15.3 tp60 -71.07 89.92 0.83 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.939 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 9.0 mt -75.24 -30.73 60.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.915 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -161.89 166.98 25.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -103.28 119.21 38.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.897 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 6.8 p -144.28 176.26 9.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.959 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -72.16 176.21 5.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.9 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -75.59 119.71 20.01 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 60.72 36.5 19.38 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.918 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 86.6 m -118.21 -38.98 3.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.952 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.55 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -79.09 146.87 29.77 Favored Glycine 0 N--CA 1.452 -0.233 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.473 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.55 HG13 ' O ' ' A' ' 77' ' ' GLY . 5.2 m -159.4 134.4 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.842 0.353 . . . . 0.0 111.072 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -96.71 138.9 33.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.874 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.733 HG21 HG13 ' A' ' 16' ' ' VAL . 29.1 m -156.19 166.46 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.122 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.29 164.65 17.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.203 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -52.15 -50.51 61.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.841 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -57.14 -28.28 62.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.643 179.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 12.3 mmtt -79.65 -25.11 41.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.835 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.597 ' CD2' HG22 ' A' ' 16' ' ' VAL . 62.6 mt -84.25 159.64 20.93 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.874 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -142.22 101.51 3.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.82 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.605 ' HA ' HG12 ' A' ' 14' ' ' VAL . 8.9 tp -59.9 143.39 51.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.983 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 22.4 mt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.101 179.944 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.183 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 m -135.0 64.97 1.58 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.924 0.392 . . . . 0.0 110.865 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 37.5 m -82.04 -31.47 30.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 131.02 43.14 0.19 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.536 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.3 m -127.06 -67.06 0.86 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.848 0.356 . . . . 0.0 110.982 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 18.6 m 60.17 -172.89 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.927 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 161.97 103.56 0.18 Allowed Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.521 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.448 HG22 HG21 ' A' ' 29' ' ' VAL . 19.4 mt -102.12 137.14 31.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.85 0.357 . . . . 0.0 111.048 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -140.0 179.58 6.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.3 t -60.3 129.18 22.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 86.28 43.93 6.08 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.476 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.629 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -144.21 137.04 13.66 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.635 0.255 . . . . 0.0 110.929 -179.902 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.22 132.31 12.47 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.466 2.111 . . . . 0.0 112.324 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.549 HG12 ' HA ' ' A' ' 87' ' ' LEU . 13.7 m -155.55 145.79 12.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.211 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.534 ' CG ' HD11 ' A' ' 88' ' ' ILE . 59.4 mttt -81.34 127.43 32.73 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.89 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.994 HG13 HG21 ' A' ' 80' ' ' VAL . 21.2 t -109.98 131.03 62.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.08 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -97.02 113.62 25.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.881 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 58.7 mt -82.03 -44.27 16.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.91 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -98.33 179.29 4.78 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.931 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.8 m -82.4 87.77 6.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.922 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.43 54.91 30.66 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.54 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -115.37 -50.01 2.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.929 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 17.5 tt0 -176.62 126.87 0.18 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.1 mttt -96.03 116.68 29.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.826 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.433 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 30.0 m-85 -86.92 131.48 44.87 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -73.42 145.52 38.23 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.478 2.119 . . . . 0.0 112.265 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.3 154.59 24.59 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.605 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.485 HG13 ' HD3' ' A' ' 30' ' ' ARG . 12.3 p -91.65 135.53 26.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.798 0.333 . . . . 0.0 111.0 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 12' ' ' CYS . 21.0 t -65.17 132.26 30.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.196 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.485 ' HD3' HG13 ' A' ' 28' ' ' VAL . 0.8 OUTLIER -113.5 -30.13 6.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.045 179.988 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -152.8 168.35 26.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.878 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.413 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 16.2 ttt-85 -155.81 123.95 5.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.847 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.64 142.47 3.71 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.465 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -56.67 -173.16 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.492 2.128 . . . . 0.0 112.252 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.502 HD13 ' CZ ' ' A' ' 64' ' ' TYR . 96.2 mt -148.57 -61.29 0.24 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 9.8 mp -83.16 -178.41 7.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.89 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -152.06 92.5 1.72 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.132 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 59.32 33.06 22.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.973 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 3.1 mtm180 -103.85 -31.46 9.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.839 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 37.4 m -141.09 -61.49 0.48 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.903 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.0 p -156.46 138.96 6.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.095 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 13.9 m -80.73 94.64 6.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -148.99 134.93 5.18 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.567 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.1 mt -75.49 130.23 36.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.793 0.33 . . . . 0.0 111.053 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -86.47 136.1 33.22 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.526 ' CB ' HD11 ' A' ' 85' ' ' LEU . 10.8 m-85 -115.66 111.89 21.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.95 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -71.47 119.64 7.87 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.382 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.626 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.8 t -129.86 136.69 58.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.77 0.319 . . . . 0.0 110.978 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -92.34 119.1 31.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.576 HD13 ' HB2' ' A' ' 57' ' ' GLN . 19.5 mt -59.07 133.91 56.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.981 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.7 -179.9 7.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.816 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.7 -29.52 39.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.062 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -63.35 -55.01 28.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.831 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.433 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -110.87 32.24 6.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.413 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 8.3 ttt180 -68.72 135.6 51.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 110.98 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 94.02 37.35 5.46 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.576 ' HB2' HD13 ' A' ' 50' ' ' LEU . 64.0 mm-40 -140.89 33.25 1.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.843 0.354 . . . . 0.0 110.948 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -102.51 145.74 16.56 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.48 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 7.6 p90 -109.94 -50.58 2.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.322 . . . . 0.0 110.972 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.5 t -62.77 -41.84 99.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.911 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 11.4 t70 60.02 30.45 19.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.988 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.413 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 94.26 -17.3 59.18 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.753 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.9 p -119.15 138.8 48.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.828 0.347 . . . . 0.0 111.18 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.502 ' CZ ' HD13 ' A' ' 35' ' ' LEU . 7.1 t80 -130.14 110.05 11.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.814 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 61.77 28.66 17.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.955 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 100.01 -27.78 18.7 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.568 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -80.27 114.65 19.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.789 0.328 . . . . 0.0 111.018 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 28.6 tp60 -81.36 92.11 6.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.903 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.57 HD12 ' CE2' ' A' ' 79' ' ' PHE . 48.1 mt -70.46 -46.61 63.48 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.972 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.413 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.5 p90 -144.24 168.96 18.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.945 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.85 130.1 55.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.892 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 1.2 m -149.93 172.06 15.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.905 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -68.78 -179.98 1.6 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.906 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -71.65 121.14 18.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.944 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 60.81 51.57 4.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.878 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 27.4 m -130.1 -46.75 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.994 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.419 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -67.17 141.71 39.92 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.612 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.626 HG22 ' O ' ' A' ' 48' ' ' VAL . 20.7 m -156.99 141.14 7.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.361 . . . . 0.0 111.112 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 69' ' ' LEU . 5.7 m-85 -110.42 134.14 52.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.994 HG21 HG13 ' A' ' 16' ' ' VAL . 18.4 m -156.9 156.6 4.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.083 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.53 154.34 42.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.062 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.416 ' CD1' HD12 ' A' ' 8' ' ' ILE . 6.5 tp -50.37 -43.86 54.47 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.917 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -56.57 -28.0 59.22 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.576 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.7 mttm -79.61 -27.11 41.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.787 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.715 ' CD2' HG22 ' A' ' 16' ' ' VAL . 92.6 mt -80.73 152.45 28.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.904 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -124.91 108.37 11.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.855 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.549 ' HA ' HG12 ' A' ' 14' ' ' VAL . 20.1 tp -59.88 124.31 19.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.534 HD11 ' CG ' ' A' ' 15' ' ' LYS . 31.1 mt -112.05 138.61 40.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.112 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -65.73 141.46 58.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.895 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 9.4 t -98.4 35.45 1.79 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.866 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -139.53 66.13 0.52 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.541 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.27 -41.68 64.64 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.573 2.182 . . . . 0.0 112.28 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 81.0 p -102.59 117.91 35.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.853 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 82.2 p -148.95 127.47 12.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.947 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.34 -1.255 . . . . 0.0 112.511 -179.992 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.235 0 N-CA-C 112.529 -0.228 . . . . 0.0 112.529 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -140.97 157.07 45.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.858 0.361 . . . . 0.0 110.859 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.2 100.98 0.66 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.929 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 105.33 159.13 23.1 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.496 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.6 m -160.84 145.13 13.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.77 0.319 . . . . 0.0 110.895 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.5 m -79.33 -77.62 0.17 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.894 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 112.85 103.74 2.65 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.457 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.649 HD12 HD12 ' A' ' 82' ' ' LEU . 27.0 mt -87.07 145.89 7.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.814 0.34 . . . . 0.0 111.099 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -155.16 -177.8 6.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.826 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.511 ' HA ' HG12 ' A' ' 29' ' ' VAL . 37.7 t -61.7 124.23 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.085 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.14 42.34 5.3 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.437 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.635 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -138.95 138.81 21.88 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.623 0.249 . . . . 0.0 110.95 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.895 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.6 Cg_endo -77.37 117.56 4.38 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.502 2.134 . . . . 0.0 112.398 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.487 HG12 ' HA ' ' A' ' 87' ' ' LEU . 16.0 m -146.8 138.47 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.117 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.44 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 26.9 mttm -81.37 156.88 25.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.992 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.661 HG13 HG21 ' A' ' 80' ' ' VAL . 21.2 t -133.3 127.23 53.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.041 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -88.49 124.06 33.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.878 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 40.2 mt -102.92 -40.13 6.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -85.59 179.88 7.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.812 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 64.7 m -95.61 79.83 3.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 73.12 49.87 14.65 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.525 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -116.73 -69.51 0.85 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.757 0.313 . . . . 0.0 110.867 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -161.93 138.3 7.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.867 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 13.2 mttt -95.67 146.13 24.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.94 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -106.0 127.74 27.78 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.788 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.601 ' HB2' HD12 ' A' ' 51' ' ' LEU . 57.0 Cg_endo -70.28 137.84 34.83 Favored 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.461 2.107 . . . . 0.0 112.348 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.92 174.96 29.24 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.512 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.414 HG13 ' O ' ' A' ' 28' ' ' VAL . 10.3 p -120.38 125.66 74.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.827 0.346 . . . . 0.0 111.017 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.635 HG23 ' O ' ' A' ' 12' ' ' CYS . 18.4 t -59.27 123.55 11.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.164 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.5 mmt180 -112.07 -31.91 6.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.889 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -144.62 166.26 25.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.428 ' HD3' ' CE2' ' A' ' 46' ' ' PHE . 38.5 ttp85 -156.77 124.3 5.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.842 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 166.6 145.17 4.36 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.419 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.497 ' HD3' HG23 ' A' ' 44' ' ' ILE . 50.6 Cg_exo -53.72 -176.98 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.511 2.14 . . . . 0.0 112.356 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.463 HD21 ' CE2' ' A' ' 64' ' ' TYR . 19.4 mt -95.73 -63.58 1.14 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.838 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -90.49 -174.8 4.25 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.774 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -121.32 31.32 6.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.083 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 53.5 mm-40 -80.45 157.27 26.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.933 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 18.0 mtt180 -66.75 -31.83 72.73 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.86 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.8 t -103.5 117.35 34.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.91 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.484 HG22 ' H ' ' A' ' 43' ' ' GLY . 11.0 p -131.38 145.75 34.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.044 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.8 p -74.53 -38.63 62.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.81 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.484 ' H ' HG22 ' A' ' 41' ' ' VAL . . . -179.99 173.07 44.66 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.478 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.497 HG23 ' HD3' ' A' ' 34' ' ' PRO . 13.8 mm -87.17 148.8 4.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.834 0.349 . . . . 0.0 111.076 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -104.36 121.35 43.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.48 ' HB2' HD11 ' A' ' 85' ' ' LEU . 13.6 m-85 -101.55 119.11 38.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.964 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.402 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -83.85 117.74 4.52 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.428 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.498 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -122.84 131.99 72.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.808 0.337 . . . . 0.0 111.092 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -85.18 117.73 24.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.885 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 14.0 mt -60.24 134.87 57.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.937 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.601 HD12 ' HB2' ' A' ' 26' ' ' PRO . 16.5 mt -80.01 -179.96 7.28 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.863 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -54.36 -29.66 49.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.05 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -60.36 -51.33 69.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.855 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -117.95 35.39 4.08 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.378 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -73.59 145.86 45.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 0.0 110.901 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.4 27.99 28.7 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.466 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -134.17 31.04 3.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.842 0.354 . . . . 0.0 110.89 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.17 149.81 18.46 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.519 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 13.4 p90 -109.94 -49.88 3.04 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.737 0.303 . . . . 0.0 110.928 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.419 HG23 ' N ' ' A' ' 61' ' ' ASP . 6.0 t -62.21 -48.25 80.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.856 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.419 ' N ' HG23 ' A' ' 60' ' ' THR . 11.7 m-20 58.17 37.04 26.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.97 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.42 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.94 -24.09 32.72 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.512 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.8 p -119.43 132.03 70.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.786 0.327 . . . . 0.0 111.132 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.463 ' CE2' HD21 ' A' ' 35' ' ' LEU . 0.3 OUTLIER -118.55 113.62 21.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.815 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 60.08 28.7 18.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.976 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.07 -24.08 32.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.571 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.95 114.07 21.43 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.821 0.343 . . . . 0.0 110.989 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 6.9 tp60 -78.47 116.42 18.86 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.855 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.462 HD12 ' CE2' ' A' ' 79' ' ' PHE . 72.1 mt -98.92 -37.71 9.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.879 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.42 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 1.8 p90 -154.41 172.68 17.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.93 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -105.29 111.44 24.17 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.001 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.44 167.88 15.65 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.907 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.8 175.27 3.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.911 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -72.53 117.89 14.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.924 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 60.83 49.5 6.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.841 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 28.5 m -130.0 -49.97 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.912 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.414 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -67.06 146.23 47.66 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.531 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.498 HG22 ' O ' ' A' ' 48' ' ' VAL . 25.8 m -156.78 142.23 9.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.778 0.323 . . . . 0.0 111.179 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.462 ' CE2' HD12 ' A' ' 69' ' ' LEU . 14.8 m-85 -109.89 131.89 54.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.917 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.661 HG21 HG13 ' A' ' 16' ' ' VAL . 30.6 m -152.61 158.05 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.112 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.94 156.61 38.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.132 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.649 HD12 HD12 ' A' ' 8' ' ' ILE . 12.9 tp -51.15 -45.41 61.68 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.87 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -57.07 -28.22 62.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.638 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -81.17 -27.02 35.58 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.865 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.624 ' CD2' HG22 ' A' ' 16' ' ' VAL . 84.9 mt -84.11 130.28 34.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.902 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 57.0 tt0 -113.78 114.01 25.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.899 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.487 ' HA ' HG12 ' A' ' 14' ' ' VAL . 8.5 tp -63.48 142.68 58.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.893 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.895 HD12 ' HB2' ' A' ' 13' ' ' PRO . 20.6 mt -95.51 146.82 6.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.094 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -112.63 159.42 18.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.8 t 56.28 96.38 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.961 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -77.55 163.83 51.77 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.467 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.27 -61.47 0.5 Allowed 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.596 2.198 . . . . 0.0 112.325 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.2 m -98.89 88.5 4.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.931 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.4 p -129.94 131.96 46.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.923 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.399 -1.223 . . . . 0.0 112.48 -179.992 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.201 0 N-CA-C 112.527 -0.229 . . . . 0.0 112.527 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 m -84.57 -32.36 23.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.749 0.309 . . . . 0.0 110.827 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 33.7 t -143.79 157.86 44.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.932 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -111.65 -156.46 13.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.519 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.9 m -147.98 145.43 28.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.775 0.321 . . . . 0.0 110.95 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.8 m -117.76 -171.35 2.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.956 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.97 114.64 1.12 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.429 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.763 HD12 HD12 ' A' ' 82' ' ' LEU . 5.2 mt -122.09 138.84 50.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.767 0.318 . . . . 0.0 111.04 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -131.78 -177.94 4.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.927 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.9 t -67.53 135.67 28.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.141 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.38 46.25 7.57 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.451 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.637 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.09 145.75 28.23 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 120.757 0.313 . . . . 0.0 110.962 -179.989 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.489 ' O ' HG13 ' A' ' 14' ' ' VAL . 74.2 Cg_endo -75.09 130.02 12.79 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.579 2.186 . . . . 0.0 112.269 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.598 HG11 HG21 ' A' ' 8' ' ' ILE . 11.8 m -158.02 138.51 4.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.14 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 47.1 mttm -79.23 140.45 37.65 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.05 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.758 HG13 HG21 ' A' ' 80' ' ' VAL . 18.4 t -115.91 135.87 54.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.062 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -97.25 110.07 22.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.857 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 83.0 mt -84.99 -56.26 3.65 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.97 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -75.06 171.99 13.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.944 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.4 m -78.01 80.26 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.885 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.62 55.49 26.84 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -120.45 -58.16 1.86 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 110.838 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -154.08 151.92 29.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.818 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -121.49 135.8 55.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.442 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 37.8 m-85 -106.11 136.49 19.32 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.838 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.545 ' HB2' HD12 ' A' ' 51' ' ' LEU . 63.1 Cg_endo -73.09 143.22 35.64 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.438 2.092 . . . . 0.0 112.431 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.98 156.58 27.98 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.526 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.2 p -95.52 126.52 48.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.771 0.32 . . . . 0.0 111.044 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.637 HG23 ' O ' ' A' ' 12' ' ' CYS . 18.6 t -59.87 135.84 24.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.119 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -119.46 -38.41 3.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.01 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.427 ' CE2' HD22 ' A' ' 69' ' ' LEU . 23.4 t80 -140.82 169.09 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.889 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.416 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 3.5 ttt180 -160.94 124.34 3.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.905 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 165.54 144.97 4.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.478 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -73.34 177.68 7.59 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.537 2.158 . . . . 0.0 112.349 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.444 HD13 ' CE1' ' A' ' 64' ' ' TYR . 60.9 mt -124.1 -66.52 0.98 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.838 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -169.47 -178.08 2.98 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.831 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -93.03 178.51 5.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.055 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -137.03 -70.28 0.45 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.904 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.5 mmt85 -145.45 -46.83 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.978 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.6 m -161.07 35.42 0.14 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.926 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 12.2 p -130.37 135.99 59.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.054 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.3 t -141.02 116.12 9.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.951 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -157.43 157.95 28.56 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.527 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.5 mt -94.37 136.65 25.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.763 0.316 . . . . 0.0 111.077 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -90.37 128.57 36.51 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.921 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.447 ' HB3' HD11 ' A' ' 85' ' ' LEU . 4.8 m-85 -111.74 109.9 19.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.875 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.46 122.68 11.01 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.344 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.624 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.9 t -137.9 130.94 41.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.805 0.336 . . . . 0.0 111.092 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -86.39 121.02 28.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.857 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.52 HD13 ' HB2' ' A' ' 57' ' ' GLN . 30.9 mt -60.45 141.27 56.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.049 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.545 HD12 ' HB2' ' A' ' 26' ' ' PRO . 13.3 mt -88.77 -179.88 6.08 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.83 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.06 -27.24 43.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.18 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -64.92 -41.57 95.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.966 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.442 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -132.13 38.67 1.86 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.47 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -74.31 161.33 29.99 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.851 0.358 . . . . 0.0 110.859 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 71.0 29.82 68.56 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.52 ' HB2' HD13 ' A' ' 50' ' ' LEU . 3.5 mm100 -135.86 34.14 2.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.816 0.341 . . . . 0.0 110.927 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.4 147.67 16.86 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.499 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -109.85 -47.78 3.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.813 0.34 . . . . 0.0 110.813 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.571 HG22 ' HA ' ' A' ' 78' ' ' VAL . 5.4 t -62.2 -47.93 82.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.943 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.414 ' N ' HG23 ' A' ' 60' ' ' THR . 0.7 OUTLIER 59.76 32.53 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.964 179.848 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.428 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.1 -24.82 28.32 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.564 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.7 p -120.85 133.28 68.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.864 0.364 . . . . 0.0 111.133 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.444 ' CE1' HD13 ' A' ' 35' ' ' LEU . 12.5 t80 -116.88 110.4 18.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.852 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 13.3 mt-30 60.45 31.01 20.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 98.04 -26.61 22.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.55 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.9 tptm -75.15 110.72 9.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.797 0.332 . . . . 0.0 110.904 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 24.2 tp60 -79.83 95.24 5.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.835 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.61 HD12 ' CE2' ' A' ' 79' ' ' PHE . 75.4 mt -81.65 -36.56 28.69 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.989 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.428 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.7 p90 -156.38 166.94 31.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.957 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -102.4 116.08 31.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.909 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -132.27 176.34 8.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.914 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -79.39 -179.94 7.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -77.69 121.35 23.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.901 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 59.7 48.04 9.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.005 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 26.6 m -129.93 -58.34 1.08 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.902 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.48 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -62.71 149.6 48.82 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.419 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.624 HG22 ' O ' ' A' ' 48' ' ' VAL . 15.3 m -158.0 146.54 9.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.873 0.368 . . . . 0.0 111.15 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.61 ' CE2' HD12 ' A' ' 69' ' ' LEU . 9.7 m-85 -108.95 131.8 54.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.758 HG21 HG13 ' A' ' 16' ' ' VAL . 13.2 m -151.01 160.35 3.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.073 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.416 ' HB3' ' HG3' ' A' ' 84' ' ' LYS . . . -75.86 153.46 36.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.054 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.763 HD12 HD12 ' A' ' 8' ' ' ILE . 11.0 tp -49.73 -44.3 48.32 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.904 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.9 t0 -58.27 -30.96 66.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.602 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.416 ' HG3' ' HB3' ' A' ' 81' ' ' ALA . 9.6 mtmt -78.08 -25.3 47.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.837 179.651 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.447 HD11 ' HB3' ' A' ' 46' ' ' PHE . 32.9 mt -81.7 130.87 35.21 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.14 105.21 14.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.963 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 27.3 tp -62.14 139.59 58.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.898 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.467 HD12 ' HB2' ' A' ' 13' ' ' PRO . 16.0 mt -102.26 128.04 55.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.074 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -120.96 -176.34 3.24 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.892 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 60.3 p -78.9 -34.32 44.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.873 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -67.24 146.12 47.19 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.503 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.59 142.84 33.26 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.582 2.188 . . . . 0.0 112.354 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 59.61 172.63 0.08 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.94 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -152.55 119.0 5.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.342 -1.255 . . . . 0.0 112.507 179.95 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.247 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -170.36 126.94 0.8 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.816 0.341 . . . . 0.0 110.911 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.4 m -135.38 128.23 31.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.887 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.25 75.81 0.19 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.486 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 83.3 p -119.33 -68.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.804 0.335 . . . . 0.0 110.912 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -155.27 -45.89 0.08 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.94 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 76.17 105.02 0.13 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.516 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.643 HD13 HG11 ' A' ' 14' ' ' VAL . 31.4 mt -112.3 128.68 68.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.851 0.358 . . . . 0.0 111.063 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 54.2 m-20 -124.75 -174.91 3.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.4 t -65.14 136.88 25.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.037 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.19 46.56 6.94 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.475 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.659 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -140.49 136.89 17.0 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.618 0.247 . . . . 0.0 110.908 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.705 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.6 Cg_endo -76.47 117.03 4.45 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.45 2.1 . . . . 0.0 112.308 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.643 HG11 HD13 ' A' ' 8' ' ' ILE . 16.3 m -141.99 138.3 30.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.154 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 30.3 mttp -81.4 132.46 35.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.665 HG22 HD23 ' A' ' 85' ' ' LEU . 21.6 t -113.3 131.71 64.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.047 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -87.07 112.94 22.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.443 ' HA ' HD23 ' A' ' 18' ' ' LEU . 15.0 mt -93.83 -44.98 7.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.19 179.59 7.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.3 p -75.24 76.51 2.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.9 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.4 35.2 84.17 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.489 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.92 -62.42 1.47 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.802 0.334 . . . . 0.0 110.895 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.22 142.25 19.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.915 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 18.3 mttm -98.26 115.56 28.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.782 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -75.71 128.12 84.32 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.831 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.434 ' HB2' HD12 ' A' ' 51' ' ' LEU . 64.3 Cg_endo -73.05 139.35 29.66 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.423 2.082 . . . . 0.0 112.311 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.49 157.91 29.62 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.614 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.1 p -95.86 136.05 28.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.774 0.321 . . . . 0.0 111.01 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 12' ' ' CYS . 23.9 t -70.0 130.69 34.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.078 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.427 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 24.9 mmt180 -114.52 -29.42 6.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.209 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -148.49 167.2 25.97 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.881 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.428 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 7.2 ttp180 -162.93 131.73 4.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.857 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 157.27 150.28 5.66 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.572 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.408 ' HD3' HG23 ' A' ' 44' ' ' ILE . 48.6 Cg_exo -55.68 160.31 9.75 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.613 2.209 . . . . 0.0 112.333 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.423 ' HB2' ' CE1' ' A' ' 45' ' ' PHE . 10.3 mt -121.02 -55.41 1.98 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.801 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.8 mt -143.0 151.42 40.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.808 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -143.62 33.03 1.29 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -110.07 110.16 20.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.89 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 6.8 mtm180 60.26 32.6 20.84 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.808 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.6 t -166.41 136.89 3.35 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.935 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 12.2 p -125.11 128.81 73.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.135 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.25 -48.15 0.2 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.944 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 123.72 -145.54 16.04 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.515 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.434 ' H ' HD12 ' A' ' 44' ' ' ILE . 4.2 mp -92.62 128.29 44.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.797 0.332 . . . . 0.0 111.089 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.423 ' CE1' ' HB2' ' A' ' 35' ' ' LEU . 66.1 m-85 -82.95 139.24 33.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.869 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.633 ' CB ' HD11 ' A' ' 85' ' ' LEU . 7.6 m-85 -117.93 113.66 22.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.986 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -78.21 117.49 4.68 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.596 HG21 HD22 ' A' ' 85' ' ' LEU . 20.2 t -123.49 143.37 36.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.766 0.317 . . . . 0.0 111.09 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -97.72 115.0 27.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.93 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 6.9 mt -59.07 128.29 36.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.032 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.434 HD12 ' HB2' ' A' ' 26' ' ' PRO . 7.2 mt -80.54 -179.93 7.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.867 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -54.85 -29.28 54.77 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.067 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.99 -41.81 99.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.892 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.04 34.64 3.05 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.563 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.9 ttt180 -71.99 144.59 48.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.773 0.321 . . . . 0.0 110.926 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 90.2 31.02 11.2 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.464 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -137.12 32.57 2.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.847 0.356 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.28 143.52 15.67 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.443 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.6 p90 -109.99 -47.92 3.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.824 0.345 . . . . 0.0 110.991 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -66.47 -42.81 86.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.973 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.1 t0 60.03 29.2 18.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.088 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.417 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 85.55 26.25 36.34 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.61 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.53 HG23 ' C ' ' A' ' 67' ' ' LYS . 12.1 p -164.04 133.29 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.775 0.322 . . . . 0.0 111.123 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 17.9 t80 -123.76 117.09 24.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 61.27 29.16 18.52 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.869 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.71 -26.86 21.44 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.547 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.53 ' C ' HG23 ' A' ' 63' ' ' VAL . 22.2 tptt -76.87 111.93 12.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.84 0.352 . . . . 0.0 110.879 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 10.9 tp60 -80.99 108.4 14.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.841 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.648 HD12 ' CE2' ' A' ' 79' ' ' PHE . 44.9 mt -86.63 -31.16 21.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.046 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.427 ' CD2' ' HB2' ' A' ' 30' ' ' ARG . 7.1 p90 -161.35 163.2 30.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -99.0 132.63 44.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.939 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -150.48 170.61 18.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.808 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -70.24 179.96 2.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.806 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -74.35 118.71 17.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 61.17 52.06 4.11 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.97 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 36.1 m -130.06 -51.79 1.12 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.967 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -64.17 138.05 41.1 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.519 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 17.7 m -150.29 140.35 16.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.761 0.315 . . . . 0.0 111.207 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.648 ' CE2' HD12 ' A' ' 69' ' ' LEU . 3.4 m-85 -104.13 122.4 45.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.838 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.617 HG21 HG13 ' A' ' 16' ' ' VAL . 4.5 m -145.85 164.73 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.208 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -76.68 155.94 32.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.189 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.536 HD12 HD12 ' A' ' 8' ' ' ILE . 13.2 tp -50.42 -40.84 51.29 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.737 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 27.8 t0 -58.45 -29.97 66.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.55 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 13.1 mmtt -78.83 -23.41 45.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.866 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.665 HD23 HG22 ' A' ' 16' ' ' VAL . 78.7 mt -82.75 143.59 30.77 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.93 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -130.29 97.59 4.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.814 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.633 ' HA ' HG12 ' A' ' 14' ' ' VAL . 19.6 tp -58.69 130.72 48.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.969 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.705 HD12 ' HB2' ' A' ' 13' ' ' PRO . 18.7 mt -82.97 151.71 4.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.091 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -114.03 139.24 49.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.928 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.5 p -72.72 110.6 7.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -107.15 144.27 15.9 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.504 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo -74.0 167.65 26.7 Favored 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.572 2.181 . . . . 0.0 112.32 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 23.2 t -80.28 129.11 34.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.916 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.1 m -140.2 122.95 16.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.899 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.438 -1.201 . . . . 0.0 112.464 -179.971 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.182 0 N-CA-C 112.577 -0.209 . . . . 0.0 112.577 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.2 m -127.9 31.68 5.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.757 0.313 . . . . 0.0 110.836 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -109.51 130.12 55.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.934 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -70.22 -174.68 15.27 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.533 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 42.3 t -67.18 -42.59 83.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.833 0.349 . . . . 0.0 110.948 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -166.73 172.3 10.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.904 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.5 -42.48 3.4 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.479 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.581 HG12 HD13 ' A' ' 87' ' ' LEU . 21.5 mt -103.29 139.83 23.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.824 0.345 . . . . 0.0 111.142 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -131.72 173.03 11.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.783 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.2 t -59.65 141.81 15.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.102 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 73.35 48.39 19.06 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.45 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.525 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.06 141.52 17.34 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.69 0.281 . . . . 0.0 110.954 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.618 ' HB2' HD12 ' A' ' 88' ' ' ILE . 73.3 Cg_endo -75.87 121.81 6.45 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.622 2.215 . . . . 0.0 112.418 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.69 HG12 ' HA ' ' A' ' 87' ' ' LEU . 16.7 m -153.2 138.36 10.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.101 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 23.3 mttt -75.01 138.03 41.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.949 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.932 HG13 HG21 ' A' ' 80' ' ' VAL . 18.6 t -119.17 136.02 57.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.12 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -90.84 112.62 24.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.972 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.453 HD13 ' HB3' ' A' ' 57' ' ' GLN . 23.3 mt -83.62 -66.27 0.91 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.86 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -73.77 172.83 10.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.874 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -76.1 85.76 2.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 61.74 54.09 38.26 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.443 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -112.5 -61.52 1.71 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.798 0.333 . . . . 0.0 110.849 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -162.78 133.09 4.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -95.23 121.9 37.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.858 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.424 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 50.0 m-85 -97.96 142.15 24.12 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.819 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.16 148.37 55.94 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.463 2.109 . . . . 0.0 112.36 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -167.24 154.42 24.7 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.509 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -98.36 127.15 51.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.834 0.349 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 12' ' ' CYS . 11.2 t -59.98 131.91 24.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.999 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -116.41 -30.64 5.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.181 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -146.79 166.0 27.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.866 0.365 . . . . 0.0 111.005 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.422 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.1 ttp180 -165.79 141.28 4.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.831 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 142.73 134.75 2.96 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.548 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -55.27 158.55 11.93 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.508 2.139 . . . . 0.0 112.245 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 61.6 mt -105.55 -56.9 2.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.795 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.505 HD12 ' HD3' ' A' ' 39' ' ' ARG . 4.0 mm? -108.21 143.48 36.98 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.784 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -146.26 48.02 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.075 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -177.68 -40.59 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.951 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.505 ' HD3' HD12 ' A' ' 36' ' ' LEU . 9.7 mpt_? -77.14 65.25 2.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.911 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 65.9 m 62.87 -78.95 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.021 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.0 m -56.91 142.47 12.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.212 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.3 t -168.73 109.75 0.51 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -160.86 156.96 28.41 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.568 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.7 mt -82.42 119.66 32.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.828 0.347 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -100.09 149.85 23.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.978 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.569 ' CB ' HD11 ' A' ' 85' ' ' LEU . 12.6 m-85 -127.8 116.98 21.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.925 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -83.66 120.67 5.27 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.41 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.597 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -133.6 129.2 55.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.868 0.366 . . . . 0.0 111.134 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -84.28 121.32 27.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.896 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.527 HD12 ' HA ' ' A' ' 76' ' ' CYS . 5.2 mt -59.99 150.23 29.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -96.71 -179.86 4.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.876 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -52.66 -30.02 29.56 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.143 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -62.86 -44.1 97.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.811 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.424 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -124.63 36.4 2.89 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.453 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt180 -75.48 140.49 42.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.898 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.8 29.85 11.27 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.518 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.453 ' HB3' HD13 ' A' ' 18' ' ' LEU . 48.4 mm-40 -137.21 36.25 2.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.866 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.41 142.43 15.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.576 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -105.65 -45.83 4.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.778 0.323 . . . . 0.0 110.864 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -63.38 -44.02 95.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.969 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.1 t0 57.72 33.73 23.6 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.928 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.42 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.72 -24.84 27.76 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.533 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.1 p -113.0 135.35 52.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.8 0.334 . . . . 0.0 111.098 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 4.0 t80 -116.82 110.43 18.36 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 77.6 mt-30 60.25 30.88 20.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.841 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.96 -26.3 23.96 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.604 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -81.85 114.11 20.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 110.968 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 31.7 tp60 -74.68 98.76 3.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.813 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.432 HD12 ' CE2' ' A' ' 79' ' ' PHE . 55.3 mt -79.79 -40.46 28.61 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.938 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.42 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -152.64 175.01 13.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.994 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.39 113.97 24.47 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 11.9 p -131.0 -180.0 5.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.01 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -65.65 179.95 0.76 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.96 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.12 118.84 22.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.034 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 59.56 50.04 7.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.023 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . 0.527 ' HA ' HD12 ' A' ' 50' ' ' LEU . 43.1 m -129.98 -45.54 1.15 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.983 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.466 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -60.91 146.39 47.53 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.563 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.597 HG22 ' O ' ' A' ' 48' ' ' VAL . 16.1 m -157.63 138.3 4.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.731 0.301 . . . . 0.0 111.074 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.432 ' CE2' HD12 ' A' ' 69' ' ' LEU . 11.2 m-85 -109.23 127.73 54.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.93 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.932 HG21 HG13 ' A' ' 16' ' ' VAL . 31.0 m -150.22 165.68 2.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.117 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.15 156.9 35.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.058 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 11.0 tp -49.55 -43.88 46.21 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.893 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -57.01 -29.85 63.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.55 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 12.5 mmtt -76.43 -25.64 54.64 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.814 179.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.904 ' CD2' HG22 ' A' ' 16' ' ' VAL . 79.2 mt -90.39 137.69 32.15 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.911 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.2 tm-20 -111.65 109.1 18.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.69 ' HA ' HG12 ' A' ' 14' ' ' VAL . 23.8 tp -64.56 128.24 34.92 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.965 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.618 HD12 ' HB2' ' A' ' 13' ' ' PRO . 22.1 mt -88.81 139.79 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.07 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -101.26 136.28 41.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.969 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.3 -41.32 2.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.831 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.402 ' N ' ' CD ' ' A' ' 92' ' ' PRO . . . 90.87 51.87 2.55 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.604 180.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 91' ' ' GLY . 57.0 Cg_endo -70.92 -178.51 2.82 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.536 2.158 . . . . 0.0 112.29 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -177.01 152.33 0.9 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.964 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 54.4 p -85.81 171.06 11.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.142 0 CA-C-O 118.456 -1.191 . . . . 0.0 112.49 -179.987 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.1 m -154.38 155.68 35.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 0.0 110.88 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 t -164.54 -177.6 4.92 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.832 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.85 166.59 20.73 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.497 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.8 t -149.48 104.12 3.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.871 0.367 . . . . 0.0 110.881 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.6 m -89.38 -177.59 5.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.925 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.61 -92.03 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.461 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.675 HD12 HD12 ' A' ' 82' ' ' LEU . 23.1 mt -89.52 147.62 5.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.82 0.343 . . . . 0.0 111.092 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -156.84 -172.14 3.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.846 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 t -60.67 136.83 23.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.212 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 75.03 46.58 15.93 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.59 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.797 ' O ' HG23 ' A' ' 29' ' ' VAL . 3.0 t -144.32 131.74 10.49 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.604 0.24 . . . . 0.0 110.969 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -76.08 122.97 6.97 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.479 2.119 . . . . 0.0 112.386 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.662 HG21 HD13 ' A' ' 85' ' ' LEU . 6.6 m -148.48 138.86 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.143 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.0 mttt -76.17 139.46 41.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.902 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.694 ' CG1' HG11 ' A' ' 80' ' ' VAL . 21.4 t -118.28 141.67 36.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.115 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -98.84 115.7 29.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.932 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 39.9 mt -98.39 -59.74 1.69 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 19.0 mtt85 -60.35 168.54 2.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.869 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.9 p -74.3 75.75 1.85 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.82 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.26 55.7 26.27 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.537 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -119.51 -67.25 1.0 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -147.9 154.51 40.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.4 mttt -112.31 152.09 28.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.865 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -116.69 135.63 23.0 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.833 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.491 ' HB2' HD12 ' A' ' 51' ' ' LEU . 61.6 Cg_endo -73.01 140.32 31.26 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.477 2.118 . . . . 0.0 112.312 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.79 148.51 16.06 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.635 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.453 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.3 p -89.83 140.66 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.737 0.303 . . . . 0.0 110.979 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.797 HG23 ' O ' ' A' ' 12' ' ' CYS . 11.9 t -72.34 131.17 35.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.098 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.453 ' HD3' HG13 ' A' ' 28' ' ' VAL . 5.8 mmm180 -112.83 -30.8 6.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.126 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -152.5 167.41 28.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.907 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.411 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 0.0 OUTLIER -154.72 130.04 9.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.755 179.931 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.33 151.12 6.14 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.507 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.04 -177.95 1.86 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.61 2.207 . . . . 0.0 112.29 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.748 HD13 ' CE1' ' A' ' 64' ' ' TYR . 4.7 mt -117.66 -50.04 2.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.924 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.5 mt -118.04 -179.51 3.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.703 ' HB1' ' O ' ' A' ' 40' ' ' THR . . . 60.66 79.01 0.26 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.134 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -85.6 -31.61 22.52 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 8.2 mmm180 -74.92 -33.13 61.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.865 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.703 ' O ' ' HB1' ' A' ' 37' ' ' ALA . 1.9 m -142.09 126.75 17.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.884 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.515 ' O ' HG13 ' A' ' 41' ' ' VAL . 11.6 p -69.56 118.26 13.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.116 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.4 t -110.12 -40.51 4.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.897 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -158.86 115.78 0.68 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.483 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.449 HD11 HG21 ' A' ' 41' ' ' VAL . 3.7 mp -92.21 156.02 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.829 0.347 . . . . 0.0 111.096 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.434 ' N ' HG22 ' A' ' 44' ' ' ILE . 18.6 m-85 -125.82 156.9 38.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.949 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.411 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 11.7 m-85 -126.78 109.89 12.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.95 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.517 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -66.98 132.73 31.26 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.356 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.618 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.7 t -144.12 130.53 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.899 0.38 . . . . 0.0 111.22 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -88.13 116.73 26.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.827 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 29.3 mt -59.97 131.96 52.48 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.491 HD12 ' HB2' ' A' ' 26' ' ' PRO . 12.0 mt -77.61 -179.89 6.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -53.41 -29.79 36.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.149 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -61.04 -55.47 32.39 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.914 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -112.05 32.44 6.33 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.514 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 8.8 ttt180 -72.83 135.26 45.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.913 0.387 . . . . 0.0 110.866 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 98.61 31.97 6.17 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.526 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 64.4 mm-40 -143.4 33.39 1.31 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.858 0.361 . . . . 0.0 110.932 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -99.8 147.99 18.4 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.521 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 23.7 p90 -109.51 -50.35 3.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.747 0.308 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.446 HG23 ' N ' ' A' ' 61' ' ' ASP . 8.7 t -68.84 -48.57 63.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.887 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.446 ' N ' HG23 ' A' ' 60' ' ' THR . 8.7 m-20 53.89 30.48 11.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.089 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.41 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 106.3 -26.38 20.46 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.506 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.446 HG23 ' C ' ' A' ' 67' ' ' LYS . 11.5 p -120.82 132.8 69.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 111.087 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.748 ' CE1' HD13 ' A' ' 35' ' ' LEU . 40.2 t80 -119.06 113.77 21.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.932 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 61.26 24.87 14.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.072 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 104.54 -27.9 17.2 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.555 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.446 ' C ' HG23 ' A' ' 63' ' ' VAL . 1.2 tpmp? -79.24 117.59 20.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.923 0.392 . . . . 0.0 110.913 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 8.6 tp60 -85.1 106.0 16.25 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.884 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.452 HD12 ' CE2' ' A' ' 79' ' ' PHE . 91.6 mt -91.01 -34.45 15.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.869 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.41 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 7.4 p90 -153.95 171.21 19.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 4.9 mm100 -102.77 121.15 41.87 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.922 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -136.52 172.85 12.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.807 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.93 173.78 10.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.905 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -65.53 118.67 9.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.991 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 59.55 52.15 5.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.852 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 87.0 m -130.07 -63.93 0.88 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -58.87 137.03 50.75 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.488 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.618 HG22 ' O ' ' A' ' 48' ' ' VAL . 5.7 m -148.07 129.79 6.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.792 0.329 . . . . 0.0 111.208 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.452 ' CE2' HD12 ' A' ' 69' ' ' LEU . 4.3 m-85 -93.02 129.77 38.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.785 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.694 HG11 ' CG1' ' A' ' 16' ' ' VAL . 4.6 m -150.32 164.56 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.235 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.7 162.58 20.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.176 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.675 HD12 HD12 ' A' ' 8' ' ' ILE . 12.8 tp -52.35 -47.99 65.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.805 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -57.64 -29.0 64.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.604 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 1.7 mttp -79.49 -25.35 41.87 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.809 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.662 HD13 HG21 ' A' ' 14' ' ' VAL . 52.5 mt -87.57 128.02 35.26 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.864 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -114.0 111.35 21.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.836 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.508 ' HA ' HG12 ' A' ' 14' ' ' VAL . 17.4 tp -60.04 134.13 56.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.957 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 29.3 mt -93.46 128.86 44.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.105 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -83.54 152.82 24.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.915 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 3.0 t -161.01 49.31 0.23 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -148.46 92.47 0.15 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.493 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.98 149.88 72.33 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.561 2.174 . . . . 0.0 112.22 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 15.9 t -119.99 112.13 18.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.935 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 49.4 m -81.77 -31.58 31.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.903 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.116 0 CA-C-O 118.35 -1.25 . . . . 0.0 112.461 179.957 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.176 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.6 p -165.1 176.41 8.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.825 0.345 . . . . 0.0 110.944 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.0 m -156.71 124.59 5.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.899 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.82 -69.01 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.412 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.9 m -163.28 -45.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.877 0.37 . . . . 0.0 110.912 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -162.2 171.1 17.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.911 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -120.91 -39.1 0.61 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.444 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.581 HD13 HG11 ' A' ' 14' ' ' VAL . 29.2 mt -113.08 155.13 14.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.761 0.315 . . . . 0.0 111.142 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.421 ' N ' HG22 ' A' ' 8' ' ' ILE . 1.0 OUTLIER -153.35 -168.94 3.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 179.964 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.408 ' HA ' ' CG1' ' A' ' 29' ' ' VAL . 24.9 t -70.16 135.27 28.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.125 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.9 46.17 7.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.408 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.684 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -144.73 137.42 13.6 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.677 0.275 . . . . 0.0 110.99 -179.965 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.1 118.07 4.61 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.477 2.118 . . . . 0.0 112.364 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.609 HG12 ' HA ' ' A' ' 87' ' ' LEU . 24.1 m -146.68 138.32 18.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.196 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 5.2 mttm -77.06 129.87 36.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.967 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 1.022 HG13 HG21 ' A' ' 80' ' ' VAL . 23.3 t -106.16 128.03 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.002 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 30.2 tt0 -97.24 110.32 22.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.912 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 88.9 mt -80.99 -45.55 16.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.835 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.28 -174.3 5.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.968 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.51 84.25 4.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.82 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.05 55.2 29.41 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.539 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.4 tt0 -117.25 -65.69 1.16 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.776 0.322 . . . . 0.0 110.892 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -158.43 123.07 4.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.866 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 24.2 mttt -90.57 144.06 26.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.419 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 74.0 m-85 -107.98 127.54 27.46 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.864 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -68.39 131.84 24.2 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.397 2.064 . . . . 0.0 112.262 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.66 163.38 30.35 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 28' ' ' VAL . 11.9 p -102.6 125.95 56.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.822 0.344 . . . . 0.0 110.97 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.684 HG23 ' O ' ' A' ' 12' ' ' CYS . 10.3 t -59.88 126.91 18.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -114.38 -31.79 6.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.054 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.558 ' CE2' HD22 ' A' ' 69' ' ' LEU . 28.0 t80 -142.58 167.43 22.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.934 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 13.5 ttp180 -159.22 129.47 5.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.72 148.34 5.15 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.505 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.456 ' HD3' HG23 ' A' ' 44' ' ' ILE . 58.1 Cg_endo -71.61 147.36 51.2 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.561 2.174 . . . . 0.0 112.274 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.404 HD22 ' CD1' ' A' ' 64' ' ' TYR . 8.0 mt -86.51 -67.73 0.79 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.867 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.432 ' O ' HD12 ' A' ' 36' ' ' LEU . 0.9 OUTLIER -88.84 93.57 9.63 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.815 -179.962 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -121.3 31.62 6.26 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.098 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.54 -50.05 6.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.895 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -104.02 85.45 2.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.968 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 96.9 m 57.06 97.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.908 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.2 p -72.0 141.56 16.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.095 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.4 t -167.88 35.18 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.908 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -164.1 89.36 0.1 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.513 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.456 HG23 ' HD3' ' A' ' 34' ' ' PRO . 23.2 mt -82.72 135.43 24.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.775 0.321 . . . . 0.0 111.18 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -106.99 150.39 26.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.98 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.421 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 9.5 m-85 -123.34 114.9 20.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.971 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.424 ' N ' ' CD1' ' A' ' 79' ' ' PHE . . . -74.93 121.84 6.77 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.48 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.573 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -129.95 133.76 64.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.823 0.344 . . . . 0.0 111.113 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -90.02 115.91 27.65 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.457 HD13 ' HB2' ' A' ' 57' ' ' GLN . 37.3 mt -58.88 133.59 56.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.993 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -81.55 -179.89 7.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.921 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -53.14 -29.63 32.26 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.106 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 -60.86 -58.35 8.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.882 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.419 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -111.12 32.72 6.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.465 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -69.74 133.06 47.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.769 0.319 . . . . 0.0 110.907 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.46 35.8 4.56 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.53 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.457 ' HB2' HD13 ' A' ' 50' ' ' LEU . 4.8 mt-30 -141.47 31.36 1.69 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.342 . . . . 0.0 110.877 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.72 147.39 16.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.513 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -108.56 -49.23 3.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.75 0.31 . . . . 0.0 110.863 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.3 t -59.43 -43.78 93.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.957 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.0 t0 59.82 29.38 18.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.052 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.422 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.47 -19.57 53.62 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.69 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.537 HG23 ' C ' ' A' ' 67' ' ' LYS . 11.2 p -124.22 140.38 47.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.865 0.364 . . . . 0.0 111.178 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.404 ' CD1' HD22 ' A' ' 35' ' ' LEU . 52.7 t80 -122.85 109.96 14.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.923 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER 60.22 26.6 16.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.001 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.12 -30.27 9.54 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.592 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.537 ' C ' HG23 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -77.34 117.93 19.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.951 0.405 . . . . 0.0 110.925 -179.988 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 2.9 tp60 -84.91 92.69 8.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.861 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.558 HD22 ' CE2' ' A' ' 31' ' ' PHE . 71.1 mt -69.49 -44.57 70.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.912 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.422 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.9 p90 -147.77 177.78 9.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.961 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -113.83 123.92 50.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.885 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 17.7 p -150.0 163.06 39.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.891 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -60.12 178.51 0.18 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.936 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -75.71 124.55 27.45 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 60.79 49.86 5.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.909 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 53.7 m -129.99 -45.93 1.14 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.907 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -69.41 132.17 24.98 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.519 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 48' ' ' VAL . 7.7 m -142.15 131.16 22.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.886 0.374 . . . . 0.0 111.094 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.454 ' CE2' HD12 ' A' ' 69' ' ' LEU . 9.1 m-85 -101.53 127.06 48.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.93 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 1.022 HG21 HG13 ' A' ' 16' ' ' VAL . 31.5 m -151.71 164.15 2.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.159 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -81.13 162.38 23.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.204 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -51.9 -49.57 62.78 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.887 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -56.89 -28.33 61.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.672 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.0 mtmm -80.03 -25.86 40.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.815 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.795 ' CD2' HG22 ' A' ' 16' ' ' VAL . 80.3 mt -82.86 161.05 22.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.913 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -137.97 104.59 5.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.84 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.609 ' HA ' HG12 ' A' ' 14' ' ' VAL . 19.8 tp -59.68 137.71 57.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.984 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.427 HG22 ' N ' ' A' ' 89' ' ' GLU . 32.3 mt -106.69 155.62 7.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.117 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . 0.427 ' N ' HG22 ' A' ' 88' ' ' ILE . 24.5 mt-10 -125.53 -48.77 1.67 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.966 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 92.3 p -115.35 -40.96 3.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.9 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.23 -148.83 16.52 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.461 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.85 145.19 61.6 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.502 2.135 . . . . 0.0 112.328 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.4 m -109.83 -42.23 4.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.978 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 38.4 m -84.61 130.54 34.71 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.968 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.128 0 CA-C-O 118.361 -1.244 . . . . 0.0 112.459 -179.963 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.163 0 N-CA-C 112.499 -0.24 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.5 t 61.26 153.77 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.831 0.348 . . . . 0.0 110.904 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.5 p 58.18 179.6 0.06 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.4 91.93 1.28 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.516 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.1 m -140.35 -170.95 3.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.854 0.359 . . . . 0.0 110.901 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 74.4 m -134.46 136.34 43.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.872 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.91 -94.62 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.521 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.563 HD12 ' CD1' ' A' ' 82' ' ' LEU . 46.0 mt -100.85 125.75 54.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -143.1 -172.02 3.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.881 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.526 HG13 ' O ' ' A' ' 30' ' ' ARG . 29.2 t -64.48 127.78 25.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.038 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 87.84 43.28 5.77 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.537 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.649 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -141.44 137.04 16.12 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 120.617 0.246 . . . . 0.0 110.952 -179.961 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -76.34 116.84 4.43 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.526 2.151 . . . . 0.0 112.343 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.618 HG12 ' HA ' ' A' ' 87' ' ' LEU . 6.8 m -144.34 138.74 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.169 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 2.3 mttt -80.42 141.23 35.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.071 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.854 HG13 HG21 ' A' ' 80' ' ' VAL . 31.9 t -115.63 133.6 61.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.053 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -94.52 121.54 36.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.915 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.404 HD12 ' HE2' ' A' ' 25' ' ' PHE . 57.4 mt -101.93 -54.48 2.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.919 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.8 -174.78 0.05 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.839 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 51.7 p -93.0 48.37 1.34 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.918 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 95.51 57.89 1.16 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.469 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -121.43 -51.93 2.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.818 0.342 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -170.02 152.4 4.32 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 10.8 mttt -107.74 138.29 44.24 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.414 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 26.5 m-85 -95.08 123.14 58.21 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.769 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.634 ' HB2' HD12 ' A' ' 51' ' ' LEU . 37.8 Cg_endo -65.97 138.86 54.22 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.464 2.109 . . . . 0.0 112.263 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -166.74 146.6 11.02 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.571 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.2 p -83.37 145.83 7.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.803 0.335 . . . . 0.0 110.961 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.705 HG13 ' O ' ' A' ' 47' ' ' GLY . 21.7 t -77.86 138.87 19.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.158 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.526 ' O ' HG13 ' A' ' 10' ' ' VAL . 0.7 OUTLIER -117.78 -40.19 3.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.804 179.988 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.411 ' CD2' ' N ' ' A' ' 32' ' ' ARG . 58.1 t80 -140.05 163.8 31.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.793 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.413 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 22.5 ttp85 -158.99 140.79 13.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.911 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 146.83 161.33 9.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.482 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.9 136.09 31.75 Favored 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.556 2.171 . . . . 0.0 112.287 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.527 HD13 ' CZ ' ' A' ' 64' ' ' TYR . 72.2 mt -62.95 -64.93 0.77 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.918 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.46 HD22 ' O ' ' A' ' 35' ' ' LEU . 3.4 mm? -122.89 156.87 33.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.843 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -73.36 153.76 40.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.11 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -149.88 161.37 42.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.867 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.4 -31.38 7.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.886 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.631 HG23 HG12 ' A' ' 41' ' ' VAL . 7.7 t -91.11 -34.64 14.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.919 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.631 HG12 HG23 ' A' ' 40' ' ' THR . 11.6 p -169.47 124.79 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 31.1 t -98.91 96.36 7.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -62.38 116.51 9.47 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.467 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.2 mp -93.42 135.62 27.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 111.064 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -117.96 146.58 43.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.918 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.413 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 7.0 m-85 -118.28 112.94 20.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.924 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.705 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -68.44 141.4 37.02 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.589 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.443 ' O ' HG22 ' A' ' 78' ' ' VAL . 25.7 t -153.52 140.92 13.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.792 0.329 . . . . 0.0 111.006 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -98.79 113.94 26.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.871 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.456 HD12 ' HA ' ' A' ' 76' ' ' CYS . 3.4 mt -57.76 128.6 37.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.056 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.634 HD12 ' HB2' ' A' ' 26' ' ' PRO . 19.8 mt -78.0 -179.9 6.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.54 -30.03 52.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.079 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -60.64 -48.68 80.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.846 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.414 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -121.57 37.13 3.03 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.488 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.1 ttt180 -74.1 151.89 40.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.802 0.334 . . . . 0.0 110.9 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 84.3 27.91 35.07 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.492 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 68.5 mm-40 -133.92 36.69 3.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.837 0.351 . . . . 0.0 110.918 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.41 145.86 15.99 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.456 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -109.98 -47.38 3.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.821 0.343 . . . . 0.0 110.921 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 4.3 t -69.98 -40.47 75.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.831 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.6 t0 58.43 29.46 18.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.043 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.414 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 99.01 -20.25 51.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.67 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.9 p -118.56 134.59 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.867 0.365 . . . . 0.0 111.124 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.527 ' CZ ' HD13 ' A' ' 35' ' ' LEU . 50.4 t80 -122.59 110.02 15.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.858 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.413 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 28.8 mt-30 58.94 26.54 15.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.037 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 105.72 -28.05 15.57 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.568 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.0 118.08 21.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.83 0.348 . . . . 0.0 110.88 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 7.7 tp60 -84.08 90.08 7.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.913 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 84.7 mt -71.36 -31.78 67.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.825 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.1 p90 -161.49 164.82 29.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.858 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -112.0 119.42 38.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.887 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 1.3 m -137.17 179.95 6.09 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.907 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -71.69 179.96 2.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.885 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -72.33 123.24 22.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.001 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 60.02 50.59 6.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . 0.456 ' HA ' HD12 ' A' ' 50' ' ' LEU . 27.9 m -130.04 -49.28 1.11 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.983 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -62.65 127.14 38.77 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.558 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.443 HG22 ' O ' ' A' ' 48' ' ' VAL . 21.3 m -146.11 156.23 12.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.748 0.309 . . . . 0.0 111.128 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.429 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 7.9 m-85 -124.47 136.61 54.16 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.889 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.854 HG21 HG13 ' A' ' 16' ' ' VAL . 28.6 m -156.59 160.04 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.11 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.527 ' HB3' ' OD1' ' A' ' 83' ' ' ASP . . . -73.3 157.48 36.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.116 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.563 ' CD1' HD12 ' A' ' 8' ' ' ILE . 14.8 tp -51.14 -46.41 61.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.845 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.527 ' OD1' ' HB3' ' A' ' 81' ' ' ALA . 27.6 p-10 -57.16 -28.94 63.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.599 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 5.0 mmtt -79.28 -25.21 42.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.745 ' CD2' HG22 ' A' ' 16' ' ' VAL . 43.7 mt -83.17 154.98 24.0 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.02 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -141.45 104.66 4.62 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.853 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.618 ' HA ' HG12 ' A' ' 14' ' ' VAL . 19.0 tp -59.51 135.14 57.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.002 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.3 mt -93.61 126.57 46.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.113 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -119.68 -38.49 2.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.024 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 7.6 p 61.49 41.51 12.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.926 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 122.29 161.16 11.18 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.458 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -68.49 124.62 11.81 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.615 2.21 . . . . 0.0 112.3 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 23.1 t -79.09 121.25 24.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.889 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.42 -31.12 53.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.903 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.411 -1.216 . . . . 0.0 112.542 179.968 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.166 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.2 m 60.43 95.45 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.792 0.33 . . . . 0.0 110.89 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.5 m -158.08 160.44 37.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.927 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 132.21 174.4 13.62 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.472 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 99.3 p -98.82 31.5 2.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.838 0.351 . . . . 0.0 110.93 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 m -100.59 178.16 4.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.872 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.75 -51.86 1.25 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.533 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.688 HG21 HG11 ' A' ' 14' ' ' VAL . 4.1 mt -127.4 143.69 39.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.918 0.39 . . . . 0.0 111.059 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -138.82 179.77 6.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.842 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 40.2 t -64.04 133.13 29.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.011 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 84.36 45.53 6.15 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.383 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.496 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -149.87 143.63 16.89 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 120.663 0.268 . . . . 0.0 110.953 -179.948 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.498 ' O ' HG13 ' A' ' 14' ' ' VAL . 74.4 Cg_endo -75.3 138.14 21.96 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.582 2.188 . . . . 0.0 112.267 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.688 HG11 HG21 ' A' ' 8' ' ' ILE . 11.3 m -158.49 138.69 4.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.232 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 21.3 mttt -82.82 125.94 31.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.948 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.838 HG22 ' CD2' ' A' ' 85' ' ' LEU . 22.0 t -104.49 138.46 29.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.03 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -102.96 112.09 24.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.939 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -85.78 -40.12 16.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.866 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -84.31 -176.3 6.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 71.8 p -100.04 48.26 0.93 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.874 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 105.71 56.89 0.66 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.553 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.95 -60.45 1.08 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.803 0.335 . . . . 0.0 110.904 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -161.63 146.18 13.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.863 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 14.8 mttt -109.21 150.62 27.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.85 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.435 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 27.3 m-85 -113.63 127.26 27.03 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.838 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.18 146.17 40.37 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.436 2.091 . . . . 0.0 112.318 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.82 153.4 21.53 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.489 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.8 p -93.27 138.85 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.772 0.32 . . . . 0.0 111.066 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.605 HG22 HG22 ' A' ' 48' ' ' VAL . 19.3 t -72.78 133.32 31.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.098 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 20.0 mmt180 -115.91 -30.45 6.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.038 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -142.78 168.3 20.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.948 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.428 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 24.3 ttp180 -161.23 123.53 3.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.858 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 168.37 145.7 4.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.545 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.532 ' HD3' HG23 ' A' ' 44' ' ' ILE . 53.0 Cg_exo -54.96 -169.31 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.583 2.189 . . . . 0.0 112.25 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.419 ' HG ' ' CD2' ' A' ' 45' ' ' PHE . 12.9 mt -118.21 -64.06 1.34 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.883 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.5 mp -130.74 139.08 50.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.7 77.42 0.12 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.085 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -93.56 -38.32 11.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.897 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 26.8 mtm180 -110.92 -33.31 6.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.939 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.8 m -151.39 147.6 27.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.886 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.7 p -77.55 146.36 8.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.084 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 13.0 t -107.07 -67.43 0.95 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.888 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -176.18 145.6 7.63 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.515 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.532 HG23 ' HD3' ' A' ' 34' ' ' PRO . 32.9 mt -81.17 123.36 37.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.794 0.331 . . . . 0.0 111.095 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.419 ' CD2' ' HG ' ' A' ' 35' ' ' LEU . 52.7 m-85 -90.39 147.81 23.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.952 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.428 ' CZ ' ' HD2' ' A' ' 32' ' ' ARG . 12.1 m-85 -117.12 111.95 20.21 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.922 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -76.67 110.27 2.99 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.498 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.605 HG22 HG22 ' A' ' 29' ' ' VAL . 21.8 t -116.97 132.13 67.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.846 0.355 . . . . 0.0 111.039 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -88.53 117.54 27.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.574 HD13 ' HB2' ' A' ' 57' ' ' GLN . 52.8 mt -59.15 135.19 57.56 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.993 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -79.78 -179.93 7.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.821 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -55.13 -30.2 59.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.079 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -63.01 -60.1 3.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.79 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.435 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -101.58 30.86 9.47 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.442 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -69.74 137.87 52.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.79 0.328 . . . . 0.0 110.88 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.01 34.06 6.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.47 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.574 ' HB2' HD13 ' A' ' 50' ' ' LEU . 31.1 mm-40 -140.9 43.84 1.81 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.906 0.384 . . . . 0.0 110.918 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -108.1 143.15 16.05 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.525 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -110.03 -32.1 7.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.87 0.367 . . . . 0.0 110.932 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -85.76 -42.31 14.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.899 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.6 t0 57.08 31.19 19.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.999 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.433 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 93.1 -16.8 59.65 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.676 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.7 p -123.01 142.1 40.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.856 0.36 . . . . 0.0 111.141 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 13.4 t80 -129.09 110.24 11.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.873 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 61.67 24.54 14.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.154 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.18 -27.81 14.7 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.566 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.6 119.53 23.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.947 0.403 . . . . 0.0 110.948 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -82.87 95.61 8.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.942 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 78.5 mt -70.83 -51.13 28.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.433 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -144.99 166.1 26.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.913 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.32 124.24 46.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.881 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 9.3 p -149.58 177.1 10.05 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -71.89 175.93 5.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.877 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -78.82 127.79 32.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.891 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 60.5 41.22 16.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.902 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 23.7 m -127.53 -46.66 1.45 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.909 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -68.32 132.25 27.67 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.538 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 12.4 m -148.44 135.96 13.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.806 0.336 . . . . 0.0 111.158 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -102.18 130.01 48.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.587 HG21 HG13 ' A' ' 16' ' ' VAL . 4.2 m -150.15 166.74 2.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.148 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.98 158.76 21.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.137 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.457 ' CD1' HD12 ' A' ' 8' ' ' ILE . 9.3 tp -50.55 -44.05 56.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.899 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -57.82 -28.82 64.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.603 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.4 mttt -82.6 -24.85 33.71 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.86 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.838 ' CD2' HG22 ' A' ' 16' ' ' VAL . 52.7 mt -88.88 128.45 35.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.013 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.9 tm-20 -114.89 107.95 16.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.81 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 13.7 tp -57.74 138.54 55.41 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.997 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 27.3 mt -94.19 133.53 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.3 mt-10 -136.18 103.75 5.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -64.63 121.23 13.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.903 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -158.38 -96.74 0.12 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.49 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -73.5 145.12 37.23 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.542 2.161 . . . . 0.0 112.285 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 69.3 p -161.06 -63.87 0.06 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.958 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.5 m -88.21 -51.5 5.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.941 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.313 -1.271 . . . . 0.0 112.509 -179.995 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.217 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -103.5 144.6 31.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.886 0.374 . . . . 0.0 110.85 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 54.1 m -157.4 120.31 3.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.858 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 148.84 158.36 8.01 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.462 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.3 t -170.82 -51.02 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.813 0.34 . . . . 0.0 110.927 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.6 m 60.31 166.88 0.08 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.28 104.19 2.3 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.506 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.707 HD13 HG11 ' A' ' 14' ' ' VAL . 20.2 mt -128.15 138.26 55.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.828 0.346 . . . . 0.0 111.02 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -120.57 -179.59 4.03 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.3 t -66.86 137.33 25.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.027 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.75 46.82 7.02 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.399 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.581 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -140.72 140.96 23.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.623 0.249 . . . . 0.0 110.955 -179.965 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.473 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.5 Cg_endo -76.51 117.17 4.49 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.566 2.177 . . . . 0.0 112.343 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.707 HG11 HD13 ' A' ' 8' ' ' ILE . 4.9 m -144.38 138.9 23.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.129 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -87.38 140.98 28.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.886 HG22 HD23 ' A' ' 85' ' ' LEU . 19.5 t -121.0 140.4 45.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.095 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -97.96 110.06 22.7 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.442 HD23 ' HA ' ' A' ' 18' ' ' LEU . 14.6 mt -84.57 -58.69 2.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.89 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.42 -174.99 0.74 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.83 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -83.77 68.72 10.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 69.18 45.35 62.09 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.536 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -99.48 -44.72 6.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 0.0 110.916 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -176.66 131.56 0.2 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.885 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -88.29 124.85 34.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.825 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -89.84 128.06 51.67 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.832 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.693 ' HB2' HD12 ' A' ' 51' ' ' LEU . 60.4 Cg_endo -72.33 139.4 31.89 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.445 2.097 . . . . 0.0 112.328 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -154.82 167.05 32.6 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.515 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.446 HG13 ' O ' ' A' ' 28' ' ' VAL . 12.6 p -108.73 124.0 64.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.75 0.31 . . . . 0.0 111.014 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 12' ' ' CYS . 16.7 t -59.46 128.55 20.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.13 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -115.73 -29.92 6.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.112 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 40.5 t80 -148.74 165.96 29.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.914 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 15.1 ttp180 -158.46 135.66 9.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.984 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 152.68 137.32 2.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.96 164.5 2.47 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.516 2.144 . . . . 0.0 112.339 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 13.7 mt -125.28 69.34 1.15 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.806 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 mt 59.92 176.96 0.09 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.82 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -171.3 124.37 0.6 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.157 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -128.73 103.43 7.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 9.5 mtt180 60.77 36.18 19.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.894 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.5 t -143.34 159.44 42.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.834 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.0 p -64.19 143.29 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.093 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.0 p -67.9 103.57 1.5 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.868 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -112.44 115.0 3.64 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.55 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 16.2 mt -73.45 146.99 9.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.795 0.331 . . . . 0.0 111.099 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -120.2 138.92 53.36 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.939 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.475 ' CB ' HD11 ' A' ' 85' ' ' LEU . 6.4 m-85 -120.84 109.91 15.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.845 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.18 119.93 9.07 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.485 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.477 HG22 HG22 ' A' ' 29' ' ' VAL . 22.3 t -134.04 130.83 55.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.774 0.321 . . . . 0.0 111.03 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -83.62 119.06 24.28 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.932 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 7.9 mt -62.26 141.95 57.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.014 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.693 HD12 ' HB2' ' A' ' 26' ' ' PRO . 7.7 mt -86.73 -179.93 6.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.854 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -54.42 -30.03 51.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.037 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -61.73 -47.06 86.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.871 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -124.43 38.38 2.39 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.482 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -77.09 151.83 35.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.819 0.342 . . . . 0.0 110.869 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 83.18 28.13 37.99 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.543 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -135.35 46.55 2.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.804 0.335 . . . . 0.0 110.859 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -118.15 150.44 18.19 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.556 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -110.09 -50.55 2.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.433 HG23 ' N ' ' A' ' 61' ' ' ASP . 7.7 t -69.03 -48.07 63.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.962 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.433 ' N ' HG23 ' A' ' 60' ' ' THR . 18.3 m-20 55.54 32.74 19.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.044 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 105.1 -25.41 25.26 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.545 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 63' ' ' VAL . 10.7 p -121.93 126.54 74.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.807 0.336 . . . . 0.0 111.103 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -116.03 113.89 23.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.86 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 12.9 mt-30 62.39 26.8 16.0 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.943 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.83 -24.39 32.35 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.616 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 12.2 tptm -81.67 114.56 20.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.882 0.372 . . . . 0.0 110.903 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.8 tp60 -82.64 97.24 8.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.924 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.476 HD12 ' CE2' ' A' ' 79' ' ' PHE . 79.0 mt -80.87 -34.74 33.46 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.012 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.411 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -156.39 169.81 23.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.986 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -103.47 124.74 49.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.889 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -140.61 173.84 11.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.823 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -76.43 179.96 5.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -76.96 120.52 22.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 60.2 41.71 16.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.885 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 78.2 m -125.18 -52.83 1.63 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.945 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -64.62 130.14 36.84 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.454 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 48' ' ' VAL . 5.6 m -142.33 143.46 26.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.853 0.359 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.476 ' CE2' HD12 ' A' ' 69' ' ' LEU . 4.5 m-85 -105.87 124.69 49.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.867 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.814 HG11 HG11 ' A' ' 16' ' ' VAL . 29.4 m -146.65 155.77 11.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.15 155.67 40.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.2 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.471 HD12 HD12 ' A' ' 8' ' ' ILE . 8.9 tp -50.57 -44.51 56.76 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.927 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -56.48 -27.03 55.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.663 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 11.8 mmtt -81.52 -26.75 34.86 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.838 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.886 HD23 HG22 ' A' ' 16' ' ' VAL . 90.2 mt -79.3 140.91 37.43 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.823 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -115.75 103.34 10.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.846 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.529 ' HA ' HG12 ' A' ' 14' ' ' VAL . 23.4 tp -59.54 130.38 46.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.473 HD12 ' HB2' ' A' ' 13' ' ' PRO . 13.6 mt -103.04 153.5 5.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.007 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . 0.404 ' N ' HG22 ' A' ' 88' ' ' ILE . 7.0 mt-10 -139.08 150.99 46.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.917 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -140.61 -68.52 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 87.44 94.9 0.93 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.529 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -68.14 -41.74 6.84 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.539 2.159 . . . . 0.0 112.322 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.8 m -103.45 151.42 22.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.0 m -161.98 89.42 0.72 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.422 -1.21 . . . . 0.0 112.506 -179.984 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 112.545 -0.222 . . . . 0.0 112.545 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.42 176.65 0.1 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.802 0.334 . . . . 0.0 110.902 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.5 t -90.33 -65.85 0.98 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.874 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 132.15 77.67 0.14 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.537 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.9 m -88.41 -61.34 1.73 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.845 0.355 . . . . 0.0 110.895 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.1 m -92.01 -78.0 0.42 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.874 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.66 103.17 2.21 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.61 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.777 HD12 HD12 ' A' ' 82' ' ' LEU . 30.0 mt -105.7 132.44 52.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.82 0.343 . . . . 0.0 111.1 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -134.75 -177.84 4.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.971 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 26.6 t -60.98 135.68 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.133 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.43 46.15 7.04 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.466 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -141.66 138.82 17.65 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.668 0.27 . . . . 0.0 110.865 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.43 ' O ' HD12 ' A' ' 87' ' ' LEU . 71.3 Cg_endo -74.48 117.25 4.89 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 122.503 2.136 . . . . 0.0 112.383 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.759 HG21 HD13 ' A' ' 85' ' ' LEU . 14.9 m -142.99 138.55 27.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.12 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 27.0 mttt -83.63 142.89 30.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.978 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.899 HG22 ' CD2' ' A' ' 85' ' ' LEU . 19.0 t -123.43 132.03 72.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -93.27 118.93 31.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.917 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.622 HD11 ' O ' ' A' ' 57' ' ' GLN . 18.1 mt -95.07 -55.8 2.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.98 -170.27 0.22 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.877 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 69.0 m -88.75 79.16 7.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.871 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.83 44.22 98.29 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.523 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -101.62 -66.54 0.91 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.798 0.333 . . . . 0.0 110.836 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -152.92 142.39 21.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.938 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.7 mtpt -103.73 133.13 49.25 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.826 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.424 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 25.8 m-85 -92.84 129.76 38.87 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.904 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -74.78 133.87 17.49 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.427 2.085 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.16 155.39 26.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.594 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -94.52 132.95 37.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.822 0.344 . . . . 0.0 111.067 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.4 t -63.75 133.83 29.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.097 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.28 -36.4 4.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.005 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 52.9 t80 -143.19 164.34 30.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.921 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.408 ' HG3' ' CE2' ' A' ' 46' ' ' PHE . 4.3 ttt180 -154.29 135.91 14.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 160.04 126.82 0.86 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.455 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.714 ' CD ' HG23 ' A' ' 44' ' ' ILE . 52.3 Cg_exo -54.74 -174.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.435 2.09 . . . . 0.0 112.295 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.441 HD12 ' CE1' ' A' ' 45' ' ' PHE . 21.5 mt -144.74 91.45 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.881 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.0 mt 60.74 34.06 19.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.981 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -88.08 132.98 34.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.083 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -67.15 -74.97 0.1 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.941 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -131.14 -78.24 0.52 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.882 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.9 t -138.36 28.78 2.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.9 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 3.2 m -103.3 32.09 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.115 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -160.01 -60.64 0.06 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.885 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.28 130.44 5.84 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.473 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.714 HG23 ' CD ' ' A' ' 34' ' ' PRO . 3.0 mt -59.48 149.26 6.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.75 0.309 . . . . 0.0 111.072 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.441 ' CE1' HD12 ' A' ' 35' ' ' LEU . 77.5 m-85 -102.28 134.94 44.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.841 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.408 ' CE2' ' HG3' ' A' ' 32' ' ' ARG . 8.7 m-85 -121.69 113.01 19.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.446 ' N ' ' CD1' ' A' ' 79' ' ' PHE . . . -73.08 118.21 6.26 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.358 179.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.508 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.6 t -125.73 131.42 71.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 111.124 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -90.55 114.81 27.12 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.839 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.3 mt -58.32 135.99 57.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.073 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -82.28 -179.97 7.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.896 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.72 -29.66 54.04 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.09 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -61.33 -50.49 72.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.902 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.424 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -121.84 37.59 2.87 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.479 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.57 145.34 41.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.794 0.33 . . . . 0.0 110.911 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 85.95 33.13 15.98 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.539 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.622 ' O ' HD11 ' A' ' 18' ' ' LEU . 7.7 mm-40 -137.3 30.86 2.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.862 0.363 . . . . 0.0 110.933 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.38 154.41 18.99 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.502 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -109.47 -49.79 3.07 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.799 0.333 . . . . 0.0 110.869 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.7 t -62.31 -46.26 89.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.946 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 57.51 35.37 25.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.003 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.407 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.49 -27.56 16.89 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.469 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.434 ' O ' HG13 ' A' ' 63' ' ' VAL . 10.8 p -117.46 124.83 73.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 0.0 111.053 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.437 ' CE2' HD13 ' A' ' 35' ' ' LEU . 37.3 t80 -111.91 115.05 28.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.96 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 30.7 mt-30 59.37 25.77 14.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.137 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.84 24.66 22.47 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.61 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.65 109.82 10.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.83 0.348 . . . . 0.0 110.859 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -75.71 97.01 3.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.946 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.443 HD12 ' CE2' ' A' ' 79' ' ' PHE . 79.0 mt -82.65 -30.81 29.1 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.858 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.407 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.9 p90 -152.82 174.64 13.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.938 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.79 110.02 19.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 26.5 p -133.17 174.71 10.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -72.55 179.97 3.29 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.881 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -74.78 119.31 18.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.975 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 60.75 51.25 4.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.906 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 47.6 m -129.98 -49.34 1.12 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.916 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -71.65 134.63 22.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.502 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 48' ' ' VAL . 8.1 m -141.9 132.61 25.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.805 0.336 . . . . 0.0 111.113 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 47' ' ' GLY . 7.9 m-85 -100.83 118.34 36.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.897 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.515 HG21 HG13 ' A' ' 16' ' ' VAL . 27.4 m -145.3 161.92 12.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.109 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -75.66 156.05 35.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.127 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.777 HD12 HD12 ' A' ' 8' ' ' ILE . 6.5 tp -50.43 -43.97 55.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.825 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -57.57 -29.27 64.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.573 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 22.6 mmtm -80.62 -27.02 37.41 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.79 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.899 ' CD2' HG22 ' A' ' 16' ' ' VAL . 39.4 mt -84.33 146.59 27.64 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.985 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -131.46 110.96 11.38 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.912 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.43 HD12 ' O ' ' A' ' 13' ' ' PRO . 34.5 tp -62.6 136.14 57.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.99 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 26.9 mt -79.57 130.86 35.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.183 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -118.31 144.25 45.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.893 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 p -95.5 -47.43 6.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.919 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -177.91 89.81 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.511 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.08 95.47 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.547 2.165 . . . . 0.0 112.32 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 68.7 m -105.82 177.38 4.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.887 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.2 m -149.01 -48.09 0.14 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.904 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.332 -1.26 . . . . 0.0 112.51 179.993 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 112.462 -0.255 . . . . 0.0 112.462 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.4 m -93.43 154.25 18.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.825 0.345 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 90.5 p -91.04 -46.9 7.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.917 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 93.69 124.15 3.78 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.443 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 p -120.88 62.48 0.87 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.931 0.396 . . . . 0.0 110.852 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.8 m 59.84 -176.78 0.1 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.977 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -161.34 -81.44 0.04 OUTLIER Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.533 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.504 HG21 HG11 ' A' ' 14' ' ' VAL . 20.2 mt -126.93 150.08 32.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.755 0.312 . . . . 0.0 111.172 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -157.91 -176.65 6.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.592 HG13 ' O ' ' A' ' 30' ' ' ARG . 39.7 t -58.89 138.93 19.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.146 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 72.06 47.33 31.52 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.512 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.726 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -147.31 136.38 11.52 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.585 0.231 . . . . 0.0 110.893 179.985 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -76.19 130.2 11.91 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.512 2.141 . . . . 0.0 112.298 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.504 HG11 HG21 ' A' ' 8' ' ' ILE . 7.3 m -151.67 138.75 13.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.156 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -81.89 135.21 35.43 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.753 HG22 HD23 ' A' ' 85' ' ' LEU . 21.4 t -116.83 139.9 41.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.14 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -103.26 116.29 32.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.937 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 50.6 mt -89.72 -44.65 9.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.954 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -86.38 172.17 10.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.87 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 43.2 t -76.43 76.22 3.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.11 69.2 1.39 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.509 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -133.38 -57.7 0.89 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.887 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -156.12 132.7 10.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.847 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 mttt -102.87 128.1 49.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.874 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.402 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 42.6 m-85 -93.18 129.56 38.88 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.817 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.63 ' HB2' HD12 ' A' ' 51' ' ' LEU . 72.9 Cg_endo -76.06 138.59 20.73 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.435 2.09 . . . . 0.0 112.282 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.27 151.49 22.8 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.552 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.0 p -92.38 130.94 40.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.791 0.329 . . . . 0.0 111.018 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.726 HG23 ' O ' ' A' ' 12' ' ' CYS . 22.1 t -64.77 140.54 19.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.051 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.592 ' O ' HG13 ' A' ' 10' ' ' VAL . 11.3 mmt180 -122.22 -41.07 2.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.042 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -138.25 164.47 29.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.947 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 3.3 ttp180 -158.11 141.94 15.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.857 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 148.04 149.18 4.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.478 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.71 154.16 64.14 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.604 2.203 . . . . 0.0 112.339 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.541 HD12 ' CE1' ' A' ' 45' ' ' PHE . 9.7 mt -84.47 58.01 4.62 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.9 mt 59.8 172.9 0.08 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.949 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.561 ' HB1' ' O ' ' A' ' 40' ' ' THR . . . -157.88 163.01 38.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.188 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -91.59 -67.08 0.88 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.874 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.67 -33.24 6.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.013 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.561 ' O ' ' HB1' ' A' ' 37' ' ' ALA . 2.0 t -133.05 141.51 48.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.443 HG23 ' O ' ' A' ' 41' ' ' VAL . 11.8 m -83.55 76.35 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.071 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.3 m -113.1 92.65 4.08 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.972 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 149.95 76.72 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.51 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.6 mt -90.9 150.73 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.749 0.309 . . . . 0.0 111.063 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.541 ' CE1' HD12 ' A' ' 35' ' ' LEU . 83.0 m-85 -136.71 147.23 46.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.941 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.448 ' HB2' HD11 ' A' ' 85' ' ' LEU . 9.6 m-85 -123.99 109.89 14.1 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.855 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.31 120.68 9.49 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.477 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.529 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -133.21 133.11 58.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.874 0.368 . . . . 0.0 111.107 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -90.24 116.93 28.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.881 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.469 HD21 HG21 ' A' ' 78' ' ' VAL . 63.6 mt -60.43 145.33 48.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.941 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.63 HD12 ' HB2' ' A' ' 26' ' ' PRO . 3.6 mt -86.44 -179.85 6.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.923 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -53.24 -29.35 32.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.111 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.09 -51.95 65.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.884 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.402 ' HA3' ' CG ' ' A' ' 25' ' ' PHE . . . -112.21 29.64 8.22 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.514 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -68.17 144.97 54.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.888 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.67 39.24 14.59 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.519 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -145.4 35.19 1.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.774 0.321 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.05 152.09 19.26 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -110.0 -43.87 3.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 0.0 110.979 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.4 t -77.61 -40.38 42.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.899 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 51.12 26.83 3.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.302 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.417 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 106.31 -31.74 8.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.622 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -111.78 128.79 68.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.89 0.376 . . . . 0.0 111.091 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.428 ' CE1' ' HG3' ' A' ' 65' ' ' GLN . 30.9 t80 -113.28 110.01 19.68 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.896 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . 0.428 ' HG3' ' CE1' ' A' ' 64' ' ' TYR . 9.9 mt-30 57.72 28.84 16.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.034 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 102.22 -26.81 22.97 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.498 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.6 tmtt? -82.17 116.82 21.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.918 0.39 . . . . 0.0 110.952 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 19.5 tp60 -78.96 98.91 6.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.832 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 79.0 mt -81.13 -37.86 28.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.949 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.417 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.0 p90 -155.96 173.3 16.99 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.936 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -107.72 123.36 48.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.889 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -139.58 177.2 8.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.911 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -76.05 179.92 5.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.886 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -73.52 114.01 11.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.913 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 42.2 m-20 60.83 45.21 10.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.912 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 62.6 m -125.63 -46.17 1.74 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.894 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -65.1 135.82 37.36 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.525 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 48' ' ' VAL . 8.6 m -148.49 138.86 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.803 0.335 . . . . 0.0 111.164 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -105.15 134.52 48.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.559 ' CG2' HD21 ' A' ' 85' ' ' LEU . 30.5 m -155.79 168.56 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.182 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -87.39 161.24 17.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.191 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 7.0 tp -49.99 -44.3 50.87 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -55.82 -27.1 49.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.665 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 16.1 mmtt -95.86 19.65 11.1 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.934 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.753 HD23 HG22 ' A' ' 16' ' ' VAL . 88.2 mt -129.18 126.71 39.82 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.93 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -107.8 110.39 22.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.963 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.435 ' HA ' HG12 ' A' ' 14' ' ' VAL . 12.2 tp -67.14 117.47 9.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.996 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.474 HG22 ' N ' ' A' ' 89' ' ' GLU . 2.0 mp -86.17 158.23 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.152 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . 0.474 ' N ' HG22 ' A' ' 88' ' ' ILE . 2.5 tt0 -146.8 161.75 40.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.931 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.75 113.91 9.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.878 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -134.25 -146.35 5.42 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.473 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.37 -26.73 40.94 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.524 2.149 . . . . 0.0 112.366 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.3 m -66.51 99.52 0.58 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 m 60.9 178.91 0.1 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.345 -1.253 . . . . 0.0 112.433 179.981 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 112.484 -0.247 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.0 t -174.81 178.28 1.88 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.834 0.349 . . . . 0.0 110.888 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.3 t -159.82 -45.33 0.05 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.922 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.01 177.18 48.34 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.516 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 60.0 p -150.26 -50.38 0.13 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.816 0.341 . . . . 0.0 110.917 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.5 m -112.92 153.92 27.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.912 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 121.18 104.99 1.95 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.456 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.455 HG21 HG11 ' A' ' 14' ' ' VAL . 8.7 mt -102.11 125.85 56.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.769 0.318 . . . . 0.0 111.058 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -133.65 -175.54 3.86 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.924 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.401 ' HA ' ' CG1' ' A' ' 29' ' ' VAL . 28.3 t -64.42 128.86 27.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.018 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 88.47 43.92 5.4 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.444 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.701 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -145.63 139.21 14.6 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.643 0.259 . . . . 0.0 110.963 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.622 ' HB2' HD12 ' A' ' 88' ' ' ILE . 72.2 Cg_endo -76.72 130.03 11.27 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.513 2.142 . . . . 0.0 112.303 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.455 HG11 HG21 ' A' ' 8' ' ' ILE . 12.6 m -151.1 138.8 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.141 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 50.2 mttt -82.21 127.49 33.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.962 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.725 HG13 HG21 ' A' ' 80' ' ' VAL . 21.4 t -108.69 137.01 42.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.029 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -92.98 121.41 34.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.971 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.1 mt -100.41 -42.49 6.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.956 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.9 mtt85 -79.68 -178.22 6.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.81 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -80.49 73.54 7.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.825 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.75 41.21 99.88 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.491 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -101.94 -61.86 1.33 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.747 0.308 . . . . 0.0 110.865 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -148.43 159.6 43.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.902 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 2.0 mttm -125.3 126.38 45.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -89.65 137.31 28.72 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.766 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.414 ' HB2' HD12 ' A' ' 51' ' ' LEU . 67.4 Cg_endo -73.88 146.15 37.23 Favored 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.424 2.082 . . . . 0.0 112.331 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -163.29 152.21 22.16 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.502 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.5 p -94.1 129.16 44.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.324 . . . . 0.0 111.138 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 12' ' ' CYS . 18.7 t -62.3 126.58 20.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.07 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 40.0 mmt180 -112.11 -31.05 7.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.012 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -148.25 167.73 24.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.976 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 9.6 ttp180 -160.85 119.39 2.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.865 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 171.52 156.34 11.8 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.55 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.08 174.53 9.65 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.586 2.19 . . . . 0.0 112.357 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.502 HD11 ' CZ ' ' A' ' 45' ' ' PHE . 4.6 mt -98.78 -33.21 10.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.919 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.5 mp -138.89 147.65 42.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.886 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -164.38 87.92 0.49 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.061 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -115.43 -73.07 0.66 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.954 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 5.2 mtp180 -86.57 -36.07 19.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.937 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.3 m -162.35 150.22 14.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.955 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 10.0 m -88.08 142.81 12.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.135 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 5.1 m -98.8 -36.22 9.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.845 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -175.98 -157.26 16.78 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.468 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 3.9 mp -142.54 117.02 4.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.794 0.33 . . . . 0.0 111.153 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.502 ' CZ ' HD11 ' A' ' 35' ' ' LEU . 33.5 m-85 -85.5 124.24 31.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.421 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 5.8 m-85 -98.16 120.0 37.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.999 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.444 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -83.56 131.64 10.52 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.418 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.679 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.5 t -139.35 126.39 24.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.876 0.37 . . . . 0.0 111.161 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 71.9 tt0 -83.0 117.14 22.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.845 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.445 HD13 ' HB2' ' A' ' 57' ' ' GLN . 13.1 mt -58.62 130.15 45.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.934 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.414 HD12 ' HB2' ' A' ' 26' ' ' PRO . 5.1 mt -76.67 -179.94 5.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.867 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -53.88 -29.2 40.56 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.134 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -61.87 -43.6 98.52 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.946 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.24 35.33 2.86 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.528 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt-85 -72.61 143.44 48.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.779 0.323 . . . . 0.0 110.889 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 86.48 34.48 11.86 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.475 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.445 ' HB2' HD13 ' A' ' 50' ' ' LEU . 30.5 mm-40 -141.69 37.63 1.65 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.83 0.348 . . . . 0.0 110.843 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -110.16 155.22 16.21 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.521 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 9.9 p90 -109.92 -50.55 2.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.775 0.321 . . . . 0.0 110.929 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.431 HG23 ' N ' ' A' ' 61' ' ' ASP . 7.2 t -64.61 -48.21 75.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.929 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.431 ' N ' HG23 ' A' ' 60' ' ' THR . 6.0 m-20 56.64 27.8 13.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.154 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.414 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 107.35 -27.05 16.61 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.571 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.494 HG23 ' C ' ' A' ' 67' ' ' LYS . 12.6 p -117.69 138.12 49.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.833 0.349 . . . . 0.0 111.158 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -121.44 109.97 15.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.911 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 17.1 mt-30 61.29 25.17 15.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.091 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 107.45 -29.27 10.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.571 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.494 ' C ' HG23 ' A' ' 63' ' ' VAL . 6.1 tmtt? -79.27 119.15 21.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.864 0.364 . . . . 0.0 110.984 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 17.9 tp60 -82.13 97.09 8.02 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.91 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.49 HD12 ' CE2' ' A' ' 79' ' ' PHE . 80.5 mt -76.85 -43.92 34.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.958 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.2 p90 -151.46 170.92 18.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.89 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.02 134.45 44.0 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -156.85 165.81 35.15 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -66.92 173.71 3.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -72.68 121.66 20.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 60.38 49.41 6.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.91 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 60.4 m -129.96 -51.65 1.13 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -66.56 142.83 42.99 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.487 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.679 HG22 ' O ' ' A' ' 48' ' ' VAL . 21.0 m -151.37 143.67 16.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.834 0.349 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.49 ' CE2' HD12 ' A' ' 69' ' ' LEU . 12.5 m-85 -109.74 128.39 55.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.881 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.725 HG21 HG13 ' A' ' 16' ' ' VAL . 30.5 m -149.85 154.93 8.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.101 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.52 156.24 33.19 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.092 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.406 ' CD1' HD12 ' A' ' 8' ' ' ILE . 16.2 tp -50.89 -47.7 60.55 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.939 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -55.84 -28.58 57.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.545 179.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 3.2 mmmp? -75.85 -26.32 57.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.727 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.577 ' CD2' HG22 ' A' ' 16' ' ' VAL . 77.7 mt -84.16 137.68 33.4 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.852 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -124.62 108.03 11.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.453 HD13 HG12 ' A' ' 8' ' ' ILE . 10.1 tp -60.91 142.54 56.26 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.88 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.852 HG21 ' HD3' ' A' ' 92' ' ' PRO . 21.5 mt -98.11 133.48 40.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.169 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.69 -36.08 4.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.923 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.3 p -92.89 -75.25 0.5 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.966 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.82 122.43 0.73 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.422 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.852 ' HD3' HG21 ' A' ' 88' ' ' ILE . 68.1 Cg_endo -74.27 -44.21 0.45 Allowed 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.43 2.087 . . . . 0.0 112.37 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 27.2 m -113.73 124.34 52.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.915 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -142.72 118.12 10.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.897 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.393 -1.226 . . . . 0.0 112.521 -179.995 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.259 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.9 p -99.34 34.35 2.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.892 0.377 . . . . 0.0 110.939 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.0 t -64.51 177.11 0.94 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.839 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.91 124.49 1.33 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.543 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.97 120.35 27.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.788 0.328 . . . . 0.0 110.956 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.5 m -91.48 146.19 24.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.98 -95.05 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.529 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.604 HG21 HG11 ' A' ' 14' ' ' VAL . 31.1 mt -120.32 119.64 60.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.819 0.342 . . . . 0.0 111.142 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -122.39 -175.75 3.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.924 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 38.3 t -66.09 135.17 28.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.077 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.75 45.85 7.05 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.514 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.646 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -143.62 139.8 16.7 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.64 0.257 . . . . 0.0 110.877 -179.974 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -74.77 122.8 7.55 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.427 2.085 . . . . 0.0 112.234 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.681 ' CG2' HD22 ' A' ' 85' ' ' LEU . 15.8 m -147.13 138.39 18.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.154 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 20.3 mttm -84.69 133.43 34.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.036 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.851 HG22 HD23 ' A' ' 85' ' ' LEU . 18.0 t -114.22 139.57 39.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.106 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -91.16 122.28 33.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.888 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 45.9 mt -104.59 -52.2 2.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.965 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.6 mtt85 -68.45 -175.86 0.7 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.885 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.2 p -94.7 70.21 3.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.82 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 81.06 47.54 6.5 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -111.92 -68.8 0.91 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.804 0.335 . . . . 0.0 110.888 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -157.57 163.09 38.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 17.0 mttm -114.72 112.29 22.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.902 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -72.25 133.41 83.42 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.746 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.575 ' HB2' HD12 ' A' ' 51' ' ' LEU . 73.0 Cg_endo -74.57 143.95 31.3 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.36 2.04 . . . . 0.0 112.392 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -162.76 156.3 27.95 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.487 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.3 p -95.12 131.47 41.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.346 . . . . 0.0 111.046 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.646 HG23 ' O ' ' A' ' 12' ' ' CYS . 22.0 t -65.9 129.75 30.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.039 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.414 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 5.1 mmt180 -114.88 -29.92 6.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -147.37 166.65 26.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.883 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.422 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 6.3 ttp180 -164.38 141.43 6.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.885 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 143.86 147.99 4.81 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.483 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -71.02 152.13 62.51 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.568 2.179 . . . . 0.0 112.336 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.407 ' C ' HD12 ' A' ' 36' ' ' LEU . 27.6 mt -62.01 -45.81 91.97 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.906 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.407 HD12 ' C ' ' A' ' 35' ' ' LEU . 9.3 mp -118.13 160.94 20.68 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.932 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -122.08 90.16 3.25 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.035 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.617 ' HB3' HG22 ' A' ' 40' ' ' THR . 4.6 mt-10 -112.16 -14.87 13.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.29 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.7 mtt180 62.7 43.96 6.95 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.946 0.403 . . . . 0.0 110.737 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.617 HG22 ' HB3' ' A' ' 38' ' ' GLU . 2.8 t -154.16 -47.81 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.81 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 29.7 m -71.85 177.86 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.102 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 9.7 t -141.47 86.74 2.03 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -148.12 61.99 0.44 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.509 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.513 ' H ' HD12 ' A' ' 44' ' ' ILE . 3.7 mp -79.33 118.05 26.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.878 0.37 . . . . 0.0 111.065 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -95.1 137.13 34.57 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.892 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.667 ' CB ' HD11 ' A' ' 85' ' ' LEU . 5.3 m-85 -114.59 109.92 18.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.408 ' N ' ' CE1' ' A' ' 79' ' ' PHE . . . -70.97 118.85 7.73 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.297 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.571 HG21 ' CD2' ' A' ' 85' ' ' LEU . 24.2 t -130.99 131.61 64.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.863 0.363 . . . . 0.0 111.139 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -89.71 116.76 28.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.801 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.668 HD13 ' O ' ' A' ' 54' ' ' GLY . 91.8 mt -57.14 145.57 30.75 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.149 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.575 HD12 ' HB2' ' A' ' 26' ' ' PRO . 13.3 mt -90.08 -179.88 5.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.836 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -53.19 -27.83 23.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.145 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -63.1 -54.92 30.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.862 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.668 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -116.59 35.65 4.12 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.3 mtt85 -74.69 123.87 25.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.818 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 113.58 25.49 4.28 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.726 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 39.2 mm-40 -135.45 45.72 2.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.847 0.356 . . . . 0.0 110.929 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.62 148.34 18.4 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.47 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 16.3 p90 -109.91 -49.95 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.794 0.33 . . . . 0.0 110.981 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 t -59.26 -46.2 89.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.0 t0 59.45 26.98 16.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.119 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.409 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 95.21 -25.49 23.92 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.712 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.6 p -114.18 147.92 17.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.809 0.337 . . . . 0.0 111.161 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 31.7 t80 -132.08 110.01 10.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 53.4 mt-30 60.21 29.62 19.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.914 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 99.49 -28.33 15.98 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.475 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 8.7 tmtt? -79.66 114.58 18.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.792 0.33 . . . . 0.0 110.932 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 24.5 tp60 -71.51 99.64 2.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.942 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 73.0 mt -78.08 -39.05 42.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CD2' ' HB2' ' A' ' 30' ' ' ARG . 2.3 p90 -163.71 167.9 20.47 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.86 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 17.4 mm-40 -93.82 129.36 40.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.942 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.64 173.96 12.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.91 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -83.27 167.62 17.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.799 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -66.04 118.35 9.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 60.56 44.34 11.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.946 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 86.8 m -127.61 -55.84 1.31 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.94 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.17 135.42 51.75 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.546 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.499 HG22 ' O ' ' A' ' 48' ' ' VAL . 6.1 m -143.73 143.84 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.803 0.335 . . . . 0.0 111.107 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.408 ' CE1' ' N ' ' A' ' 47' ' ' GLY . 3.8 m-85 -109.68 131.48 55.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.762 HG21 HG13 ' A' ' 16' ' ' VAL . 20.4 m -155.96 157.72 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.082 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . 0.411 ' HB3' ' HG3' ' A' ' 84' ' ' LYS . . . -70.54 155.12 41.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.999 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 10.2 tp -50.4 -45.8 55.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -57.26 -29.54 63.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.606 179.759 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.411 ' HG3' ' HB3' ' A' ' 81' ' ' ALA . 14.2 mttm -77.9 -24.68 48.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.902 179.716 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.851 HD23 HG22 ' A' ' 16' ' ' VAL . 66.6 mt -81.82 158.09 24.2 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.908 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -142.99 109.31 5.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.92 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.455 ' HA ' HG12 ' A' ' 14' ' ' VAL . 34.6 tp -61.8 135.81 57.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.965 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 2.4 mt -103.1 140.33 21.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.052 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -134.71 173.55 11.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.954 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 p -72.79 117.41 14.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.933 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -168.6 76.74 0.11 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.515 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.18 133.91 48.71 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.528 2.152 . . . . 0.0 112.347 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 1.9 p -152.08 160.58 43.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 44.7 p -68.38 120.67 14.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.913 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.389 -1.228 . . . . 0.0 112.559 -179.918 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.163 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.37 -37.26 4.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.863 0.363 . . . . 0.0 110.894 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -98.26 -169.97 1.89 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.899 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.59 158.4 19.23 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.509 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 m -100.26 -31.76 11.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.842 0.354 . . . . 0.0 110.94 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.8 m -119.61 178.04 4.71 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.916 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 120.4 106.1 2.08 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.53 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.505 HD12 HD12 ' A' ' 82' ' ' LEU . 32.1 mt -97.07 125.77 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.83 0.348 . . . . 0.0 111.109 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -122.51 172.93 8.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.888 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.423 HG13 ' C ' ' A' ' 30' ' ' ARG . 37.2 t -60.65 133.08 26.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.117 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 85.5 45.14 5.91 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.455 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.494 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.44 139.26 14.75 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 120.638 0.256 . . . . 0.0 110.908 -179.94 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -74.17 133.33 17.76 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.486 2.124 . . . . 0.0 112.253 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.468 ' CG2' HD22 ' A' ' 85' ' ' LEU . 6.2 m -153.83 138.87 10.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.139 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -84.02 131.16 34.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.968 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.802 HG22 HD23 ' A' ' 85' ' ' LEU . 16.8 t -113.26 132.4 62.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.102 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.59 116.02 28.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.957 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.564 HD12 ' CE2' ' A' ' 25' ' ' PHE . 36.7 mt -91.56 -57.33 2.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -70.44 -172.11 0.56 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.941 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 t -84.5 79.52 9.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.5 39.04 94.43 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.486 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 -95.03 -61.97 1.39 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.858 0.361 . . . . 0.0 110.905 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -155.54 144.58 20.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 21.3 mttt -106.72 124.84 50.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.862 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.564 ' CE2' HD12 ' A' ' 18' ' ' LEU . 61.3 m-85 -87.84 132.59 39.79 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.77 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.416 ' HB2' HD12 ' A' ' 51' ' ' LEU . 65.8 Cg_endo -73.72 141.64 31.02 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.426 2.084 . . . . 0.0 112.34 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -161.67 147.83 14.67 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.557 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.531 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.9 p -90.47 133.13 33.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.771 0.32 . . . . 0.0 110.984 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.494 HG23 ' O ' ' A' ' 12' ' ' CYS . 23.4 t -65.07 136.68 26.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.138 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.531 ' HD3' HG13 ' A' ' 28' ' ' VAL . 13.9 mmm180 -117.68 -38.04 3.35 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.021 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -143.11 166.27 25.13 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.877 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.429 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 6.8 ttp180 -159.6 133.84 7.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.81 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 155.3 151.45 5.87 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.511 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -54.33 157.29 11.83 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.56 2.173 . . . . 0.0 112.233 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.423 ' HG ' ' CD1' ' A' ' 45' ' ' PHE . 71.0 mt -127.06 80.9 1.98 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.804 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.449 HD23 ' H ' ' A' ' 37' ' ' ALA . 0.3 OUTLIER -113.48 152.72 29.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.987 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.449 ' H ' HD23 ' A' ' 36' ' ' LEU . . . -167.87 33.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.984 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -170.33 -65.72 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.956 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.439 ' C ' HD21 ' A' ' 36' ' ' LEU . 0.2 OUTLIER -176.13 -68.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.866 179.958 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.9 t -59.08 161.79 4.87 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.962 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.2 p -167.45 150.63 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.027 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 9.1 t -91.23 -38.22 12.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 154.58 -157.39 27.52 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.532 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.9 mm -75.56 141.37 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.827 0.346 . . . . 0.0 111.034 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.423 ' CD1' ' HG ' ' A' ' 35' ' ' LEU . 83.5 m-85 -114.87 139.38 49.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.429 ' CD2' ' HG3' ' A' ' 32' ' ' ARG . 7.6 m-85 -120.85 109.93 15.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.414 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -72.06 128.82 14.58 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.414 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.52 HG21 HD21 ' A' ' 85' ' ' LEU . 21.5 t -137.12 136.78 47.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.796 0.331 . . . . 0.0 111.065 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -94.19 115.4 27.67 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.553 HD13 ' O ' ' A' ' 54' ' ' GLY . 65.2 mt -59.17 130.94 49.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.918 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.416 HD12 ' HB2' ' A' ' 26' ' ' PRO . 12.5 mt -77.5 -179.94 6.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.852 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.05 -29.8 45.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.067 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -61.79 -42.97 99.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.958 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.553 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -123.89 34.46 3.57 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.445 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -75.74 132.54 40.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.864 0.364 . . . . 0.0 110.874 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.04 29.96 6.94 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.524 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -140.97 33.38 1.76 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.802 0.334 . . . . 0.0 110.888 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -99.51 152.67 19.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.529 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -109.98 -50.95 2.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.853 0.358 . . . . 0.0 110.941 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.453 HG22 ' HA ' ' A' ' 78' ' ' VAL . 6.1 t -66.58 -48.56 69.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.947 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.425 ' N ' HG23 ' A' ' 60' ' ' THR . 18.4 t70 60.36 23.77 13.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.203 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.427 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 103.81 -31.96 8.09 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.671 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -103.7 133.73 46.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.861 0.362 . . . . 0.0 111.199 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -118.95 109.98 16.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.879 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 60.21 28.11 17.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.956 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.37 23.82 25.72 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.596 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 5.6 tttm -132.3 109.95 10.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.861 0.363 . . . . 0.0 110.88 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 11.9 tp60 -69.72 95.56 0.89 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 83.0 mt -82.32 -37.53 25.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.92 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.427 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.5 p90 -149.0 165.45 31.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -98.25 128.36 44.66 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.907 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.39 164.51 32.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.781 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.89 174.24 9.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -62.84 113.17 2.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.888 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 60.33 54.63 3.85 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.858 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 68.7 m -129.57 -56.47 1.14 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.441 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -59.57 140.28 48.08 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.511 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.453 ' HA ' HG22 ' A' ' 60' ' ' THR . 6.0 m -156.61 127.84 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.754 0.311 . . . . 0.0 111.157 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -90.4 130.31 36.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.848 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.526 HG11 ' CG1' ' A' ' 16' ' ' VAL . 6.1 m -150.41 164.86 2.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.181 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -83.87 157.4 22.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.128 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.505 HD12 HD12 ' A' ' 8' ' ' ILE . 11.3 tp -50.39 -44.21 54.81 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.848 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -57.39 -28.75 63.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.571 179.698 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.448 ' HE3' HG12 ' A' ' 80' ' ' VAL . 5.2 mtmt -81.4 -26.67 35.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.813 179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.802 HD23 HG22 ' A' ' 16' ' ' VAL . 83.8 mt -85.42 146.16 27.11 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.891 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -133.35 107.89 8.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.925 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 12.4 tp -60.07 121.65 12.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.92 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 1.9 mp -81.26 135.91 24.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.162 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -70.48 -174.69 0.9 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.881 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.8 p -77.96 -51.82 9.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.876 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -167.55 170.61 41.78 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.515 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -54.15 -171.78 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.595 2.197 . . . . 0.0 112.248 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.68 164.97 25.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.921 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.8 m -60.77 -73.11 0.1 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.883 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.428 -179.939 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.217 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -119.32 35.67 4.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.844 0.354 . . . . 0.0 110.864 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 p -131.14 132.75 44.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.931 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 169.65 172.97 36.77 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.52 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 44.1 m -96.34 -64.79 1.02 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.779 0.323 . . . . 0.0 110.907 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.44 -172.21 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.843 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.85 -31.88 0.22 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.505 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.438 HG21 HG11 ' A' ' 14' ' ' VAL . 11.3 mt -118.01 145.23 24.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.799 0.333 . . . . 0.0 111.051 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -150.72 -177.83 6.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.402 ' HA ' HG12 ' A' ' 29' ' ' VAL . 40.3 t -59.71 127.66 19.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.027 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 84.89 43.59 6.7 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.478 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.675 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -139.51 139.32 22.12 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.66 0.267 . . . . 0.0 110.923 -179.897 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.544 ' HB2' HD12 ' A' ' 88' ' ' ILE . 75.3 Cg_endo -77.38 117.38 4.33 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.516 2.144 . . . . 0.0 112.427 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.472 HG12 ' HA ' ' A' ' 87' ' ' LEU . 13.7 m -145.67 138.52 20.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.075 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.414 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 13.3 mttm -84.16 141.19 31.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.072 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.677 HG22 HD23 ' A' ' 85' ' ' LEU . 21.9 t -117.29 134.84 59.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.067 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -92.79 110.1 21.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.946 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.425 HD12 ' CE2' ' A' ' 25' ' ' PHE . 71.2 mt -81.5 -47.05 13.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.801 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.53 145.8 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.957 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 30.2 t -74.57 86.75 2.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.958 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.83 67.8 1.44 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.437 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -149.46 -58.46 0.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.833 0.349 . . . . 0.0 110.984 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 tm-20 -175.97 164.09 2.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 40.6 mttt -117.11 160.36 21.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.896 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.44 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 56.6 m-85 -126.4 121.92 23.77 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.822 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.414 ' HA ' ' HA ' ' A' ' 15' ' ' LYS . 38.3 Cg_endo -66.04 140.6 60.66 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.513 2.142 . . . . 0.0 112.4 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.9 158.0 28.99 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.403 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.9 p -99.46 129.21 50.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.868 0.365 . . . . 0.0 111.098 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.675 HG23 ' O ' ' A' ' 12' ' ' CYS . 19.5 t -65.4 132.65 31.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.097 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.411 ' HB2' ' CD2' ' A' ' 70' ' ' PHE . 4.5 mmm180 -116.05 -35.55 4.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.006 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -146.37 169.45 18.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.931 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.426 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 9.6 ttt180 -157.54 120.76 4.01 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.879 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -178.86 146.94 7.53 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.492 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -73.1 177.13 8.18 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.603 2.202 . . . . 0.0 112.252 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 84.0 mt -132.08 31.18 4.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.926 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 24.8 mt 60.62 -176.21 0.11 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.869 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -129.29 108.37 10.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.119 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 59.0 mm-40 -97.29 -67.44 0.85 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.818 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.68 31.75 3.35 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.92 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 8.3 t -158.93 173.9 15.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.839 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 4.7 m -97.64 33.78 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.186 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 20.6 p -59.9 127.18 30.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.965 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -102.71 -146.76 18.04 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.487 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 2.0 mt -70.05 134.33 30.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.758 0.313 . . . . 0.0 111.168 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.439 ' HB3' ' CD1' ' A' ' 79' ' ' PHE . 82.8 m-85 -104.67 144.79 31.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.912 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.543 ' CB ' HD11 ' A' ' 85' ' ' LEU . 6.2 m-85 -119.46 109.93 16.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.87 119.86 8.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.58 ' O ' HG22 ' A' ' 78' ' ' VAL . 21.4 t -132.03 133.09 61.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.869 0.366 . . . . 0.0 111.189 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -87.71 116.61 25.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.44 HD13 ' O ' ' A' ' 54' ' ' GLY . 94.5 mt -60.18 130.41 46.52 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.952 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 mt -78.82 -179.93 6.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.767 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.24 -30.06 48.96 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.057 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -61.43 -41.54 97.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.873 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.44 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -127.5 34.04 3.13 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.445 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 mtt180 -72.88 138.26 46.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.799 0.333 . . . . 0.0 110.868 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 95.42 29.52 8.79 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.513 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -141.51 43.42 1.75 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.792 0.33 . . . . 0.0 110.898 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -113.18 150.18 18.5 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.525 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 5.6 p90 -110.06 -51.22 2.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.78 0.324 . . . . 0.0 110.879 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.445 HG23 ' N ' ' A' ' 61' ' ' ASP . 9.3 t -69.72 -48.32 59.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.835 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.445 ' N ' HG23 ' A' ' 60' ' ' THR . 8.6 m-20 53.91 36.22 23.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.09 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.422 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 97.97 -26.15 24.6 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.555 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.472 HG23 ' C ' ' A' ' 67' ' ' LYS . 12.0 p -118.51 137.23 53.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.809 0.337 . . . . 0.0 111.104 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 3.1 t80 -122.68 111.13 16.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.945 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 62.18 27.15 16.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.037 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 103.04 -28.43 15.85 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.526 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.472 ' C ' HG23 ' A' ' 63' ' ' VAL . 0.5 OUTLIER -79.44 116.63 19.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.871 0.367 . . . . 0.0 110.956 179.998 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 21.7 tp60 -80.31 99.5 7.92 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.42 HD12 ' HE2' ' A' ' 79' ' ' PHE . 88.0 mt -79.21 -44.93 20.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.853 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.422 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 3.8 p90 -146.81 176.45 9.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.93 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 2.5 mm-40 -99.37 128.6 45.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -152.05 165.59 34.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -80.66 171.94 14.38 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 -68.9 126.21 29.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 59.02 43.79 17.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 37.5 m -129.87 -60.84 1.02 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -58.6 135.66 51.74 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.535 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.58 HG22 ' O ' ' A' ' 48' ' ' VAL . 22.1 m -148.05 141.28 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.788 0.328 . . . . 0.0 111.131 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.439 ' CD1' ' HB3' ' A' ' 45' ' ' PHE . 3.0 m-85 -104.99 126.82 52.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.842 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.671 HG11 ' CG1' ' A' ' 16' ' ' VAL . 28.9 m -150.22 164.24 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.105 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -78.26 158.04 29.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.113 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.406 HD12 HD12 ' A' ' 8' ' ' ILE . 8.6 tp -50.68 -44.41 57.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.867 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -57.42 -29.27 63.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.591 179.668 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.26 -26.03 42.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.763 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.677 HD23 HG22 ' A' ' 16' ' ' VAL . 89.0 mt -82.19 125.04 30.45 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.954 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 5.2 tm-20 -112.05 107.48 16.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.472 ' HA ' HG12 ' A' ' 14' ' ' VAL . 31.6 tp -60.36 131.19 50.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.906 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.544 HD12 ' HB2' ' A' ' 13' ' ' PRO . 4.9 mt -86.46 140.93 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.109 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -152.73 129.49 10.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.842 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 47.9 t -86.47 -46.5 10.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -166.13 -161.2 14.64 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.473 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -52.2 -41.12 67.41 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.587 2.191 . . . . 0.0 112.358 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -124.19 105.04 9.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.845 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 15.4 p -175.92 -43.61 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.867 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.423 -1.209 . . . . 0.0 112.457 -179.989 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.203 0 N-CA-C 112.469 -0.253 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.29 31.89 20.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.875 0.369 . . . . 0.0 110.961 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.34 31.2 5.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.989 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -118.91 129.54 8.17 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.527 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.2 m -113.36 104.84 12.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.751 0.31 . . . . 0.0 110.902 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.1 m -141.79 150.73 42.08 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.73 -69.03 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.529 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.53 HG12 HD13 ' A' ' 87' ' ' LEU . 30.8 mt -123.61 136.65 59.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.82 0.343 . . . . 0.0 111.115 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -144.58 -172.52 3.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.812 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 30' ' ' ARG . 33.9 t -65.42 144.49 14.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.152 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 68.88 49.11 44.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.506 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.608 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -145.89 139.91 15.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 120.662 0.268 . . . . 0.0 111.002 179.899 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.09 126.7 8.8 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.544 2.163 . . . . 0.0 112.293 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.413 HG21 HD22 ' A' ' 85' ' ' LEU . 13.3 m -154.04 138.27 9.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.153 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.408 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 39.3 mttt -88.32 138.11 31.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.005 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.777 HG22 HD23 ' A' ' 85' ' ' LEU . 26.2 t -117.35 141.57 35.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.997 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.0 tt0 -103.11 110.03 21.82 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.881 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.1 mt -80.78 -51.07 9.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.02 -169.84 1.72 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.9 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -104.75 87.09 2.59 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.865 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 67.96 56.6 10.38 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.452 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.03 -52.86 1.75 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.36 . . . . 0.0 110.935 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -176.06 139.89 0.39 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.913 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 67.1 mttt -100.96 122.79 44.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.91 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.44 ' CD1' ' HA3' ' A' ' 54' ' ' GLY . 46.6 m-85 -87.67 129.84 49.29 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.821 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.412 ' HB2' HD12 ' A' ' 51' ' ' LEU . 63.0 Cg_endo -73.0 141.02 32.34 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.503 2.135 . . . . 0.0 112.301 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -160.47 150.22 20.09 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.51 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.628 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.7 p -93.78 133.75 33.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.836 0.35 . . . . 0.0 111.085 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 47' ' ' GLY . 15.8 t -67.96 136.23 26.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.11 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.628 ' HD3' HG13 ' A' ' 28' ' ' VAL . 1.7 mmm180 -118.86 -38.75 3.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.984 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -139.88 165.98 25.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.408 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 36.9 ttp85 -160.49 127.55 4.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 161.33 146.56 4.67 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.45 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -54.04 169.78 0.59 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.504 2.136 . . . . 0.0 112.325 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.633 ' HB3' HD12 ' A' ' 36' ' ' LEU . 6.9 mt -120.08 -60.97 1.65 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.817 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.633 HD12 ' HB3' ' A' ' 35' ' ' LEU . 4.6 mp -121.31 124.93 45.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.881 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -162.25 111.69 1.47 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.137 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -160.81 -58.71 0.05 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.867 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.04 -33.09 6.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.928 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.6 t -127.83 121.95 31.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.821 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.4 m -67.71 132.78 32.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.164 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 19.6 m -113.06 -50.44 2.88 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.877 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 130.6 161.3 10.3 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.45 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.5 mt -77.52 150.93 5.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.835 0.35 . . . . 0.0 111.191 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -119.44 139.96 51.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.494 ' CB ' HD11 ' A' ' 85' ' ' LEU . 6.5 m-85 -118.56 109.95 16.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.92 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.635 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -69.09 140.9 34.96 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.557 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.426 HG21 ' CD2' ' A' ' 85' ' ' LEU . 21.9 t -152.37 134.64 6.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.844 0.355 . . . . 0.0 111.109 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -92.62 116.34 28.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.435 HD13 ' O ' ' A' ' 54' ' ' GLY . 74.7 mt -60.03 136.55 58.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.986 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.412 HD12 ' HB2' ' A' ' 26' ' ' PRO . 0.9 OUTLIER -81.08 -179.94 7.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.902 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -53.8 -30.04 43.19 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.141 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -62.26 -47.48 84.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.847 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.44 ' HA3' ' CD1' ' A' ' 25' ' ' PHE . . . -120.12 35.76 3.67 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.444 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -76.88 133.84 39.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.774 0.321 . . . . 0.0 110.898 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.28 30.26 6.71 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.586 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -140.68 38.84 1.84 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 0.0 110.936 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.57 150.31 17.17 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.456 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 10.5 p90 -109.35 -45.73 3.67 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.747 0.308 . . . . 0.0 110.852 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.595 HG22 ' HA ' ' A' ' 78' ' ' VAL . 8.8 t -71.0 -48.45 53.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.927 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.43 ' N ' HG23 ' A' ' 60' ' ' THR . 14.6 m-20 56.05 28.6 13.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.126 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.15 -24.88 28.14 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.702 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -117.59 129.95 73.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.865 0.364 . . . . 0.0 111.151 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.457 ' CZ ' HD13 ' A' ' 35' ' ' LEU . 62.4 t80 -114.95 110.01 18.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.946 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 59.37 24.71 13.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.113 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.13 23.66 16.74 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.558 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -125.37 109.81 13.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.89 0.376 . . . . 0.0 110.812 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 17.5 tp60 -71.47 95.25 1.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.906 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.404 HD12 ' HE2' ' A' ' 79' ' ' PHE . 44.1 mt -84.5 -38.09 20.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CD1' ' N ' ' A' ' 70' ' ' PHE . 3.0 p90 -152.25 171.54 17.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.843 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -101.01 112.63 25.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -137.85 170.07 16.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.913 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -78.96 172.3 13.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.925 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -72.14 123.4 22.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.922 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 60.34 37.91 19.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.885 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 34.7 m -121.46 -64.61 1.21 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.939 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.14 144.62 44.94 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.502 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.595 ' HA ' HG22 ' A' ' 60' ' ' THR . 15.3 m -152.41 142.78 15.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.347 . . . . 0.0 111.201 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.404 ' HE2' HD12 ' A' ' 69' ' ' LEU . 2.8 m-85 -104.24 119.52 39.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.837 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.453 HG11 HG11 ' A' ' 16' ' ' VAL . 27.1 m -142.77 163.59 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.239 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -76.31 161.27 28.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.241 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.494 HD12 HD12 ' A' ' 8' ' ' ILE . 13.6 tp -51.55 -47.46 63.41 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.912 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -56.5 -27.23 56.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.711 179.719 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -80.91 -5.26 57.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.232 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.777 HD23 HG22 ' A' ' 16' ' ' VAL . 43.8 mt -104.58 140.43 38.01 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.894 0.378 . . . . 0.0 111.032 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -122.02 110.16 15.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.802 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.53 HD13 HG12 ' A' ' 8' ' ' ILE . 7.9 tp -59.16 138.52 57.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.05 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.489 HG22 ' N ' ' A' ' 89' ' ' GLU . 5.3 mt -109.28 158.53 9.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.037 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . 0.489 ' N ' HG22 ' A' ' 88' ' ' ILE . 2.3 mm-40 -85.34 102.46 13.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.87 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 20.8 p -109.35 103.18 12.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 177.01 -60.2 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.587 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -71.96 -178.56 3.23 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.605 2.203 . . . . 0.0 112.316 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 66.9 m -105.23 91.08 3.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.88 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.1 t -155.82 -54.87 0.09 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.915 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.101 0 CA-C-O 118.36 -1.245 . . . . 0.0 112.473 -179.997 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.176 0 N-CA-C 112.526 -0.229 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 m -82.66 -43.43 16.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.892 0.377 . . . . 0.0 110.944 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 56.5 m -69.53 106.42 3.0 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.874 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 132.66 87.66 0.35 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.531 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.4 t -159.09 31.95 0.21 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.844 0.354 . . . . 0.0 110.95 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.2 m -166.08 177.5 6.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.36 -63.91 0.26 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.518 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.508 HD13 HG11 ' A' ' 14' ' ' VAL . 33.4 mt -81.4 146.47 7.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.782 0.325 . . . . 0.0 111.142 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -144.77 -177.58 5.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.931 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.405 HG13 ' C ' ' A' ' 30' ' ' ARG . 38.3 t -67.04 129.71 31.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.132 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 88.04 43.9 5.53 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.482 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.688 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.35 140.36 18.95 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.584 0.23 . . . . 0.0 110.893 179.986 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.652 ' HB2' HD12 ' A' ' 88' ' ' ILE . 71.9 Cg_endo -77.14 118.87 4.83 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.528 2.152 . . . . 0.0 112.366 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.508 HG11 HD13 ' A' ' 8' ' ' ILE . 4.5 m -141.8 138.92 31.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.135 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 0.1 OUTLIER -84.01 126.44 33.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.996 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.608 HG22 ' CD2' ' A' ' 85' ' ' LEU . 29.8 t -102.24 128.81 54.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.997 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -89.31 131.65 35.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.947 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -111.37 -56.84 2.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.812 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -67.65 171.3 6.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.932 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.2 m -72.71 78.4 1.11 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.923 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.17 62.24 6.42 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.535 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -122.44 -65.09 1.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.811 0.339 . . . . 0.0 110.84 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 18.4 mt-10 -143.39 162.51 35.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.891 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 12.5 mttt -127.03 113.06 15.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.887 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -76.89 127.72 83.21 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.823 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 15' ' ' LYS . 59.0 Cg_endo -71.32 149.99 58.0 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.452 2.102 . . . . 0.0 112.34 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.507 ' HA2' HD12 ' A' ' 51' ' ' LEU . . . -170.59 149.93 13.44 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.521 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.7 p -88.36 132.71 32.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.826 0.346 . . . . 0.0 111.072 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.688 HG23 ' O ' ' A' ' 12' ' ' CYS . 28.4 t -67.96 132.2 32.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.018 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.405 ' C ' HG13 ' A' ' 10' ' ' VAL . 1.0 OUTLIER -114.59 -37.0 4.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.959 179.975 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -136.93 166.74 22.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.934 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HG3' ' CD2' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -164.36 120.34 1.55 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.882 179.971 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 163.54 154.04 7.56 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.51 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.88 146.48 53.4 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.616 2.211 . . . . 0.0 112.328 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.422 ' HG ' ' CD2' ' A' ' 45' ' ' PHE . 74.0 mt -74.85 -68.88 0.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.82 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 mt -161.4 163.68 30.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.868 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -134.6 119.61 18.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.054 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -130.31 -68.43 0.7 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -120.41 -40.18 2.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.984 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.0 t -66.69 173.08 3.68 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.478 HG22 ' N ' ' A' ' 42' ' ' SER . 11.0 p -66.33 158.33 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.068 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.478 ' N ' HG22 ' A' ' 41' ' ' VAL . 40.6 t -92.8 95.8 9.75 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.993 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -107.82 -169.5 21.67 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.542 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.409 HG22 ' N ' ' A' ' 45' ' ' PHE . 25.2 mt -129.11 154.43 40.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.834 0.35 . . . . 0.0 111.139 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.422 ' CD2' ' HG ' ' A' ' 35' ' ' LEU . 85.9 m-85 -124.24 142.59 51.12 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.858 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.622 ' CB ' HD11 ' A' ' 85' ' ' LEU . 10.4 m-85 -123.92 111.05 15.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.848 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -75.76 117.73 5.24 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.438 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.567 HG22 HG22 ' A' ' 29' ' ' VAL . 21.3 t -130.31 127.22 62.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.811 0.339 . . . . 0.0 111.132 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -84.14 118.84 24.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.913 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 18.8 mt -58.93 139.26 56.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.095 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.507 HD12 ' HA2' ' A' ' 27' ' ' GLY . 0.0 OUTLIER -84.52 -179.84 7.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.827 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -50.63 -28.8 9.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.188 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.04 -61.56 2.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.854 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -108.58 29.0 10.44 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.459 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 1.9 ttt180 -64.76 126.3 27.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.855 0.359 . . . . 0.0 110.933 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.8 36.26 4.31 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.485 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -141.08 32.57 1.75 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.835 0.35 . . . . 0.0 110.924 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -92.47 150.56 20.17 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.485 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -110.04 -33.63 6.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.739 0.304 . . . . 0.0 110.945 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.7 t -83.34 -44.36 14.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.941 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.0 t0 54.93 30.21 13.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.069 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.41 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 96.44 -28.02 14.92 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.438 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.456 ' O ' HG13 ' A' ' 63' ' ' VAL . 11.0 p -115.09 122.99 70.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.749 0.309 . . . . 0.0 111.107 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -108.1 114.11 27.77 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.941 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 43.0 mt-30 59.55 26.08 15.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.057 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.08 24.94 23.48 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.601 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 13.4 tttt -134.15 109.92 9.23 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.866 0.365 . . . . 0.0 110.89 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -67.3 121.28 15.37 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.876 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 95.3 mt -108.89 -32.38 7.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.41 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.3 p90 -156.71 170.48 22.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.838 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.66 116.93 32.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.803 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 5.0 p -139.55 175.31 9.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -74.69 170.4 15.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.83 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -66.84 116.39 7.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.932 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 60.79 46.0 9.34 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 65.7 m -125.56 -45.93 1.77 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.896 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -68.85 139.75 33.47 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.541 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.538 HG22 ' O ' ' A' ' 48' ' ' VAL . 6.3 m -150.56 131.5 4.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.789 0.328 . . . . 0.0 111.175 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 14.1 m-85 -99.99 119.93 39.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.835 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.568 HG21 HG13 ' A' ' 16' ' ' VAL . 29.1 m -142.2 168.77 14.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.124 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -81.56 159.69 24.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.194 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 6.3 tp -50.06 -43.18 51.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.894 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -57.02 -28.06 62.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.595 179.664 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -81.79 -27.07 33.89 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.792 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.622 HD11 ' CB ' ' A' ' 46' ' ' PHE . 91.1 mt -88.7 142.41 27.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.922 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -133.43 112.93 11.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.885 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.45 140.09 56.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.652 HD12 ' HB2' ' A' ' 13' ' ' PRO . 6.2 mt -103.2 148.88 7.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.063 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 79.8 mt-10 -121.36 -69.51 0.83 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.2 t -176.86 -40.17 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 110.57 -168.06 12.84 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.487 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -52.16 -49.31 17.81 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.621 2.214 . . . . 0.0 112.329 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -88.29 132.98 34.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.27 87.35 7.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.883 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.368 -1.24 . . . . 0.0 112.565 179.98 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -113.91 116.11 28.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.831 0.348 . . . . 0.0 110.831 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.8 m 61.35 113.24 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.961 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.42 -174.47 29.63 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.508 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.7 m -137.02 177.98 7.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.831 0.348 . . . . 0.0 110.848 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -156.64 163.91 38.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.988 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.49 111.25 2.72 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.617 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.49 HD12 HD12 ' A' ' 82' ' ' LEU . 22.5 mt -95.39 136.91 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.864 0.364 . . . . 0.0 111.138 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -133.55 -169.27 2.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.846 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 26.1 t -74.28 135.4 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.063 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.32 45.9 7.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.509 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.555 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -143.26 136.84 14.21 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 120.561 0.22 . . . . 0.0 110.927 -179.974 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.526 ' HB2' HD12 ' A' ' 88' ' ' ILE . 70.5 Cg_endo -74.58 118.4 5.31 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.54 2.16 . . . . 0.0 112.327 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.629 HG12 ' HA ' ' A' ' 87' ' ' LEU . 17.9 m -145.66 138.46 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.15 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.0 mtpt -74.36 133.63 42.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.907 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 1.049 HG13 HG21 ' A' ' 80' ' ' VAL . 23.5 t -111.07 139.63 34.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.012 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -98.69 129.45 45.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.93 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.6 mt -100.1 -52.46 3.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.35 171.94 10.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 65.2 p -68.27 74.4 0.23 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.837 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.89 66.35 2.62 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.492 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.8 tt0 -124.79 -47.19 1.82 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.816 0.341 . . . . 0.0 110.921 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -167.27 132.75 2.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.836 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 4.9 mttt -104.06 129.41 51.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.96 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -96.33 135.05 22.74 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.781 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.603 ' HB2' HD12 ' A' ' 51' ' ' LEU . 58.8 Cg_endo -71.82 140.78 35.96 Favored 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.432 2.088 . . . . 0.0 112.328 -179.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.85 146.47 10.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.506 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.2 p -85.1 143.06 12.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 111.025 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.555 HG23 ' O ' ' A' ' 12' ' ' CYS . 23.2 t -72.99 136.81 24.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.022 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -116.93 -32.45 5.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.21 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 30.8 t80 -150.39 167.84 25.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.8 0.333 . . . . 0.0 111.003 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.421 ' HG3' ' CE2' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -153.38 125.51 7.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.923 179.924 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.62 158.0 18.31 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.473 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.97 163.46 38.36 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.479 2.119 . . . . 0.0 112.301 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 28.1 mt -153.01 -71.99 0.14 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.9 mt -120.25 145.79 46.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.968 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -106.51 95.41 5.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.11 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -102.15 133.28 47.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.901 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 60.8 mtt85 62.85 -79.61 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.088 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.02 146.49 31.96 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.962 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 10.9 p -78.67 134.95 26.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.091 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 15.2 t 60.21 100.73 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.9 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -129.22 131.84 6.91 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.483 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 24.5 mt -93.25 135.3 28.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.838 0.351 . . . . 0.0 111.152 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -103.24 174.01 6.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.947 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.705 ' CB ' HD11 ' A' ' 85' ' ' LEU . 28.6 m-85 -145.89 109.93 4.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -69.9 118.35 8.14 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.457 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.602 HG21 ' CD2' ' A' ' 85' ' ' LEU . 21.0 t -126.37 140.08 49.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.743 0.306 . . . . 0.0 111.069 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -99.19 114.47 27.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.866 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.501 HD13 ' HB2' ' A' ' 57' ' ' GLN . 34.4 mt -57.49 138.27 55.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.038 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.603 HD12 ' HB2' ' A' ' 26' ' ' PRO . 1.8 mt -80.41 -179.9 7.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.802 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -54.48 -29.96 51.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.046 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -61.14 -60.46 3.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.816 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -103.26 28.5 15.42 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.488 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -67.67 131.06 44.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 110.919 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.55 33.57 4.42 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.522 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.501 ' HB2' HD13 ' A' ' 50' ' ' LEU . 99.6 mm-40 -140.25 34.54 1.89 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.85 0.357 . . . . 0.0 110.916 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.1 146.52 16.09 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.49 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 32.3 p90 -109.88 -49.23 3.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.749 0.309 . . . . 0.0 110.912 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.423 HG23 ' N ' ' A' ' 61' ' ' ASP . 6.9 t -63.51 -48.49 77.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.898 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.423 ' N ' HG23 ' A' ' 60' ' ' THR . 9.1 m-20 55.38 29.96 14.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.083 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.417 ' HA2' ' CE1' ' A' ' 70' ' ' PHE . . . 98.35 -28.78 13.24 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.35 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.1 p -110.72 128.24 67.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.864 0.364 . . . . 0.0 111.102 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -116.29 112.02 20.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.946 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 58.95 26.93 15.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.103 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.93 21.35 33.64 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.564 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 3.4 tptp -126.46 109.82 12.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.859 0.361 . . . . 0.0 110.834 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 18.4 tp60 -68.08 89.99 0.31 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.856 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 16.8 mt -78.16 -42.29 32.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.888 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.417 ' CE1' ' HA2' ' A' ' 62' ' ' GLY . 2.0 p90 -151.15 169.52 21.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.918 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.43 134.22 40.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.918 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -159.49 165.57 32.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -72.26 176.24 5.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.89 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -75.2 120.97 21.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 60.7 47.63 7.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.971 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 84.8 m -130.03 -58.8 1.07 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.851 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -59.3 139.63 48.54 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.616 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 27.3 m -151.54 125.68 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 111.049 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -89.45 127.86 35.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.952 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 1.049 HG21 HG13 ' A' ' 16' ' ' VAL . 31.0 m -148.65 157.89 7.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.079 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -71.02 156.99 38.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.101 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.49 HD12 HD12 ' A' ' 8' ' ' ILE . 6.6 tp -51.17 -46.55 62.13 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 64.9 m-20 -56.88 -28.86 62.37 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.651 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 17.1 mmtt -77.78 -24.27 48.94 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.879 179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.705 HD11 ' CB ' ' A' ' 46' ' ' PHE . 62.1 mt -83.48 151.59 25.36 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.989 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -135.37 105.86 6.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.839 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.629 ' HA ' HG12 ' A' ' 14' ' ' VAL . 16.8 tp -61.09 133.8 56.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.975 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.526 HD12 ' HB2' ' A' ' 13' ' ' PRO . 28.0 mt -91.23 134.61 29.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.12 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -161.65 122.45 2.7 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.888 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 10.3 p 59.78 110.6 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.95 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 155.32 99.75 0.17 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.525 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.7 176.47 5.06 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.499 2.132 . . . . 0.0 112.253 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.73 158.86 18.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.2 t -97.47 -39.95 8.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.933 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.427 -1.207 . . . . 0.0 112.574 179.979 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.2 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 76.7 p -163.39 130.14 3.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.854 0.359 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.36 30.82 4.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.879 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 106.44 58.08 0.62 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.513 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -168.73 -69.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.779 0.323 . . . . 0.0 110.876 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -60.41 -173.3 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.864 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 118.46 24.45 3.17 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.897 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.625 ' CG2' HG11 ' A' ' 14' ' ' VAL . 19.7 mt -68.39 94.95 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.5 -176.94 3.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.903 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.3 t -66.43 138.69 22.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.018 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 81.65 38.63 13.7 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.552 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.621 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.1 OUTLIER -135.12 139.4 31.73 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-O 120.658 0.266 . . . . 0.0 110.929 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.3 118.5 5.21 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.548 2.165 . . . . 0.0 112.304 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.625 HG11 ' CG2' ' A' ' 8' ' ' ILE . 16.4 m -144.76 138.5 22.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.209 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 35.6 mttt -77.87 126.33 30.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.934 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.733 HG13 HG21 ' A' ' 80' ' ' VAL . 26.3 t -105.46 137.68 34.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.049 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -99.06 112.24 24.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.915 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 88.4 mt -73.77 -58.4 3.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.95 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 8.0 ttt-85 -83.96 168.91 15.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.888 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.8 m -80.13 61.07 3.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.852 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 103.61 64.22 0.69 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.499 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -130.0 -66.4 0.79 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.782 0.325 . . . . 0.0 110.883 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -164.96 130.04 2.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.2 mttt -95.33 111.45 23.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.918 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.425 ' CG ' ' HA3' ' A' ' 54' ' ' GLY . 38.4 m-85 -86.56 138.87 33.56 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.759 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -68.79 148.85 72.11 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.496 2.13 . . . . 0.0 112.43 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.83 148.05 11.47 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.519 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.446 HG13 ' HD3' ' A' ' 30' ' ' ARG . 10.9 p -88.76 132.45 33.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.79 0.328 . . . . 0.0 111.142 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 12' ' ' CYS . 19.6 t -66.18 135.17 28.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.114 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.446 ' HD3' HG13 ' A' ' 28' ' ' VAL . 0.6 OUTLIER -118.28 -36.09 3.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 -179.914 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -141.16 166.0 25.99 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.917 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.415 ' HD2' ' CE2' ' A' ' 46' ' ' PHE . 5.1 ttt180 -158.7 114.91 2.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.875 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 176.46 145.46 5.63 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.447 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.628 ' HD3' HG23 ' A' ' 44' ' ' ILE . 52.3 Cg_exo -54.76 -170.26 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.527 2.152 . . . . 0.0 112.287 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.402 HD13 ' CZ ' ' A' ' 64' ' ' TYR . 82.4 mt -115.94 -71.67 0.73 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.881 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.28 171.66 11.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.871 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -120.63 113.78 20.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.106 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.566 ' HB3' HG22 ' A' ' 41' ' ' VAL . 4.7 tt0 -163.03 169.74 19.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.862 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.39 -30.9 11.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.435 HG23 ' N ' ' A' ' 41' ' ' VAL . 7.8 t -61.33 -47.5 85.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.912 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.566 HG22 ' HB3' ' A' ' 38' ' ' GLU . 18.5 m -77.75 177.58 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.156 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.4 t -176.39 68.63 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -138.88 124.11 2.75 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.541 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.628 HG23 ' HD3' ' A' ' 34' ' ' PRO . 35.4 mt -97.43 129.11 48.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.761 0.315 . . . . 0.0 111.11 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 14.5 m-85 -91.08 144.97 25.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.843 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.415 ' CE2' ' HD2' ' A' ' 32' ' ' ARG . 6.4 m-85 -119.34 123.88 45.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.996 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.556 ' O ' HG13 ' A' ' 29' ' ' VAL . . . -87.48 131.5 10.64 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.323 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.611 ' HB ' HG21 ' A' ' 16' ' ' VAL . 21.7 t -139.37 127.5 26.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.758 0.313 . . . . 0.0 111.209 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -85.89 116.66 24.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.764 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.429 HD13 ' O ' ' A' ' 54' ' ' GLY . 60.1 mt -55.98 140.32 43.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.19 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -87.55 -179.89 6.42 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.85 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -51.97 -29.71 21.74 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.207 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -60.24 -51.34 69.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.889 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.429 ' O ' HD13 ' A' ' 50' ' ' LEU . . . -122.31 38.96 2.42 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.468 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 4.6 ttt180 -76.52 133.15 39.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.843 0.354 . . . . 0.0 110.931 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.57 23.36 8.9 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.681 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 -130.75 45.37 2.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.861 0.362 . . . . 0.0 110.818 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -107.86 148.45 16.62 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.576 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -110.05 -47.98 3.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.771 0.32 . . . . 0.0 110.908 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.4 t -65.29 -44.84 86.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.994 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 18.3 t0 57.28 30.6 18.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.061 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.43 -28.17 14.33 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.797 -0.715 . . . . 0.0 112.426 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.431 ' O ' HG13 ' A' ' 63' ' ' VAL . 11.8 p -113.47 125.02 70.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.819 0.342 . . . . 0.0 111.063 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.402 ' CZ ' HD13 ' A' ' 35' ' ' LEU . 51.7 t80 -111.25 110.09 20.42 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 58.46 28.45 16.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.084 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.28 24.38 22.04 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.492 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.8 tptt -131.55 109.89 10.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.795 0.331 . . . . 0.0 110.805 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLN . . . . . . . . . . . . . 15.3 tp60 -71.07 89.92 0.83 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.939 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 9.0 mt -75.24 -30.73 60.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.915 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -161.89 166.98 25.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -103.28 119.21 38.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.897 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' CYS . . . . . . . . . . . . . 6.8 p -144.28 176.26 9.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.959 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -72.16 176.21 5.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.9 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -75.59 119.71 20.01 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 60.72 36.5 19.38 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.918 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' CYS . . . . . . . . . . . . . 86.6 m -118.21 -38.98 3.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.952 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.55 ' O ' HG13 ' A' ' 78' ' ' VAL . . . -79.09 146.87 29.77 Favored Glycine 0 N--CA 1.452 -0.233 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.473 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.55 HG13 ' O ' ' A' ' 77' ' ' GLY . 5.2 m -159.4 134.4 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.842 0.353 . . . . 0.0 111.072 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -96.71 138.9 33.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.874 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.733 HG21 HG13 ' A' ' 16' ' ' VAL . 29.1 m -156.19 166.46 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.122 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -86.29 164.65 17.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.203 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 8.9 tp -52.15 -50.51 61.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.841 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -57.14 -28.28 62.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.643 179.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 12.3 mmtt -79.65 -25.11 41.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.835 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.597 ' CD2' HG22 ' A' ' 16' ' ' VAL . 62.6 mt -84.25 159.64 20.93 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.874 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -142.22 101.51 3.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.82 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.605 ' HA ' HG12 ' A' ' 14' ' ' VAL . 8.9 tp -59.9 143.39 51.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.983 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 22.4 mt -112.36 146.59 16.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.101 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.44 124.68 45.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.892 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.2 t -167.59 126.58 1.31 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.962 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 80.82 155.71 12.62 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.511 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.73 62.96 2.34 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.6 2.2 . . . . 0.0 112.311 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -90.38 -47.16 7.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.916 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.3 p -117.42 178.0 4.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.873 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.348 -1.251 . . . . 0.0 112.506 -179.993 . . . . . . . . 0 0 . 1 stop_ save_